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Summary 
Pharmaceutical residues in aquatic systems constitute a major environmental risk as 
pharmaceuticals are designed to interact with specific biological processes. These processes are 
mostly conserved among all vertebrate groups (e.g. signal transduction, metabolism), thus, 
drugs may have similar effects in fish as they have in mammals. In particular, endocrine 
disruptive chemicals (EDCs) are of high ecotoxicological concern as they may interfere with 
hormonal signaling via multiple pathways and can affect health and reproduction of organisms. 
EDCs which directly interfere with the reproductive system via sexual steroid hormones such as 
estrogens and androgens have been in the focus of ecotoxicological risk assessment for decades, 
but potential interactions with other hormonal groups are so far poorly investigated. One of 
these neglected hormonal groups are Glucocorticoids (GCs), a subclass of steroid hormones, 
which regulate metabolism and immune function. Drug interference with the GC pathway may 
thus hamper an organism’s survival, but research efforts examining the complex interactions of 
these compounds with this pathway are so far limited. 
In this thesis, I developed an in vivo testing approach, which enables to detect EDCs of the 
GC system and to investigate their mechanisms of action. I have applied a bioluminescence-
based test system with transgenic zebrafish larvae, the GRIZLY assay, to screen an FDA-approved 
drug library for compounds that may affect the GC pathway. By means of conducting three assay 
modes I aimed to identify inhibitors of GC signalingin vitro and in vivo as well as disruptors of GC 
biosynthesis in vivo. 
I detected 29 compounds that showed significant inhibitory activity in at least one of the 
assay modes. Interestingly, I also found five superactivators of GC signaling, substances which 
increased and/ or extended the bioluminescence signal activity. Concentration-dependent 
retests validated high reliability of the screen performance. The combined evaluation of 
compound effects in three assay modes enabled me to pre-categorize the potential substance 
mechanisms of action according to either direct interference with GC signaling activity or 
disruption of GC biosynthesis. In order to follow up on the compound mechanisms of action, I 
conducted chemical and gene expression analysis experiments with selected in vivo inhibitors 
and superactivators. The obtained results for substance effects on larva-internal steroid levels 
and target gene expression, combined with the GRIZLY outcomes, allowed me to group the 
compounds according to their potential mechanisms of action. For example, anti-inflammatory 
drugs interfered with GC signaling without affecting the GC biosynthesis pathway. Estrogens and 
retinoids inhibited GC signaling and synthesis, while for progestins both inhibitory and 
stimulatory effects were observed, suggesting a complex interaction of this compound class with 
the GC pathway. 
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Overall, I validated that the GRIZLY assay is a highly suitable in vivo test system to detect 
pharmaceutical interference with the GC system via various effect pathways. The combined 
evaluation of three different GRIZLY modes furthermore allows for pre-categorization of 
compound effect mechanisms, which facilitates the selection of specific follow-up experiments 
for an in-depth risk assessment for effects of EDCs on the GC system. Moreover, my results show 
that several of the most-widely prescribed drugs which enter aquatic systems may interfere with 
GC signaling and steroid hormone biosynthesis in fish. Given the GC regulation of metabolism 
and the immune system, this may possibly lead, especially under chronic exposure, to a 
weakened ability of organisms to cope with stressors. In the long-term view, pharmaceutical 
residues in the environment might thus lead to a reduced biological fitness, which may 
constitute an additional, so far largely neglected burden for aquatic Organisms. 
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Zusammenfassung  
Arzneimittelrückstände in aquatischen Systemen stellen ein hohes Umweltrisiko dar, weil 
Pharmazeutika speziell für die Interaktion mit spezifischen biologischen Prozessen konzipiert 
sind. Da diese Prozesse größtenteils in allen Wirbeltiergruppen konserviert sind (z.B. 
Signaltransduktion, Metabolismus) können Arzneimittel in aquatischen Organismen ähnliche 
Effekte wie in Säugetieren zeigen. Insbesondere endokrin disruptive Chemikalien (EDCs) sind 
hierbei von hoher ökotoxikologischer Relevanz, da sie mit Hormonsignalwegen über zahlreiche 
Wirkungspfade interagieren und somit die Gesundheit und Reproduktionsfähigkeit von 
Organismen beeinträchtigen können. EDCs, die direkt über Sexualhormone wie zum Beispiel 
Östrogene und Androgene mit Reproduktionsmechanismen interagieren, sind seit Jahrzehnten 
im Fokus der ökotoxikologischen Risikobewertung, jedoch sind mögliche Interaktionen mit 
anderen Hormongruppen bislang nur wenig erforscht. Eine dieser wenig beachteten 
Hormongruppen ist die der Glukokortikoide (GCs), eine Unterklasse der Steroidhormone, welche 
den Metabolismus und Immunfunktionen regulieren. Medikamente, die mit dem GC Signalweg 
interagieren, könnten daher die Überlebensfähigkeit eines Organismus beeinträchtigen, jedoch 
sind wissenschaftliche Bemühungen, die komplexen Substanzinteraktionen mit diesem 
Signalweg zu untersuchen, bislang begrenzt.  
In dieser Doktorarbeit habe ich einen in vivo Testansatz entwickelt, der es erlaubt, EDCs des GC-
Systems zu identifizieren und ihre Wirkmechanismen zu untersuchen. Ich habe ein ein 
biolumineszenzbasiertes Testsystem mit transgenen Zebrabärblingslarven angewendet, den 
GRIZLY Assay, um eine Bibliothek aus von der FDA zugelassenen Medikamenten auf Substanzen 
zu durchmustern, die Effekte auf den GC-Signalweg haben können. Mithilfe der Durchführung 
dreier Assay-Modi war es mein Ziel, in vitro und in vivo Inhibitoren des GC-Signals und 
Disruptoren der GC-Biosynthese zu identifizieren.  
Ich habe dabei 29 Substanzen ermittelt, die signifikant inhibierende Aktivität in mindestens 
einem der Assay-Modi zeigten. Interessanterweise habe ich auch fünf Superaktivatoren 
gefunden, also Substanzen, die die Biolumineszenzsignalaktivität intensiviert und/ oder zeitlich 
verlängert haben. Konzentrationsabhängige, Nachtests validierten eine hohe Verlässlichkeit des 
Verfahrens. Die kombinierte Auswertung von Substanzeffekten in drei Assay-Modi ermöglichte 
es mir, potentielle Wirkmechanismen entweder als direkte Interaktionen mit der GC-
Signalaktivität oder als indirekte Interaktionen mit der GC-Biosynthese zu prä-kategorisieren. Um 
diese Substanzwirkmechanismen weiter zu verfolgen habe ich chemisch-analytische und 
Genexpressionsanalyse-Experimente mit ausgewählten in vivo Inhibitoren und Superaktivatoren 
durchgeführt. Die Resultate der Substanzeffekte auf larveninterne Steroidlevel und 
Zielgenexpression, in Kombination mit den GRIZLY-Ergebnissen, erlaubten es mir, die Substanzen 
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entsprechend ihrer potentiellen Wirkmechanismen zu gruppieren. Beispielsweise interagierten 
entzündungshemmende Pharmazeutika mit dem GC-Signal ohne die GC-Biosynthese zu 
beeinträchtigen. Östrogene und Retinoide inhibierten das GC-Signal und die Synthese, während 
für Progestine sowohl inhibitorische als auch stimulierende Effekte zu beobachten waren, 
welche komplexe Interaktionen dieser Substanzklasse mit dem GC-Wirkungspfad andeuten.  
Insgesamt validierte ich den GRIZLY Assay als ein geeignetes in vivo Testsystem, um 
Arzneimittelinterferenz mit dem GC-System über verschiedene Wirkmechanismen zu 
detektieren. Die kombinierte Evaluation von drei verschiedenen GRIZLY-Modi erlaubt es darüber 
hinaus, Substanzeffektmechanismen zu prä-kategorisieren, was es vereinfacht, spezifische 
Folgeexperimente für eine tiefergreifende Risikobewertung der Effekte von EDCs auf das GC-
System auszuwählen. Darüberhinaus zeigen meine Ergebnisse, dass einige der 
meistverschriebenen Arzneimittel, die in aquatische Systeme gelangen, möglicherweise mit dem 
GC-Signal und der Steroidhormonbiosynthese in Fischen interferieren können. Sie könnten so 
potenziell Metabolismus und Immunfunktion beeinträchtigen und insbesondere unter 
chronischen Expositionsbedingungen zu einer verminderten Fähigkeit des Organismus, mit 
anderen Stressoren zurecht zu kommen, führen. Auf lange Sicht könnten Arzneimittelrückstände 
als eine zusätzliche, bislang größtenteils vernachlässigte Umweltbelastung daher zu einer 
reduzierten biologischen Fitness von aquatischen Organismen führen. 
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Chapter 1 
1. Introduction 
Pharmaceutical residues in aquatic systems are a major issue for environmental risk assessment 
(Corcoran, Winter, and Tyler 2010; Fent, Weston, and Caminada 2006). As many drugs act 
specifically on target mechanisms that are conserved within all vertebrate groups (e.g. enzymes 
and receptors), a pharmaceutical may have similar effects in fish as it has in mammals (Christen 
et al. 2010; Corcoran et al. 2010; Fent et al. 2006; Gunnarsson et al. 2008). Especially compound 
effects on the endocrine system are of high ecotoxicological concern, as they may interfere with 
hormonal signaling via a multitude of pathways and can affect health and reproduction of an 
organism (WHO 2002). Endocrine disrupting chemicals (EDCs), which directly interfere with the 
reproductive system and with sexual steroid hormonessuch as estrogens and androgens, have 
been in the focus of ecotoxicological risk assessment for decades (Sanderson 2006), but drug 
interactions with other hormonal groups are poorly investigated. 
One of the hormone groups that was rather disregarded within environmental risk evaluation up 
to now is that of glucocorticoids (GCs), a subclass of steroid hormones, which plays important 
roles in various physiological processes, including major drug targets such as metabolism, 
inflammation, cardiovascular function and the nervous system (Bamberger et al. 1996). Although 
GCs are involved in these vital processes and pharmaceutical interference with them may 
hamper an organism’s survival, research efforts targeting the complex compound interactions 
are so far limited. Therefore, in this study, an in vivo testing approach was developed, which 
enables to detect EDCs of the GC system and to investigate their mechanisms of action. 
1.1 Steroid hormones 
Steroid hormones are small organic molecules which are structurally derived from cholesterol. 
They are endogenously synthesized by specific organs and secreted into the bloodstream, where 
they circulate either freely or bound to plasma carrier proteins. Upon uptake from the systemic 
circulation into target tissues, they act as signaling molecules. Within cells, they can exert their 
physiological effects via different mechanisms, whereof their binding to steroid hormone 
receptors and regulation of target gene transcription are the best-investigated steroid hormone 
signaling pathways. 
In all vertebrates, steroid hormones mediate major physiological processes such as 
development, metabolism, inflammation, homeostasis and tissue function, and regulate 
important behavioral conditions within the central nervous system, reproduction processes and 
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the adrenal axis (Evans 2005; Godowski et al. 1987; Laudet 1997; Mangelsdorf et al. 1995; Neave 
2008; O’Malley 1990, 2005; Thornton 2001).  
1.1.1 Types of steroid hormones 
Steroid hormones can be divided into two groups, sex steroids and corticosteroids. Sex steroids 
mainly regulate sexual differentiation, reproduction and patterns of behavior. They consist of 
three different types, androgens, estrogens and progestogens. To the group of corticosteroids 
belong mineralocorticoids and GCs. While mineralocorticoids maintain salt and water balances 
in the body, GCs regulate primarily developmental and metabolic processes, immune functions 
and stress (Adcock, Ito, and Barnes 2004; De Bosscher et al. 2005; Capper, Rae, and Auchus 
2016; Weikum et al. 2017). For all types of steroid hormones, the chemical structure of the 
respective major active ligand in humans and of their common precursor cholesterol is shown in 
Figure 1. Each hormone type has its own cognatereceptors, designated as estrogen receptor 
(ER), androgen receptor (AR), progesterone receptor (PR), mineralocorticoid receptor (MR) and 
GC receptor (GR). One major signaling pathway, common for all types of steroid hormones, is 
binding to their specific receptor, which functions as a ligand-regulated transcription factor and 
induces or represses target gene transcription (Africander, Verhoog, and Hapgood 2011; De 
Bosscher et al. 2005; Heitzer et al. 2007; Karin et al. 1998; Louw-du Toit et al. 2017; Ronacher et 
al. 2009; Weikum et al. 2017). 
 
Figure 1: Groups of steroid hormones 
The five types of steroid hormones  and their  major active form in humans (name and chemical 
structure): estrogens (Estradiol),  androgens (Testosterone), progestogens (Progesterone), 
glucocorticoids (Cortisol)  and mineralocorticoids (Aldosterone) . All  steroid  hormones are 
structurally  derived from their  common precursor ,  cholesterol (top).  
Steroid hormones
Glucocorticoids Mineralocorticoids
Estrogens Androgens Progestogens
Estradiol
Cortisol Aldosterone
Testosterone
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Progesterone
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1.1.2 Steroid hormone production 
Endogenously, steroid hormones and their precursors are synthesized in steroidogenic cells of 
several organs including adrenal gland, gonads (ovary and testis), placenta, brain, liver, intestine, 
skin, kidneys and adipose tissue. Adrenal, testis, ovary and the central nervous system are 
specialized for de novo steroid production. While the adrenal gland primarily synthetizes GCs 
(zona fasciculata), mineralocorticoids (zona glomerulosa) and precursors of androgens (zona 
reticularis), the gonads are responsible for the biosynthesis of the sex steroids. The other – 
peripheral – tissues, predominantly take steroid hormones up from the blood circulation and 
convert them into active or inactive metabolites (Capper et al. 2016; Louw-du Toit et al. 2017; 
Miller and Auchus 2011; Sanderson 2006). 
1.2 Glucocorticoids 
GCs have a broad physiologic role as they regulate important biological processes including cell 
cycle, development, metabolism, immune and stress response. In humans, the major active 
endogenous GC mediating these effects is Cortisol (Cort). GCs were discovered in the 1930s in 
extracts from adrenal glands. In the 1950s, their physiological effects were studied by Edward 
Kendall, Tadeus Reichstein and Philip Hench, who were jointly awarded the Nobel Prize in 
Physiology or Medicine for their work. These effects were found in the 1970s to be mediated via 
GC binding to specific GRs, and in the 1980s it was discovered that the GR can bind to specific 
DNA sequences and regulate the expression of target genes via transcriptional activation and 
repression (Beato, Herrlich, and Schütz 1995; Heitzer et al. 2007; Karin et al. 1998; Ward et al. 
1951; Yamamoto 1985). 
1.2.1 Regulation of glucocorticoid synthesis 
The production of endogenous GCs is regulated in all vertebrates via a major endocrine system 
that consists of three parts. In mammals, hypothalamus, pituitary and adrenal gland compose 
the hypothalamic-pituitary-adrenal (HPA) axis, which controls the release of Cort via complex 
interactive mechanisms between the single parts (Capper et al. 2016). The HPA axis maintains 
the homeostasis of the metabolic, immune, cardiovascular, reproductive and central nervous 
system and controls numerous processes including digestion, energy storage, mood, emotions 
and expenditure. It regulates dynamic changes of Cort levels in the blood, which underlie a 
circadian rhythmicity. In humans, the Cort concentration peaks between 6 and 8 o´clock in the 
morning, in order to increase physiological and metabolic activity, and declines throughout the 
day with the lowest level around midnight (Chan and Debono 2010; Debono et al. 2009; 
Dickmeis 2009; Weitzman et al. 1971).  
 
Not only basal GC levels are controlled by the HPA axis, it is also susceptible to external stressors 
that can induce the production and release of Cort. Such stressors may imply physiological and 
psychological challenges, such as illness and inflammation, physical activity, stress or anxiety. 
When the HPA axis is stimulated to increase the endogenous Cort production, neuropeptides 
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including the corticotropin-releasing hormone (CRH), are synthesized from neuroendocrine cells 
localized within the paraventricular nucleus (PVN) of the hypothalamus. CRH is released into the 
hypophyseal portal system, a vascular networkin the brain that connects the hypothalamus with 
the anterior pituitary. Via this system, CRH is transported to the anterior pituitary, where it 
induces the production of adrenocorticotropic hormone (ACTH) within corticotropic cells. ACTH 
is secreted into the blood stream and enters the adrenal gland, where it stimulates the 
biosynthesis and the release of GCs within the adrenal cortex. From the adrenal cortex, Cort 
enters the blood stream and is transported into the cells of target organs, where it mediates 
physiological changes that enable the organism to adapt to the stressor (Oakley and Cidlowski 
2013; Papadimitriou and Priftis 2009).  
If the endogenous Cort biosynthesis needs to be reduced, the HPA axis can decrease the 
production rate via negative feedback-loops. For instance, high levels of Cort have a negative 
feedback effect on the hypothalamus and the pituitary gland where the synthesis and secretion 
of CRH and the production of ACTH are reduced (Jacobson 2005). Long-term activation of the 
HPA axis can thus be avoided by this classical negative feedback mechanism. The function of the 
HPA axis and the negative feedback loops is shown schematically in Figure 2.  
 
 
Figure 2: Negative feedback mechanism via the hypothalamic -pituitary-adrenal (HPA) axis  
The  HPA axis is stimulatedby an external stressor  (e.g. low blood glucose,  inflammation)  to 
increase the production of Cort ,  corticotropin releasing hormone (CRH) is synthesized within the 
hypothalamus. CRH is transported to the anterior pituitary, where it induces the production of 
adrenocorticotropic hormone (ACTH). Via t he blood ACTH enters the adrenal cortex, where it 
stimulates Cort biosynthesis.  Cort is released into the blood and transported into target tissues 
where it can mediate gene transcription regulation in order to counteract the effects of the 
stressor, e.g. by induction of glucose production or by repression of the inflammatory response. 
Cort production can be inhibited via negative feedback loops by which Cort mediates the decrease 
of CRH and ACTH synthesis and secretion.  
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1.2.2 Glucocorticoid biosynthesis 
Upon stimulation via the HPA axis, GCs are produced in the zona fasciculata of the adrenal 
cortex. Within the steroid hormone synthesis pathway, described as steroidogenesis, the 
common precursor of all steroid hormones, cholesterol, is converted via multiple serial steps 
into downstream steroids. With each metabolization step, a new steroid hormone is produced, 
until the required metabolite is obtained. In this way, progestogens are synthetized first and 
serve as precursors for all other groups of steroid hormones, GCs, mineralocorticoids, 
androgens, estrogens and their intermediate products. 
This reaction cascade is catalyzed by a number of steroidogenic enzymes. Two classes of 
enzymes are involved in the steroid hormone biosynthesis pathway; P450 monooxygenases 
(CYPs), containing heme as a cofactor and catalyzing irreversible reaction steps, and 
hydroxysteroid dehydrogenases (HSDs), which mediate reversible reactions (Louw-du Toit et al. 
2017). In Figure 3, important metabolization steps involved in the production of GCs are shown 
in the context of the steroid biosynthesis pathway. 
 
 
Figure 3: Steroid hormone biosynthesis pathway  
Schematic v isualization of  progestogen (orange), GC (red),  androgen (blue) and estrogen (purple) 
biosynthesis from the common precursor cholesterol (green). CYP11A1  -  cytochrome P450 side-
chain cleavage; 17α-hydroxylase  -  cytochrome P450 17α -hydroxylase (CYP17A1); 17,20-lyase  -  
cytochrome P450 17,20 -lyase (CYP17A1); 3β -HSD  -  3β-hydroxysteroid dehydrogenase;  21-
hydroxylase  -  cytochrome P450 21-hydroxylase (CYP21A2); Aromatase  -  cytochrome P450 
aromatase (CYP19A1); 11β-hydroxylase  -  cytochrome P450 11β -hydroxylase (CYP11B1 in humans; 
CYP11C1 in zebrafish); 11β-HSD1  -  11β-hydroxysteroid dehydrogenase 1 (not identified in  
zebrafish),  11β-HSD2  -  11β-hydroxysteroid dehydrogenase 2; 17β-HSD  -  17β -hydroxysteroid-
dehydrogenase (HSD17B). Gene names for 11β -hydroxylase and 11β -HSD2 of zebrafish in ital ics .  
1.2.3 Glucocorticoid receptor (GR) 
The best-studied mechanisms of Cort signaling involve regulation of gene expression via binding 
to the intracellular GR. The GR is ubiquitously expressed in organisms but its expression levels 
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are tissue- and cell-cycle specific (Africander et al. 2011; Lu et al. 2006). Like all steroid hormone 
receptors, the GR belongs to the nuclear receptor superfamily. This family consists, beside of the 
receptors for gonadal and adrenal steroids, also of receptors for nonsteroidal ligands (e.g., 
thyroid hormones, retinoic acid, vitamin D and fatty acids) and "orphan" receptors, for which the 
endogenous ligands are not yet completely identified (Mangelsdorf et al. 1995; Willson and 
Moore 2002). Nuclear receptors are ligand-inducible transcription factors. Accordingly, upon 
binding of an appropriate ligand, they mediate ligand-specific functions via regulation of target 
gene transcription. 
1.2.3.1 GR structure and function 
The GR shares a common structure with the other steroid hormone receptors, all being 
organized into several functional domains. These domains allow them to bind their respective 
ligands, recognize specific DNA-binding sequences on target genes and regulate mRNA 
transcription. The steroid receptor domain organization is illustrated in Figure 4. 
 
 
 
Figure 4: Scheme of the steroid hormone receptor domain organization  
The N-terminal domain, where AF -1 is located, regulates transcription while the DNA -binding 
domain (DBD) recognizes specif ic DNA sequences. The hinge -region (H) allows structural f lexibi li ty 
during receptor binding and the ligand binding domain (LBD) enables bindi ng to the respective 
ligands and ligand-dependent transcriptional activation via AF -2. 
 
The amino (N)-terminal domain (NTD) has a variable sequence and length, which is unique to 
each steroid hormone receptor. The NTD carries an autonomous transcriptional activation 
function (AF-1), which is highly variable but rich in negatively charged acidic amino acids and 
weakly conserved within the superfamily of nuclear receptors. The AF-1 can be responsible for 
differential promotor regulation as it modulates transcription cell- and gene-specifically. It 
interacts directly with the basal transcriptional machinery, transcription factors and numerous 
cofactors, which enables certain transcriptional functions that are ligand-independent, but can 
also mediate transcriptional activation synergistically with another transcriptional activation 
function (AF-2) at the C-terminal end (Lavery and Mcewan 2005; McEwan et al. 1993; Weikum et 
al. 2017). 
The zinc-finger DNA-binding domain (DBD) is highly conserved and centrally localized. It contains 
a nuclear localization signal (NLS), a nuclear export signal (NES) and is important for receptor 
dimerization, specificity of DNA binding and cofactor interactions. The DBD binds specific DNA 
sequences via a three dimensional configuration of the zinc fingers. While the N-terminal zinc 
finger recognizes the specific DNA response elements, the C-terminal zinc finger mediates 
receptor dimerization (Freedman and Luisi 1993; Griekspoor et al. 2007; Tang et al. 1998; 
Weikum et al. 2017). 
 
NTDN-terminal DBD H LBD C-terminal
AF-1 AF-2
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The hinge region (H) also contains an NLS and serves as a flexible pivot, linking the DBD and the 
adjacent ligand binding domain (LBD) and allowing conformational changes of the receptor. The 
LBD at the carboxyl (C)-terminal end and the second transcriptional activation function AF-2 
localized herein are highly conserved. The LBD allows binding of the corresponding ligands, 
contributes to the dimerization process of homologous receptors and interacts with heat shock 
protein 90 (HSP90). HSP90 is a general molecular chaperone that mediates folding of various 
proteins, including the steroid hormone receptors. In the absence of a ligand, it stabilizes the 
receptor and protects it from protease degradation. HSP90 also blocks the DBD and the NLSs, 
preventing receptor binding to DNA-response elements. Upon ligand binding, HSP90 dissociates 
from the receptor, enabling the NLSs to mediate translocation of the ligand-receptor complex 
from the cytoplasm via the nuclear pore into the nucleus (Africander et al. 2011; Beato et al. 
1995; Bourguet, Germain, and Gronemeyer 2000; Heitzer et al. 2007; Savory et al. 1999; 
Weikum et al. 2017). 
The receptor binds to the DNA as a homodimerized ligand-receptor complex and the second, 
ligand-dependent transcriptional activation function AF-2, located in the LDB, supports the 
initiation of transcriptional processes. AF-2 recruits transcriptional coactivators or corepressors, 
which interact with the transcriptional activation machinery (e.g. via chromatin remodeling 
proteins) and either induce or repress target gene transcription (Beato et al. 1995; Bourguet et 
al. 2000).  
Although all steroid hormone receptors share these common domains, their individual 
structures within the NTD ensure a high specificity for their respective DNA-binding sites, which 
are denominated GC response element (GRE) for the GR. Also, individual sequences within the 
LBD increase the receptor affinity for the respective steroid hormone and their synthetic 
derivatives. 
 1.2.4 GR-mediated signaling 
GR activity can be initiated by Cort or other natural and synthetic GC ligands. In the absence of 
ligands, the GR resides in the cytoplasm in a folded, inactive state, associated with protein 
complexes. Proteins involved include chaperones (dimerized HSP90, HSP70, p23) and 
immunophilins of the FK506-binding protein family (FKBPs; FKBP5 and FKBP52).  
Steroids can enter the cell via passive diffusion across the plasma membrane, due to their 
lipophilic properties. Their binding to the LBD of the GR induces a specific conformational change 
of the receptor, which depends on the chemical structure of the ligand. Thereupon, the protein 
complex dissociates from the GR, enabling the NLSs to mediate translocation of the ligand-
receptor complexfrom the cytoplasm into the nucleus, involving microtubules and passing 
through the nuclear pore. Within the nucleus, the activated ligand-receptor complex can be 
recruited to DNA-binding sites within hormone-regulated genes via different mechanisms. One 
major mechanism of GC signaling is direct DNA binding to specific GREs within the regulatory 
regions of target genes. Via this process, the ligand-receptor complex can either activate 
(transactivation) or reduce (transrepression) gene expression, depending on the type of GRE. 
However, the GR can also regulate target gene transcription without direct DNA binding, but via 
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tethering, a physical interaction with other transcription factors (Africander et al. 2011; Hammes 
and Levin 2007; Heitzer et al. 2007; Oakley and Cidlowski 2013; Pratt and Toft 1997; Schaaf and 
Cidlowski 2002). 
1.2.4.1 Transactivation 
Genes whose transcription is transactivated by the GR, among which are many genes involved in 
metabolic functions, frequently carry positive GREs. These GREs show high similarity with a 
palindromic consensus sequence that consists of two “half sites” with six base pairs each, 
separated by three spacer base pairs: AGAACAnnnTGTTCT. This consensus sequence can in 
principle be bound by GRs, MRs, ARs and PRs, due to their high conservation within the DBD. 
However, the specific GRE sequence and its environment defines the potential for binding of the 
GR or other steroid hormone receptors and influences the efficiency of receptor signaling 
activity.  
For the attachment to the palindromic DNA sequences, head-to-head homodimerization of two 
ligand-receptor complexes, mediated via the C-terminal zinc finger of the DBD, is necessary 
(Figure 5 a). Homodimer binding initiates the recruitment of coactivators and transcriptional 
cofactors, which assemble as a macromolecular complex within the promotor region and 
stimulate chromatin remodeling, e.g. via histone acetylation. This engages the basal 
transcriptional machinery, and RNA polymerase II is enabled to bind within the opened 
chromatin structure and transcribes the target gene mRNA (Adcock et al. 2004; Africander et al. 
2011; Bamberger et al. 1996; Beato 1989; Freedman and Luisi 1993; Griekspoor et al. 2007; 
Heitzer et al. 2007; Oakley and Cidlowski 2013; Schaaf and Cidlowski 2002; Tang et al. 1998; 
Weikum et al. 2017). 
1.2.4.2 Transrepression 
In case of transrepression, the GR binds to negative GREs (nGREs), which resemble an inverted-
repeat of the consensus sequence and contain CTCC(N)0-2GGAGA. This element cannot be bound 
by steroid hormone receptors other than the GR (Weikum et al. 2017). The GR can bind to nGREs 
either as one or two monomers, assembling on opposite sides of the DNA, and initiate the 
recruitment of corepressors and other transcriptional cofactors. Corepressors, such as nuclear 
receptor corepressor (NCoR) and silencing mediator or retinoid and thyroid receptors (SMRT), 
are proteins that repress target gene expression either in the absence of a ligand or if the GR is 
bound by an antagonist. Most cells express both corepressors and coactivators that interact with 
each other, but their ratio is crucial for the level of target gene expression. Thus, during 
transrepression, predominantly corepressors are recruited and mediate histone deacetylation, 
chromatin structure closure, prevention of RNA polymerase II binding, arrest of the basal 
transcription machinery and repression of target gene expression (Figure 5 b). One example for 
GR-mediated transrepression is the regulation of Cort production via a negative feedback loop of 
the HPA axis. Upon Cort activation of the GR, the ligand-receptor complex binds to nGREs within 
the promotor region of the proopiomelanocortin (POMC) gene, and in that way stopsthe 
production of ACTH and Cort biosynthesis (Beato 1989; Heitzer et al. 2007; Oakley and Cidlowski 
2013; Schaaf and Cidlowski 2002; Weikum et al. 2017). 
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1.2.4.3 Tethering 
Alternative to direct DNA binding, the GR can also trigger target gene expression via tethering to 
another DNA-bound transcription factor. By this protein-protein interaction, the DBD of the GR 
attaches to a transcription factor that in turn is attached to a specific recognition site of the 
target gene regulatory sequences (Adcock et al. 2004; Africander et al. 2011; Heitzer et al. 2007; 
Karin et al. 1998; Oakley and Cidlowski 2013; Weikum et al. 2017). Tethering of the GR can either 
induce or repress gene expression, but it is not known yet exactly if these mechanisms require a 
monomeric or a dimeric GR (Weikum et al. 2017). 
Especially the anti-inflammatory properties of GCs are considered to be primarily mediated via 
tethering. For instance, in case of suppression of pro-inflammatory genes, the GR tethers to 
active, pro-inflammatory transcription factors within the regulatory regions of target genes 
(Figure 5 c). This induces the recruitment of transcriptional cofactors and corepressors which 
mediate histone deacetylation, closure of the chromatin structure and, thus, suppress gene 
expression (Adcock et al. 2004; Africander et al. 2011; Heitzer et al. 2007; Karin et al. 1998; 
Oakley and Cidlowski 2013; Schaaf and Cidlowski 2002; Weikum et al. 2017). 
 
 
Figure 5: Glucocrticoid receptor -mediated signaling  
The inactive GR resides in  the cytoplasm, bound to a multimeric complex of a HSP90 -dimer, 
HSP70, FKBPs, p23 and other proteins. GCs enter the cel l and bind to the GR, which induces 
receptor activation, dissociation of the receptor -protein complex and receptor translocation.  
Within the nucleus, the GR can mediate GC signaling v ia three different major mechanisms. a)  
Transactivation requires b inding of a GR homodimer to a specif ic positive GRE within the 
regulatory sequences of target gene DNA. Numerous coactivators and other transcriptional 
cofactors arerecruited, which induce histone acetylation, opening of the chromatin structure, RNA 
polymerase II  binding and target gene expression. b)  Transrepression is currently  thought to 
involve either monomeric binding of the GR to a negative GRE or binding of two GRs on two sides 
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of the DNA-binding sequence (second GR faded, as not necessarily  involved). GR binding initiates 
the recruitment of corepressors and other transcription cofactors that mediate histone 
deacetylation, closure of the chromatin structureandsuppression of target gene transcription. c)  
Tethering involves no direct GR binding to the DNA, but tethering to another DNA -bound 
transcription factor (TRF). This process may be mediated by a GR monomer or dimer (second GR 
faded, as not necessarily  involved) and induce or prevent the transcript ion factor target gene 
expression. In case of gene expression inhibit ion, GR tethering to an active TRF induces 
corepressor  recruitment, histone deacetylation and closure of the chromatin structure, which 
stops further gene transcription.  
1.2.4.4 Context-specificity of glucocorticoid signaling 
Whether GR binding results in activation or repression of gene transcription depends on the 
cofactors recruited by the ligand-receptor complex. Ligand binding to the GR may either induce 
an agonistic or an antagonistic effect, which in turn depends on the ligand itself and the 
presence of other competitive ligands. While an agonist activates a response on target gene 
transcription, an antagonist inhibits the effect mediated by an agonist, without inducing a 
response itself (Africander et al. 2011). 
Agonistic effects are generally accompanied by hyper-phosphorylation of the receptor and a 
conformational change, which enables coactivator binding. An antagonist does not induce 
hyper-phosphorylation of the receptor and leads to a different conformational change, resulting 
in corepressor recruitment. (Africander et al. 2011; Nettles and Greene 2005; Schaaf and 
Cidlowski 2002). 
Furthermore, in numerous vertebrate organisms including humans and fish, the GR is expressed 
in two isoforms, GRα and GRβ, which are generated from the primary transcript by alternative 
splicing. Although the expression of GRα is ubiquitous, the receptor levels can vary organ- and 
cell specifically. Some organs express no or only very low mRNA levels of GRβ under 
physiological conditions and within the tissues that generate both isoforms, GRβ expression is 
much weakerthan that of GRα. The comparably widespread distribution of GRα can be explained 
by the circumstance that exclusively this isoform is responsible for transactivation and 
transrepression of target gene transcription, while GRβ cannot bind ligands and is thought to act 
as a dominant negative inhibitor of GRα-mediated effects that may modulate the GC sensitivity 
in target organs (Bamberger et al. 1995; Lewis-Tuffin et al. 2007; Norbiato 2013; Oakley and 
Cidlowski 2013; Pujols et al. 2002; Pujols, Mullol, and Picado 2007; Schaaf and Cidlowski 2002; 
Weikum et al. 2017). The two GR isoforms can be expressed tissue-specifically, which leads to 
differential recruitment of coactivators and corepressors and can induce highly specific 
responses to GC binding, depending on the ligand characteristics and on the cellular context 
(Africander et al. 2011; Heitzer et al. 2007). 
1.2.5 Anti-inflammatory effects of glucocorticoids 
Due to their immunomodulatory properties GCs can suppress and stimulate immune reactions 
via transcription repression of inflammatory genes and induction of anti-inflammatory gene 
expression and protein production (Adcock et al. 2004; Besedovsky et al. 1975; Brown, Smith, 
and Blalock 1987; Gwosdow, Kumar, and Bode 1990; Silverman et al. 2005).It is considered that 
GCs mediate their anti-inflammatory properties primarily via tethering to proinflammatory 
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transcription factors and transcription suppression of their target genes (Adcock et al. 2004; 
Heitzer et al. 2007; Schaaf and Cidlowski 2002; Weikum et al. 2017).The glucocorticoid-induced 
leucine zipper (GILZ) protein is an important mediator of the anti-inflammatory effects of GCs 
and plays a major role in GC immunomodulation(Ayroldi and Riccardi 2009; Ronchetti, 
Migliorati, and Riccardi 2015; Scheschowitsch, Leite, and Assreuy 2017). 
 
During immune challenges (e.g. infection, inflammation, injury, auto-immune responses), the 
immune system releases pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6 or tumor 
necrosis factor (TNF)-α. These proteins mediate the immune response and recruit the 
transcription factors activator protein 1 (AP-1) or nuclear factor-κB (NF-κB) to bind to specific 
regulatory elements within the promotor region of pro-inflammatory genes in immune cells 
(Adcock et al. 2004; Epstein, Barnes, and Karin 1997). 
AP-1 and NF-κB recruit other transcriptional cofactors, which assemble as a multi-protein 
complex within regulatory regions and enable the transcription of pro-inflammatory genes 
(Adcock et al. 2004; Heitzer et al. 2007; Schaaf and Cidlowski 2002; Weikum et al. 2017). 
In order to suppress pro-inflammatory responses, cytokines can also induce the release of Cort 
by acting at all three levels of the HPA axis. Cort binds to the GR of immune cells, whereupon the 
ligand-receptor complex translocates to the regulatory regions of the transcriptionally active 
pro-inflammatory gene. The GR tethers to AP-1 or NF-κB, triggers histone deacetylation via 
cofactor and corepressor recruitment and thus suppresses the expression of the inflammatory 
gene (Adcock et al. 2004; Heitzer et al. 2007; Schaaf and Cidlowski 2002; Weikum et al. 2017). 
In this way, Cort can suppress the production of more cytokines and their release via a negative 
feedback mechanism, and it maintains via the action of the HPA axis a critical balance between 
the beneficial and adverse effects of pro-inflammatory cytokines and the downstream 
immunomodulation. This prevents the organism from threatening effects of an overactive 
immune response (Kapcala, Chautard, and Eskay 1995; Munck, Guyre, and Holbrook 1984; 
Silverman et al. 2005; Silverman, Pearce, and Miller 2003). 
1.2.5.1 Glucocorticoids in medical applications 
Synthetic GCs are produced in large amounts and with broad diversity in order to mimic the 
immunosuppressive and anti-inflammatory properties of Cort for the treatment of inflammatory 
and autoimmune diseases. Today, they belong to the most widely prescribed drugs in the world. 
They were therapeutically applied over the last half century against numerous diseases including 
asthma, allergies, rheumatoid arthritis, sepsis, ulcerative colitis, multiple sclerosis and lymphatic 
cancer (Busillo and Cidlowski 2013; Miner, Hong, and Negro-Vilar 2005; Oakley and Cidlowski 
2013; Rhen and Cidlowski 2005; Schaaf and Cidlowski 2002).Besides their anti-inflammatory 
applications, synthetic GCs are also used to treat individuals suffering from adrenal insufficiency, 
where the adrenal glands do not produce enough Cort endogenously (Oelkers 1996). 
1.2.5.2 Side effects of glucocorticoids in medical applications  
Unfortunately, long-term use of GC treatment can be accompanied by severe side effects, which 
limits their therapeutic benefits. Chronic intake of synthetic GCs may lead to diabetes, 
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abdominal obesity, skin atrophy, glaucoma, osteoporosis, hypertension and retarded growth in 
children (Gupta and Bhatia 2008; Louw-du Toit et al. 2017; Miner et al. 2005; Oakley and 
Cidlowski 2013; Rhen and Cidlowski 2005). Often these symptoms are a consequence of 
misguided homeostasis of endogenous hormones and their physiological functions. This ability 
of synthetic GCs to interfere with processes that are normally regulated by natural hormones is 
defined as endocrine disruption. For instance, treatment with the synthetic GCs Dexamethasone 
and Prednisolone was described to disrupt the biosynthesis of steroid hormones via suppression 
of the HPA axis(Gupta and Bhatia 2008; Louw-du Toit et al. 2017). 
In order to develop novel, safer GCs with higher therapeutic benefits and lower side effects and 
to better understand beneficial mechanisms of action of GCs, medical and pharmacological 
research institutions undertake considerable efforts (Miner et al. 2005; Oakley and Cidlowski 
2013; Rhen and Cidlowski 2005). 
1.3 Endocrine disruption 
Endocrine disruption per definition is induced by “an exogenous substance or mixture that alters 
function(s) of the endocrine system and consequently causes adverse health effects in an intact 
organism or its progeny or (sub)populations” (WHO 2002). Inherent in this definition is an 
extremely wide margin of possible effects of endocrine disruption, which may be mediated by 
numerous divergent pathways within an organism. Concern about possible health risks by EDCs 
is furthermore raised by studies in animal models and clinical observations in humans, which 
indicated EDC interference with metabolism, reproductive, neuroendocrine and cardiovascular 
systems, and their potential to trigger obesity and cancer development (Diamanti-Kandarakis et 
al. 2009). 
 
Synthetic compounds that were designed to mimic the functions of natural steroid hormones 
are per se endocrine disruptors, as it is their main task to take over hormone-regulated effects. 
Drugs containing synthetic GCs for the applications described in section 1.2.5.1 belong to these 
intended endocrine disruptors, together with synthetic derivatives of progestogens, estrogens, 
androgens and mineralocorticoids that are applied in medications for contraception, hormone 
replacement, cancer therapy, adrenal insufficiency, heart failure, kidney disease, high blood 
pressure or low blood potassium (Africander et al. 2011; Gupta and Bhatia 2008; Louw-du Toit et 
al. 2017). 
However, also agents without an intended direct function on the hormonal system can have 
endocrine disruptive effects, often mediated by similarities with steroid hormones in their 
chemical structures or characteristics. Among those are pesticides, plastics, plasticizers, 
parabens, industrial chemicals and fuels(Craig, Wang, and Flaws 2011; Diamanti-Kandarakis et al. 
2009). 
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1.3.1 Mechanisms of glucocorticoid signaling disruption 
According to the Environmental Protection Agency (EPA), endocrine disruptive chemicals (EDCs) 
can interfere with synthesis, secretion, transport, metabolism, receptor binding and elimination 
of endogenous hormones (Craig et al. 2011; Hotchkiss et al. 2008). 
1.3.1.1 Direct interference with GR signaling 
The best-studied mechanism of endocrine disruption is direct compound interference with 
steroid hormone receptor-mediated signaling. EDCs can bind to steroid hormone receptors and 
agonize or antagonize their transcriptional function on target gene expression, irrespective of 
whether the receptor acts via transactivation, transrepression, tethering or other mechanisms. 
Thus, all factors involved in GR mediated regulation of transcription are possible targets for 
EDCs.  
 
The ligand-receptor binding affinity and nuclear localization can be affected by FKBPs, such as 
FKBP51 and FKBP52, which belong to the group of immunophilins. These immunosuppressive-
drug-binding proteins can increase the GR response to ligands by inhibiting steroid export 
molecules and, thus, elevate the intracellular ligand concentration and GR activity. Furthermore, 
they can stimulate GR hormone binding affinity and translocation to the nucleus. 
Immunosuppressive ligands such as synthetic GCs can enhance the GR ligand-binding affinity and 
translocation via substitution of the negative regulator FKBP51 for the positive regulator FKBP52 
within the receptor-protein heterocomplex (Davies, Ning, and Sánchez 2002, 2005; Mazaira et al. 
2015).  
 
The translocation of the ligand-receptor-complex into the nucleus can also be prevented by 
other mechanisms, for instance via the cytokines IL-2 and IL-4, which induce the p38 mitogen-
activated protein kinase (MAPK) to phosphorylate the GR and reduce its nuclear import, a 
process which leads to GC resistance during chronic inflammatory disease (Irusen et al. 2002). 
Other MAPK proteins involved in nucleocytoplasmic GR shuttling can in turn enhance the 
nuclear export of the GR, which reduces the transcriptional efficiency and induces the hormone-
dependent downregulation ofthe GR (Liu and DeFranco 2000). 
 
Hormone-dependent GR downregulation can be mediated via autoregulatory transrepression of 
the GR gene. This mechanism often underlies GC resistance in response to long-term medication 
of chronic inflammations with synthetic GCs (Corrigan et al. 1991; Okret et al. 1986; 
Ramamoorthy and Cidlowski 2013; Rosewicz et al. 1988; van Rossum and Lamberts 2006; Schaaf 
and Cidlowski 2002). However, also other steroid hormone receptors can trigger GR 
downregulation. For instance, receptor crosstalk between the GR and the ER has been shown in 
human breast-cancer cell lines, where estrogen agonists provoked GR degradation (and inhibited 
GR target gene expression)(Kinyamu and Archer 2003). 
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Also the ligand-specific recruitment of coactivators and corepressors (e.g. SMRT) can affect the 
GR transcriptional efficiency and signaling response (Heitzer et al. 2007). For example, 
overexpression of SMRT can counteract coactivator effects on GR-mediated target gene 
transcription (Szapary, Huang, and Simons 1999). 
1.3.1.2 Disruption of GC biosynthesis 
EDCs can moreover prevent the production and release of all classes of steroid hormones via the 
HPA axis. Some EDCs (e.g. azole fungizides such as prochloraz or triazine herbizides such as 
atrazine), are capable to disrupt the steroid hormone biosynthesis by inhibition of steroidogenic 
enzymes such as 3β-hydroxysteroid dehydrogenase or 11β-hydroxylase (for an overview of the 
steroid hormone biosynthesis pathway see Figure 3) (Louw-du Toit et al. 2017; Sanderson 2006). 
Also other enzymes, regulating the availability of active and inactive forms of steroid hormones 
can be affected, for instance the enzyme 11β-hydroxysteroid dehydrogenase 2, which converts 
active Cort into inactive Cortisone (Figure 3)(Louw-du Toit et al. 2017; Miller 1988; Sanderson 
2006). 
1.3.1.3 Disruption of GC homeostasis via drug metabolism 
Several enzymes involved in steroid hormone biosynthesis belong to the group of CYPs. While 
steroidogenic enzymes metabolize only one or a few endogenous substrates, other members of 
the CYP family are capable to catalyze reactions with multiple substrates of both endogenous 
and exogenous origin. These enzymes are responsible for the hormonal homeostasis and induce 
the deactivation and excretion of xenobiotics.The group of xenobiotics comprises all substances 
that either normally do not occur within the organism or are produced naturally in much lower 
concentrations. The most abundant CYPs involved in vertebrate drug and steroid metabolism 
belong to the CYP1, CYP2 and CYP3 families, which is the reason why numerous pharmaceuticals 
are designed to decrease the transcription and activity of these enzymes (Zanger and Schwab 
2013). 
 
Possible targets for such pharmaceutical actions are ligand activated transcription factors of the 
nuclear receptor superfamily, which regulate the expression of CYP enzymes upon xenobiotic 
and steroid binding. Predominantly, the pregnane x receptor (PXR), aryl hydrocarbon receptor 
(AHR) and constitutive androstane receptor (CAR) are involved in the transcriptional regulation 
of xenobiotic enzymes, but also other nuclear receptors such as the GR or the vitamin D receptor 
(VDR) may interfere with the expression of CYP genes (Bainy et al. 2013; Goodwin et al. 2001; 
Kliewer et al. 1998; Moore and Kliewer 2000; Pascussi et al. 2000). 
 
Thus, it depends on the chemical properties of thepharmaceutical to which extent its uptake 
triggers the transcription and activity of xenobiotic enzymes. This may result in a fast breakdown 
and elimination of the causative substance, but also in alterations ofendogenous hormone 
homeostasis. It is therefore another pathway by which drugs may disrupt steroid hormone 
signaling (Creusot et al. 2015; Hotchkiss et al. 2008).  
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1.4 Endocrine disruptors in the environment 
Most of the endocrine disruptive effect pathways are highly conserved among all vertebrate 
groups. Thus, EDCs can be threatening not only to humans, but also to wildlife. Especially aquatic 
organisms are affected, as EDCs can enter the aquatic environment via various entry paths. 
Municipal and hospital wastewaters, containing incompletely removed drug residues and their 
metabolites, constitute the major source for human pharmaceuticals in surface waters (Christen 
et al. 2010; Corcoran et al. 2010; Fent et al. 2006). Additional contributions to the environmental 
pollution of aquatic systems derive from discharges by chemical and pharmaceutical industries 
(Larsson 2014), from veterinary pharmaceuticals in aquaculture, and from manure produced by 
life stock, which is distributed on farmlands together with pesticides, causing both to enter 
surface waters via runoff and drainage (Christen et al. 2010; Colborn, vom Saal, and Soto 1993; 
Corcoran et al. 2010; Durhan et al. 2006; Fent 1996; Fent et al. 2006; Hotchkiss et al. 2008; 
Hutchinson et al. 2005; Jobling and Tyler 2003; Kugathas and Sumpter 2011; Larsson et al. 1999; 
Oehlmann et al. 2009; Runnalls et al. 2010; Tyler, Jobling, and Sumpter 1998). 
Accordingly, human and veterinary pharmaceuticals represent a major part of environmental 
EDCs. Among the most commonly applied pharmaceuticals are anti-inflammatory drugs, 
antibiotics, steroids and lipid regulators (Daughton and Ternes 1999; Fent et al. 2006; Halling-
Sørensen et al. 1998). Drug residues from these therapeutic classes were measured in effluents 
from sewage treatment plants in concentrations within a range of ng/L to µg/L, and 
concentrations in the range of ng/L were measured for fresh- and seawater systems (Christen et 
al. 2010; Daughton and Ternes 1999; Fent et al. 2006; Halling-Sørensen et al. 1998).  
As most pharmaceuticals are designed for oral ingestion and have a nonpolar structure, they 
pass biological membranes easily via diffusion and are taken up by aquatic organisms via their 
dermal and gill surfaces. Therefore, both the designated pharmacological target pathways of 
drugs as well as their other, potentially not-yet characterized, side-effect mechanisms of action 
constitute health risks to aquatic organisms. Up to now, it is difficult to estimate which 
pharmaceuticals may pose a threat and which are of no environmental concern, but further 
elucidations of drug mechanisms can improve this understanding for environmental and human 
risk assessment.  
1.4.1 Biotests for the assessment of endocrine disruption 
For human risk assessment of pharmaceuticals, several in vitro bioassays are available, applying 
transfected cell lines in order to detect either steroid hormone receptor agonism and 
antagonism (e.g. OECD 455, OECD 457, Yeast Estrogen/Androgen Screening [YES/YAS] Tests) or 
the production of estrogens and androgens, as e.g. in the H295R Steroidogenesis Assay (OECD 
456). However, in vitro models have a limited value for risk assessment as they represent an 
artificial, cell-specific scenario where drug effects may be completely different from their invivo 
responses in different organs, tissues and cells, due to varying availabilities and activities of 
ligands, receptors, enzymes or other proteins involved.  
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Hence, in vivo models constitute more reliable test systems, as they include all the above-
mentioned variations and reflect realistic effects, resulting from the organism-specific metabolic 
and endocrine response to drug pharmacodynamics and kinetics. For human and veterinary 
pharmaceutical testing, rodents are the preferred model organism for many ethical and 
economical reasons. Several in vivo assays were therefore established for endocrine disruption 
testing in rodents, including for instance the Hershberger Bioassay in Rats (OECD 441), the 
Uterotrophic Bioassay in Rodents (OECD 440) and one- or two-generation studies (OECD 415 and 
OECD 416). 
However, although metabolic and endocrine physiological pathways are highly conserved among 
all vertebrate groups, some endocrine processes and reproductive functions vary from one 
species to another and the extrapolation of EDC effects in animals to human risk assessment has 
to be considered carefully (Habert et al. 2014; Hult et al. 2004).  
1.4.2 Environmental risk assessment for endocrine disruptors 
Pharmaceuticals with endocrine active properties and other EDCs are also within the focus of 
environmental risk assessment. In the last three decades, numerous laboratory and field studies 
have been conducted to assess the effects of all kinds of EDCs on aquatic organisms (for details 
see reviews by Christen et al. 2010; Corcoran et al. 2010; Fent et al. 2006; Hotchkiss et al. 2008). 
However, as for human risk assessment, the applied test systems are primarily designed to 
detect direct disruption of sexual steroid hormones (estrogens, androgens, progestagens) and 
are based on endpoints related to hormone and protein levels, sexual development and 
reproduction of the organism (e.g. OECD 229, OECD 230, OECD 231, OECD 234). 
1.4.3 Requirement for new testing strategies for endocrine disruption  
The in vivo assessment of reproduction-related endpoints nowadays requires long-term studies 
with higher developmental stages of mammals and aquatic vertebrates (e.g. OECD 229, OECD 
230, OECD 231, OECD 234, OECD 415, OECD 416, OECD 440, OECD 441). These studies are time- 
cost- and animal-intensive and disregard the 3Rs principles of reduction, refinement and 
replacement of animal testing (Russell and Burch 1959). 
Furthermore, the evaluation of pharmaceutical interference with other groups of steroid 
hormones than the sex steroids, such as GCs, is badly covered by the regulations for human and 
environmental risk evaluation and the available assays. The assessment of the above mentioned 
reproduction-related endpoints may still ignore the potential of a drug to interrupt metabolic 
pathways and to indirectly affect sexual development and the fitness of organisms and 
populations. Certainly, the evaluation of such complex mechanisms further highlights the 
limitations of in vitro systems as appropriate options for alternative testing methods. 
New in vivo testing strategies are therefore urgently needed for endocrine disruption risk 
assessment, which should enable to elucidate also metabolism- and steroidogenesis-based 
effects, but which would equally reduce and refine animal testing and contribute to the 3Rs 
principles. 
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1.4.4 Zebrafish as a potential model organism for endocrine disruption testing 
Zerafish (Danio rerio) constitute a good model organism for endocrine disruption testing, as they 
offer numerous ethical and economical advantages compared to other model organisms. 
Furthermore, the zebrafish is an established test system for genetic modifications, as its genome 
has been completely sequenced and numerous genetic tools are available. The already 
established zebrafish reporter lines for hormone signaling of e.g. GC, estrogenic and thyroid 
hormone signaling are promising tools for the elucidation of endocrine effects, as they allow 
short-term assessment of hormonal disruptors already in larval stages (Benato et al. 2014, Krug 
et al. 2014, Lee et al. 2012, Weger et al. 2012, Gorelick and Halpern 2011, Terrien et al. 2011, 
Chen et al. 2010, Tong et al. 2009).  
1.5 Zebrafish and their general advantages 
Zebrafish are tropical freshwater fish that originate from the southeast of Asia (Bangladesh, 
India and Pakistan), where they live in stagnant or slow current water (e.g. paddy fields). They 
are easy to cultivate due to their small size (4‐5 cm) and low aggressiveness. Moreover, the short 
generation cycles, year-round fecundity and large progeny numbers of zebrafish enable 
continuous and high-throughput test applications (Delvecchio, Tiefenbach, and Krause 2011; 
Rennekamp and Peterson 2015). 
Already after 48-72 hours post fertilization (hpf) zebrafish larvae start to hatch, and their 
organogenesis is mostly completed at 120 hpf. This rapid, external development of zebrafish 
embryos and larvae makes them highly suitable for genetic and chemical manipulations, which 
can be monitored easily by live imaging techniques thanks to their transparency (Keller 2013, 
Kaufman, White, and Zon 2009, Tiso, Moro, and Argenton 2009).Because of these advantages, 
the zebrafish has become a well-established vertebrate model organism in numerous biological 
fields (Braunbeck et al. 2005; Scholz et al. 2008). 
1.5.1 Zebrafish in environmental risk assessment 
Within environmental risk assessment, several bioassays for the detection of toxic effects are 
conducted with zebrafish nowadays, instead of using larger fish species such as rainbow trout 
(Oncorhynchus mykiss) or common carp (Cyprinus carpio). These local fish species were for a 
long time un-replaceable especially for the risk evaluation of pesticides, but the economic 
advantages of zebrafish progressively have paved the way for the small fish into aquatic 
ecotoxicology testing (e.g. OECD 203 and OECD 215 with zebrafish have obtained regulatory 
approval). 
 
Furthermore, toxicity assays for the detection of chemical impacts nowadays can be applied on 
zebrafish larvae and juveniles instead of requiring studies with adult fish (e.g. OECD 203 can be 
replaced by OECD 236 in several cases). As developing fish stages are more sensitive to chemical 
exposure than adults, application of such assays enables more conservative assessment of acute 
toxicity (Braunbeck and Lammer 2006). Moreover, the replacement of adult fish by embryonic 
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and larval stages contributes to the reduction of animal suffering, as their mental and physical 
concerns may be deemed less ethically problematic than those of full-grown fish. 
 
Regarding the environmental risk assessment for endocrine disruptors, zebrafish studies with 
adult stages are used to investigate abnormalities of sexual development and reproduction 
(OECD 229, OECD 230, OECD 234). As these endpoints require sexual maturity, which is reached 
in zebrafish the earliest after 2 months, these conventional testing approaches cannot be 
conducted with larval stages.  
1.5.2 Zebrafish larvae for endocrine disruption testing 
Besides their use in the regulatory framework of environmental and EDC risk assessment, 
zebrafish have emerged as important model organisms in the field of endocrinology in recent 
years. They have been used successfully in studies of endocrine physiology for the elucidation of 
embryonic development of various endocrine glands (Lohr and Hammerschmidt 2011, Pogoda 
and Hammerschmidt 2009, Tiso, Moro, and Argenton 2009). Furthermore, many aspects of the 
hormone system and the impacts of diverse hormone groups could already be studied in 
larvae(Weger et al. 2012; Terrien et al. 2011; Alsop and Vijayan 2009; Dickmeis et al. 2007). 
 
Substantial research has also been conducted with zebrafish larvae in order to assess endpoints 
related to sexual development. Changes in steroid hormone levels and the expression of 
enzymes and marker genes have been shown to be measurable upon EDC treatment already in 
zebrafish larvae (Lee et al. 2012; Menuet et al. 2005; Muncke and Eggen 2006; Schiller et al. 
2013; Scholz et al. 2008). According to recent studies are endocrine markers already detectable 
in 48 hpf old embryos (Trant et al., 2001;  Bardet et al., 2002;  Lassiter et al., 2002;  Lassiter and 
Linney, 2007;  Kim et al., 2009;  Sassi-Messai et al., 2009;  Gibert et al., 2011).  
1.5.3 Zebrafish larvae for the examination of GC signaling disruption 
Zebrafish larvae represent an equally suitable tool for the evaluation of pharmaceutical 
interference with other groups of steroid hormones, i.e. GCs. Due to the phylogenetical 
conservation of the endocrine system among all vertebrate groups, zebrafish also possess an 
HPA axis, which is termed hypothalmic-pituitary-interrenal (HPI) axis in fish. As the human 
adrenal gland sits on top of the kidneys and fish do not develop kidneys in the way mammals do, 
their adrenal gland is more of a diffuse tissue which is spread out through the front end of the 
kidney and, thus, termed interrenal gland instead of adrenal. 
Between 96-120 hpf, the HPI axis is fully developed in zebrafish larvae and all major hormonal 
pathways are already completely functional by this time (Pijanowski et al. 2015). This allows to 
elucidate functions of the GC system already at these developmental stages. Another advantage 
of zebrafish for GC signaling disruption testing is that they possess only one GR, like mammals, in 
contrast to many other teleost fish species which form two GRs due to a gene duplication within 
their genomes during evolution. Moreover, (zebra-) fish share with humans and most other 
mammals Cort as the main active GC, which is released in fish by the interrenal glands. In 
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rodents, however, corticosterone is the major endogenous ligand of the GR (Anacker et al. 
2011). Considering the generally high conservation of steroidogenic and metabolic pathways in 
all vertebrates (McGonnell and Fowkes 2006) and the advantages of testing with zebrafish larvae 
compared to rodent studies, this close analogy of the fish and human GC system adds up one 
more argument for the application of zebrafish larvae for research regarding endocrine 
disruption of GC signaling. 
For the assessment of potential compound effects on xenobiotic metabolism are zebrafish 
equally well suited. For instance, one of their major xenobiotic enzymes, which is expressed in 
the small intestinal and liver, is CYP3A65, the analog to human CYP3A4 (Bainy et al. 2013). Gene 
expression of these two members of the CYP3A subfamily is regulated by the same nuclear 
receptors (PXR, CAR, VDR, GR) and can be induced by the same ligands, e.g. by the synthetic GC 
Dexamethasone (Burk and Wojnowski 2004; Creusot et al. 2015; Goodwin et al. 2001; Moore 
and Kliewer 2000; Tseng et al. 2005). 
Accordingly, zebrafish larvae possess all the endocrine and metabolic physiological requirements 
for the elucidation of complex disruptive effects of the GC system. They enable to detect 
compound interference with GR-mediated signaling, with the endogenous production of steroid 
hormones via the HPA axis and via steroidogenic enzymes, and with the xenobiotic metabolism. 
Therefore, zebrafish larvae constitute an excellent in vivo model for human and environmental 
risk assessment of GC signaling disruption.  
 
Recently, research groups investigating the effects of synthetic GCs on zebrafish development 
showed morphological effects, which are similar to phenotypes observable in mammals with 
endogenous GC overproduction or after long-term administration of synthetic GCs. 
For instance, adult zebrafish showed an osteoporosis phenotype in regenerating scalar bone 
when treated with 25 µM Prednisolone, a synthetic GC which has been repeatedly detected in 
the aquatic environment (de Vrieze et al. 2014). 
At environmentally relevant concentrations (0.006-42 μg/l), in adult zebrafish, exposed for 21-
daysto Fludrocortisone acetate (FLU), another commonly prescribed corticosteroid, alterations 
in plasma glucose levels and the circadian rhythm network, as well as reduced numbers of blood 
leukocytes (immune cells) were found even at 42 ng/l (Zhao, Zhang, and Fent 2016). The group 
showed furthermore that early markers for such morphological changes can already be found in 
zebrafish embryos. The progeny of GC-treated adults (F1 embryos) revealed significant 
behavioral and developmental changes, with increases in heartbeat, hatching success and 
swimming activity at 6 and 42 ng/l. These effects were also observed in eleuthero-embryos 
when exposed to FLU at 81 ng/l. Furthermore, significant changes in the transcription of 
biomarker genes involved in gluconeogenesis, circadian rhythm and immune response enabled 
to confirm the observed effects from adults already in embryonic stages. 
Another group observed similar effects in zebrafish embryos when exposed to prednisolone 
[0.1-10 ng/l]. Treated embryos showed alterations in ontogeny and behavior, with a reduced 
frequency of spontaneous muscle contractions at 24 hpf and increased escape response in 
response to a mechanosensory stimulus at 48 hpf [0.1 μg/l]. Also, hatching success was 
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increased [1 and 10 μg/l] and a higher heart rate and oxygen consumption was measurable in 
zebrafish embryos (McNeil, Nebot, and Sloman 2016). 
Furthermore, Hidasi (2016) observed that 5 dpf zebrafish larvae exposed to 0.1 nM of the highly 
potent synthetic GC Clobetasol propionate showed a significantly reduced inflammatory 
response when inflammation was induced by bacterial lipopolysaccharides (LPS). Also, the 
expression of several anti-inflammatory and GC-mechanism-related genes was significantly 
altered in these larvae when treated with Clobetasol propionate at 0.05 nM. 
 
These studies highlight that synthetic GCs can alter the endocrine system of zebrafish, leading to 
morphological and behavioral effects which show analogies to those observable in humans. 
Accordingly, zebrafish are susceptible to GC signaling disruption and already in embryonic 
stages, showing behavioral abnormalities and developmental changes on the morphological, as 
well as on the genetical level upon GC treatment in environmental relevant concentrations. This 
constitutes zebrafish larvae as a suitable model to investigate disruption of the GC system also 
by other compounds. 
1.6 A new bioassay for the detection of glucocorticoid activity  
In order to develop a new testing strategy for the detection of GC signaling disruption, the 
zebrafish was selected as model organism due to its numerous advantages compared to other 
model organisms. Especially the broad spectrum of tools for genetic modification in zebrafish, 
which easily enables the generation of transgenic reporter lines, constitutes an opportunity to 
develop new in vivo testing strategies with straightforward endpoints and readouts.  
1.6.1 Transgenic Tg(GRE:Luc) zebrafish line 
Therefore, our working group has developed a transgenic zebrafish line which is able to detect 
GC signaling (Weger et al. 2012). The Tg(GRE:Luc) zebrafish line (Figure 6) carries a transgenic 
construct that expresses a luciferase reporter gene under the control of four concatenated GREs 
and a minimal TATA-box promotor (Pmin). A poly(A) tail (pA) within the transgenic construct 
enhances transcriptional efficiency of the reporter gene and the whole reporter construct was 
stably integrated into the zebrafish genome via the Tol2 transposon (Tol2) system. Natural and 
synthetic GR agonists can activate the endogenous GRs in zebrafish and induce ligand-receptor 
binding to the 4xGREs. Thereupon, reporter gene transcription and expression of luciferase is 
induced. Luciferase catalyzes the oxidation of luciferin (added to the medium) that leads to the 
emission of a bioluminescent signal, which can be captured by a bioluminescence reader. 
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Figure 6: Transgenic zebraf ish l ine Tg(GRE:Luc) for the detection of  GC activity  
A luciferase reporter gene is under the control of  four concatenated GREs [(GRE) 4] and a minimal 
TATA-box promotor (Pm in) .  (pA), poly (A) tail  The whole transgenic construct is f lanked by Tol2 
sites (Tol2) for integration into the zebrafish genome mediated by the Tol2 transposase. GR 
agonists activate endogenous GRs and initiate l igand -receptor binding to the (GRE) 4.  Luciferase 
expression is induced and light -emitting enzymatic activ ity  of luciferase can be captured by a 
bioluminescent reader.  
1.6.2 Transgenic zebrafish cell line AB.9-GRE:Luc 
In order to obtain also a cell-based reporter, which carries the same reporter cassette as the 
Tg(GRE:Luc) zebrafish line, zebrafish AB.9 cells, originally derived from fin fibroblast tissue, were 
stably transfected with the GRE:Luc reporter (Weger et al. 2012). Parallel measurement of a 
compound in transgenic larvae and in AB.9-GRE:Luc cells enables comparison of in vivo with in 
vitro effects, which may allow to distinguish cell autonomous from whole animal effects (e.g. 
organ, tissue or cell type specific responses, metabolism or cross talk between organs). 
1.6.3 The Glucocorticoid Responsive In vivo Zebrafish Luciferase activitY (GRIZLY) assay 
Based on these two established reporter systems an assay principle was developed which 
facilitates high-throughput screening and allows comparison of in vivo with in vitro effects. As 
shown in Figure 7, transgenic larvae and cells are distributed into 96-well plates and incubated in 
luciferin-containing medium before they are treated with a compound library. Immediately after 
the start of the treatment, the 96-well plates are placed into the bioluminescent reader and the 
emitted bioluminescent signal is traced for a certain time period (e.g. 24 h). The GRIZLY assay 
has been shown in a former study to specifically re-identify known (bonafide) activators of 
GCsignaling from an FDA approved drug library and to detect Pregnenolone induced Cort 
production in vivo (Weger et al. 2012). 
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Figure 7: Pr inciple of the GRIZLY assay for screening procedures  
Application of Tg(GRE:Luc)  zebrafish and AB.9-GRE:Luc cells al lows comparison of in vivo  with in  
vitro  effect. Larvae and cells are distr ibuted into 96 -well p lates, incubated in luciferin -containing 
medium and treated with a drug library for high -throughput screening. A bioluminescence reader 
measures the reporter bioluminescence over time. Conversion of the data into area under the 
curve (AUC) values enables straightforward data analysis and stat i stical evaluation.  
1.7 Aim of the study 
The GC system has a broad physiological role as it regulates various important processes within 
the body such as cell cycle, development, metabolism, immune- and stress-response. 
Pharmaceuticals are likely to interfere with the GC system, which may lead to disruption of GC 
signaling pathways and can be accompanied by side-effects, which are often not well-elucidated. 
As disruption of the GC system is badly covered by human and environmental risk assessment 
and no appropriate in vivo biotests are available so far to target these mechanisms, it is the 
major objective of this project to establish a suitable test system for the detection of GC 
signaling disruption. This system will extend research regarding chemical interference with GC 
signaling and help to investigate the mechanisms underlying endocrine disruption. 
For this purpose, the test design of the GRIZLY assay will be modified in order to detect inhibitors 
of GC signaling. Validation of this testing approach will further verify the specificity and reliability 
of the GRIZLY assay and its suitability to detect chemical interference with the GC system at 
diverse levels. Once validated, the assay will be applied to identify GC signaling disruptors from 
drug libraries. Confirmed hits will be further investigated for the mechanisms underlying their 
disruptive effects on GC signaling. By conducting different modes of the GRIZLY assay, it will be 
possible to pre-categorize compound inhibitory mechanisms into either direct interference with 
GR-mediated signaling or indirect disruption via inhibition of GC biosynthesis. In the latter case, 
putative inhibition of GC production will be followed-up by chemical analysis (UHPLC-MS/MS) of 
endogenous steroid levels. Furthermore, gene expression analysis (real-time qPCR experiments) 
of GC and xenobiotic targets will provide valuable information about the molecular mechanisms 
of identified compounds and may indicate the mechanistic origin of GC signaling disruption. This 
will help to verify hits with - so far - unknown potential to interfere with GC signaling and 
improve the understanding of drug non-target mechanisms of action and their side-effects on 
the GC system.  
 
 
AB.9-GRE:Luc
cells
GRE:Luc larvae
3-10 replicates
3 replicates
in vivo
in vitro
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In summary, the aims of this study are, 
 
1) to assess the suitability of the GRIZLY assay for the detection of GC signaling inhibitors, 
2) to identify disruptors of the GC biosynthesis pathway and 
3) to identify compounds with - so far - unknown potential to interfere with GC signaling or with  
    - so far - unknown mechanisms of action, 
 
with the long-term objective to establish with this reporter an alternative testing method for 
endocrine disruption of the GC system, which could contribute to the reduction, refinement and 
replacement (3Rs) of animal testing (Russell and Burch 1959). 
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Chapter 2 
2. Material and Methods 
2.1 Material 
2.1.1 Instruments 
96-channel pipette  LIQUIDATOR96®, Steinbrenner Laborsysteme GmbH  
Analysis scale  ES 220A, 0.01-220 g (e = 1 mg; d = 0.1 mg), Precisa Gravimetrics AG 
Analytical column  Kinetex 2.6u XB-C18 100 A, 100 x 2.1 mm, Phenomenex 
Bioluminescence  Wallac EnVision™ 2104 (with stacker 2101-1010), PerkinElmer 
multilabel plate reader  
Centrifuge (5-50 ml) ZK 380,  HermleLabortechnik GmbH 
Centrifuge (1.5-2.0 ml) Microcentrifuge 5417R, Eppendorf® 
Counting chamber Neubauer ZK06, A. Hartenstein GmbH 
ELISA Microplate  VERSAmax, tunable, Molecular Devices 
reader  
Evaporator   Vapotherm basis mobil II, Barkey GmbH & Co. KG 
Fluorescence reader Lambda Fluor 320 Plus, BioTek Instruments, Inc. 
Microinjector  Femtojet express, Eppendorf 
Micropipette puller  Sutter Instrument Company 
RT-qPCR system  StepOnePlus system, Applied Biosystems 
Spectrophotometer  NanoDrop™ 1000,Thermo Scientific 
Stereo microscope  SMZ 645, Nikon 
Tissue homogenizer  ULTRA-TURRAX®, IKA Works 
UPLC-MS/MS   UHPLC: ExionLC™ AD;  LC-MS/MS: API 4000™ System, both AB Sciex 
Vortex    Genie 2, Scientific industries, Inc. 
2.1.2 Software 
Analyst® Software  version 1.6.3, AB Sciex 
GraphPad Prism 6   GraphPad Software, Inc. 
LAMBDA KC4  Kineticalc for Windows, MWG-Biotech A 
NanoDrop™ Software  version 3.7.0, Thermo Scientific™ 
StepOne™ Software  version 2.3, Applied Biosystems 
Wallac EnVision™ version 1.12, PerkinElmer 
Manager   
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2.1.3 Consumables 
6-well plates CELLSTAR®  # M8562 Greiner Bio-One 
96-well PCR plate   # SL-AM0910C Steinbrenner Laborsysteme GmbH 
96-well plate CELLSTAR®, flat bottom # M0812 Greiner Bio-One 
96-well CulturPlate-96 (white)  # 6005680 PerkinElmer 
96-well OptiPlate-96 (white)  # 6005299  PerkinElmer 
96-well storage plates Abgene 0.8 ml # AB0765 Thermo Fischer Scientific  
adhesive seals TopSeal-A PLUS   # 6050185 PerkinElmer 
borosilicate glass capillaries (GC100-10) # 30-0016 Warner Instruments 
brown glass vials1.5 ml, screw-thread  # VT1101211 Dr. R. ForcheChromatographie 
cell culture flasks CELLSTAR® 25 cm2 # 690170 Greiner Bio-One 
cell culture flasks CELLSTAR® 75 cm2 #  658170 Greiner Bio-One 
Microloader    # 5242956.003 Eppendorf AG 
needlesSterican®  0.45 x 25 mm G26 # 4657683 B. Braun Melsungen AG  
PCR strips, 0.2 ml/well, clear  # SL-PSF08 Steinbrenner Laborsysteme GmbH 
petri dishes 94/16 mm   # 633180 Greiner Bio-One 
pipette tips 0.1-10 µl, barrier  # 70803 Corning 
pipette tips 1-200 µl, barrier  # 70833 Corning 
pipette tips 100-1000 µl, barrier # 70853 Corning 
polypropylene tube CELLSTAR® 50 ml  # 227261 Greiner Bio-One 
polypropylene tube CELLSTAR® 15 ml  # 188261 Greiner Bio-One 
qPCR plate seal, clear   # SL-AM0560 Steinbrenner Laborsysteme GmbH 
reaction tubes  1.5 ml, colorless # 0030120086 Eppendorf AG 
reaction tubes  2.0 ml, colorless # 0030120094 Eppendorf AG 
reaction tubes 5.0 ml, colorless  # 0030119401 Eppendorf AG 
silicone/PTFE caps    # CT11S3015 Dr. R. ForcheChromatographie 
syringes Injekt® 2 ml   # 4606027V B. Braun Melsungen AG 
2.1.4 Solvents 
The solvents used to dissolve chemicals for single compound testing, for molecular biological 
techniques and for UPLC-MS/MS experiments were purchased from different suppliers as 
indicated in Table 1. 
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Table 1: Solvents and l iquid chemicals  
Name CAS no. Order no. Supplier 
    Acetonitril HiPerSolv CHROMANORM® 75-05-8 83.640.320 VWR International 
Chloroform for analysis EMSURE® 67-66-3 102445 Merck 
Dimethylsulfoxid 67-68-5 A994.2 Carl Roth GmbH & Co. KG 
Ethanol absolute ≥99.8% 64-17-5 83672.290 VWR International 
Ethyl acetate for analysis EMSURE® 141-78-6 1096231000 Merck  
Formic acid for analysis 98-100% EMSURE® 64-18-6  100264 Merck 
Methanol HiPerSolv CHROMANORM® 67-56-1 83.638.320 VWR International 
2-Propanol, ROTIPURAN® ≥99,8% 67-63-0 6752.1 Carl Roth GmbH & Co. KG 
2.1.5 Chemicals  
The FDA approved drug library was purchased from ENZO Life Science (# BML-2841) and 
supplied in 96-well plates, each plate containing 80 compounds, dissolved in Dimethylsulfoxid 
(DMSO) at a concentration of 2 mg/ml. For screening procedures, the chemicals were diluted 
1:50 with E3 medium, obtaining a concentration of 0.04 mg/ml and total volume of 2% v/v 
DMSO. 
 
The compounds used for concentration range testing were purchased from different suppliers as 
indicated in Table 2. Stocks of 100 mM were prepared in DMSO and stored at –20°C.  
 
Table 2: Compounds for concentration range testing  
Name CAS no. Order no. Supplier 
 
 
 
  
10-Hydroxycamptothecin 64439-81-2 LKT-C0155.25 biomol 
11-Ketotestosterone 564-35-2  K8250-5MG Sigma Aldrich 
Acitretin 55079-83-9  LKT-A0933.25 biomol 
Amorolfine 78613-38-4  SML0283-10MG Sigma Aldrich 
Corticosterone 50-22-6  27840-100MG Sigma Aldrich 
Cortisone 53-06-5  C2755-250MG Sigma Aldrich 
Dehydroepiandrosterone 53-43-0 Cay-15728 biomol 
Dexamethasone 50-02-2 D1756-100MG Sigma Aldrich 
DL-Aminoglutethimide 125-84-8  A9657-100MG Sigma Aldrich 
Erlotinib 183321-74-6 Cay10483-250 biomol 
Estriol 50-27-1  E1253-100MG Sigma Aldrich 
Estrone 53-16-7  E9750-500MG Sigma Aldrich 
Ethisterone 434-03-7  46272-250MG Omnilab 
Etomidate 33125-97-2  E6530-10MG Sigma Aldrich 
Fenbufen 36330-85-5  F8755-5G Sigma Aldrich 
Flutamide 13311-84-7  F9397-1G Sigma Aldrich 
Galanthaminehydrobromide 1953-04-4  G1660-2MG Sigma Aldrich 
Gestrinone 16320-04-0 16320-04-0 
Cayman 
Chem. 
Hydrocortisone 50-23-7  H4001-1G Sigma Aldrich 
Ibudilast 50847-11-5  I0157-10MG Sigma Aldrich 
Ketoconazol 65277-42-1  K1003-100MG Sigma Aldrich 
Leflunomide 75706-12-6  Cay-14860 biomol 
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Levonorgestrel 797-63-7 L0551000 Sigma Aldrich 
Melengestrolacetate 2919-66-6 33998-100MG-R Sigma Aldrich 
Methyltestosterone 58-18-4 69240-5G Sigma Aldrich 
Metyrapone 54-36-4  M2696-10MG Sigma Aldrich 
Mifepristone 84371-65-3  M8046-100MG Sigma Aldrich 
Nabumetone 42924-53-8  N0020000 Sigma Aldrich 
Nisoldipine 63675-72-9  N0165-10MG Sigma Aldrich 
Norethindrone 68-22-4  N4128-50MG Sigma Aldrich 
Paroxetine 110429-35-1 LKT-P0297.25 biomol 
Pioglitazone MFCD00865504  CDS021593-50MG Sigma Aldrich 
Prednisolone 50-24-8  P6004-100MG Sigma Aldrich 
Prednisone 53-03-2  P6254-1G  Sigma Aldrich 
Pregnenolone 145-13-1  P9129-1G Sigma Aldrich 
Progesterone 57-83-0  P0130-25G  Sigma Aldrich 
RetinoicAcid 302-79-4 R2625-50MG Sigma Aldrich 
Spironolactone 52-01-7 S3378-1G Sigma Aldrich 
Stanozolol 10418-03-8  S7132-1G Sigma Aldrich 
Tranilast 53902-12-8 T0318-10MG   Sigma Aldrich 
Trenbolone 10161-33-8  T3925-250MG Sigma Aldrich 
Vitamin A acetate 127-47-9  PHR1236-1G Sigma Aldrich 
 
2.1.6 Buffers, solutions and media 
Buffers and solutions were purchased from different suppliers or prepared from powders as 
indicated in Table 3. Media were prepared with the ingredients listed in Table 4 according to the 
given recipes. 
 
Table 3: Buffers and solutions  
Name Order no. Supplier 
DPBS (1x), no calcium, no magnesium (PBS) 14190094 Gibco™ 
HBSS, calcium, magnesium, no phenol red 14025050 Gibco™ 
D-Luciferin stock, 50 mM 
  
  Firefly, potassium salt dissolved in H2O, at –80°C L-8220 Biosynth 
Methylen blue solution 1 g/l (0.1% w/v) 
  
  Methylen blue dissolved in H2O, at 4°C M9140-100G Sigma Aldrich 
Triton™ X-100 X100-100ML Sigma-Aldrich 
Trypan blue T8154 Sigma-Aldrich 
Trypsin-EDTA (0.25%), phenol red 25200056 Gibco™ 
Phenol red solution P0290-100ML Sigma Aldrich 
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Table 4: Media  
Name Composition Order no. Supplier 
E3 medium  5 mM NaCl P029.2 Carl Roth GmbH + Co. KG 
(60x) 0.17 mMKCl 6781.1 Carl Roth GmbH + Co. KG 
 
0.33 mM CaCl2 CN93.2 Carl Roth GmbH + Co. KG 
 0.33 mM MgSO4 x H2O 0261.1 Carl Roth GmbH + Co. KG 
 
   
AB.9 cell  500 ml Leibovitz's L-15 Medium (red) 11415056 Gibco™ 
maintenance  100 ml (17% (v/v)) FBS S0115 Biochrom AG 
medium 100 U/ml Penicillin 15140148 Gibco™ 
 
100 µg/ml Streptomycin 15140148 Gibco™ 
 
50 µg/ml Gentamicin 15750045 Gibco™ 
 
   
AB.9-GRE:Luc 100 ml AB.9 cell maintenance medium   
medium 250 µg/ml Geneticin™ (G418 Sulfate) 11811064 Gibco™ 
    
E3-luciferin  Luciferin stock diluted to 500 µM in E3    
medium 
(larvae) 
medium   
    
L-15-luciferin  Luciferin stock diluted to 500 µM in    
medium 
(cells) 
Leibovitz's L-15 Medium (clear) 21083027 Gibco™ 
 
2.1.7 Kits and reagents 
All kits and reagents used for molecular- and cell-biological techniques are listed in Table 5.  
 
Table 5: Kits and reagents  
Name Order no. Supplier 
alamarBlue® reagent BUF012B Bio-Rad Lab. Inc. 
Cytotoxicity Detection Kit (LDH) 11 644 793 001 Roche Diagnostics 
DNase I, RNase-free M6101 Promega 
FuGENE® HD Transfection reagent  E2311 Promega 
GoTaq® qPCR Master Mix  A6002 Promega 
mMESSAGE mMACHINE™ SP6 Transcription Kit AM1340 Invitrogen™ 
pGL3-Control Vector E174A Promega 
Random Hexamer Primer SO142 Thermo Scientific™ 
RNAse free water P1193 Promega 
RNasin® Ribonuclease Inhibitor N2511 Promega 
SuperScript™ III Reverse Transcriptase 18080044 Invitrogen™ 
TRIzol™ Reagent 15596026 Invitrogen™ 
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2.2 Methods 
2.2.1 Zebrafish handling and general techniques 
2.2.1.1 Zebrafish stock and maintenance 
Wild-type zebrafish originate from the AB strain (University of Oregon, Eugen) and were bred for 
several years in the European Zebrafish Research Center (EZRC) in Karlsruhe. The transgenic line 
Tg(GRE:Luc)sb6 was generated in this genetic background. At the EZRC, zebrafish were 
maintained in glass aquaria in a recirculating system under flowthrough conditions, with a 
14 : 10 light : dark photoperiod. Fish were kept in groups of up to 50 fish and cultured in 
fishwater that was pre-heated to 26 ± 2°C, UV-sterilized and activated charcoal and particle-
filtered. They were fed twice a day with flake food, pellets and on-site hatched, live artemia. 
2.2.1.2 Zebrafish breeding 
Fish were bred and raised according to the procedures as described by Westerfield (1995). On 
the day before mating, groups of four male and four female zebrafish were transferred into 
small, two-compartment mousecages that were separated by a mesh. The next morning, 
immediately after the onset of light, male and female fish were put together into the upper 
compartment. Spawned eggs sank through the mesh and were collected from the lower 
compartment. 
2.2.1.3 Culture and staging of embryos 
The harvested eggs were cleaned from dirt and unfertilized or dead eggs in order to avoid 
contamination of the embryo culture. Groups of 30-50 eggs were transferred into 10 cm petri 
dishes (# 633180, Greiner Bio-One) containing E3 medium with methylene blue (approximately 1 
mg/l) to prevent fungal infections. The petri dishes were kept in an incubator at 28°C, and each 
day dead embryos were removed and E3 medium was replaced until the start of the experiment. 
Larvae that were bred for raising were moved into fish tanks in the EZRC between 2-5 days post 
fertilization (dpf). Embryo developmental stages were determined on a stereo microscope 
according to Kimmel et al. (1995). 
2.2.1.4 Generation of a new stable Tg(GRE:Luc) reporter line 
The Tg(GRE:Luc)sb6 zebrafish reporter line was generated by Weger et al. (2012) and since then 
maintained in the EZRC. However, several generations of outcrossing probably weakened the 
transgenic construct, therefore, I injected the reporter plasmid anew in wild-type zebrafish eggs. 
 
The pT2-GRE:Luc plasmid 
The pT2-GRE:Luc plasmid was cloned by Weger et al. (2012). The vector carries two Tol2 
transposable elements, which enable Tol2 transposase binding (Kawakami 2004). The Tol2 
transposon system has been shown to facilitate genome integration of the reporter construct 
during zebrafish transgenesis (Suster et al. 2009). 
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Tol2 transposase RNA 
For a successful integration of the pT2-GRE:Luc plasmid into the zebrafish genome via the Tol2 
transposon system, Tol2 transposase RNA has to be supplemented to the injection mix. Capped 
Tol2 RNA was synthesized by digesting the pCS-TP plasmid (Kawakami et al. 2004) with NotI and 
transcribing it with the mMESSAGE mMACHINE™ SP6 Transcription Kit (# AM1340, Invitrogen™) 
according to the manufacturer’s protocol. RNA quality was verified by agarose gel 
electrophoresis (gel: 1% agarose in TAE; 50 x TAE: 2 M Tris, 1 M glacial acetic acid, 0.05 M EDTA). 
Only RNA of high quality was used for microinjection. 
 
Microinjection 
Microinjection was conducted as described by Müller et al. (1999). Injection needles were 
produced from borosilicate glass capillaries (GC100-10, # 30-0016, Warner Instruments) with a 
micropipette puller (Sutter Instrument Company). Injection mixes containing 30 ng/µl of the 
pT2-GRE:Luc vector and 20 ng capped Tol2 transposase RNA were prepared and supplemented 
by 0.1% (v/v) phenol red, enabling the tracing of injection success and progress. The mix was 
injected with a microinjector (Femtojet express, Eppendorf) into one-cell stage zebrafish eggs. 
Embryos were raised in E3 medium supplemented with methylene blue until they were 
identified for transient expression of the GRE:Luc reporter construct. 
 
Breeding 
The injected larvae (4 dpf) were transferred into 96-well plates and luciferase reporter activity 
was assessed with a bioluminescence reader (Wallac EnVision™ 2104, PerkinElmer) according to 
the procedure described below (section 2.2.3 and 2.2.3.1). Individuals showing transient 
reporter activity were raised and outcrossed with wild-type zebrafish. F1 larvae were screened 
for stable integration of the reporter gene construct and founders were isolated. Progeny of the 
founder showing the strongest reporter activity (Founder 1) was used to breed a new generation 
of Tg(GRE:Luc) zebrafish by in- and out-crossing them with wild-type. Notably, as before, when 
the transgenic line was first established by Weger et al. (2012), Tg(GRE:Luc) larvae showed no 
bioluminescence from endogenous GC levels, but responded specifically to GC treatment. 
Apparently, basal GC levels are not sufficient to induce the luciferase reporter gene 
transcription.  
2.2.2 Cell culture 
2.2.2.1 Cell lines and their maintenance 
The AB.9 (ATCC, CRL-2298) zebrafish cells, originally derived from fibroblast tissue, were a kind 
gift of N. S. Foulkes. Stable AB.9-GRE:Luc cells were generated by Weger et al. (2012) according 
to the protocol of Vallone et al. (2007). The cell lines were cultured in their specific AB.9 and 
AB.9-GRE:Luc maintenance media, according to the descriptions by Vallone et al. (2007). Cells 
were kept in 75 cm² cell culture flasks (CELLSTAR®, #  658170, Greiner Bio-One) at 28°C and were 
passaged at a ratio of 1:10 once per week. 
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2.2.2.2 Generation of the AB.9-pGL3-Control cell line 
As a control for compound interference with the luciferase reporter activity, AB.9 cells were 
transiently transfected with the pGL3-Control vector (# E174A, Promega), which drives 
constitutive luciferase expression. Cells were transfected with the FuGENE® HD Transfection 
reagent (# E2311, Promega) according to the manufacturer´s protocol. Briefly, cells were washed 
once with 1 x DPBS (PBS) and trypsinized (Trypsin-EDTA [0.25%], phenol red, # 25200056, 
Gibco™) for approximately  5 min at 27°C (day 1). Detached cells were transferred into a 50 ml 
polypropylene tube (CELLSTAR® # 227261, Greiner Bio-One) and the cell number was 
determined with the Trypan blue (# T8154, Sigma-Aldrich) exclusion method in a Neubauer 
counting chamber (ZK06, A. Hartenstein GmbH). The density was adjusted to 200 000 cells per 
ml by adding AB.9 medium to the culture. Cells were seeded into 6-well plates (CELLSTAR®, # 
M8562, Greiner Bio-One) with 800 000 cells per well in order to obtain 80% cell confluency after 
overnight incubationat 28°C. The next day (day 2), cells were washed with PBS and the AB.9 
medium was replaced by culture medium free of antibiotics (L-15 red medium + FBS). The 
transfection mix was prepared with 100 µl L-15 medium, 1 µg vector DNA (1 µl) and 4 µl 
FuGENE® HD Transfection reagent. The reagent mixture was incubated for 15 - 20 min at RT to 
enable the formation of the transfection complex before it was added drop-wise to the cells. 
After overnight incubation at 28°C, the cells were washed with PBS, trypsinized and transferred 
into white 96-well plates (CulturPlate-96, # 6005680, PerkinElmer) with AB.9 medium (day 3). 
Cell attachment was allowed overnight before cells were measured for luciferase activity (day 4) 
as described below (in section 2.2.3.2). 
2.2.3 Bioluminescence measurements 
Luciferase-expressing transgenic cells and zebrafish larvae, which are exposed to luciferin 
medium, can convert D-luciferin into oxyluciferin in a light-emitting reaction. A bioluminescent 
reader can capture the light and thereby quantify the luciferase activity. The EnVision 
bioluminescence multilabel plate reader, equipped with an enhanced luminescence sensitivity 
sensor (Wallac EnVision™, # 2104-0010A, PerkinElmer) and a stacker unit for measurements up 
to 50 plates (# 2101-1010, PerkinElmer), was used for in vivo luciferase activity measurements. 
The reader was setup in a separate dark room with a controlled temperature of 28°C. The 96-
well plates carrying transgenic cells or larvae were covered with adhesive seals sealed (TopSeal-
A PLUS, # 6050185, PerkinElmer) to prevent medium evaporation, and in vivo luciferase activity 
was monitored for 24 h using the Wallac EnVision™ Manager software (version 1.12,  
PerkinElmer). 
2.2.3.1 Detection of glucocorticoid signaling in Tg(GRE:Luc) larvae 
At 4 dpf, Tg(GRE:Luc) larvae were transferred into 96-well plates and incubated in E3-luciferin 
medium [0.5 mM] for 24 h. At 5 dpf, the larvae were treated with Dex [20 µM] and luciferase 
reporter activity was measured on the EnVision bioluminescence reader. 
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2.2.3.2 Detection of glucocorticoid signaling in AB.9-GRE:Luc cells 
Stable AB.9-GRE:Luc cells were washed with PBS, trypsinized and the cell number was adjusted 
to 200 000 cells/ml as described in section 2.2.2.2. In each well of a 96-well plate, 22 500 cells 
were seeded with 250 µl AB.9-GRE:Luc maintenance medium and allowed to attach over night. 
The next day, the cells were washed with PBS and incubated for 1 h at 28°C in 200 µl L-15-
luciferin medium. Chemical treatments were applied according to the experimental setups as 
specified for screening procedures in Figure 11 and for single compound testing in Figure 12. 
Subsequently, in vivo luciferase activity was monitored with the EnVision bioluminescence 
reader. 
2.2.3.3 Compound effects on luciferase activity in AB.9-pGL3-Control cells 
Transfected AB.9-pGL3-Control cells obtained as specified in section 2.2.2.2 were washed with 
PBS before 200 µl L-15-luciferin medium were added to each well of a 96-well plate. Cells were 
incubated at 28°C for 1 h before 50 µl of treatment solution were supplemented in order to 
achieve exposure conditions according to the scheme in Figure 8. Immediately after exposure 
start, bioluminescence was measured. 
 
 
Figure 8: Treatment scheme for the assessment of compound effects on luciferase activity  
Compound effects on transiently  transfected AB.9 -pGL3-Control  cells with constitutively  active 
luciferase expression (orange) and on non-transfected AB.9 cells (grey) were assessed. Negative 
control treatments consisted of DMSO or Dex [20 µM]. The compound effects were assessed by 
exposing the cel ls  to a treatment combination of Dex [20 µM] with one concentration each of  
Mifepristone (Mife [1 µM]),  10-Hydroxycamptothecin (10-HC [20 µM]),  Tranilast (Trani [50 µM]),  
Acitretin (Aci  [20 µM]),  Retinoic ac id (Ret. acid [2 µM]),  which led to a strong decrease of  
luciferase activ ity  in AB.9 -pGL3-Control  cel ls.  The no-transfection control cel ls  w ere treated with  
DMSO. The amount of DMSO was 0.2% (v/v) in all  wells.  
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2.2.4. The GRIZLY assay 
2.2.4.1 Assay principle 
The FDA library was screened for disruptors of GC signaling with three different variations of the 
GRIZLY assay (Figure 7) as shown in Figure 9:  
 
 
 
Figure 9: Three different approaches of the GRIZLY assay  
I)  GRIZLY 1: Direct activation of GC signaling in AB.9-GRE:Luc cells with Dex [20 µM]. Mife [1 µM] 
serves as a control inhibitor,  acting v ia GR antagonism. II)  GRIZLY 2: Direct activat ion of GC 
signaling in Tg(GRE:Luc) larvae with Dex [20 µM]. Mife [1 µM] serves as a control inhibitor,  acting 
v ia GR antagonism.  I I I)  GRIZLY 3: Indirect activation of GC signaling in Tg(GRE:Luc) larvae with 
Preg [5 µM] as control activator and Mety [40 µM]  as reference inhibitor.  
 
GRIZLY 1 - Inhibition of directly activated GC signaling (with Dex) in AB.9-GRE:Luc cells (I) 
GRIZLY 2 - Inhibition of directly activated GC signaling (with Dex) in Tg(GRE:Luc) larvae (II) 
GRIZLY 3 - Inhibition of indirectly activated GC signaling (with Preg) in Tg(GRE:Luc) larvae (III) 
2.2.4.2 Experimental setup for FDA drug library screening 
The bioluminescence measurements with AB.9-GRE:Luc cells and Tg(GRE:Luc) larvae were 
conducted as described above (sections 2.2.3 - 2.2.3.2). Deep-well plates with chemical stocks 
diluted in E3 medium were prepared for the screening procedures and treatment was carried 
out with a 96-channel pipette (Figure 10). All test plates were loaded with eight replicate wells 
of the positive (DMSO + Dex/ Preg) and the negative (Mife/ Mety + Dex/ Preg) control and one 
well per library compound. Each of the eight library plates was measured in three replicates in 
GRIZLY 1 and in three to ten replicates in GRIZLY 2 and GRIZLY 3, with a maximum of twelve test 
plates per screen run. 
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Figure 10: Treatment schemes for the screening procedure with three different GRIZLY assay 
approaches  
Larvae and cells are distr ibuted with 200 µl luciferin medium into the wells of a 96 -well plate. For 
activation of GC signaling in GRIZLY 1 and GRIZLY 2, 25 µl of Dex are pipetted to each well and 
immediately, 25 µl of the negative control (DMSO; n = 8) and the posit ive control (Mife; n = 8) for 
inhibition of GC signaling are added to the wells of column 1 and 12 and 25  µl of the FDA drug 
library (n = 1) are supplemented to the wells  of column 2  -  11.  The f inal volume of each well  is 250 
µl,  with 0.2% DMSO and 20 µM Dex in each well.  The test concentration of Mife is 1 µM and that 
of the library compounds 0.4 mg/l.  In GR IZLY 3, GC signaling in larvae is activated by the addition 
of 25 µl  Preg to all  wel ls.  To columns 1 and 12, 25 µl of the negative control (DMSO; n = 8) and the 
positive control (Mety; n = 8) are added and columns 2  -  11 are treated with 25 µl of the FDA d rug 
library (n = 1).  The test concentrations in total volumes of 250 µl are 5 µM Preg, 40 µM Mety and 
0.4 mg/l FDA drug library compounds. Each test p late was measured in 3 -10 repl icates.  
2.2.4.3 Experimental setup for single compound testing 
The bioluminescence measurements were performed as described above. Deep-well stock plates 
were prepared and treatment was applied with a 96-channel pipette according to Figure 11. All 
test plates were loaded with eight replicate wells of the positive (DMSO + Dex/ Preg) and the 
negative (Mife/ Mety + Dex/ Preg) control and 16 wells for each of the five concentrations of the 
compound. 
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Figure 11: Treatment schemes for  s ingle compound testing with three different GRIZLY assay 
approaches  
Larvae and cells are distr ibuted  with 200 µl luciferin medium into the wells of a 96 -well plate. For 
activation of GC signaling in GRIZLY 1 and GRIZLY 2, 25 µl of Dex are pipetted to each well.  25 µl 
of the negative control (DMSO; n = 8) and the positive control (Mife; n = 8) for inhibit ion of GC 
signaling are added to the wells of column 1 and 12 and 25  µl of the single compound stock plate 
are supplemented to the wells of column 2  -  11, with five different concentrations of the 
compound (n = 16 per concentration). The final volume of each well is 250 µl,  with 0.2 % DMSO 
and 20 µM Dex in each well.  The test concentration of Mife is 1 µM. In GRIZLY 3, GC sign aling in 
larvae is activated by the addition of 25 µl Preg to all  wells.  To columns 1 and 12, 25 µl of the 
negative control (DMSO; n = 8) and the positve control (Mety; n = 8)  are added and columns 2  -  11 
are treated with 25 µl of the single compound stock  plate, with five different concentrations of 
the compound (n = 16 per concentration). The test concentrations in total volumes of 250 µl are 5 
µM Preg and 40 µM Mety. Each test plate was measured in 3 -10 replicates.  
2.2.4.4 Data processing  
For the GRIZLY assay as for all other bioluminescence measurements (section 2.2.3), data files 
are were imported to Excel for further processing. For each well, area under the curve (AUC) 
values were calculated from the bioluminescent traces over time and normalized relative to the 
respective negative and positive control. Mean relative AUC values ± SEM were subjected to 
GraphPad Prism 6 for statistical evaluation.  
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2.2.5 Larvae toxicity 
Larvae were checked for toxic treatment effects immediately at the end of 24 h bioluminescence 
measurements. Larval movement upon a tactile stimulus was monitored and immotile 
individuals were considered dead. Toxicity for larvae was calculated according to the following 
formula: 
𝐿𝑎𝑟𝑣𝑎𝑒 𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 [%] =
𝑥 (𝑛𝑜𝑛 − 𝑚𝑜𝑡𝑖𝑙𝑒 𝑙𝑎𝑟𝑣𝑎𝑒 𝑝𝑒𝑟 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑)
𝑛 (𝑟𝑒𝑝𝑙𝑖𝑐𝑎𝑡𝑒 𝑙𝑎𝑟𝑣𝑎𝑒 𝑝𝑒𝑟 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑)
∗  100 
 
To achieve a high stringency of the toxicity evaluation, compounds were considered as 
potentially toxic in vivo if the number of immobile larvae exceeded 10%.  
2.2.6 Cell toxicity 
In vitro toxicity of the FDA drug library compounds was assessed in a separate screen as 
medium-requirements were divergent for the cytotoxicity assays and for the GRIZLY setup. Two 
different cytotoxicity tests, the AlamarBlue® cell proliferation (AlamarBlue®) and the Lactate 
Dehydrogenase (LDH) assay, were conducted in parallel and each was repeated in triplicates. 
2.2.6.1 Experimental setup for cytotoxicity screens of the FDA drug library 
For preparation, cells were seeded into clear, 96-well plates (CELLSTAR®, flat bottom, # M0812, 
Greiner Bio-One) with 60 000 cells per well and incubated in AB.9-GRE:Luc medium over night at 
28°C to allow cell attachment. The following day, cells were washed with PBS and incubated in 
200 µl L-15 medium for 1 h. Deep-well plates with chemical stocks diluted in E3 medium were 
prepared for the controls and library compounds as shown in Figure 12 and treatment was 
carried out accordingly with a 96-channel pipette. All test plates were loaded with four replicate 
wells of cytotoxicity positive control (Triton 0.1%; wells 1 A - D) (Triton™ X-100, # X100-100ML, 
Sigma-Aldrich), negative control for cytotoxicity and for GC signaling inhibition in the GRIZLY 
assay (Dex + DMSO, wells 1 E - H), blank (L-15 + E3 medium without cells, wells 12 A - D) and 
positive control for GC signaling inhibition in the GRIZLY assay (Mife + Dex, wells 12 E - H) and 
with one well per library compound + Dex. All wells were treated for 4h (except the positive 
control, where 0.5 h of Triton X - 100 exposure were sufficient to induce 100% cytotoxicity). This 
treatment duration was selected accordig to the GRIZLY 1 measurements, where the uninhibited 
bioluminescent signal peaks after 4 h and is, thus, the timepoint of interest for the assessment of 
compound toxicity. As an onset of compound cytotoxicity later than 4h of exposure time was not 
expected to have a remarkable effect on the signal intensity of the GRIZLY response at the peak 
timepoint, but a longer exposure duration may instead have led to a false-positive assignment of 
cytotoxicity in case of real inhibitors of GC signaling (between 0 and 4h) of exposure, the shorter 
treatment period of 4h appeared to provide the  more relevant information for this testing 
approach than the exposure duration of 24 h, as in the GRIZLY assay. Each of the eight library 
plates was measured in three replicates with both cytotoxicity assays. The procedures for the 
alamarBlue® and the LDH assay will be described in the next chapters. 
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Figure 12: Cytotoxicity screen of the FDA drug l ibrary  
A 96-well plate seeded with cells (except wells 12 A  -  D) in 200 µl L-15 medium for 1 h. Controls 
and library compounds were applied from deep -well stock plates with a 96-channel pipette. Al l  
test plates containedfour  replicate wells  each of no treatment (wells 1 A  -  D),  negative control for 
cytotoxicity  and for GC signaling inhibition in the GRIZLLY assay (Dex  + DMSO, wells 1 E-H), blank 
(L-15  +  E3 medium without cells,  wells 12 A  -  D) and posit ive control for GC signaling inhibition in  
the GRIZLY assay (Mife  + Dex, wells 12 E-H) and one well per l ibrary compound  + Dex when the 
cytotoxicity  screen started.  Plates were incubated at 28°C for 3.5 h before 25 µl medium were 
removed from wells 1 A  -  D where 50 µl [Tr iton X  -  100 0.5%] were added as cytotoxicity  positive 
control (Tr iton X  -  100, 0.1%). Plates were incubated for another 0.5 h to let the Triton destroy 
the cells.  From each well of the test plate, 80 µl of cell -free medium were transferred into a new 
flat-bottom, 96-well plate for LDH assay procedures. Another 70 µl cell -free medium were 
discarded from the test plate in order to keep the cells with 100  µl of medium for the 
AlamarBlue® cell proliferation assay. Each of the eight l ibrary plates was measured in three 
replicates with both cytotoxicity  assays.  
2.2.6.2 AlamarBlue® cell proliferation assay 
Assay principle 
The alamarBlue® reagent was used to indicate cell viability. It contains non-fluorescent 
Resazurin, a cell permeable reagent that is continuously reduced by living cells into the 
fluorescent molecule Resorufin (Figure 13). This irreversible reaction enables the quantification 
of cell viability. 
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Figure 13:  Measurement of  cell  viabil ity with the AlamarBlue® cell proliferation assay  Resazurin 
permeates the cell and is reduced by liv ing cells  into Resorufin, which can be quantified 
colorimetrically .  NADH + H+  is  reduced to NAD +  + H 2O in this reaction step.  
 
Assay procedure 
The alamarBlue® assay was conducted according to the manufacturer´s protocol (BioRad; 
QIFUBUF012 alamarBlue® Technical Datasheet IFU, Issue no.3, 3.9.2013). Briefly, the 
alamarBlue® mix (alamarBlue® reagent, # BUF012B, Bio-Rad Lab. Inc.) was diluted 1:10 in Hank's 
Balanced Salt Solution (HBSS) buffer (# 14025050, Gibco™) and 100 µl of the alamarBlue® mix 
were pipetted to all wells containing 100 µl cells+medium (1:1). The plates were incubated 
overnight (19-21 h) at 28°C. The next day, 180 µl of each well were transferred into a new clear, 
flat-bottom 96-well plate. Cell viability was quantified by the colorimetrical measurement of 
resorufin produced by the cells with a flourescence reader (Lambda Fluor 320 Plus, BioTek 
Instruments, Inc.), at Ex/Em: 560/620 nm. Data were exported as txt.files from the software 
(LAMBDA KC4, Kineticalc for Windows, MWG-Biotech AG) and processed in Excel for statistical 
analysis.  
2.2.6.3 Lactate Dehydrogenase (LDH) assay 
Assay principle 
Lactate Dehydrogenase (LDH) is a stable enzyme which is present in the cytoplasm of all cells. 
Upon plasma membrane damage, it is rapidly released into the cell culture medium. Incubation 
of the cell-free supernatant with the substrate mixture of the Cytotoxicity Detection Kit (LDH) 
enables quantification of LDH activity. In a coupled enzymatic reaction, LDH oxidizes lactate, 
which is provided by the substrate mix, into pyruvate. In this step, NAD+  is reduced to 
NADH + H+, whereby the free H+ subsequently allows the reduction of tetrazolium salt INT (a dye 
in the substrate mixture) into the red dye formazan salt (Figure 14). The red dye can then be 
quantified colorimetrically. 
 
Resazurin
NADH/ H+ NAD+, H2O
Resorufin
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Figure 14: Measurement of  cell plasma membrane damage with the lactate dehydrogenase (LDH) 
assay  
Upon plasma membrane damage, LDH is released from cells into the cel l culture medium. When 
the cel l-free supernatant is incubated in darkness with the substrate mix from the Cy totoxicity  
Detection Kit (LDH), LDH oxidizes lactate, which is provided by the substrate mix, into pyruvate in 
a f irst reaction. In this step, NAD +    is reduced to NADH + H + ,  whereby the free H +  enables the 
second reaction step, the reduction of tetrazolium salt (a dye in the substrate mixture) into 
formazan salt (red dye). Formazan salt can quantified colorimetrically . (source: Figure 5 from the 
Cytotoxicity  Detection Kit (LDH) protocol,  version 11 from march 2016, Roche Diagnostics)  
 
Assay procedure 
The LDH assay was conducted according to the manufacturer´s protocol. (Cytotoxicity Detection 
Kit [LDH], version 11 from march 2016, Roche Diagnostics). Shortly, the LDH mix (Cytotoxicity 
Detection Kit (LDH), # 11 644 793 001, Roche Diagnostics) was prepared protected from light, 
with 0.125 ml solution 1 + 5.6 ml solution 2 + 5.6 ml PBS per 100 reactions. Immediately, 80 µl of 
the mix were added to the 80 µl cell-free supernatant (1 :  1) in each well of the 96-well plate 
that was prepared according to Figure 12. The plates were incubated at RT in darkness for 1.5 -
 2.5 h, until the cytotoxicity positive control wells (Triton X - 100 0.1%) changed their color to 
pinkish. The plate was placed into the ELISA plate reader (VERSAmax tunable microplate reader, 
Molecular Devices) and LDH activity was measured spectrophotometrically via the quantification 
of formazan salt production, at Ex/Em:495/650 nm. Data were exported as txt.files from the 
software (SOFTmax Pro Software, Molecular Devices) and processed with Excel for subsequent 
statistical evaluation. 
2.2.6.4 Data processing and cytotoxicity calculations 
Means were calculated from the four replicate wells for each of the controls. The blank mean 
was substracted from all data before cytotoxicity was calculated according to the following 
formula (as also described by  (Chan, Moriwaki, and De Rosa 2013): 
 
𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 [%] =  
𝑠𝑎𝑚𝑝𝑙𝑒 −  𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝐷𝑀𝑆𝑂)
𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝑇𝑟𝑖𝑡𝑜𝑛)  − 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝐷𝑀𝑆𝑂)
 ∗ 100 
 
Mean ± SEM values were calculated and subjected to Graph Pad Prism 6 for statistics. 
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2.2.7 Chemical analysis of steroid hormone levels in zebrafish larvae 
2.2.7.1 Larvae exposure 
For chemical analysis experiments, wild-type zebrafish larvae were bred as previously described 
(2.2.1.3). At 3 dpf, each 100 zebrafish larvae were distributed with 20 ml E3 medium into 25cm2 
cell culture flasks. At 4 dpf, the larvae were co-treated with 2.5 ml activator and 2.5 ml inhibitor 
solution (total volume 25 ml, 0.2% DMSO, no solvent in E3 medium control) according to Table 
6.  
Timecourse experiments were performed in triplicates and compound tests in four replicates. 
For the timecourse experiments, larvae were exposed for 0, 1, 2, 4, 8 and 24 h and compound 
tests were conducted with 24 h treatment durations.  
At the end of the exposure time, the larvae were poured into a small net and the cell culture 
flasks were rinsed twice with E3, in order to ascertain that all larvae were collected. Remaining 
steroid-containing treatment medium was removed by rinsing the larvae carefully with E3 
medium, followed by three successive washing steps in PBS before the larvae were transferred 
with blunt pipette tipsinto autoclaved 1.5 ml reaction tubes (# 0030120086, Eppendorf AG). All 
liquid was removed from the tubes prior to flash-freezing the larvae in liquid nitrogen. Samples 
were stored at –20°C until homogenization. 
 
Table 6: Treatment scheme for chemical analysis experiments  
 
Experiment
Direct 
activation of  
GC signaling
Indirect 
activation of 
GC signaling
Inhibition of directly or indirectly 
activated GC signaling
0 h 1 h 2 h 4 h 8 h 24 h
100 larvae 
in 20 ml E3
Activator  /               
(2.5 ml)
Activator                 
(2.5 ml)
+ Inhibitor (2.5 ml)
3      E3 E3 + E3
 3 3 3 3 3 DMSO DMSO + DMSO
 3 3 3 3 3 Dex [20 µM] Preg [5 µM] + DMSO
 3 3 3 3 3 Dex [20 µM] Preg [5 µM] + Mety [40 µM]
    4 DMSO / DMSO + DMSO
    4 Dex [20 µM] / Preg [5 µM] + DMSO 
    4 Dex [20 µM] / Preg [5 µM] + Retinoic acid [2 µM] 
    4 Dex [20 µM] / Preg [5 µM] + Spironolactone [2 µM]
    4 Dex [20 µM] / Preg [5 µM] + Estrone [4 µM]
    4 Dex [20 µM] / Preg [5 µM] + Norethindrone [10 µM]
    4 Dex [20 µM] / Preg [5 µM] + Gestrinone [4 µM]
4 Dex [20 µM] / Preg [5 µM] + Mifepristone [1 µM]
4 Dex [20 µM] / Preg [5 µM] + 10-Hydroxycamptothecin [4 µM]
4 Dex [20 µM] / Preg [5 µM] + Nabumetone [4 µM]
4 Dex [20 µM] / Preg [5 µM] + Tranilast [10 µM]
4 Dex [20 µM] / Preg [5 µM] + Stanozolol [12 µM]
4 Dex [20 µM] / Preg [5 µM] + Estriol [12 µM]
4 Dex [20 µM] / Preg [5 µM] + Ethisterone [4 µM]
4 Dex [20 µM] / Preg [5 µM] + Leflunomide [4 µM]
4 Dex [20 µM] / Preg [5 µM] + Dehydroepiandrosterone [4 µM]
4 Dex [20 µM] / Preg [5 µM] + Fenbufen [4 µM]
4 Dex [20 µM] / Preg [5 µM] + Acitretin  [4 µM]
    4 Dex [20 µM] / Preg [5 µM] + Metyrapone [40 µM]
Replicates for each experiment per 
treatment duration
Timecourse 
Preg
Compound 
test
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2.2.7.2 Homogenization of zebrafish larvae and sample spiking 
Frozen samples were put on ice and 0.5 ml PBS were added to each tube containing 100 larvae. 
The samples were homogenized (tissue homogenizer, ULTRA-TURRAX®, IKA Works) for 2 x 20 sec 
and put back on ice. The stainless-steel blades of the homogenizer were cleaned after each 
sample by rinsing them once with isopropanol (ROTIPURAN® ≥99,8%, # 6752.1, Carl Roth GmbH 
& Co. KG), once with PBS and washing them for 5 sec in a 15 ml tube filled with 10 ml PBS in 
order to avoid carry-over of steroid residues.  
The samples were spiked with internal standards (ISTDs). To all larval homogenates 250 ng 
(10 µl) deuterated pregnenolone ([500 ng/ml]; Preg-D4 = Pregnenolone 17α,21,21,21-D4, 98%, 
# 61574-54-7 D5341, CNN Isotopes Inc.) which was dissolved in methanol (MeOH; # 83.638.320, 
VWR International) were added. The samples were stored at –20°C until steroid extraction.  
 
2.2.7.3 Preparation of external calibration standards 
External calibration standards were prepared in triplicates by spiking 0.5 ml PBS with 
Hydrocortisone (Cort), Corticosterone (Cortico), Progesterone (Prog), Dexamethasone (Dex) [25 
ng each, 50 ng/ml, in MeOH] and Pregnenolone (Preg) [500, 1000 ng/ml; in MeOH]. The 
standards were diluted 1:1 with PBS in 4 serial steps in order to obtain standard ranges of 50, 25, 
12.5, 6.25, and 3.125 ng/ml for Cort, Cortico, Prog and Dex, and a range of 1000, 500, 250, 125 
and 62.5 ng/ml for Preg. The ISTD Preg-D4 was added to each sample of the calibration series 
[250 ng, 500 ng/ml] and samples were vortexed (Genie 2, Scientific industries, Inc.) before they 
were stored at –20°C for steroid extraction. 
2.2.7.4 Liquid-liquid extraction (LLE) of steroid hormones 
The larvae homogenates were vortexed (Vortex-Genie 2, Scientific industries, Inc.) for 20 sec and 
transferred into 5 ml reaction tubes (# 0030119401, Eppendorf AG). For the extraction of steroid 
hormones, 2 ml Ethyl acetate (# 1096231000, Merck) were added and samples were vortexed 
thoroughly for 2 x 20 sec and centrifuged (ZK 380, Hermle Labortechnik GmbH) for 1 min at 5000 
rpm for phase separation. After centrifugation, 1.8 ml of the organic phase, containing the 
steroid fraction, were transferred into new 5 ml reaction tubes and dried under a liquid nitrogen 
stream at 45°C on an evaporator (Vapotherm basis mobil II, Barkey GmbH & Co. KG). The dry 
samples were stored at -20°C for further processing. The frozen samples were reconstituted in 
0.5 ml MeOH and vortexed for 20 seconds. Then, they were transferred into 1.5 ml screw-thread 
brown glass vials (art. no.: VT1101211, Dr. R. Forche Chromatographie), closed with silicone/ 
PTFE caps (art. no.: CT11S3015, Dr. R. Forche Chromatographie) and subjected to UPLC-MS/MS 
analysis as described in the following section. 
2.2.7.5 UPLC-MS/MS 
Detection and quantification of steroid hormones in zebrafish larvae samples was conducted by 
Ultra-performance liquid chromatography tandem mass spectrometry UPLC-MS/MS. 
Chromatographic separation was performed by an ExionLC™ AD system (AB Sciex). From each 
sample, a volume of 4 µl was injected and fractionated by a Kinetex XB-C18 2.6 µm, 100 mm x 
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2.1 mm, column (Phenomenex). In direct analyses, mobile phase were A, 0.1% formic acid (FA;, # 
100264, Merck) in acetonitrile (# 83.640.320, VWR International) and B, 0.1% FA in water. The 
gradient condition 0 - 0.10 min, 60% B; 0.10 - 0.65 min, 60 - 20% B; 0.65 - 1.20 min; 20% B; 1.20 - 
1.25 min, 20 - 60% B; 1.25 - 2.00 min, 60% B was applied for the elution of steroids from the 
column. The flow rate was 0.80 ml/min, and the column was maintained at 45°C using a column 
oven. Mass spectrometry was conducted using an API 4000™ tandem mass spectrometer with a 
TurboIonSpray source (AB Sciex) in the positive mode. Mass detection was achieved operating in 
the multiple reaction monitoring (MRM) mode analyzing precursor ion/product ion mass 
transitions. The optimized MS parameters and the MRM mass transitions for each compound 
are given in the appendix as Supplementary Table A.  
2.2.7.6 Data aquisition and processing 
The Analyst software (version 1.6.3, AB Sciex) was used for data acquisition and analysis. The 
samples were normalized based on their internal standards (ISTDs) and quantified by 
comparison with the standard calibration series. Data were exported to Excel. "No Peak"= limit 
of detection (LOD) was replaced manually by 0. Values smaller than the smallest standard of the 
external standard-curve (62.5 ng/ml for Preg and 3.125 ng/ml for the other standards) were 
below the limit of quantification (LOQ). For the timecourse experiments, mean, SD and SEM 
were calculated for each steroid from the raw data of replicate measurements and subjected to 
statistical analysis. For compound testing, ratios were calculated by dividing the raw data from 
each test compound by the mean of the respective negative control (Dex + DMSO for direct 
activation of GC signaling, Preg + DMSO for indirect activation of GC signaling). In case of 
0-values for raw data and 0-values for the mean of the negative control, 0 would be divided by 0, 
thus, the occurring error ("#DIV/0!") was replaced by a ratio value of 0 manually. For each 
steroid, mean, SD and SEM were calculated from the replicate ratio values and subjected to 
statistical analysis. 
2.2.8 Gene expression analysis 
2.2.8.1 Larvae exposure 
For real-time quantitative polymerase chain reaction (qPCR) experiments, wild-type zebrafish 
larvae were bred as described in section 2.2.1.3. At 4 dpf, they were distributed into small cell 
culture flasks (CELLSTAR® 25 cm2 # 690170, Greiner Bio-One), with 30 larvae in 6 ml E3 medium 
per flask. The next day, the larvae were co-treated with 0.75 ml activator and 0.75 ml inhibitor 
solution (total volume 7.5 ml, 0.2% DMSO, no solvent in E3 medium control) according to 
Table 7. 
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Table 7: Treatment scheme for qPCR analysis  
 
2.2.8.2 Cell exposure 
The cell experiments for qPCR analysis were carried out in triplicates. The first day, 400 000 
AB.9-GRE:Luc cells per well were seeded with 4 ml AB.9-GRE:Luc medium into 6-well plates. Cells 
were allowed to attach over night at 28°C before they were washed with 4 ml PBS and treated 
either with DMSO or with DMSO + Dex [20 µM] (L-15, end volume 5 ml, 0.2% DMSO) for 4 h at 
28°C. At the end of the exposure duration, the treatment solution was completely removed prior 
to RNA extraction.  
 
2.2.8.3 Total RNA extraction 
To the snap-frozen larvae and the cells, 1 ml of TRIzol™ Reagent (# 15596026, Invitrogen™) were 
added. The cells were transferred into 1.5 ml reaction tubes. Cell membranes were disrupted 
with a tissue homogenizer for 2 x 20 sec before the samples were stored at –80°C for at least 12 
h. Total RNA was isolated following the manufacturer’s instructions of the TRIzol™ Reagent. RNA 
quantity and integrity were determined spectrophotometrically (NanoDrop™ 1000, using 
NanoDrop™ Software, version 3.7.0, both Thermo Scientific™) and only samples with a 260/280 
ratio above 1.7 were carried forward for cDNA synthesis. The RNA concentration was adjusted to 
200 ng/µl. 
Experiment
Direct 
activation of  
GC signaling
Indirect 
activation of 
GC signaling
Inhibition of directly or indirectly 
activated GC signaling
0 h 1 h 2 h 4 h 12 h 24 h
30 larvae in 
6 ml E3
Activator  /               
(0.75 ml)
Activator                 
(0.75 ml)
+ Inhibitor (0.75 ml)
3      - E3 + E3
 3 3 3 3 3 - DMSO + DMSO
 3 3 3 3 3 - Preg [5 µM] + DMSO
 3 3 3 3 3 - Preg [5 µM] + Mety [40 µM]
   3  DMSO / DMSO + DMSO
   3  Dex [20 µM] / Preg [5 µM] + DMSO 
   3  Dex [20 µM] / Preg [5 µM] + Retinoic acid [2 µM] 
   3  Dex [20 µM] / Preg [5 µM] + Spironolactone [2 µM]
   3  Dex [20 µM] / Preg [5 µM] + Estrone [4 µM]
   3  Dex [20 µM] / Preg [5 µM] + Norethindrone [10 µM]
   3  Dex [20 µM] / Preg [5 µM] + Gestrinone [4 µM]
3 Dex [20 µM] / Preg [5 µM] + Mifepristone [1 µM]
3 Dex [20 µM] / Preg [5 µM] + 10-Hydroxycamptothecin [4 µM]
3 Dex [20 µM] / Preg [5 µM] + Nabumetone [4 µM]
3 Dex [20 µM] / Preg [5 µM] + Tranilast [10 µM]
3 Dex [20 µM] / Preg [5 µM] + Stanozolol [12 µM]
3 Dex [20 µM] / Preg [5 µM] + Estriol [12 µM]
3 Dex [20 µM] / Preg [5 µM] + Ethisterone [4 µM]
3 Dex [20 µM] / Preg [5 µM] + Leflunomide [4 µM]
3 Dex [20 µM] / Preg [5 µM] + Dehydroepiandrosterone [4 µM]
3 Dex [20 µM] / Preg [5 µM] + Fenbufen [4 µM]
3 Dex [20 µM] / Preg [5 µM] + Acitretin  [4 µM]
   3  Dex [20 µM] / Preg [5 µM] + Metyrapone [40 µM]
Replicates for each experiment per 
treatment duration
Timecourse 
Preg
Compound 
test
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2.2.8.4 cDNA synthesis 
Any genomic DNA was removed from the samples by treatment with 1 U DNAse I (# M6101, 
Promega) at 37°C for 30 min and cDNA was synthetized with Random Hexamer Primer (# SO142, 
Thermo Scientific™), RNasin® Ribonuclease Inhibitor (# N2511, Promega), SuperScript™ III 
Reverse Transcriptase (# 18080044, Invitrogen™) and RNAse free water (# P1193, Promega) 
according to the manufacturer´s protocols. The concentration of the obtained cDNA was 
adjusted to 10 ng/µl. 
2.2.8.5 Primer selection 
For real-time quantitative PCR measurements, the two housekeeping genes ribosomal protein 
L13 (rpl13) and elongation factor 1-alpha (ef1α) were selected for data normalization. Genes of 
interest were GR (NR3C1, gr) with the two splice variants GR α (grα) and GR β (grβ), 11β-
hydroxysteroid dehydrogenase 2 (hsd11b2), cytochrome P450 11β-hydroxylase (cyp11c1), 
cytochrome P450, family 3 subfamily A polypeptide 65 (cyp3a65), cytochrome P450 family 1 
subfamily A member 1 (cyp1a1), progesterone receptor (NR3C3, pgr), pregnane x receptor 
(NR1I2, pxr), FK506 binding protein 5 (fkbp5), GC-induced leucine zipper (gilz), 
proopiomelanocortin (pomc), androgen receptor (NR3C4, ar) and mineralocorticoid receptor 
(NR3C2, mr). 
 
Primers for hsd11b2 (Wilson et al. 2013), cyp11c1 (Wilson et al. 2013), cyp3a65 (Bainy et al. 
2013), cyp1a1 (Brammell 2010; Lister et al. 2009), gr (both splice variants; Alsop & Vijayan 2008), 
grα (Manuel et al. 2014), pgr (Bainy et al. 2013; Chen et al. 2010) were used as previously 
reported and for rpl13, ef1α, fkbp5, gilz, pomca, grβ, ar and mr, appropriate primers were 
selected and designed as follows: The transcript sequences and accession numbers for the genes 
of interest were obtained by searching the zebrafish database of the NCBI webpage. The Refseq 
mRNA was then used to design appropriate oligonucleotide primer pairs in application of the 
Primer-BLAST tool from the ncbi webpage (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). 
For primer selection, it was considered that oligonucleotides should have a content of 40 - 60% 
of the nucleotide bases guanine (G) or cytosine (C), with minimal clusters of the two bases 
together and 20 - 40 base pairs in length. It was aimed to pick primers with melting 
temperatures between 57°C and 63°C and with a maximum difference of 3°C between the 
primer pair. If possible, primers were designed to span an exon/exon junction to prevent 
genomic DNA amplification and self-complementarity was avoided in order to decrease the 
possibility of primer-dimer formation. 
 
All primers were purchased as lyophilized powders from Invitrogen by Thermo Fischer Scientific 
and were reconstituted in RNAse free water as 100 µM stocks for storage at –20°C. For all 
utilized primers, the gene names, accession numbers, forward and reverse sequences, as well as 
their product sizes are listed in Table 8. Italicized primer names correspond to the official 
zebrafish gene symbol. 
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Table 8: Primers used for real-t ime quantitative PCR measurements  
Primer 
name 
Accession 
number 
Forward sequence Reverse sequence 
Product 
length 
rpl13 NM_212784.1 CCATGAAGTTGGCTGGAAGT GAAGAGAAAGGAAAAGGCCAA 69 
ef1α NM_131263.1 ACCTACCCTCCTCTTGGTCG GGAACGGTGTGATTGAGGGA 164 
hsd11b2 NM_212720.2 GGGGGTCAAAGTTTCCACTAT GTACTCTGCGTTACTGCTCTGC 67 
cyp11c1 NM_001080204.1 ACGCAGGATAGCAGAGAACG TCAGCTTGAAGGTCCTCAGAA 65 
fkbp5 NM_213149.1 TTCCACACTCGTGTTCGAGA ACGATCCCACCATCTTCTGT 72 
gilz NM_200569.2 CAAGATCGAACAAGCAATGG CCTTGATCTGCTCCTTCAAGA 89 
cyp3a65 NM_001037438.1 ATGGTGCCGACCTACGCCCTC GGGCCCAGACCGAACGGCAT 135 
cyp1a1 NM_131879.2 CTGGACGAAAACTCCAACCTG  GATAGTGTCGAAACCGGCTCC 87 
pomca NM_181438.3 GAAGAGGAATCCGCCGAAA CCAGTGGGTTTAAAGGCATCTC 98 
gr (α+β) NM_001020711.3 ACAGCTTCTTCCAGCCTCAG CCGGTGTTCTCCTGTTTGAT 116 
gr α EF436284.1 ACTCCATGCACGACTTGGTG GCATTTCGGGAAACTCCACG 90 
gr β EF436285.1 TCCAAAGCCCTAGTGAGCTG AGCGGAATCACTATGACGCA 135 
pgr NM_001166335.1.1 GGGCCACTCATGTCTCGTCTA TCTCCACTCTGAAAATATGTGGACTTT 95 
ar NM_001083123.1. TACGGCCGAAGTACTGCTCTG AAATGTCACTCCTCCCTCCGT 181 
mr NM_001100403.1 TGCCACTACGGGGTTGTTAC GTGCCCCAAGATTCATCCCA 181 
pxr NM_001098617.1 GCATTCGCGTCCATATCACAGAG CTAACTAGGGCTCCACTTCCTGG 101 
2.2.8.6 Real-time quantitative PCR measurements 
The qPCR measurements were carried out using the qPCR Master Mix kit (GoTaq® qPCR Master 
Mix , # A6002, Promega). Each sample was measured in technical duplicates and in biological 
triplicates. According to the manufacturer’s instructions, the 20 µl reaction volumes were 
composed of 10 μl 2 x PCR Master Mix, 2 μl of primer mix (forward and reverse primer, 2 µM 
each), 0.2 µl reference dye and 3.8 µl H2O and 4 μl cDNA (10 ng/µl). Master-mixes were 
prepared and distributed on a translucent 96-well plate. A template control without cDNA (NTC) 
for each primer pair and a transcription control without the SuperScript™ III Reverse 
Transcriptase (-RT) for each cDNA was also included. The plate was sealed with an adhesive film 
(qPCR plate seal, # SL-AM0560, Steinbrenner Laborsysteme GmbH) and placed into the Real-
Time PCR reader (StepOnePlus™ System, # 4376600, Applied Biosystems). The following 
parameters were used for product amplification: 5 min at 94°C for denaturation, followed by 40 
annealing cycles at 95°C for 15 sec and 60°C for 30 sec. The melting curves of the products were 
determined at the end of the amplification phase and Ct values were determined by the 
StepOne™ Software (version 2.3, Applied Biosystems). Data were exported as txt. files from the 
software and processed in Excel for statistical analysis.  
2.2.8.7 Data processing  
The relative mRNA expression of each target gene was normalized to that of the two 
housekeeping genes rpl13a and ef1α. Ratios of mRNA expression relative to the negative control 
(Dex/Preg + DMSO) were calculated according to the ∆∆Ct method (Livak and Schmittgen 2001). 
For the assessment of nuclear receptor mRNA expression in untreated (DMSO) AB.9-GRE:Luc 
cells, ratios were calculated as follows: 1/(Ct target - Ct ef1a). For all experiments, mean 
ratios ± SEM were calculated and subjected to GraphPad Prism 6  for statistical evaluation.  
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2.2.9 Statistics 
Statistical analysis was conducted with the GraphPad Prism 6 software (GraphPad Software, 
Inc.). With all mean ± SEM data obtained from GRIZLY, cytotoxicity, UPLC-MS/MS and qPCR 
experiments, a grouped analysis was conducted with a multiple t-test (α = 0.05) where each 
condition (and each steroid in case of UPLC-MS/MS) was individually tested against the negative 
control. The obtained data were corrected for multiple comparisons using the Holm-Šídák 
method, where the significance level is adjusted according to this formula: 𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝛼 =
1 − (1 − 𝛼)(1/𝑖)(Holm 1979), with i = 640 for GRIZLY and cytotoxicity screens, i = 7 for 
concentration-dependent retests and single compound tests with the GRIZLY assay and i = 19 for 
UPLC-MS/MS and qPCR experiments. 
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Chapter 3 
3. Results 
In order to pursue the first objective of this study, to assess the suitability of the GRIZLY assay for 
the detection of GC signaling inhibition, the testing conditions needed to be adjusted 
accordingly. The two generated transgenic reporter lines, Tg(GRE:Luc) zebrafish larvae and the 
AB.9-GRE:Luc zebrafish cells, were applied under comparable testing conditions to enable the 
discrimination between in vivo and in vitro compound effects. An FDA-approved drug library 
(FDA library), consisting of 640 compounds, was selected to be screened with the reporter lines. 
The application of a library of known compounds should enable the identification of already 
established inhibitors and, moreover, facilitate the substance classification in cases where 
unknown inhibitory effects on GC signaling are detected. 
3.1 Preparation: Validation experiments for an inhibitory GRIZLY assay 
Inhibition of directly activated glucocorticoid signaling 
Before the FDA library could be screened for GC signaling inhibitors, a control activator of GC 
signaling was needed, which is functional in vivo and in vitro. The synthetic GC Dexamethasone 
(Dex) is a reference compound for specific GR agonism and was identified to induce GC signaling 
in both reporter lines within a previous screen for activation of GC signaling (Weger et al. 2012). 
For the present study, these findings were validated by retesting, where Dex showed 
concentration-dependent induction of GC signaling in transgenic zebrafish larvae (Figure 15 a). 
Statistically significant activation was induced by 5, 10 and 20 µM, with 20 µM Dex showing the 
strongest induction. 
 
 
Figure 15: Direct  activation of glucocorticoid s ignaling with Dexamethasone  
Glucocorticoid signaling was asse ssed in vivo  (a)  and in vitro  (b).  Relative AUC values are shown 
for a range of f ive different concentrations of Dex (grey, n = 16). The data are normalized relative 
to the negative control ( blue, n = 8) and the positive control ( blue, n = 8, Dex [20 µM]). The 
amount of DMSO was 0.1% in al l  treatment  conditions.  Data are shown as means + SEM. Statistical  
significance is determined by comparison of each treatment condition with the negative control in 
D e x a m e th a s o n e  la rv a e
T re a tm e n t
R
e
la
ti
v
e
 A
U
C
 [
%
]
D
M
S
O
1
.2
5
 µ
M
2
.5
 µ
M
5
 µ
M
1
0
 µ
M
2
0
 µ
M
D
e
x  
2
0
 µ
M
0
5 0
1 0 0
1 5 0
a
*
**
*
D e x a m e th a s o n e  c e lls
T re a tm e n t
R
e
la
ti
v
e
 A
U
C
 [
%
]
D
M
S
O
1
.2
5
 µ
M
2
.5
 µ
M
5
 µ
M
1
0
 µ
M
2
0
 µ
M
D
e
x
 2
0
 µ
M
0
5 0
1 0 0
1 5 0
2 0 0
* * * * * *
b
3.1 Preparation: Validation experiments for an inhibitory GRIZLY assay  
50 
a multiple t-test,  α  = 0.01. After multiple test ing correction with the Holm -Šídák method, 
significance is defined as p  < α < 0.002= *.  
 
In vitro, the same concentrations of Dex were applied in order to ensure comparable exposure 
conditions between the two systems. The transgenic cells have a higher sensitivity for Dex than 
the Tg(GRE:Luc) zebrafish larvae (Weger et al. 2012) . This possibly relies on their more direct 
exposition to Dex and the higher number of reporter constructs in a multitude of single cells, 
filling the entire bottom of the testing plate well, compared to the exposure to one larva, where 
Dex has to pass the skin barrier and metabolic clearance mechanisms first. Accordingly, no 
concentration-dependent signal increase was observable with the selected range from 1.25-20 
µM (Figure 15 b). Instead, all concentrations significantly activated GC signaling. Albeit lower 
concentrations of Dex [2.5-10 µM] could have been equally or more suitable for cell exposure, 
the concentration of 20 µM  was determined for the control activation concentration, as it 
showed the strongest activation in larvae and was still appropriate for the in vitro system.  
 
With Dex as a reference activator for GC signaling, a control inhibitor had to be selected next. 
Due to the direct GR agonism of Dex, the reference GR antagonist Mifepristone (Mife) was the 
prior choice, in order to have an inhibitor which acts via the same mechanism as the activator. 
Further, Mife has already been shown to antagonize GC signaling in zebrafish (Krug et al. 2014; 
Weger et al. 2012). In the experiments, Mife concentration-dependently inhibited Dex-induced 
GC signaling in both, larvae (Figure 16 a) and cells (Figure 16 b). All tested Mife concentrations 
significantly reduced the Dex-activated signal, when compared to the negative control 
DMSO + Dex. Consistent with previous results (Weger et al. 2012), the highest concentration of 
Mife [1 µM] resulted in the strongest inhibition and was therefore selected as the control 
inhibitor concentration for the inhibitory GRIZLY screening applications. 
 
 
Figure 16: Inhibition of  Dexamethasone-induced glucocorticoid signaling with Mifepristone  
Effects on glucocorticoid signaling were assessed in vivo  (a)  and in vitro  (b).  Relative AUC values 
are shown for a range of f ive different concentrations of Mife  + Dex [20 µM] (grey, n = 16, 
all  0.2% DMSO). The data are normalized relative to the negative control ( blue, n = 8, DMSO + Dex 
[20 µM]) and the positive control ( blue, n = 8, Mife [1 µM]  +  Dex [20 µM). The amount of DMSO 
was 0.2% in all  treatment  conditions. Data are shown as means + SEM. Statistical significance is  
determined by comparison of each treatment condit ion with the negative control in a  multiple t -
test,  α  = 0.01. After multiple testing correction with the Holm -Šídák method, significance is  
defined as p  <  α < 0.002= *.  
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Inhibition of indirectly activated glucocorticoid signaling 
Beside the GC signaling activation by synthetic GR agonists like Dex, also signal induction by 
natural GCs can be detected with the GRE:Luc reporter (Weger et al. 2012). However, the 
bioluminescent signal coming from basal levels of endogenous GCs is relatively low in larvae and 
cannot be distinguished from background noise. Stimulation of endogenous GC over-production, 
in contrast, results in an enhanced bioluminescent signal. This possibility, to detect indirect 
induction of GC signaling, represents another attractive application of the GRIZLY assay, based 
on which a second screening approach was elaborated. 
For the second screen, the endogenous production of cortisol (Cort), the main active GC in fish 
and humans, is induced. This indirect stimulation of Cort biosynthesis and thereby GC signaling 
not only targets to identify candidates which directly interfere with GR-mediated signaling, it 
enables furthermore the identification of compounds inhibiting GC signaling via disruption of 
Cort production. One possibility to induce Cort over-production in larvae is their exposure to 
natural precursors of the GC synthesis pathway, which then are endogenously metabolized into 
Cort. Pregnenolone (Preg), a natural prohormone which itself is not known to activate the GR, is 
a suitable candidate for this approach. Preg was identified within the previous screen to activate 
the GRE:Luc reporter as a substrate, that induced Cort biosynthesis (Weger et al. 2012). This 
observation was confirmed by concentration-depentent retesting, which validated Preg as a 
suitable positive control for indirect activation of GC signaling.  
As shown in Figure 17 a, a constant signal increase was observable for the concentrations of 
1.25, 2.5 and 5 µM. At 10 and 20 µM, Preg started to show toxic effects in larvae and the signal 
decreased. Therefore, 5 µM, showing the highest signal induction, was determined as control 
concentration for indirect GC signaling activation in further applications. In contrast to the in 
vivo response, no signal activation could be detected when AB.9-GRE:Luc cells were treated with 
a range of Preg concentrations (Figure 17 b). The lack of GC signaling activation in vitro was not 
surprising, as the metabolization of Preg into Cort requires a whole cascade of adrenal enzymes, 
a circumstance which is unlikely to be available in cultured fibroblast-like fish cells. 
 
 
Figure 17: Indirect activation of g lucocorticoid s ignaling with Pregnenolone  
Pregnenolone activated GC signaling in vivo  (a)  but not in vitro  (b).  Relative AUC values are shown 
for a range of f ive different concentrations of Preg (grey, n  = 16). The data are normalized relative 
to the negative control ( blue, n = 8) and the positive control ( blue, n = 8, Dex [20 µM]).  The 
amount of DMSO was 0.2% in al l  treatment  condit ions.  Crosses indicate toxic ity  in the tested 
concentration.  Data are sh own as means  + SEM. Statistical s ignificance is  determined by 
comparison of each treatment condition with the negative control in a multiple t -test,  α=0.01. 
After multiple test ing correction with the Holm -Šídák method, significance is defined as 
p  < α < 0.002= *.  
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However, as Preg could possibly induce GC signaling directly via binding to the PR due to 
structural similarities of GR and PR and then unspecifically activate the GRE:Luc reporter in 
larvae, it appeared necessary to proof that not a lack of PR expression in cells might be the 
reason for the failed signal induction. I conducted qPCR experiments in order to ascertain that 
the  PR gene (pgr) was expressed in AB.9-GRE:Luc cells. I also assessed the presence and 
abundance of the two housekeeping genes (hkgs) ribosomal protein L13 (rpl13) and elongation 
factor 1-alpha (ef1α), of the genes for the two GR isoforms GRα (grα) and GRβ (grβ),  and of the 
nuclear receptors MR (mr), AR (ar) and PXR (pxr).  
In Figure 18 a, the expression ratios are shown for each target gene relative to ef1α. The pgr 
gene was indeed expressed in DMSO (0.1%) -treated cells, which further substantiates the 
assumption that the lack of signal induction in Preg-treated AB.9-GRE:Luc cells underlies the 
inability of the cells to synthesize Cort from Preg. Although a significant difference between ef1α 
and rpl13 was detected by statistical analysis, both hkgs were expressed in nearly equal 
abundance in the cells. The gene expression for all nuclear receptors except GRβ was 
significantly lower than for ef1α, with GRα mRNA being the most and PXR the least abundant. 
Furthermore, I assessed if Dex treatment changed the expression of grα, grβ, mr, ar, pxr in AB.9-
GRE:Luc cells. As shown in Figure 18b, the levels of grα, G grβ and mr significantly decreased 
when cells were treated with Dex ([20 µM], 0.1% DMSO), compared to the control treatment 
(DMSO 0.1%). Apparently, a cell-autonomous negative feedback loop down-regulated the mRNA 
expression of these three transcripts, probably to prevent or counteract overactivation of the 
corticosteroid receptors by Dex. 
Interestingly, albeit not significant due to variations between the test replicates, pxr expression 
was strongly induced by Dex, suggesting increased, xenobiotic clearance activity within the cells. 
Although Dex is a known PXR ligand, the nuclear receptor majorly mediates xenometabolism by 
regulating the expression of CYP enzymes in the liver and intestine (phase I metabolic enzymes), 
which are not expected to be available in these cultured cells. However, the PXR can regulate 
xenobiotic and endobiotic clearance via various mechanisms, which may induce the cellular 
export of drugs (here Dex) via enzymes other than those involved in phase I xenobiotic 
metabolism in liver and intestine (Ihunnah, Jiang, and Xie 2011; Xu, Li, and Kong 2005). For 
instance via phase II metabolic enzymes, which can be located in numerous tissues, or via 
xenobiotic transportert proteins (Ihunnah et al. 2011), may the PXR may have induced 
xenobiotic clearance activity in the cells.  
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Figure 18: Expression of  nuclear receptor and housekeeping genes in AB.9-GRE:Luc  cells  
AB.9-GRE:Luc  cells were exposed for 4h to ( a)  DMSO or (b)  Dex [20 µM].  The amount of DMSO was 
0.1% in al l  treatment  conditions.  (a)  Mean gene expression ratios of three biological 
replicates  + SEM are shown for rpl13 ,  grα ,  grβ , mr,  ar  and pxr  (all  grey, n = 3),  relative to ef1α  
(blue, n = 3)  mean CT values. ( b)  Mean gene expression ratios of  three biological replicates + SEM 
are v isualized for the nuclear receptors grα,  grβ ,  mr,  ar  and pxr  measured in cells  exposed for 4h 
to Dex (grey, n = 3),  relat ive to 4h of DMSO treatment (not shown, n = 3).  Statist ic evaluation of 
gene expression data was conducted with the 2CT method, measured with two technical 
replicates per plate and two housekeeping  genes ,  rpl13a and ef1α .  (a  + b)  Stat ist ical s ignificance 
is determined by comparison of the mean ratio of the control (a:  ef1α;  b:  DMSO) with the mean 
ratio of the target genes in a multiple t -test,  α=0.05 .  After multiple testing correction with the 
Holm-Šídák method, signi f icance is def ined as p<α<0.002=* .  
 
Now, with Preg as a control activator of endogenous GC production in vivo, an appropriate 
reference inhibitor was needed for the second screening approach, which enables the 
identification of substances specifically inhibiting Preg-induced GC signaling. Such inhibitors can 
either interact directly with GR-mediated signaling or indirectly, independent from the GR, e.g. 
by disrupting  the GC biosynthesis pathway. For direct interaction with GR signaling, Mife serves 
also within this testing approach as a good positive control. The antagonistic effect of Mife on 
GR signaling, induced by  either directly administered Cort (a) or endogenously produced Cort 
(b), is shown in Figure 19. In both cases, Mife concentration-dependently inhibited GC signaling.  
 
 
Figure 19:  Inhibit ion of Cortisol - and Pregnenolone-induced glucocorticoid signaling with 
Mifepristone in vivo  
Cort- (a)  and Preg- (b)  induced GC signal ing was inhibited concentration -dependently  in larvae 
with Mife. Relat ive AUC values are shown for a range of f ive different concentrations of 
Mife  +  Cortisol [30 µM] (a)/  Preg [5 µM] (b)(grey, n = 16). The data are normalized relative to the 
negative control DMSO + Cort  [30 µM] (a)/ DMSO + Preg [5 µM] ( b)  (blue,  n = 8)  and the positive 
control Mife [1 µM] + Cort  [30 µM] (a)/ Mety [40 µM] + Preg [5 µM] (b)  (blue,  n = 8).  The amount 
of DMSO was 0.2% in all  treatment conditions.  Data are shown as means + SEM. Statistical  
significance is determined by comparison of each treatment condition with the negative control in 
a multiple t-test,  α  = 0.01. After multiple test ing correction with the Holm -Šídák method, 
significance is defined as p  < α < 0.002= *.  
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Selection of a suitable control for glucocorticoid biosynthesis disruption 
In need of an appropriate control for indirect inhibition of Preg-induced GC signaling in the 
second screening approach, certain requirements had to be fulfilled by the inhibitor. A suitable 
candidate was expected to specifically and significantly reduce Preg-induced GC signaling. 
Further, unlike Mife, it had to be ineffective on signaling induced by the synthetic GC Dex, 
because otherwise interference of the candidate with the GR might rather be the mechanism of 
inhibition than disruption of GC biosynthesis. In the literature, several disruptors of the GC 
synthesis have been described, mostly acting on diverse enzymes within the GC biosynthesis 
pathway. Three of them, Ketoconazole (Keto), Etomidate (Eto) and Metyrapone (Mety), were 
tested for their suitability as a control for glucocorticoid biosynthesis disruption in the GRIZLY 
screening approach (Figure 20). 
 
 
Figure 20: Glucocorticoid biosynthesis  disruptors  
Keto ( I) ,Eto ( II)  and Mety ( III)  were co-exposed with Preg ([5 µM], blue) and Dex ([20  µM], red) to 
Tg(GRE:Luc)  larvae. Relative AUC values are shown for a range of f ive different concentrations (n  = 
16). The data are normalized relative to the DMSO control (n=8) and the negative control 
DMSO + Preg  [5 µM]/ DMSO + Dex [20  µM] (n=8). The amount of DMSO was 0.2% in all  treatment 
conditions. Data are shown as means + SEM. Statistical s ignificance is determined by comparison 
of each treatment condition with the negative control in a multiple t -test,  α=0.01. After multiple 
testing correction with the Holm -Šídák method, significance is defined as p <α<0.002=*. Sublethal 
toxic effects = (†),  lethality  = † (a) . Bioluminescent traces [Mean RLUs] of the treatments for 
Preg + Keto ( I)/ Eto ( II)/ Mety ( III)  (b)  and for Dex + Keto ( I)/ Eto ( I I)/ Mety ( III)  (c)  are monitored 
over the exposure duration of 24  h.  
 
Keto is a synthetic imidazole drug, which is used primarily to treat fungal infections but also finds 
application in the treatment of hypercortisolism in Cushing´s syndrome, as it suppresses the 
biosynthesis of Cort (Sonino et al. 1991; Loli et al. 1986; Graybill et al. 1983). It has been shown 
to inhibit the cholesterol side-chain cleavage enzyme (P450scc, CYP11A), which converts 
cholesterol into Preg, and also cytochrome P450 (CYP)17A1 (CYP17A1), an enzyme that has 17α-
hydroxylase (production of GCs) and 17,20-lyase (production of estrogens and androgens) 
activity whereby it catalyzes diverse steps downstream of Preg in the steroid biosynthesis 
pathway (Ankley et al. 2012; DeVore and Scott 2012; Hilscherova et al. 2004). Moreover, it 
inhibits 11β-hydoxylase (CYP11B1 in human, CYP11C1 in fish), the enzyme which converts 
11-deoxycortisol into Cort (Bergström et al. 1998; Yin et al. 2012; Zhu et al. 2016). In addition to 
its broad potency in disrupting the GC biosynthesis directly, Keto is furthermore a reference 
inhibitor of diverse xenobiotic enzymes, including the CYP3A family and CYP1A1 (Eagling, Tjia, 
and Back 1998; Greenblatt et al. 2011; Paine, Schmiedlin-Ren, and Watkins 1999). Thus, Keto has 
the potency to disrupt the GC biosynthesis directly, via inhibition of several steroidogenic 
enzymes, but also indirectly, by affecting the xenobiotic clearance, which may alter the 
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availability of GCs and their precursors in the organism. Therefore, its suitability as a specific 
control inhibitor of GC biosynthesis is questionable. 
 
When exposed to larvae, sufficient inhibition of the Preg-induced signal was only detectable 
when the concentrations of Keto started to induce also toxic effects [> 8 µM] (Figure 20 a). 
Accordingly, no specific inhibition but toxicity was observable. In co-treatment with Dex, the 
higher concentrations of Keto [> 8 µM] also led to larvae toxicity. However, at sub-toxic 
concentrations [4 and 8 µM], Keto showed a tendency to co-induce GC signaling with Dex. 
Although these effects were not significant when compared to the negative control 
(Dex + DMSO), this observation might be related to the above mentioned inhibitory effect of 
Keto on xenobiotic enzymes. Potentially, Keto reduced the xenobiotic clearance of Dex, which is 
a known substrate of enzymes involved in phase I xenobiotic metabolism such as CYP3A 
(Lanzarotti and Rossi 2013; McDonagh et al. 2012; Natale et al. 2016). In this case, increased Dex 
activity in the larvae might be expectable due to compound accumulation. To further pursue this 
consideration and for comparison of in vivo and in vitro effects of Keto, I co-exposed the 
substance with Dex to AB.9-GRE:Luc cells. As xenobiotic CYP enzymes are primarily located in 
liver and intestine, their inhibition requires a whole-organism environment and thus, I expected 
no such co-inductive effect in cultured fibroblast-like fish cells. The cell experiment (Figure 21) 
was conducted with lower concentrations of Keto [1-5 µM] than before with larvae [4-20 µM] 
due to the observed in vivo toxicity at ≥ 2 µM. Still, in case Keto had a disruptive effect on cell 
xenometabolism, a signal increase could have been expected in this concentration range, as the 
cells are normally more sensitive to compound treatment than the larvae. However, no increase 
of the Dex-induced signal by Keto treatment was observable in vitro. This result supports the 
possibility that co-induction in vivo may have underlain xenobiotic clearance, which led to a 
higher Dex level in larvae. Furthermore, the highest Keto concentration [5 µM] showed reduced 
activation compared to the negative control (DMSO + Dex). This signal decrease may have been 
caused by weak cytotoxic effects of Keto, occurring at this concentration, but was not further 
assessed for this thesis work. 
 
 
Figure 21: Effect of Ketoconazole on Dexamethasone-induced glucocorticoid s ignaling  in vitro  
Relative AUC values are shown for a range of f ive different concentrations of Keto + Dex [20  µM] 
(grey, n = 16) measured in AB.9-GRE:Luc  cells.  The data are normalized relative to the negative 
control DMSO + Dex  [20 µM] (blue, n = 8) and the DMSO control (blue,  n = 8).  The amount of 
DMSO was 0.2% in all  treatment conditions. Data are shown as means + SEM. Statistical 
significance is determined by comparison of each treatment condition with the negative control in 
a multiple t-test,  α=0.05. After multiple testing correction with the Holm -Šídák method, 
significance is defined as p  < α < 0.005= *.  
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Eto is an anesthetic, used for operations of short durations under sedation (Forman 2011; Giese 
and Stanley 1983). Furthermore, it suppresses the corticosteroid synthesis by inhibiting only one 
enzyme, 11β-hydroxylase, for which reason it is also therapeutically used to treat Cushing´s 
syndrome (Bergström et al. 1998; Greening et al. 2005; Preda et al. 2012), and which is why I 
considered it generally suitable as a control inhibitor for the current testing approach. 
As shown in Figure 20 b, Eto inhibited the Preg-activated GC signaling, but it also appears to 
decrease the Dex-activated signal. Furthermore, and probably being involved in the signalk 
decreases, Eto induced toxic effects in larvae at all tested concentrations, with both activators. 
Lower concentrations [2 - 6 µM] showed mostly sub-lethal effects, including malformations of 
heart and yolk, reduced to no bloodflow and enlarged eyes (data not shown). At 8 µM, these 
effects aggravated and several larvae had no heartbeat and thus, were considered dead. At 10 
µM most larvae were dead. These toxic effects in combination with the primary medical 
application of Eto as an anesthetic suggest insufficient effect specificity of the compound, which 
makes it unsuitable as a reference inhibitor of GC biosynthesis. 
 
Mety is a drug used for the diagnosis of adrenal insufficiency and, like the former two 
candidates, for the treatment of Cushing's syndrome (Paek et al. 2015; Sosenko, Lewis, and 
Frank 1986). It is mechanistically suited as a control inhibitor, as it also blocks the biosynthesis of 
Cort by reversibly inhibiting steroid 11β-hydroxylase (Bergström et al. 1998; Gold et al. 1960). 
Inactivation of this enzyme reduces the negative feedback mechanism on adrenocorticotropic 
hormone (ACTH) production, which induces the secretion of ACTH and thereby increases the 
plasma levels of 11-deoxycortisol, the direct precursor of Cort. 
As shown in Figure 20 c, Mety concentration-dependently inhibited the Preg-induced GRIZLY 
signal, but had no effect on Dex-induced signaling. This is consistent with the expected effect 
mechanism of Mety to not directly interfere with the GR activity (as Mife does) in the transgenic 
larvae, but to inhibit the biosynthesis of endogenous Cort. Moreover, in contrast to the two 
other candidates, Mety showed no indications of toxicity or harm for the larvae at any 
concentration tested. These results qualify Mety as a suitable control inhibitor of Preg-induced 
Cort biosynthesis. The concentration of 40 µM was selected for control applications in the 
GRIZLY assay. In Figure 22, a broader range [10 - 50 µM] of test concentrations (than in Figure 20 
c; 30 - 50 µM) is shown for Mety in co-exposure with Preg (a) and Dex (b) in order to emphasize 
a clear concentration-dependency in the inhibitory effect of Mety. 
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Figure 22:  Metyrapone inhibits  Pregnenolone-, but not Dexamethasone-induced glucocorticoid  
signaling in vivo  
Metyrapone inhibited concentration -dependently  Preg- (a) ,  but not Dex-induced (b)  GC signal ing 
in larvae. Relat ive AUC values are shown for a range  of f ive different concentrations of 
Mety  + Preg [5 µM] (a)/ Dex [20 µM] (b)(grey, n = 16). The data are normalized relative to the 
negative control DMSO + Preg  [5 µM] (a)/ Dex [20 µM] (b)  (blue, n = 8) and the DMSO control 
(blue,  n = 8).  The amount of DMSO was 0.2% in all  treatment condit ions.  Data are shown as 
means + SEM. Statist ical significance is determined by comparison of each treatment condition 
with the negative control in a multiple t -test,  α  = 0.01. After multiple test ing correction with the 
Holm-Šídák method, significance is def ined as p  < α < 0.002= *.  
 
Combined compound analysis with different variations of the GRIZLY 
The validation experiments with the selected controls show in summary that the combined 
application of two different GRIZLY testing approaches does indeed represent a revealing tool to 
investigate diverse mechanisms of GC inhibition. While both setups detect inhibitors that 
interfere directly with GR signaling in larvae, exclusively the first approach also allows GC 
signaling induction in cultured cells and, thus, enables the comparison of compound effects in 
vivo and in vitro. In return, the second approach additionally permits the identification of 
upstream inhibitors and disruptors of the GC biosynthesis pathway in vivo. Therefore, the 
comparative analysis of a compound screen conducted with three variations of the GRIZLY assay 
(Figure 9) will provide first hints of compound-specific mechanisms of action. The three variants 
of the GRIZLY assay and their endpoints are: 
 
GRIZLY 1 - Inhibition of directly activated GC signaling (with Dex) in AB.9-GRE:Luc cells 
GRIZLY 2 - Inhibition of directly activated GC signaling (with Dex) in Tg(GRE:Luc) larvae 
GRIZLY 3 - Inhibition of indirectly activated GC signaling (with Preg) in Tg(GRE:Luc) larvae 
3. 2 Testing strategy - A tiered approach 
The FDA drug library should be screened with these three variations of the GRIZLY assay in order 
to target the three aims of my study, 1) to assess the suitability of the GRIZLY assay for the 
detection of GC signaling inhibitors, 2) to identify disruptors of the GC biosynthesis pathway and 
3) to identify compounds with - so far - unknown potential to interfere with GC signaling or with 
unknown mechanisms of action. The outcomes of the screens with the three GRIZLY assay 
variations should allow me to pre-categorize compounds, for instance as putative GR antagonists 
or as disruptors of the Cort biosynthesis. In order to validate the screen results and to proof the 
GRIZLY assay suitability for the detection of GC signaling inhibitors, the identified hits will have to 
P re g n e n o lo n e  [5  µ M ] +  M e ty  la rv a e
T re a tm e n t
R
e
la
ti
v
e
 A
U
C
 [
%
]
D
M
S
O
 +
 P
re
g
1
0
 µ
M
 +
 P
re
g
2
0
 µ
M
 +
 P
re
g
3
0
 µ
M
 +
 P
re
g
4
0
 µ
M
 +
 P
re
g
5
0
 µ
M
 +
 P
re
g
D
M
S
O
0
5 0
1 0 0
1 5 0
*
*
**
*
a D e x a m e th a s o n e  [2 0  µ M ] +  M e ty  la rv a e
T re a tm e n t
R
e
la
ti
v
e
 A
U
C
 [
%
]
D
M
S
O
 +
 D
e
x
3
0
 µ
M
 +
 D
e
x
3
5
 µ
M
 +
 D
e
x
4
0
 µ
M
 +
 D
e
x
4
5
 µ
M
 +
 D
e
x
5
0
 µ
M
 +
 D
e
x
D
M
S
O
0
5 0
1 0 0
1 5 0
*
b
3. 2 Testing strategy - A tiered approach  
58 
be confirmed by retesting. For further characterization of the compound effects, also suitable 
follow-up studies will have to be conducted.  
Therefore, I planned my experiments according to the principle of a tiered testing approach 
(Figure 23), whereby I aimed to isolate real candidates of interest out of a library of compounds. 
With increasing testing complexity and endpoint specificity, substances which are beyond the 
focus of the study should successively be excluded. 
 
Tier 1 is designated to detect GC signaling disruptors from the drug library. The three GRIZLY 
screens are performed and the FDA library compounds are measured for their potential to 
inhibit directly activated GC signaling in cells (GRIZLY 1), directly activated GC signaling in larvae 
(GRIZLY 2) and indirectly activated GC signaling in larvae (GRIZLY 3). Furthermore, compound 
toxicity is assessed in this step, in order to distinguish between specific inhibitors and false-
positive hits, where compounds decrease the GC signal because they are toxic to cells or larvae. 
Statistically significant, non-toxic hits are then transferred to the next level. 
 
In tier 2, the screen hits are validated. The respective substances are purchased from a different 
supplier in order to exclude false-positive screen hits that derived e.g. from contaminated library 
compounds. Test solutions in at least five nominal concentrations are prepared for each 
substance and they are exposed to cells and larvae in the same three testing setups as before in 
the screen. Compounds that are confirmed during retesting are considered verified disruptors of 
GC signaling. With a high correlation between the detected screen hits and the confirmed GC 
signaling disruptors, a good assay reliability is indicated, whereby the first aim of this study, to 
assess the suitability of the GRIZLY assay for the detection of GC signaling inhibitors, would be 
achieved. Confirmed disruptors of GC signaling are then considered in a combined analysis of 
compound effects in all three GRIZLY approaches. This will provide more information about the 
compound effect dynamics and may help to pre-categorize their potential mechanisms of action. 
Validated compounds with disruptive effects on GC signaling are subjected to selected follow-up 
experiments. 
 
Tier 3 serves a more detailed characterization of compound effects in order to address the two 
other aims of this study, to identify 2) disruptors of the GC biosynthesis pathway and 3) 
compounds with - so far - unknown potential to interfere with GC signaling and/ or with 
unknown mechanisms of action. 
In tier 3a, confirmed in vivo disruptors of GC signaling are examined for their effects on 
endogenous steroid hormone levels. For this, larvae are exposed to reasonable concentrations 
of the selected compounds in co-exposure with Dex and Preg, respectively. UPLC-MS/MS 
experiments are conducted with larvae homogenates and endogenous concentrations of Preg, 
Prog, Cort and Dex (only in Dex-exposed larvae) are measured. Altered steroid hormone levels 
identified by chemical analysis provides valuable information about inhibitory compound effects 
on the steroid hormone biosynthesis pathway, drug uptake and -metabolism. 
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Tier 3b consists of gene expression analysis with validated in vivo GC signaling disruptors. The 
same treatments as for UPLC-MS/MS experiments are applied to the larvae. Real-time qPCR 
experiments are performed and a set of selected target genes is analyzed for compound effects 
on mRNA expression. The obtained gene expression patterns provide  more insight into the 
compound mechanisms of action. 
 
 
Figure 23: Schematic structure of the tiered testing approach  
With increasing endpoint specific ity,  the number of l ibrary compounds is  successively reduced 
until  the candidates of interest are isolated from a library of compounds. From each level,  only 
statistically  signif icant  and relevant hits are carr ied forward. Tier  1 consists of the drug library 
screen with three variations of the GRIZLY assay in order to de tect inhibitors of GC signaling. In 
tier  2, screen hits are retested concentration -dependently  in all  three GRIZLY variants. Tier 3 
serves to gain more information about the compound effect  mechanisms in order to identify 
disruptors of GC biosynthesis and GC signaling inhibitors with unknown mechanisms of action . In 
tier  3a, UPLC-MS/MS experiments are conducted with validated in vivo  disruptors of GC signaling. 
Compound effects on endogenous steroid hormone levels and on Dex uptake and metabolism are 
assessed in chemical analysis.  In tier  3b, qPCR experiments are performed with validated in vivo  
disruptors of GC signaling. A set of target genes is analyzed for expression changes mediated by 
the compounds. The obtained gene expression patterns provide more in formation about the 
compound mechanisms of action.  
3.3 Tier 1: Screening of the FDA library 
The FDA library was screened with the three GRIZLY variants. In GRIZLY 1, GC signaling was 
directly activated with Dex [20 µM] in AB.9-GRE:Luc cells in order to detect compounds that 
interfere with GR signaling in a cell autonomous fashion. Mife [1 µM] served as a control 
inhibitor, as it directly antagonizes the GR and prevents GC target gene transcription. The in vitro 
approach specifically enables the detection of substances which disrupt GC signaling without 
prior metabolic activation or tissue-specific interactions. 
In GRIZLY 2, the same controls were applied as in GRIZLY 1, but to Tg(GRE:Luc) larvae. This setup 
targets to detect disruptors of GR signaling in vivo, taking into account whole-organism effects of 
the compounds. GRIZLY 3 was also conducted in vivo, but with Preg [5 µM] as control activator 
and Mety [40 µM] as reference inhibitor. In this approach, GC signaling is indirectly stimulated, 
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as the Tg(GRE:Luc) larvae metabolize Preg into Cort, which then agonizes the GR. In addition to 
GC signaling inhibition by mechanisms also targeted in GRIZLY2, indirect effects, in especially 
disruptions of the Cort biosynthesis pathway can be detected in this assay mode. The same 
testing conditions were applied in order to assess toxicity in the three screening setups. 
3.3.1 Screens for toxicity assessment 
For the in vivo assays, larvae toxicity was assessed after 24 h exposure. Immediately at the end 
of each GRIZLY screen, the cover films of the 96-well plates were opened and immobile and dead 
larvae were scored. Compounds were considered as potentially toxic in vivo if the amount of 
immobile larvae was ≥ 10%. Out of 640 library compounds, 133 were regarded as toxic in at least 
one of the two in vivo assays. 
In vitro, toxicity was assessed in a separate screen. Two different cytotoxicity testing methods 
were applied simultaneously, the AlamarBlue® and the LDH assay. Compounds were considered 
as cytotoxic when statistically significant reduction of cell viability (AlamarBlue®) or induction of 
cell death (LDH) was confirmed in one of the two assays. By means of the AlamarBlue® cell 
proliferation assay, 12 compounds were identified as cytotoxic. Assessment with the LDH assay 
did not lead to any significant results.  
 
In total, toxicity was detected in 140 out of 640 compounds. The numbers of toxicants and their 
overlap between the different screening approaches are shown in the Venn diagram in 
Figure 24. In GRIZLY 1, 12 substances were toxic, 77 in GRIZLY 2 and 97 in GRIZLY 3. According to 
the low number of substances that were toxic in vitro, only two compounds were identified as 
toxic in all three screens. Two other compounds were found in both the larvae and the cell 
culture screen for inhibition of directly activated GC signaling. Between GRIZLY 1 and GRIZLY 3, 
only one substance was found to be toxic in common. Seven compounds showed toxicity in the 
cell assay while they were not harmful for larvae. The overlap of toxicants found between the 
two in vivo screens was 50% for GRIZLY 2 (39 out of 77) and 40% for GRIZLY 3 (39 out of 97). 
 
 
Figure 24: Venn diagram showing toxicity in the FDA library screens  
FDA ibrary compounds were defined as toxic in vivo ,  i f  ≥ 10% of larvae were immobile ,  or in vitro ,  
if  cytotoxicity  was statist ical ly  significant with p  <  α <   0.0001 in at  least one out of the 
AlamarBlue® and the LDH assay. In 140 out of 640 screening compounds, toxicity was found. The 
numbers of toxic compounds identif ied in each screen  are indicated in colored circles. GRIZLY 1 - 
inhibition of directly  activated  GC signaling in cells : blue; GRIZLY 2 - inhibition of directly  
activated GC signaling in larvae: orange; GRIZLY 3 - inhibition of indirectly  act ivated GC signal ing 
in larvae: pink. Numbers assigned to o verlapping areas between the circles  indicate the number 
of compounds with common toxicity  in two or three screens.  
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3.3.2 Screens for inhibitors of GC signaling in three GRIZLY assay modes 
 
Figure 25: Result overview of the FDA approved drug library screen in the three GRIZLY screen 
modes 
Data are normalized relative to the negative control (100%) and the positive control (0%), mean 
relative AUC values are shown (DMSO in all  treatments 0.2%). a)  Inhibition of directly  activated 
GC signal ing in vitro  (n = 3  -  4).  b)  Inhibit ion of directly  activated GC signaling in vivo  (n = 5  -  10).  a 
+ b)  Treatment conditions:  Dex [20 µM] +  l ibrary compounds (black),  negative control: D ex [20 
µM] + DMSO (grey); positive control D ex [20 µM] + M ife [1 µM] (not shown). c)  Inhibition of 
indirectly  activated GC signaling in vivo  (n = 3  -  10) . Treatment: Preg [5 µM] +  l ibrary compounds 
(black),  negative control: P reg [5 µM] + DMSO (grey); positive control P reg [5 µM] + Mety [40 µM] 
(not shown). The amount of DMSO was 0.2% in all  treatment conditions.  Stat istical s ignificance is  
determined by a multiple t -test (α = 0.05) and corrected for multiple comparisons according to the 
Holm- Šídák method with p < α < 0.0001. Significant inhibitors (green) and superactivators  (red) 
are highlighted.  
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Overview of screen results 
The FDA library was screened with the three variations of the GRIZLY assay. Statistical analysis 
was conducted for all 640 compounds, but the 140 potentially toxic candidates were excluded 
from data visualization, in order to highlight only real (non-toxic) significant hits. In Figure 25, 
the outcomes of GRIZLY 1 (a), GRIZLY 2 (b) and GRIZLY 3 (c) are shown. Mean relative AUC values 
are indicated for 500 library compounds (black), normalized on their controls (negative control: 
grey, positive control not shown). 
The data distribution is diverse between the three screens. The majority of values is scattered 
closely around the negative control, but in each screen, several significant hits were identified. 
These mostly reduced GC signaling, (green) but in some cases, also superactivation of GC 
signaling was detected (red). 
 
Altogether, 16 inhibitors and two superactivators were identified with GRIZLY 1, nine inhibitors 
and two superactivators with GRIZLY 2 and 12 inhibitors plus one superactivator in GRIZLY 3. The 
total numbers of identified compounds and their overlaps between the different screening 
approaches are visualized as Venn diagrams in Figure 26. Among the 29 inhibitors (a), two 
compounds were identified as significant hits in all three screens and four candidates were 
inhibitors in two screens each, but the majority was uniquely detected within the respective 
setup. For the five identified superactivators (b), no overlap occurred between the single 
screens. 
 
  
Figure 26: Venn diagrams - inhibitors and superactivators of  glucocorticoid signaling  
The Venn diagrams show the distr ibution of significant inhibitors  (a)  and superactivators (b)  of 
glucocorticoid signaling according to the three GRIZLY assay variants . The numbers of signif icant 
inhibitors and superactivators identified in each screen are indicated in colored circles.  GRIZLY 1 - 
inhibition of directly  activated  GC signaling in cells : blue; GRIZLY 2 - inhibition of directly  
activated GC signaling in larvae: orange;  GRIZLY 3 - inhibition of indirectly  activated GC signaling 
in larvae: pink. Numbers assigned to o verlapping areas between the circles  indicate the number 
of compounds with common inhibitory or superativating effects  in two or three screens.  
 
Detailed screen results 
The detailed screen results are shown as color code profiles in Figure 27. Color code profiles are 
shown for controls and library compounds. No difference of the substance effect compared to 
the negative control (Dex [20 µM]/ Preg [5 µM] + DMSO) is indicated in yellow. A significantly 
increased or decreased signal intensity compared to the negative control is indicated in green  
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Figure 27:  Significant hits identif ied in three GRIZLY screening approaches  
Color code profiles are show n for controls and library compounds. No difference of the substance 
effect compared to the negative control ( Dex [20 µM]/ Preg [5 µM]  + DMSO) is indicated in yellow. 
A significantly  increased or decreased signal intensity  compared to the negative control is 
indicated in green and red, respectively. Non-significant trends (p < α < 0.05)  for  increase or 
decrease are shown in orange and light green, respectively. Significan ce is defined as 
p < α < 0.0001.   
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of signal intensity; significance  = p < α = 0.0001
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and red, respectively. The FDA library screen concentration was 4 mg/l, the corresponding 
concentrations in [µM] are indicated for each compound. 
In addition to the 34 compounds with significant effects in at least one of the three GRIZLY 
approaches, Estriol is included in the figure. Although it had no significant effect, it showed a 
strong trend to inhibit Preg-induced signaling, which was confirmed by concentration-dependent 
retesting (see below, chapter 3.2.2). Mife, which was applied as positive control inhibitor of 
directly activated GC signaling was identified as a library compound. It was one of the two 
substances in the FDA library which inhibited GC signaling in all three GRIZLY screens. The 
recovery of this reference GR antagonist from a library of 640 compounds within all setups 
serves as a proof of principle for the suitability and reliability of the GRIZLY assay screening 
approach. 
 
Selection of compounds for tier 2 
During the screening procedures, several inhibitors and also superactivators of GC signaling were 
detected. However, these findings had to be confirmed by retesting procedures, in order to 
show the reproducibility and reliability of the results, and to qualify the GRIZLY assay as a 
suitable test system for the detection of GC signaling disruptors. 
For retesting, the total number of candidates should be reduced due to feasibility issues. 
According to the second aim of the study, to identify potential disruptors of the GC biosynthesis 
pathway, all compounds that inhibited Preg-, but not Dex-induced signaling were most 
promising and thus selected for the next testing step. 
Furthermore, covering the third aim of the study, to identify disruptors of GC signaling with 
unknown mechanisms of action, all candidates which significantly inhibited in two or three 
GRIZLY setups were selected, as well as several inhibitors of Dex-activated signaling only, four 
from the larvae- and two from the cell screen. Of the five superactivators, all except one 
(Fulvestrant) were retested, as Fulvestrant was the only compound which exclusively 
superactivated in vitro without any effect trend in vivo, and thus was aside the focus of this 
study. Altogether, 11 compounds were excluded from retesting (highlighted in grey in Figure 27) 
and 24 substances were selected for tier 2.  
3.4 Tier 2: Retesting of screen hits 
In order to validate the findings from the chemical screens, the selected compounds were 
retested concentration-dependently. For this, they were ordered from a different supplier in 
order to eliminate potential unspecific effects due to e.g. impure synthesis procedures or 
contaminations during library preparation. Then, these compounds were retested in all three 
GRIZLY setups, in at least five different nominal concentrations each. The range of 
concentrations was selected surrounding the applied screening concentration. In cases where 
none of these concentrations appropriately reproduced the screening results, the range was 
adjusted accordingly.  
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3.4.1 Assessment of screen reliability 
For the assessment of the assay reliability, the screening outcomes are compared with the 
retesting results in Figure 28. The compounds are grouped according to their effect patterns in 
the retest. Color code profiles are shown for controls and library compounds. No difference of 
the substance effect compared to the negative control (Dex [20 µM]/ Preg [5 µM] + DMSO) is 
indicated in yellow. A significantly increased or decreased signal intensity compared to the 
negative control is indicated in green and red, respectively. The FDA library screen concentration 
was 4 mg/l, the corresponding concentrations in [µM] are indicated for each compound. 
Validated inhibitors or superactivators from retesting are indicated with their lowest observed 
effect concentration (LOEC) in the respective GRIZLY assay. Assay reliability is surveyed by direct 
comparison of a screen result with the respective retesting outcome. Confirmed screen hits or 
trends are noted with a check. Confirmation was given when at least one of the retesting 
concentrations significantly reflected the screen result. Diverging results are indicated with a 
cross.  
In general, the retesting results largely confirmed the screening outcomes. From 72 screen 
results, 16 could not be confirmed, which accounts for 22%. Thereof, nine compounds (12.5%) 
were false-negatively not detected by the screen, but identified during concentration-dependent 
retesting. In some cases, the LOEC in the retest was higher than the screen concentration, which 
explains the lack of identification within the screen. For the compounds where the screen 
concentration was as high as or higher than in retesting, a high variance within screen replicates 
was potentially the reason why they were not detected as significant inhibitors or 
superactivators in the first place. 
From the total 22% of non-confirmed results, the other seven compounds (9.5%) were 
false-positively identified in the screen. In these cases, lacking reproducibility by concentration-
dependent retesting with newly ordered compounds might indicate that single wells on the 
library stock plates were possibly contaminated (which may have bben the case for instance 
Nisoldipine, which showed superactivation in GRIZLY 2 in the screen). Potentially, carry-over 
from other library compounds may have induced the effects within screening conditions. 
Altogether, with a recovery rate of 78%, the screen reliably detected disruptors of GC signaling. 
Not only significant hits but also observed trends in the screen (e.g. reduced GC signaling in 
GRIZLY 3 by Estriol) were reproduced and confirmed during retesting. Accordingly, the first aim 
of this study was achieved. The GRIZLY assay is a suitable tool to detect inhibitors of GC 
signaling. Moreover, it enabled the detection of superactivators, which constitutes an additional 
useful application of the assay. 
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Figure 28: Comparison of screen and retest  indicates reliable performance of the screen protocol  
Color code profiles are shown for controls and library compounds. No difference of the substance 
effect compared to the negative control ( Dex [20 µM]/ Preg [5 µM]  + DMSO) is indicated in yellow. 
A significantly  increased or decreased signal intensity  compared to the negative control is 
indicated in green and red, respectively. Non-significant trends (p < α < 0.05  for  increase or 
decrease are shown in orange and light green, respectively. Significance is defined as 
p < α < 0.0001 for the screen (α = 0.05) and p < α < 0.002 for retesting (α = 0.01). Validated 
inhibitors or superactivators from retest ing are indicated with their  lowest observed effect  
concentration (LOEC) in the respective GRIZLY assay. Assay reliabili ty  is surveyed by direct 
comparison of a screen result with the respective retesting outcome. Confirmed screen hits or 
trends are noted with a check. Confirmation was given when at least one of the retesti ng 
concentrations significantly  reflected the screen result.  Diverging results are indicated with a 
cross.  
3.4.2 Combined analysis of compound effects in all three GRIZLY assay modes 
For a more detailed analysis of the identified substances and their impacts on GC signaling, 
compounds showing the same effect patterns in the three GRIZLY assay screens are compared 
with each other on the following pages. Within this context, also the bioluminescence traces 
over time, which were measured for each treatment condition, are considered, as they can 
sign. decrease/ decreasing trend/ no change/ increasing trend/ sign. increase of signal intensity;
significance = p < α = 0.0001 for screen and  p < α = 0.002 for retesting results; trends = p < α = 0.05
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possibly provide useful information about compound-specific dynamics. As examples for normal-
shaped bioluminescence dynamics, an overview of the signal traces measured over time for this 
study´s control activators and inhibitors is given in Figure 29.  
 
 
Figure 29: Bioluminescen ce traces of control activators and inhibitors of  glucocorticoid  
signaling  
Bioluminescence traces were detected over 24h of exposure to treatment combinations with 
control activators (Dex, Preg a nd Cort) and inhibitors (Mife [0.2  -  1 µM], Mety [10  -  50 µM]).  
Bioluminescence was measured in relative l ight units (RLUs). Data are shown as mean  relat ive 
light units (RLUs) ± SEM. (a)  Dex [20 µM] + Mife in cel ls and ( b)  in larvae. (c)  Peg [5 µM] + Mife,  
(d)  Cort [30 µM] + Mife (e)  Dex [20 µM] + Mety, ( f)  Preg [5 µM] + Mety, (g)  Cort [30 µM] + Mety, 
all  in larvae. All  treatments are presented  relative to the respective negative (Dex [20 µM]/ Preg 
[5 µM]/ DMSO + DMSO; blue)  and posit ive (Dex [20 µM]/ Preg [5 µM] + Mife [1 µM]/ Mety [40 
µM]/ Dex [20 µM]; red) control.  The amount of DMSO was 0.2% in all  treatments.  
 
The activators Dex, Preg, and also directly administered Cort are each co-exposed with either 
Mife or Mety. The graphs show that the uninhibited bioluminescence traces of all activators 
(negative controls, blue) form a bell-shaped signal over time. The timepoints of signal peaks vary 
between the different setups, with cells showing maximal bioluminescence earliest, after 4h. In 
larvae, the signal peaks later, between 5 h (g) and 16 h (c), depending on the individual testing 
conditions. However, it is noticeable in all larvae exposures (b - g) that the activator signal starts 
to decrease between 5h (g) and 16h (c). This effect may rely on homologous downregualion of 
the GR (GRα), a mechanisms which is often observable under chronic stimulation of GC signaling 
(as it will be described in detail below in section 4.4.2.4).  Despite this decrease, the 
bioluminescence signal measured in larvae does not fall back to the ground level from the 
exposure start. Instead, it remains elevated until the end of the exposure duration. This is in 
contrast to the cell behavior, where the signal height falls back to ground intensity after 20 h 
exposure (a). 
Regarding the inhibitors (positive controls, red), Mife reduces the height of the signal curve in all 
exposure scenarios in a concentration-dependant manner (a - d). Mety does not affect signal 
activation by Dex (e) or directly administered Cort (g), as the bioluminescence signal curves are 
not altered when compared to the negative controls, but it inhibits concentration-dependently 
the Preg-induced signal (f).  
 
Similar to this example, the bioluminescence traces of the validated inhibitors and 
superactivators from Figure 28 will be taken into account for the evaluation of compound 
effects. Abnormal shapes of signal traces could provide information about the effect dynamics of 
a compound. Therefore, the bioluminescence signal curves may also constitute a revealing 
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resource for the pre-catigorization of compound mechanisms of action. In the following figures, 
compounds with the same effect patterns are grouped together and their bioluminescence 
traces in all three GRIZLY assay variants are examined for abnormalities.  
 
Pattern group 1 
Compounds which inhibited in all three GRIZLY assays were assigned to pattern group 1. In 
Figure 30, their effect patterns with LOECs for each assay and  the bioluminescence traces are 
shown. The five members of this group are Mife, 10-Hydroxycamptothecin (10-HC), Tranilast 
(Trani), Retinoic acid (Ret. acid) and Acitretin (Aci). 
 
 
Figure 30:  Bioluminescence traces of effect  pattern group 1 compounds  
Effect patterns with LOECs [µM] and the bioluminescence traces from all three GRIZLY assay 
variants are shown for Mifepristone (Mife; a - d) ,  10-Hydroxycamptothecin (10-HC; e - h) ,  
Tranilast  (Trani; i  -  l) ,  Retinoic acid (Ret. ac id; m - p)  and Acitretin (Aci; q -  t)  in combination with 
Dex [20 µM] in cel ls and larvae and with Preg [5 µM] in larvae.  Bioluminescence was measured for 
24h and data are shown as mean  relative light units (RLUs) ± SEM. All treatments are presented  
relative to the respective negative (Dex [20 µM]/ Preg [5 µM] + DM SO; blue)  and positive (Dex [20 
µM]/ Preg [5 µM] + Mife [1 µM]/ Mety [40 µM]; red) control.  The amount of DMSO was 0.2% in all  
treatments.  
 
Mife reduced GC signaling in all three GRIZLY assay variants (a - d) because it directly 
antagonizes the GR, irrespective of whether the agonistic ligand is Dex or Cort. The signal 
pattern of Mife could thus be expected for every GR antagonist which is active in vitro and 
in vivo. As all inhibitors of pattern group 1 showed the same signal kinetics as they are observed 
Mife, with some minor differences, GR antagonism could be assumed to be their mechanism of 
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action. However, to my knowledge, none of them has been annotated as a GR antagonist so far 
in the literature.  
 
Effects on luciferace enzyme activity 
Alternative mechanisms have to underlie the observed signal decreases. As these compounds 
inhibited in all three GRIZLY assays, it may  also be possible that they had inhibitory effects on 
the activity of the luciferase enzyme itself. Therefore, I conducted a control experiment in order 
to assess the luciferase activity independent from GC signaling. I transiently transfected wildtype 
AB.9 cells with the pGL3-Control vector, which contains a constitutively active promoter driving 
luciferase expression. Transfected cells were then co-treated with Dex and the inhibitors from 
pattern group 1, which were applied in one concentration that showed an equally strong signal 
inhibition within retesting as the positive control. The relative AUC values of these treatment 
conditions were normalized to those of transfected cells treated with the negative control 
condition Dex + DMSO. 
 
The outcomes of the experiment are shown in Figure 31. Ret. acid [2 µM] signlificantly reduced 
the luciferase activity (67 %) compared to the control condition (100 %). All other compounds 
had no significant effects on the activity of the luciferase enzyme, which excludes the possibility 
that their inhibitory effects in the GRIZLY assay relay on compound interference with the 
reporter protein. Only the inhibitory effect of Ret. acid on the luciferase activity may have 
contributed to the observed GC signaling disruption in all three GRIZLY assays. However, this 
effect alone cannot have been responsible for the observed inhibition, as the signal decrease 
was considerably stronger on the GRE-containing promotor sequence than with the pGL3-
Control vector. Thus, the reduction of luciferase activity will not be considered in later 
discussions as the main mechanism by which Ret. acid inhibited the GRE:Luc reporter. 
 
 
Figure 31: Effects  of inhibitors from pattern group 1 on l uciferase reporter activity in t ransiently  
transfected AB.9-pGL3-control  cells  
Wildtype AB.9 cells were transiently  transfected with the pGL3 -Control vector that contains a 
constitutively  active promoter driv ing luciferase expression. AB.9-pGL3-control  cells were treated 
either with Dex [20  µM] + DMSO (blue, negative control)  or with Dex [20 µM] + the five inhibitors 
from pattern group 1 (grey) ,  Mife, 10 -HC, Trani,  Ret. acid and Aci,  respectively. Untransfected 
AB.9 cells were treated with DMSO as a trans fection control (no signal induction).  The amount of 
DMSO was 0.2% in all  treatment conditions. AUC values are given relat ive to the negative control.  
Data are shown as means  + SEM (n = 3).  S ignificanly  altered relative AUC values are indicated 
with an asteriks.  Stat istical  s ignificance is determined by comparison of each treatment condition 
with the negative control in a multiple t -test,  α=0.05.  After  multiple test ing correction with the 
Holm-Šídák method, significance is def ined as p  < α < 0.005 = *.  
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Pattern group 2 
All compounds which superactivated the Dex-induced signal in larvae were assigned to pattern 
group 2. Their effect patterns with LOECs for each assay and  the bioluminescent traces are 
shown in Figure 32. The five members of this group are Gestrinone (Gestri), Norethindrone 
(Nor), Ethisterone (Ethi), Stanozolol (Stano) and Spironolactone (Spiro). Despite the common 
superactivation in GRIZLY 2, the compound effects in GRIZLY 1 and GRIZLY 3 are diverse. Gestri, 
Nor, Stano and Spiro inhibited GC signaling in cells but Ethi had no effect in GRIZLY 1 in any 
retested concentration. Gestri and Nor inhibited also Preg-induced GC signaling in larvae, which 
is interesting as it is opposite to their in vivo effect on Dex-activated GC signaling. Ethi had no 
effect in GRIZLY 3, which makes the superactivation in GRIZLY 2 the only impact of the 
compound on GRIZLY activity. Stano and Spiro, similar to their effects in GRIZLY 2, superactivated 
GC signaling also in GRIZLY 3. Thus, they showed the same effect in larvae with both activators 
they were co-exposed with.  
 
Figure 32: Bioluminescence traces of effect  pattern group 2 compounds  
Effect patterns with LOECs [µM] and the bioluminescence traces from all three GRIZLY assay 
variants are shown for Gestr inone (Gestr i;  a - d) ,  Norethindrone (Nor; e - h) ,  Ethisterone (Ethi; i  -  
l) ,  Stanozolol (Stano; m - p)  and Spironolactone (Spiro; q - t)  in combination with  Dex [20 µM] in  
cells and larvae and with Preg [5 µM] in larvae. Bioluminescence was measured for 24h and data 
are shown as mean relative light units (RLUs) ± SEM. All treatments are presented  relative to the 
respective negative (Dex [20 µM]/ Preg [5 µM] + DM SO; blue)  and posit ive (Dex [20 µM]/ Preg 
[5 µM] + Mife [1 µM]/ Mety [40 µM];  red) control.  The amount of DMSO was 0.2% in al l  
treatments.  
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The bioluminescence traces reveal that all inhibitors in GRIZLY 1 had concentration-dependent 
effects (b, f, n, r). In GRIZLY 2, where all compounds superactivated the Dex-induced signal, the 
bioluminescence traces appear to increase constantly with Gestri (c), Nor (g), Ethi (k) and Stano 
(o), without the expectable signal decrease that normally sets in somewhere between 5 - 16 h of 
GC exposure (see Figure 29, e.g. f or c, blue lines for negative control). For Stano, the increase is 
not completely constant; a saddle point is visible between 14 - 16 h, before the signal augments 
a second time until the end of the measurement. With Spiro (s), the signal was already relatively 
high from the beginning. The slope of the bioluminescence signal is much stronger than that of 
the negative control (blue line). Towards the end of the exposure time, after 18 h, the signal 
appears to rest on a plateau or to decrease slightly, which is in contrast to the bioluminescence 
kinetics of all other superactivators in GRIZLY 2.  
The two inhibitors in GRIZLY 3, Gestri (d) and Nor (h), strongly inhibited the Preg-induced signal 
in all concentrations tested. Retests with lower concentrations will be necessary to assess the 
concentration-dependency of their effects. For Ethi, which had no significant effect in GRIZLY 3 
(l), the bioluminescence traces may indicate a slightly altered effect kinetic, as the signal appears 
to constantly increase over time, similar to the signal curve shape observed with the compound 
in GRIZLY 2. The bioluminescence signal of Stano increases constantly in GRIZLY 3 (p) and shows 
no saddle point between 14 - 16 h as in GRIZLY 2. Also in contrast to the kinetic observed for this 
compound in GRIZLY 2, the bioluminescence signal of Stano remains on a constant level after 17 
h of larvae exposure until the end of the measurements. Spiro shows a similar effect kinetic in 
GRIZLY 3 (t) as in GRIZLY 2; the bioluminescence signal increases quickly from the beginning  
before it starts to rest on a plateau after 16 - 18 h of exposure.  
 
Compound interference with GR activity 
The superactivation in GRIZLY 2 that was observed with Gestri, Nor, Ethi, Stano and Spiro 
suggests that the five compounds activated the GR in larvae. They may have agonized the 
receptor either with higher affinity than Dex, or their ligand binding led to a stronger induction 
of GC signaling. However, none of the substances is known to agonize the GR. Also, none of 
these compounds was identified in the pilot chemical screen, where the FDA library was tested 
with the GRIZLY assay for compounds that activate GC signaling (Weger et al. 2012). As the 
testing conditions may have been slightly different back then or the current  generation of 
Tg(GRE:Luc) zebrafish may have a different sensitivity than that used for the published screen,  I 
retested if the five compounds activated GC signaling under the present testing conditions when 
they were exposed to the larvae as single substances. In case of GR agonism, I expected that GC 
signaling induction should also be detectable without the co-treatment with Dex or Preg. 
However, this was not the case, as shown in Figure 33. None of the five compounds induced GC 
signaling when exposed to the larvae as single substance treatments, although the same 
concentrations were applied as before. 
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Figure 33:  GRIZLY assay results for pattern group 2 compounds with exposure alone or in 
combination with directly administered Cort isol  
Effects of the compounds from pattern group 2 in all  three GRIZLY assays and during retest ing  
with compound exposure alone and in co -treatment with directly  administered Cort are shown. 
The LOECs for Gestr i,  Nor, Ethi,  Spiro and Stano are indicated for each exposure condi tion. Color 
code profiles are shown for controls and compounds. No difference of the substance effect  
compared to the negative control ( Dex [20 µM]/ Preg [5 µM]  + DMSO) is indicated in yellow. A 
significantly  increased or decreased signal intensity  compared to the negative control is indicated 
in green and red, respectively. Non-significant trends (p < α < 0.05  for  increase or decrease are 
shown in orange and light green, respectively. Signif icance is  defined as p < α < 0.0001 for the 
screen (α = 0.05) and p < α < 0.002 for retesting (α = 0.01). Validated inhibitors or superactivators 
from retesting are indicated with their  lowest observed effect concentration (LO EC) in the 
respective GRIZLY assay. Assay reliabil ity  is surveyed by direct comparison of a screen result with 
the respective retest ing outcome. Confirmed screen hits or trends are noted with a check.  
Confirmation was given when at least one of the retesti ng concentrations significantly  reflected 
the screen result.  Diverging results are indicated with a cross .  
 
Apparently, the presence of Dex is necessary for the observed effect. Maybe the ligands do not 
directly activate the GR, but they support GR-mediated signaling by Dex via more indirect 
means. The effect kinetics observed for the five ligands in co-treatment with Dex, as they were 
shown in Figure 32, may support this hypothesis. The rather continuous signal increase over 
time that was visible for larvae treated with Dex in combination with Gestri (c), Nor (g) and Ethi 
(k), the biphasic kinetic with Dex + Stano (o) and the extended signal activation with Dex + Spiro 
(s) probably indicate that the compounds intensified, reinforced or stabilized the GR activation 
by Dex. 
 
sign. decrease/ decreasing trend/ no change/ increasing trend/ sign. increase of signal intensity; significance = p < α = 0.002
Cells
DMSO + DMSO
Preg [5 µM] + DMSO
Dex [20 µM] + DMSO
Cort [30 µM] + DMSO
Dex [20 µM] + Mety [40 µM] -
Preg [5 µM] + Mety [40 µM] -
Preg [5 µM] + Mife [1 µM] -
Dex [20 µM] + Mife [1 µM]
Compounds + Dex + Dex + Cort alone + Preg
Gestrinone 4 4 4 4
Norethindrone 40 10 10 10
Ethisterone 4 4
Stanozolol 12 12 4 8
Spironolactone 6 2 2 2
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As  Gestri (a), Nor (e) and Ethi (i) showed different effects on Preg- than on Dex-activated GC 
signaling, I furthermore wanted to assess if the observed superactivation in GRIZLY 2 might be a 
Dex-specific effect. Therefore, I co-exposed the compounds with directly administered Cort. In 
addition to that, I co-treated Spiro and Stano with Cort, as this could provide more information 
about the activator-dependency of the observed effects. 
As also visible in Figure 33, all five compounds superactivated Cort-induced GC signaling. This 
outcome is comparable to the observed overinduction of GC signaling by the compounds in 
combination with Dex. Apparently, superactivation is not a Dex-specific effect of Gestri, Nor Ethi, 
Spiro and Stano, but a direct GR agonist is needed. The results imply furthermore that Preg-
induced signal inhibition by Gestri and Nor is not a Cort-specific effect, but that the Preg-induced 
signal probably is inhibited before Cort can be synthesized. 
 
Next, I wanted to know if the superactivation of Gestri and Nor in GRIZLY 2 and their inhibitory 
effects in GRIZLY 3 would show a concentration-dependency if the compounds were retested in 
lower concentrations. For each compound, I applied a range  of 0.125 - 4 µM to larvae and co-
exposed them with either Dex or Preg. The whole range of test concentrations [0.25-20 µM] is 
shown in in Figure 34. Gestri (a) and Nor (c) still superactivated the Dex-induced signal in all 
concentration tested. The extend of signal increase was similar for all concentrations, it just 
varied a little between 1.8 - 3.1-fold of the negative control (Dex/ Preg + DMSO) signal intensity. 
In co-exposure with Preg, Gestri (b) and Nor (d) showed a concentration-dependent signal 
decrease, with a LOEC of 0.5 µM for Gestri and 2 µM for Preg. Interestingly, Nor also showed 
superactivation of Preg-induced GC signaling in the lowest concentrations [0.25 - 1 µM], with 
0.25 µM beign the LOEC for this effect. Gestri did not induce significant superactivation with 
Preg, but a trend for increased GC signaling might also be indicated for 0.25 µM Gestri + Dex.  
Apparently, the effect mechanisms of Gestri and Nor on GC signaling are complex and it depends 
on the applied compound concentration and on the activator substance whether superactivation 
or inhibition is induced by the treatment.  
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Figure 34: Retest of  Gestr i and Nor in a range of lower concentrations  
Gestri (a  + b)  and Nor (c  + d)  were retested in lower concentrations [0.25-4 µM] for their  effects 
on Dex-(a  + c)  -  and Preg- (b  + d)  act ivated GC signal ing in larvae. Relative AUC values are shown 
for  the whole range of ten different concentrations of Gestr i  [0.25-20 µM]/ Nor [0.25-50 µM] 
+ Dex [20 µM] (grey, n = 16). The data are normalized relative to the negative control Dex [20 
µM]/ Preg [5 µM] + DMSO (blue, n  = 8) and the positive control Dex [20 µM]/ Preg [5 µM] + Mife 
[1 µM]/ Mety [40 µM] (blue,  n = 8) .  The amount of DMSO was 0.2% in  al l  treatments.  Data are 
shown as means + SEM. Statistical  s ignificance is determined by comparison of each treatment 
condition with the negative control in a multiple t -test,  α = 0.05. After multiple testing correction 
with the Holm-Šídák method, significance is def ined as p < α < 0.002  = *.  
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Pattern group 3 
Compounds that inhibited in both in vivo GRIZLY assays but which were ineffective in vitro were 
assigned to pattern group 3. In Figure 35, the effect patterns of Nabumetone (Nabu) and 
Fenbufen (Fen) are shown, with LOECs for each assay and the bioluminescence traces. 
Nabu strongly inhibited Dex- (c) and Preg- (d) mediated GC signaling in all concentrations tested. 
Therefore, I retested the compound in a range of lower concentrations and obtained  LOECs of 
2 µM for Dex + Nabu (see appendix, Supplementary Figure I a) and of 0.25 µM for Preg + Nabu 
(see appendix, Supplementary Figure I b). For Fen, a concentration-dependent inhibition of Dex- 
(g) and Preg (h)-mediated GC signaling was indicated by the bioluminescence traces and the 
compound was therefore not retested in lower concentrations.  
 
 
Figure 35: Bioluminescence traces of effect  pattern group 1 compounds  
Effect patterns with LOECs [µM] and the bioluminescence traces from all three GRIZLY assay 
variants are shown for Nabumetone (Nabu; a - d)  and Fenbufen (Fen; e -  h)  in combination with 
Dex [20 µM] in cel ls and larvae and with Preg [5 µM] in larvae. Bioluminescence was measured for 
24h and data are shown as mean  relative light units (RLUs) ± SEM. All treatments are presented  
relative to the respective negative (Dex [20 µM]/ Preg [5 µM] + DM SO; blue)  and positive (Dex [20 
µM]/ Preg [5 µM] + Mife [1 µM]/ Mety [40 µM]; red) control.  The amount of DMSO was 0.2% in all  
treatments.  
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3.4 Tier 2: Retesting of screen hits  
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Pattern group 4 
All compounds which inhibited in GRIZLY 1 and GRIZLY 3 but not in GRIZLY 2 were assigned to 
pattern group 4. Their effect patterns with LOECs for each assay and  the bioluminescent traces 
are shown in Figure 36.  
 
 
Figure 36: Bioluminescence traces of effect  pattern group 5 compounds  
Effect patterns with LOECs [µM] and the bioluminescence traces from all three GRIZLY assay 
variants are shown for Estrone (a - d) ,  Dehydroepiandrosterone (DHEA; e - h) ,  Ibudilast  ( Ibudi; i  -  
l)  and Galanthamine, (Galant; m - p)   in combination with Dex [20 µM] in cells and larvae and with 
Preg [5 µM] in larvae. Bioluminescence was measured for 24h and data are shown as mean  
relative light units (RLUs) ± SEM. All treatments are presented relative to the respective negative 
(Dex [20 µM]/ Preg [5 µM] + DM SO; blue)  and positive (Dex [20 µM]/ Preg [5 µM ] + Mife [1  µM]/ 
Mety [40 µM]; red) control.  The amount of DMSO was 0.2% in all  treatments.  
 
Estrone, Dehydroepindrosterone (DHEA), Ibudilast (Ibudi) and Galanthamine (Galant) inhibited 
Dex-induced signaling in vitro (b, f, j, n) and Preg-induced signaling in vivo (d, h, l, p). According 
to this effect pattern, these compounds may be inhibitors of the GC biosynthesis pathway. 
Estrone (b) and DHEA (f) showed concentration-dependent inhibition of Dex-induced GC 
signaling in vitro, but of Ibudi and Galant, all concentrations strongly inhibited the signal in 
GRIZLY 1. In GRIZLY 3, the inhibition of Preg-induced GC signaling in larvae by Ibudi (l) was 
concentration-dependent, but Estrone (d), DHEA (h) and Ibudi (p) strongly suppressed the signal 
at all concentrations tested. As Estrone and DHEA were selected for follow-up experiments (as it 
will be described below), I retested the two compounds at lower concentrations [0.25 - 4 µM] 
for their effects on Preg-induced GC signaling. From this experiment (see appendix, 
Supplementary Figure II), I obtained a LOEC of 0.25 µM for Estrone and a LOEC of  4 µM for 
DHEA. 
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Pattern group 5 
Compounds which inhibited only in GRIZLY 3 were assigned to pattern group 5. In Figure 37, 
their effect patterns with LOECs for each assay and  the bioluminescence traces are shown. As 
the two compounds Leflunomide (Leflu) and Estriol inhibited Preg-(d + h) but not Dex-(c + g) 
induced GC signaling in vivo, they are potential inhibitors of the GC biosynthesis pathway.  
Leflu strongly inhibited the Preg-induced signal in all concentrations tested (d) and was hence 
retested in lower concentrations. In this experiment (see appendix, Supplementary Figure III), I 
obtained a LOEC of LOEC 0.5 µM for Leflu. Estriol showed a clear concentration-dependency (h) 
with the higher concentrations and a LOEC of 12 µM. 
 
 
Figure 37: Bioluminescence traces of effect  pattern group 5 compounds  
Effect patterns with LOECs [µM] and the bioluminescence  traces from all three GRIZLY assay 
variants are shown for Lef lunomide (Leflu;  a - d)  and Estr iol  (e - h)  in combination with Dex [20 
µM] in cells and larvae and with Preg [5 µM] in larvae. Bioluminescence was measured for 24h and 
data are shown as mean  relative l ight units (RLUs) ± SEM. All treatments are presented relat ive to 
the respective negative (Dex [20 µM]/ Preg [5 µM] + DM SO; blue)  and positive (Dex [20 µM]/ Preg 
[5 µM] + Mife [1 µM]/ Mety [40 µM]; red) control.  The amount of DMSO was 0.2% in all  
treatments.  
 
According to their effects, several compounds were assigned to pattern group 6 and 7 
(Figure 28, highlighted in grey). However, as Amorolfine and Nisoldipine solely inhibited GC 
signaling in vitro, without any in vivo effects (pattern group 6) and Erlotinib, Pioglitazone and 
Paroxetine could not be confirmed to affect GC signaling during retesting (pattern group 7), they 
are outside the focus of this study and, thus, not discussed further within the combined analysis 
of compound effects in all three GRIZLY assay screens nor considered for follow-up experiments. 
Furthermore, two compounds from pattern group 4, Ibudi and Galant (highlighted in grey) were 
not carried forward, in order to cut down the number of candidates for more detailed 
investigations within the next steps. 
 
Summary of tier 2 
In order to summarize the outcomes of the tier 2 experiments, not only the first aim of the study 
was achieved, but also the two other objectives, to identify GC biosynthesis disruptors and GC 
signaling inhibitors with unknown mechanisms of action, were addressed. The combined analysis 
of compound effects in all three GRIZLY assay screens revealed more detailed insights in the 
effect dynamics on GC signaling and helped to pre-categorize the substances for their potential 
mechanisms of action. For instance, Gestri, Nor, Estrone, DHEA, Galant, Leflu, Ibudi and Estriol 
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potentially act via GC synthesis disruption, while for 10-HC, Trani, Ret. acid and Aci, as for Mife, a 
more direct effect on the GR appears to underlie signal inhibition. 
 
These observations were followed up on in the next steps of this study. In tier 3 a, several 
compounds were analyzed for their effects on the endogenous steroid hormone biosynthesis. 
Especially disruptors of the Cort biosynthesis should be pinpointed by this strategy. In tier 3 b, 
the compound effects on the expression of selected target genes were examined. This should 
provide more information about their presumptive effect mechanisms and help to pursue the 
third aim of this study, to identify GC signaling inhibitors with - so far - unknown mechanisms of 
action. 
3.5 Tier 3 a: Chemical analysis 
By means of chemical analysis, I investigated validated GC signaling disruptors for their effects 
on the endogenous steroid hormone biosynthesis in larvae. As Preg treatment leads to an 
endogenous overproduction of Cort in larvae, which was measured as GC signaling activation in  
the GRIZLY assay, I expected to find increased amounts of Cort and of upstream metabolites 
within the steroid hormone biosynthesis pathway. Therefore, I aimed to determine compound 
effects on the larvae-internal concentrations of Preg, Progesterone (Prog), Corticosterone 
(Cortico) and Cort in application of the UPLC-MS/MS technique. As a first step, timecourse 
experiments with 0 - 24h of exposure to control treatments were carried out in order to identify 
a suitable timepoint for sample taking. 
3.5.1 Timecourse experiments 
Timecourse experiment 1: Preg 
In Figure 38, the outcomes of the timecourse experiment for Preg are shown. Endogenous levels 
of Cort, Cortico, Prog and Preg were measured after 0, 1, 2, 4, 8 or 24h treatment with either 
DMSO (a), Preg [5 µM] + DMSO (b) or Preg [5 µM] + Mety [40 µM] (c). Steroid mean 
concentrations [ng/ 100 larvae] are shown for all exposure times. Concentrations of Cortico 
were below the limit of detection (LOD) in all exposure conditions, and are, thus, not included in 
the graphs. The measurements of untreated larvae (0 h) are shown in all graphs in order to 
visualize treatment-mediated changes of steroid levels. Statistically significant changes between 
treatment and control conditions are marked with an asteriks. 
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Figure 38: UPLC-MS/MS timecourse experiment Pregnenolone  
Steroid hormone concentrations measured in homogenates from larvae exposed to DMSO (a, d, g) ,  
Preg [5  µM] + DMSO (b, e,  h)  and Preg [5 µM] + Mety [40 µM] ( c,  f,  i)  for several hours. The 
amount of DMSO was 0.2 % in all  treatments.  Concentrations  of Cort (blue),  Prog (v iolet) and Preg 
(green) were measured by UPLC-MS/  MS. Mean concentrations [ng/ 100 larvae]  +  SEM (n  =  3) are 
shown. Limit of quantificat ion (LOQ)  =  1.6 ng/  100 larvae for Cort and Prog (external calibration 
standards: 1.6  -  25.0 ng/  100 larvae) and LOQ = 31.3 ng/  100 larvae for Preg (external calibration 
standards: 31.3  -  500.0 ng/  100 larvae). Concentrations  <   l imit of detection (LOD) were set to 0.  
Concentrations  >  LOD  <  LOQ are shown but have to be considered carefully. Data for Preg are from 
1:10 diluted samples, as the undiluted P reg concentrations exceeded the highest internal standard 
(500 ng/  100 larvae) for Preg.  Data for Cort and Prog are from undiluted samples.  Statistical 
significance was determined by comparison of the mean concentration  of a metabolite for each 
exposure duration with the respect ive mean concentration of the control treatment. Controls 
were untreated larvae (0h) for ( a ,  d ,  g) ,  DMSO 0 - 24h for (b ,  e ,  h)  and Preg 0 -  24h for (c ,  f ,  i).  A 
multiple t-test was applied with  α  =  0.05.  After multiple testing correction with the Holm -Šídák 
method, significance was defined as p  < α  < 0.008 = *.  
 
In the first column of Figure 38, larvae were exposed to DMSO for different durations. Each 
timepoint was assessed for statistically significant changes of the metabolite concentrations 
compared to untreated larvae, which were sampled at the timepoint of exposure start (0 h).  No 
significant differences were detected between the steroid concentrations measured in DMSO- or 
untreated larvae. Levels of Cort (a) and Preg (g) were below the LOD for all treatments and, thus, 
set to 0. Prog-(d) concentrations were detectable (between 0.7 and 1.2 ng/ 100 larvae), but they 
were below the limit of quantification (LOQ: 1.6 ng/100 larvae). Nevertheless, with this caveat, 
the Prog measurements are shown in order to document that the endogenous amount of the 
metabolite remained relatively constant between 0 and 24h of DMSO exposure. 
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The second column of Figure 38 shows the steroid mean concentrations [ng/ 100 larvae] for 
larvae treated with Preg. For each timepoint, changes in the metabolite concentrations between 
DMSO- and Preg-treated larvae were assessed statistically. Preg treatment strongly increased 
the endogenous amounts of Cort (b), Prog (e) and Preg (h). Already after 1h of exposure, the 
Cort (b) concentration significantly increased from LOD to 2.7 ng/100 larvae. With prolonged 
exposure durations, it further increased. After 24h of exposure, the highest concentration of 
17.4 ng/100 larvae was measurable. The effect of Preg treatment on Prog (e) concentrations was 
clearly visible after 1h of exposure, when a significant increase from 0.7 (below LOQ) to 2.8 
ng/100 larvae was detectable. An exposure duration of 2h showed further elevated Prog 
concentrations with 4.5 ng/100 larvae. From 2 to 24h, Prog stayed on a relatively constant level, 
with concentrations between 3.9 and 4.8 ng/100 larvae. The amount of Preg (h) was significantly 
increased in larvae homogenates at all timepoints measured.  Already after 1h of exposure, a 
concentration 4590 ng/100 larvae was measured. The concentration continuously increased 
with prolonged exposure durations until 8h, where 6870 ng/ 100 larvae were detected. After 8h, 
the concentration decreased and only 3760 ng/ 100 larvae were measured after 24h. 
 
The effect of Mety on Preg-treated larvae is visualized in the third column of Figure 38. The 
steroid mean concentrations [ng/ 100 larvae] for larvae treated with Preg + Mety are shown. 
Changes in the metabolite concentrations between larvae treated either with Preg + DMSO or 
Preg + Mety were assessed statistically for each timepoint. Mety significantly reduced the 
endogenous amount of Cort (c) in larvae at all timepoints. Between 1h and 8h of exposure, the 
Cort concentrations were below the LOD. After 24 h, a concentration of 1.3 ng Cort/ 100 larvae 
was measured, which is slightly below the LOQ. The larvae-internal amount of Prog (f) remained 
relatively constant during the different exposure durations of 1 - 24 h. Prog concentrations 
between 2.7 and 4.8 ng/ 100 larvae were detected. These concentrations are highly similar to 
those measured for Prog (2.8 - 4.8 ng/ 100 larvae) when larvae were exposed to Preg alone and 
were, thus, not significantly altered by Mety. Likewise, the amount of Preg (i) in larvae exposed 
to Preg + Mety was with 2860 -  6400 ng/ 100 larvae similar to that measured for Preg + DMSO 
treatment (3760 - 6870 ng/ 100 larvae). Interestingly, the highest concentrations of Preg were 
measured after 1 and 2h of exposure to Preg + Mety, while, when larvae were exposed to 
Preg + DMSO, the Preg concentrations increased more slowly, and showed the highest values 
after 4 and 8h. Potentially, when Preg is co-exposed with Mety, it accumulates already after 1-
2 h, possibly as Mety blocks the downstream metabolization of Preg by inhibiting 
11β-hydroxylase. In contrast, when Preg + Mety are co-exposed for a longer duration, maybe 
Preg is degraded via other pathways after a while. 
 
Although the measurements of Cortico were removed from the graphs as its concentration was 
always below the LOD at any treatment condition, the assessment of this metabolite still showed 
that Preg treatment and increased larvae-internal Preg concentrations had no effect on the 
amount of Coco. As Cortico is synthesized from Prog via the metabolite 11-deoxyvorticosterone 
(see the steroid hormone biosynthesis pathway in 1.2.2, Figure 3), elevated concentrations of 
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Cortico could have been expected from the Preg-induced increase of Prog and Cort, but this was 
not shown.  
 
Timecourse experiment 2: Dex 
The timecourse experiment for Dex is shown in Figure 39.  Larvae-internal concentrations of 
Cort, Cortico, Prog, Preg and Dex were measured after 0, 1, 2, 4, 8 or 24h treatment with either 
DMSO (a), Dex [20 µM] + DMSO (b) or Dex [20 µM] + Mife [1 µM] (c). Steroid mean 
concentrations [ng/ 100 larvae] are indicated for all exposure times. Here, the endogenous 
amounts of Preg, Prog and Cortico were below the LOD in all test conditions and were, thus, not 
included in the graphs. The measurements of untreated larvae (0 h) are shown in all graphs in 
order to visualize treatment-mediated changes of steroid levels. Statistically significant changes 
between treatment and control conditions are marked with an asteriks. 
 
The first column of Figure 39 shows the steroid concentrations measured in larvae that were 
exposed to DMSO for 0-24 h. Each condition was assessed for statistically significant changes of 
the steroid concentrations compared to untreated larvae, which were sampled at the timepoint 
of exposure start (0 h). No significant differences were detected between the steroid 
concentrations measured in DMSO- or untreated larvae. In case of Cort (a), inconsistency of 
replicate measurements below and above the LOD was the reason why the means were below 
the LOD in Figure 38, but within the Dex timecourse experiment, low concentrations between 
0.8 and 1.0 ng/ 100 larvae were detectable in all replicates. Although these values were still 
below the LOQ (LOQ: 1.6 ng/100 larvae), Cort concentrations are included in the graphs in order 
to visualize treatment effect trends on endogenous concentrations of Cort. Larvae-internal 
concentrations of Dex (d) were below the LOD and set to 0. 
 
In the second column of Figure 39, the steroid mean concentrations [ng/ 100 larvae] for larvae 
treated with Dex are shown. For each timepoint, changes in the steroid amounts between 
DMSO- and Dex-treated larvae were assessed statistically. Upon Dex treatment, the Cort 
concentrations (b) appear to be reduced at all timepoints measured. After 4 h and 24 h, the 
concentration decreases could even be confirmed to be statistically significant. Although these 
data are not reliable, as they are below the LOQ, they are consistent with the inhibitory effect of 
Dex on endogenous Cort levels, which is caused by HPA feedback mechanisms as it is reported in 
various systems, including zebrafish larvae. Regarding the concentrations of Dex (e) that were 
measured in larvae-homogenates, the amount of the synthetic GC increased significantly at all 
timepoints measured. The highest Dex concentrations were detected after 1h and 24h, each 
with 15 ng/ 100 larvae. Exposure durations of 2h, 4h and 8h showed slightly lower Dex 
concentrations, with values between 10.3 and 13.9 ng/ 100 larvae. 
 
The effect of Mife on Dex-treated larvae is visualized in the third column of Figure 39. The 
steroid mean concentrations [ng/ 100 larvae] for larvae treated with Dex + Mife are shown. 
Changes in the steroid concentrations between larvae treated with Dex + DMSO or with Dex + 
Mife were assessed statistically for each timepoint. Cort (c) concentrations were not altered by 
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Mife. For the larvae-internal amount of Dex (f), a significant concentration increase was 
detectable after 2h with 38.4 ng/ 100 larvae. At all other timepoints, the measured values lay 
between 17.2 and 23.8 ng/ 100 larvae, which is considerably higher than when larvae were 
treated with Dex alone (10.3 and 13.9 ng/ 100 larvae; e). Thus, the Dex concentration in larvae is 
elevated by trend at all timepoints measured when larvae were treated with Dex + Mife; only 
after 2h and 4h of exposure, the increase of Dex was significant. 
 
 
Figure 39: UPLC-MS/MS timecourse experiment Dexamethasone  
Steroid hormone concentrations measured in homogenates from larvae exposed to DMSO (a and  
b) ,  Dex [20 µM] (b and  e)  and Dex [20 µM]  +  Mife [1 µM ] (c and  f)  for several hours. The amount 
of DMSO was 0.2 % in all  treatments.  Concentrations of Cort (blue) and Dex (turqoise)  were 
measured by UPLC-MS/  MS. Mean concentrations [ng/ 100 larvae]  +  SEM (n  =  3) are shown. Limit 
of quantificat ion (LOQ)  =  1.6 ng/  100 larvae for Cort and Dex (external cal ibration standards: 1. 6  -
 25.0 ng/  100 larvae). Concentrations  <   l imit of detection (LOD) were set to 0.  
Concentrations  >  LOD  <  LOQ are shown but have to be considered carefully. Data for are from 
undiluted samples.  Statistical  s ignificance was determined by comparison of the mean 
concentration of a steroid for each exposure duration with the respective mean concentration of 
the control treatment. Controls were untreated larvae (0h) for ( a  and  d) ,  DMSO 0 - 24h for (b  and  
e)  and Dex 0 - 24h for (c  and  f).  A multiple t-test was applied with  α  =  0.05. After multiple test ing 
correction with the Holm -Šídák method, significance was def ined as p  <  α  < 0.008 = * .  
 
Summary of timecourse experiments 
1) Suitability of the applied  method to detect steroid concentrations in larvae homogenates 
The main purpose of the chemical analysis experiments was to determine uptake and 
accumulation of Preg and Dex into the larvae and to obtain a first mapping of their effects on 
endogenous metabolites within the steroid hormone biosynthesis pathway. Furthermore, I 
aimed to detect disruption of this pathway by compounds, which I was able to see in 
homogenates from larvae that were co-treated with Preg + Mety.  
The applied extraction method and the UPLC-MS/ MS technique were well suitable to measure 
Preg-induced Cort levels. Also disruption of the Preg-induced Cort production by the reference 
inhibitor of Cort biosynthesis, Mety, was well detectable with this technique.  The UPLC-MS/ MS 
results furthermore showed that the larvae-internal Cort concentrations continuously increased 
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within 24h of exposure to Preg, while Prog concentrations remained on a constantly elevated 
level and Preg concentrations decreased after several hours. Also, it indicated that Prog levels 
were not affected by Mety treatment. Thus, once induced, compound effects on endogenous 
steroids and their dynamics were well detectable. 
 
However, the applied technique had some limitations, as non-stimulated endogenous steroid 
concentrations were below the detection limit of the UPLC-MS/ MS setup (with the exception of 
Cort in the timecourse experiment with Dex, which however was still below the limit of 
quantification). Especially in case of the timecourse experiment with Dex, where no induction of 
endogenous steroid hormones was expected, as Dex treatment rather decreases than induces 
the Cort biosynthesis pathway due to negative feedback mechanisms via the HPA axis, the 
possibility to quantify Cort, Cortico, Prog and Preg was very limited. Still, also in these conditions, 
the method allows to measure the dynamic effects of Dex and co-exposed compounds on Dex 
concentrations in the larvae extracts. 
 
2) Unequal uptake of Preg and Dex by the larvae 
Interestingly, the detected concentrations of Dex were with 10 - 15 ng/ 100 larvae several orders 
of magnitude lower than the Preg concentrations of 3760 - 6870 ng/ 100 larvae, even though the 
concentration of Dex treatment was with 20 µM (7.85 mg/l) four-fold higher than the 
concentration of Preg treatment with 5 µM (1.58 mg/l). 
Exemplarily, 10 ng/ 100 larvae were detected when larvae were exposed to 7.85 mg/l Dex. The 
total treatment volume for 100 larvae was 7.5 ml, wherein 59 µg Dex were available. 
Accordingly, as calculated below in formula a), 0.017% of the administered amount of Dex were 
detected in the extract of 100 larvae. 
In case of Preg, where 3760 ng/ 100 larvae were measured, a concentration of 1.58 mg/l served 
12 µg of Preg in the total exposure volume of 7.5 ml for 100 larvae. As the outcome of 
calculation b), 31,33% of Preg were recovered from the larvae homogenate, which is 1840-fold 
more than the quantified amount of Dex. The initial measurement of Preg concentrations in 
untreated larvae (see e.g. Figure 38 g, h, i, 0 h) showed that endogenous Preg levels are 
negligible for this calculation. 
 
a)   
        10 𝑛𝑔/ 100 𝑙𝑎𝑟𝑣𝑎𝑒 
59000 𝑛𝑔/ 100 𝑙𝑎𝑟𝑣𝑎𝑒
 𝑥 100% =  0.02%      b)  
    3760 𝑛𝑔/ 100 𝑙𝑎𝑟𝑣𝑎𝑒
12000 𝑛𝑔/ 100 𝑙𝑎𝑟𝑣𝑎𝑒
 𝑥 100% = 31.33% 
 
As the measurements were conducted with whole larvae extracts, no information is available 
about the portion of absorbed compound from the recovered percentage. The possibility that 
parts of the compound were not absorbed, but instead adhered to the larvae skin, cannot be 
excluded, but several thorough washing steps of the larvae, before they were anesthetized, 
were aimed to minimize this effect. The varying levels of Preg and Dex over different exposure 
durations might further indicate dynamic changes in internal larvae concentrations of both 
compounds. As the endogenous concentration of Cort cumulated statistically significant with 
increasing Preg levels, potential amounts of externally bound but non-absorbed compounds 
might be negligible for the aim of the experiment. However, the significantly higher impact of 
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Preg on endogenous steroid concentrations might be related to the better recovery rate of Preg 
from larvae extracts. The possibility of externally provided Preg having a higher bioavailability for 
larvae than Dex should be considered for the Preg effect within all experiments of this study.  
 
3) Selection of exposure duration for the assessment of library compound effects 
According to the timecourse experiments, the highest concentration of Cort in Preg-treated 
larvae was measured after 24 h of exosure. For Dex, the highest amount in larvae extracts was 
also detected after 24 h of Dex treatment, although the amount of Dex was after 1 h of exposure 
nearly as high. In order to detect the most distinct compound effects on endogenous steroid 
levels, and to have comparable exposure conditions between Dex and Preg, I selected the 
exposure duration of 24 h for the assessment of library compound effects on larvae-internal 
steroid levels. 
3.5.2 Library compound effects on larvae-internal steroid levels 
For chemical analysis of library compound effects on larvae-internal steroid levels, one effective 
concentration of each substance was applied to the larvae. This was usually the LOEC from the in 
vivo GRIZLY assays. In cases where the LOEC did not lead to a strong effect on GC signaling in the 
GRIZLY assay, an appropriate higher concentration was used. After 24 h of exposure, larvae 
extracts were subjected to UPLC-MS/ MS. 
As before, within the timecourse experiments, endogenous concentrations of Cortico could not 
be detected (< LOD) in larvae treated with Preg or Dex in combination with the library 
compounds. Likewise, no concentrations of Cort, Preg or Prog were quantifiable (< LOQ) when 
GC signaling was induced by Dex in larvae. Thus, these metabolite measurements were not 
visualized.   
 
Changes of Dex levels in larvae treated with Dex + library compounds are shown in Figure 40 a. 
Concentration ratios are indicated for each treatment condition, relative to the negative control 
Dex + DMSO [20 µM]. No traces of Dex were detectable in the DMSO control. Larvae-internal 
amounts of Dex significantly increased upon Dex treatment when compared with the DMSO 
control. Stano significantly increased the measured Dex concentration when compared with the 
negative control. Further, Mife (p = 0.0140), Leflu (p = 0.0428), Ethi (p = 0.0204) and Nor 
(p = 0.0249) showed trends for higher Dex concentrations. In contrast, 10-HC (p = 0.0205) tended 
rather to reduce the Dex concentration. 
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Figure 40: UPLC-MS/MS experiment with FDA l ibrary compounds  
Effects of FDA drug libr ary compounds in combination with Dex [20 µ] on larvae -internal Dex- (a)  
levels and in combination with Preg [5 µM] on endogenous Preg - (b) ,  Prog- (c)  and Cort- (d)  levels 
in larvae are shown. Mean ratio concentrations + SEM (n = 4) are indicated for each substance, 
relative to the respective negative control (Preg [5  µM] + DMSO, n = 4,  for Preg + l ibrary 
compound; Dex [20 µM] + DMSO, n = 4, Dex + l ibrary compound). The amount of DMSO was 0.2% 
in all  treatment conditions.  For Preg, ratio concentrations from  measurements of a 1:10 di lution 
were calculated, for al l  other steroids, ratio concentrations were calculated from measurements 
of undiluted samples. Statistical significance was determined by comparison of the mean ratio 
concentration of each treatment condition with the mean ratio concentration  of the negative 
control in a multiple t -test,  α =  0.05.  After multiple testing correction with the Holm -Šídák 
method, significance was defined as p < α < 0.005 = *.  
 
The effects of Preg + library compounds on endogenous levels of Preg, Prog and Cort are 
presented in Figure 40 b - d. Concentration ratios are shown for each treatment condition, 
relative to the negative control Preg + DMSO [5 µM]. Treatment with Preg + DMSO significantly 
induced larval levels of Preg, Prog and Cort, when compared with the DMSO control (DMSO).  
In Figure 40 b, library compound effects on larvae-internal Preg levels are shown. Only two 
compounds significantly changed the amount of Preg in larvae. Aci significantly reduced the Preg 
level, while Mife (p = 0.0287) and Leflu (p = 0.0139) show a trend for decreased Preg 
concentrations. Gestri, signficantly induced Preg accumulation in larvae and Mety (p = 0.0180), 
Spiro (p = 0.0092) and Nor (p = 0.0075) showed trends for elevated Preg levels. 
Library compound effects on endogenous Prog levels are presented in Figure 40 c. Ethi 
significantly reduced the amount of Prog in larvae. For Aci (p = 0.0110), also a trend for reduced 
Prog level is visible. In contrast, Mife (p = 0.0426), Fen (p = 0.0431) and Spiro (p = 0.0142) tend to 
further increase Prog concentrations. 
In Figure 40 d, the compound effects on endogenous Cort concentrations are shown. Ten 
compounds significantly reduced the amount of Cort produced by the larvae. With Mety, DHEA, 
Estrone, Nor and Gestri, similar Cort levels as for the DMSO control were measured. The other 
compounds with significant effects, Stano, Estriol, Aci and Ret. acid, reduced the Cort level by 
40-70% when of the negative control. Spiro(p = 0.0114) also showed a trend to reduce 
endogenous Cort, but the effect was not significant. The only compound, which tended to 
further increase the endogenous Cort level was Mife (p = 0.0102). 
 
Correlation between library compound effects on GC signaling and on endogenous steroid 
levels 
In order to assess the correlation between the compound effects on GC signaling and on the 
endogenous steroid levels, the chemical analysis outcomes are summarized as steroid level 
profiles and compared with the GRIZLY retesting results (replotted from Figure 28) in Figure 41. 
In case of exposure to library compound + Dex, larvae-internal Dex concentrations from chemical 
analysis are shown, while in co-treatment with Preg, measurements of Preg, Prog and Cort are 
indicated. For both experiments, the GRIZLY assay and chemical analysis, the controls are shown 
with the respective color code profiles. Yellow indicates no difference of the compound effect 
compared to the negative control. Significant reduction or co-induction of signal intensity/ 
steroid concentrations are indicated in green and red, respectively; non-significant trends 
(p < α < 0.05) for reduction or co-induction in orange and light green, respectively. Significance is 
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defined as p < α < 0.0001 for the GRIZLY assay and p < α < 0.005 for chemical analysis results. The 
applied concentrations for UPLC-MS/MS experiments are indicated in the right column. 
 
   
 
Figure 41: Comparison of GRIZLY retesting results with steroid level profi les  
Color code profiles are shown for controls and library compounds. No difference of the substance 
effect compared to the negative control ( Dex [20 µM]/ Preg [5 µM]  + DMSO) is indicated in yellow. 
A significantly  increased or decreased signal intensity  or steroid level compared to the negative 
control is indicated in green and red, respectively. Non-significant trends (p < α < 0.05 )  for 
increase or decrease are shown in orange and light green, respectively. Significance is def ined as 
p < α < 0.0001 for the GRIZLY retests  (α = 0.01)  and as p < α < 0.005 (α = 0.05 )  for chemical 
analysis.  Val idated inhibitors and  superactivators from retest ing are indicated with their  lo west 
observed effect  concentration (LOEC) in the respective GRIZLY assay.  
 
Leflu only inhibited in GRIZLY 3. Although this made it a candidate substance for a disruptor of 
GC biosynthesis, the level of Cort was unaffected as determined by the chemical analysis. 
Instead, trends for reduced Preg and induced Dex were observable. This might imply an impact 
of Leflu on Dex and Preg metabolism in the larvae, but cannot solely explain the inhibition of 
Preg-induced GC signaling.  
 
Conc.
Cells Dex Preg Prog Cort Confirmed?
DMSO + DMSO
Preg [5 µM] + DMSO -
Dex [20 µM] + DMSO - - -
Dex [20 µM] + Mety [40 µM] - - - -
Preg [5 µM] + Mety [40 µM] - -
Preg [5 µM] + Mife [1 µM] - -
Dex [20 µM] + Mife [1 µM] - - -
Compounds + Dex + Dex + Preg + Dex [µM] Group
Leflunomide 4 4
Fenbufen 8 4 4
Nabumetone 4 4 4
Tranilast 10 10 10 10
10-Hydroxycamptothecin 4 4 4 4
Mifepristone 0.2 0.4  0.2  1
Acitretin 4 8 4 4
Retinoic Acid 0.4 1.2 1.6 2
Gestrinone 4 4 4 4
Norethindrone 40 10 10 10
Ethisterone 4 4
Stanozolol 12 12 8 12
Spironolactone 6 2 2 2
Estrone 8 4 4
Dehydroepiandrosterone 20 4 4
Estriol 12 12
+ Preg
1
2
4
5
3
Controls
Retest LOEC [µM] Chemical analysis
Larvae
sign. decrease/ decreasing trend/ no change/ increasing trend/ sign. increase
of signal intensity/ steroid concentration in larvae; significance = p < α = 0.0001 for GRIZLY 
and  p < α = 0.005 for chemical analysis; trends = p < α = 0.05
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Fen and Nabu, the two compounds which had no effect in vitro but inhibited Dex- and 
Preg-activated GC signaling in vivo, showed negligible impacts on endogenous steroids. For 
Nabu, no effect on any of the measured steroids was visible and Fen solely indicated a trend for 
induced Prog, but effects on Preg and Cort were lacking. Thus, no impact on Cort biosynthesis or 
Dex metabolism can be hypothesized on these results, the observed inhibition has to result from 
other mechanisms.  
 
Mife, the positive control for direct inhibition of GC signaling, inhibited in all three GRIZLY 
screens. By this outcome, the GR antagonistic mechanism of inhibitition was confirmed. In 
chemical analysis, Mife showed a tendency to increase the larval Dex concentration and, in 
co-treatment with Preg, trends for reduced Preg, but elevated Prog and Cort levels were 
observable. These results might suggest that Mife could potentially induce the uptake or reduce 
the metabolization of Dex. In co-treatment with Preg, the opposite effect might be possible, 
reduced uptake or induced metabolism of Preg. The elevated Prog and Cort levels resemble a 
normal expectable in vivo response to Mife treatment. GR antagonism by Mife signals an 
endogenous GC shortage, which is attempted to be compensated via the HPI axis, resulting in a 
higher Cort production. In this context, the steroid level profile might thus be interpreted by 
induced Preg metabolism, leading to accumulation of Prog and Cort in larvae. Notably, although 
induced GC signaling could be expected from the chemical analysis results, due to the elevated 
Dex and Cort levels, the GR antagonistic effect of Mife dominated GC signaling, as observed in all 
three GRIZLY screens. 
 
For the other inhibitors in all three GRIZLY screens, Trani, 10-HC, Aci and Ret. acid, an effect 
mechanism similar to that of Mife was expected. However, not one of the four inhibitors 
reproduced the steroid profile of Mife. Trani had no effect on any of the tested steroids. As Mife, 
Trani appears to inhibit GC signaling by a mechanism other than reducing endogenous Dex or 
Cort. 
10-HC solely showed a trend for reduced Dex. With Preg, the steroid levels remained unaffected, 
which suggests that GC signaling inhibition by 10-HC, at least in GRIZLY 3, was mediated 
independently from steroid biosynthesis and metabolism. 
Interestingly, Aci and Ret. acid significantly decreased endogenous Cort. In addition, Aci showed 
significant reduction of Preg and a trend for reduced Prog. This response to Aci might suggest a 
decreased Preg uptake or induced conversion of Preg into metabolites other than Prog and Cort. 
For Ret. acid, reduced synthesis or induced metabolization of Cort might be a possible 
explanation. Accordingly, the inhibitory effects of Ret. acid and Aci on GC signaling in GRIZLY 3 
could be related to the reduced Cort levels. However, their inhibition in GRIZLY 1 and GRIZLY 2 
cannot be explained by this, as changes in endogenous Cort in co-treatment with Dex would not 
dominate the Dex effect. As chemical analysis did further not reveal any changes in Dex 
concentrations, the observed inhibition is probably the consequence of mechanisms other than 
the reduction of endogenous activator concentrations. 
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In addition to Leflu, the GRIZLY results suggested also a potential for GC biosynthesis disruption 
for Gestri, Nor, Estrone, DHEA, Estriol. For all five candidates, significantly reduced Cort levels 
were detected by chemical analysis, which substantiates disruption of GC biosynthesis as one 
main mechanism of action. However, the compound effects on larval levels of the other steroids 
Dex, Preg and Prog are diverse, which might imply different points of action among these GC 
biosynthesis disruptors.  
For comparison, the positive control for disruption of GC biosynthesis, Mety, inhibited Preg- 
induced GC signaling and was ineffective in co-treatment with Dex. Mety significantly reduced 
Cort, while the Prog concentration remained unaffected and Preg showed a trend to be induced. 
These results are traceable in Figure 42, where Mety inhibits 11β-hydroxylase, the enzyme 
which enables the last step of the GC biosynthesis pathway. Thus, the conversion of 
11-deoxycortisol into Cort is blocked, which consequently leads to an accumulation of the 
precursor metabolites, including Preg. In literature, strongly elevated levels of 11-deoxycortisol 
are frequently reported when Mety is applied and serve as a reliable indicator for the inhibition 
of 11β-hydroxylase (Nicola & Dahl 1971; Spark 1971). As Prog was not altered by Mety 
treatment and Preg had no inductive effect on Cortico levels in the present study, it appears 
likely that Preg was predominatly metabolized into Cort via 17α-hydroxyprogesterone and 
11-deoxycortisol, whereas conversion of Preg into Cortico via Prog and 11-deoxycorticosterone 
played a minor role, occurred in a much lesser extend.  
 
 
 
Figure 42: Inhibition of  the steroidogenic enzyme 11β -hydroxylase by Metyrapone  
The scheme of the steroid hormone biosynthesis pathway is replotted from Figure 3 and sl ightly 
modified in order to show the point of Cort biosynthesis disruption by Mety.  Also the enzyme 5α -
reductase and an additional androgen, Dihydrotestosterone are included.More detailed 
information about all  other metabolites and enzymes was provided in the original scheme in  
Figure 3  (chapter 1.2.2) .  
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Interestingly, among the putative other GC biosynthesis inhibitors, Nor showed the same steroid 
level profile as Mety in co-exposure with Preg, which suggests that this compound also inhibits 
11β-hydroxylase activity. The only difference in the profile of Mety and Nor is that Nor 
treatment led to higher Dex levels in the larvae, while they were not affected by Mety. However, 
this is in accordance with the GRIZLY results, as Mety did not interfere with Dex-induced GC 
signaling, but Nor superactivated it. Correspondingly, this effect of Nor might potentially be 
explained by interference of the compound with induced uptake or reduced metabolism of Dex. 
 
Very similar to that of Nor is the steroid level profile of Gestri, with significant reduction of Cort, 
unaffected Prog and even significantly elevated Preg. Here, also inhibition of 11β-hydroxylase 
might be the point of disruption, but the more distinct accumulation of Preg could further imply 
a stronger effect than that of Mety, potentially involving the inhibition of other enzymes, for 
instance 3β-HSD or 17α-hydroxylase. The effect of Gestri in the GRIZLY assay was the same as for 
Nor, inhibition with Preg but co-induction with Dex. However, in contrast to Nor, no tendency 
for an elevated Dex concentration was detectable for Gesti, which makes interference with Dex 
uptake or metabolism a rather unlikely explanation for the observed GRIZLY effect. Potentially, 
as hypothesized within the comparative compound analysis for all candidates from Figure 32, a 
more direct interference of Gestri (and Nor, Ethi, Spiro, Stano) with Dex-mediated ativation of 
the GR could rather explain the co-induction of Dex signaling. 
 
For Stano, Spiro and Ethi, the comparative compound analysis of the GRIZLY results gave no 
direct indications for inhibition of GC biosynthesis, as Preg-induced signaling was not reduced. 
However, chemical analysis revealed reduced Cort levels for all of them. 
 
Stano superactivated GC signaling in co-treatment with both activators. Chemical analysis 
showed a significantly elevated Dex concentration in the larvae, which might explain the co-
inductive effect with Dex. However, this does not apply for the observed superactivation with 
Preg, as Stano significantly reduced Cort without affecting Preg and Prog. Therefore, the Stano 
effect on GC signaling is  independent of the endogenous Cort levels in co-treatment with Preg, 
which might also be true for Dex. The observed reduction of Cort probably underlies disrupted 
GC biosynthesis, but Stano has apparently additional mechanisms of action that are capable to 
disrupt/ induce GC signaling.   
 
Spiro also co-induced GC signaling with Dex, as well as with Preg. As the UPLC-MS/MS data 
showed unaffected Dex levels, this superactivation with Spiro apparently did not involve changes 
in Dex metabolism. The same applies for co-treatment with Preg, as the measured steroid levels 
do not indicate increased Cort. Thus, like for Stano, the co-inductive effect on GC signaling 
appears to be independent of the endogenous steroid levels. Instead, chemical analysis of 
Spiro + Preg showed trends for elevated Preg and Prog and reduced Cort. Irrespective of the 
GRIZLY results, this steroid level profile indicates disruption of GC biosynthesis, possibly by 
inhibition of 17α-hydroxylase and potentially in combination with 11β-hydroxylase or 
21-hydroxylase. As blocking of 11β-hydroxylase led to reduced Cort and a trend for elevated 
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Preg in case of Mety, but as Prog levels were not changed by this, another enzyme might be 
inhibited by Spiro, explaining the Prog accumulation. As visible in the schematic steroid hormone 
biosynthesis pathway above in Figure 42, blocking of 17α-hydroxylase would most likely lead to 
accumulation of Preg and Prog while Cort would be reduced. Inhibition of 11β-hydroxylase and/ 
or 21-hydroxylase could also play a role in this context, but, compared to the Mety effect, 
accumulation of Prog would not be expectable, as long as 17α-hydroxylase is blocked. 
 
Ethi solely superactivated GC signaling with Dex in larvae. The steroid level profile shows a trend 
for increased Dex in the larvae, which suggests an effect of Ethi on Dex metabolization that 
might explain the co-induction in the GRIZLY assay. Moreover, Ethi significantly reduced Prog 
and Cort, but the Preg concentration remained stable. According to the UPLC-MS/MS 
measurements in Figure 40 c + d, the amount of Prog is reduced by 50%, while the inhibition of 
Cort is more pronounced, with only 10% of the steroid remaining. This implies that Cort 
production was nearly completely prevented, while the disruption of Prog was incomplete or 
partly compensated via other metabolites. Regarding the enzymes involved in the steroid 
hormomone biosynthesis pathway (Figure 42), only disruption of 3β-HSD has the potential to 
reduce Prog levels. Accumulation of Preg could be expected in case of 3β-HSD inhibition, as Preg 
levels were even elevated when the downstream enzyme 11β-hydroxylase was blocked by Mety. 
However, maybe the inhibition of 3β-HSD involves a different effect cascade, which could imply 
accumulation of 17α-hydroxypregnenolone or induction of other enzymes, enabeling the 
metabolization of Preg and 17α hydroxypregnenolone into androgens.  
Regarding the GRIZLY response to Ethi + Preg, no significant change in GC signaling was 
detectable. However, as it was described in the combined analysis of compound effects in all 
three GRIZLY assay approaches and as it is visible in Figure 32 l, Ethi tended to further increase 
the bioluminescent signal with Preg, similar to the compound effect on Dex-induced signaling 
(Figure 32 k) or the response of Stano + Preg (Figure 32 t), but weaker, and thus, not significant.  
 
Estrone, DHEA and Estriol inhibited Preg-induced GC signaling in the GRIZLY assay, but had no 
effect on Dex. Within chemical analysis, all three significantly reduced Cort, but Preg, Prog and 
Dex were not affected. As none of the three compounds showed accumulation of any of the 
metabolites, prevention of cortisol production is indicated, but probably via inhibition of 
steroidogenic enzymes other than those inhibited by Mety, Gestri and Nor.  
 
In summary, the UPLS-MS/MS experiments largely supported the hypotheses from the 
combined analysis of compound effects in all three GRIZLY assays (section 3.2.2.2) and provided 
important information about the compound effects on endogenous steroid levels. For Mife, 
Trani, 10-HC, Ret. acid, Aci, Fen, Nabu, Spiro, Stano and Ethi, GC signaling inhibition independent 
from the endogenous Cort levels was assumed, which was substantiated by chemical analysis. 
Although Mife, Ret. acid, Aci, Spiro, Stano and Ethi interestingly had effects on the Cort levels, 
these observations do not (fully) reflect the compound effects within the GRIZLY assay. 
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Like for Mety, disruption of GC biosynthesis was assumed to underly the effects of Leflu, Gestri, 
Nor, Estrone, DHEA and Estriol on Preg-induced GC signaling. This was further supported by 
chemical analysis, as reduced Cort levels were detected for all candidates, except Leflu. 
 
Accordingly, the second aim of this study was achieved, a number of GC biosynthesis disruptors 
was identified from the drug library. Gestri, Nor, Estrone, DHEA, Estriol, Ret. acid, Spiro, Stano 
and Ethi led to reduced Cort levels when larvae were co-treated with Preg. For several, the 
putative point of disruption could even be narrowed down to certain enzymes. Aci may or may 
not be considered a presumptive disruptor of GC biosynthesis, as also Preg and Prog levels were 
strongly reduced, which might possibly indicate inhibition of cholesterol biosynthesis or also a 
disrupted Preg-uptake or induced -metabolization. 
 
Regarding the observed superactivation of GC signaling with Spiro, Stano, Gestri, Nor and Ethi, a 
potential direct interaction at the level of the GR was hypothesized. Additionally or alternatively, 
elevated Dex levels with Stano, Nor and Ethi were found, which could potentially explain their 
effect on Dex-induced GC signaling. 
In order to obtain more information about the compounds, whose effect mechanisms could not 
be further clarified by chemical analysis, gene expression analysis was conducted in the next 
step. Assessment of substance effects on a set of GC target genes and selected indicator genes 
for xenobiotic metabolism should help to specify the origin of GC signaling disruption and to 
further examine aspects of the GC signaling disruption  
3.6 Tier 3b: Gene expression analysis 
In tier 3b, the compound effects on selected target genes were examined in order to gain more 
insight into the mechanisms of GC signaling disruption. Prior to that, validation studies were 
carried out for the selection of suitable target genes and an assessment of the exposure time 
optimum.  
3.6.1 Pretests for the selection of  target genes and exposure duration 
In order to identify the optimal exposure time for compound effects on target gene expression, 
larvae were exposed to Preg [5 µM, 0.2%] and DMSO [0.2%] for durations between 1h and 24h. 
Subsequently, qPCR analysis of a set of GC-signaling related genes was conducted. In Figure 43, 
the expression ratios of the six selected genes are shown upon exposed for 1, 2, 4, 12 or 24h to 
Preg or for 24h to E3. Values are given relative to those of the DMSO control for the respective 
durations. 
 
For the GC target genes hsd11b2 (b), gilz (d) and fkbp5 (e), mRNA expression significantly 
increased already after 1h of exposure to Preg. The strongest up-regulation at this timepoint, 
with a ratio of 15, was measured for fkbp5. The mRNA levels for all three genes increased further 
when larvae were exposed for 2 and 4h. The highest expression ratios for hsd11b2 and gilz were 
detected after 4h, with 9 and 3.5, respectively. For fkbp5, the strongest up-regulation was 
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measurable after 2h, with a ratio of 28, but after 4h the ratio was with 27.5 only slightly lower. 
After 12h of exposure, the mRNA levels of all three target genes were moderately less induced; 
in case of hsd11b2 and gilz, the expression was not significantly elevated anymore. 
 
The other selected targets, cyp11c1 (a), pomca (c) and gr (f)were not affected by Preg 
treatment. Potentially, their mRNA transcription is not mediated by Cort binding to the GR, or 
they are regulated by mechanisms other than receptor binding. Especially in case of cyp11c1, 
encoding 11β-hydroxylase, GC effects on the enzyme activity and availability probably underlie 
more dynamic effects than transcription regulation. In the case of pomca, downregulation of 
expression in the anterior pituitary (as seen with Dex treatment by Liu et al. 2003) may be 
masked by unchanged expression levels in the posterior pituitary or the arcuate nucleus, 
rendering this effect not detectable by qPCR from larval extracts. 
 
 
Figure 43: Gene expression timecourse experiments Pregnenolone  
Expression ratios of GC-signaling related target genes in exposure to Preg. Expression of mRNA is 
measured for cyp11c1  (a) ,  hsd11b2  (b) ,  pomca  (c) ,  gilz  (d) ,  fkbp5  (e)  and gr  (f)  after larvae were 
exposed for 1,2,4,12 or 24  h to Preg ([5 µM], 0.1%) or DMSO (0.1%, data not shown] or to E3 for 
24 h.The ratios of treatment with DMSO to treatment with Preg/ E3 are calculated for the 
respective exposure times. Mean gene expression ratios of three biolog ical repl icates + SEM (n=3) 
are shown. Statistic evaluation of gene expression data was conducted with the 2CT method, 
measured with two technical replicates per plate and two housekeeping genes ,  rpl13a and ef1α .  
Statist ical s ignificance is determined by comparison of the mean ratio of each treatment condition 
with the mean ratio of the DMSO control for each exposure time in a multiple t -test,  α=0.05 .  After 
multiple testing correction with the Holm -Šídák method, significance is def ined as p < α < 0.02 =*.  
 
According to the pretesting results, hsd11b2, fkbp5 and gilz were selected as GC target genes for 
gene expression analysis of the library compounds. As for these three genes the exposure time 
of 4h showed the highest expression ratios, this duration was selected as the optimal exposure 
time for the assessment of compound effects on target gene expression. 
Furthermore, although cyp11c1 was not regulated by Preg treatment, the library compound 
effects on this target gene were still assessed because of its role in GC metabolism. In addition, 
without pretesting, two genes related to xenobiotic metabolism, cyp1a1 and cyp3a65, were 
selected based on their implication in GC drug metabolism. Regulation of cyp1a1 or cyp3a65 
might indicate compound effects on xenobiotic metabolism, which could affect endogenous 
concentrations of Dex and Preg and would in turn disrupt GC signaling. 
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Next, the compound gene expression patterns are examined upon co-exposure with Dex and 
Preg in vivo. This will provide more information about their presumptive effect mechanisms and 
should help to pursue the third aim of this study, to identify GC signaling inhibitors with - so far - 
unknown mechanisms of action. 
3.6.2 Library compound effects on target gene expression 
For library compound effect analysis on the selelcted genes, larvae were exposed for 4 h to the 
same compound concentrations as applied for chemical analysis, each substance in co-treatment 
with Dex [20 µM] as well as with Preg [5 µM]. Afterwards, qPCR experiments were conducted. 
Gene expression ratios were calculated by comparing the treatment with the negative control 
results. The results are shown in Figure 44. As Preg had an overall stronger impact on target 
gene expression, the results for Preg will be described first. 
 
The expression ratios for all genes after co-exposure to Preg + library compounds are shown in 
Figure 44.II. Preg (Preg [5 µM] + DMSO, negative control) significantly induced the expression of 
fkbp5 (a), hsd11b2 (b), gilz (c), cyp3a65 (e) and cyp1a1 (f) when compared to the DMSO control 
(DMSO + DMSO, 0.2%). The strongest up-regulation was observable for  fkbp5 with a 25-fold and 
hsd11b2 with a 17-fold induced gene expression by Preg, consistent with the obsevations from 
the time course experiments, while the increase of gilz, cyp3a65 and cyp1a1 was between four- 
and five-fold. As the negative control effect served as reference for all other treatments, lower 
or higher induction of gene expression by drug library compounds was defined as reduced or 
induced gene expression. Also the DMSO control leads to “reduced” expression in this view, as 
no induction can occur here. 
 
The data reveal that most library compounds reduced the expression of all tested genes, except 
that of cyp11c1. Only Trani (p=0.0354) and Estrone (p=0.0329) showed a trend to decrease 
cyp11c1 mRNA levels (d). This low effect on the gene encoding 11β-hydroxylase is consistent 
with the results from pretesting experiments and strengthens the assumption that GC effects on 
the enzymatic action of 11β-hydroxylase may not predominatly be mediated via changes in 
mRNA transcription, but rather by more dynamic mechanisms. 
 
For fkbp5 (a), hsd11b2 (b) and gilz (c), distinct patterns of regulation are observed, showing that 
several library compounds had common effects on all three genes. Especially Estrone, Gestri, 
Nor, Mety, Mife and DHEA strongly decreased the Preg-induced gene expression, with mRNA 
levels for Estrone, Gestri and Nor even comparable to those of the DMSO control. Only three 
compounds did not affect gilz expression, namely Ret. acid, Leflu and Ethi, while fkbp5 
expression was unaffected by six compounds, Nabu, Spiro, Stano, Ethi, Fen, and Leflu. All other 
substances showed at least a trend (p < α < 0.05) to reduce the expression of fkbp5, hsd11b2 and 
gilz, most of them had a significant (p < α < 0.0.0027) effect. 
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Figure 44: Gene expression experiments with FDA library compounds 
Expression ratios of GC-signaling- (a ,  b ,  c ,  d)  and xenobiotic metabolism - (e ,  f)  related genes in  
co-exposure to Dex ( I)  or  Preg ( II)+ l ibrary compounds. Expression of mRNA is measured for fkbp5  
(a) ,  cyp11c1  (b) ,  hsd11b2  (c) ,  gilz  (d)  cyp3a65  (e)  and cyp1a1  (f)  after larvae exposure for 4  h to 
Preg [5 µM]/ Dex [20 µM ]  +   l ibrary compound (different concentrations) or to the negative control 
Preg + DMSO [5 µM]/ Dex + DMSO [20 µM ].  The amount of DMSO was 0.2% in all  treatment 
conditions.  The ratios of treatment and negative control are calculated. Mean gene expression 
ratios of three biological replicates + SEM (n=3) are sho wn. Statistic evaluation of  gene expression 
data was conducted with the 2CT method, with two technical replicates per plate and two 
housekeeping genes ,  rpl13a and ef1α .  Statist ical significance is determined by comparison of the 
mean ratio of each treatment condition with the mean ratio of the negative control for each 
exposure time in a multiple t -test,  α=0.05 .  After multiple test ing correction with  the Holm -Šídák 
method, significance is  defined as p < α < 0.0027=*  
 
Regarding the genes related to xenobiotic metabolism, Preg-induced mRNA expression of 
cyp3a65 (d) was attenuated by all compounds except Fen, Nor and DHEA, which had no impact 
at all. The expression of cyp1a1 (f) was significantly downregulated by all candidates except 
Leflu, which interestingly even intensified the induction by Preg.  
In Figure 44.I, the gene expression ratios for larvae exposure to Dex + library compounds are 
shown. Dex (Dex + DMSO, negative control) generally had a lower impact on mRNA expression 
than Preg, as only two genes were significantly up-regulated, hsd11b2 (b) and gilz (c), and an 
induced trend was visible for fkbp5 (p=0.0239) (a). The most sensitive gene was hsd11b2, with a 
seven-fold induction, while mRNA expression of all other targets was two-fold higher with Dex. 
However, compared to the 17-fold hsd11b2 increase by Preg, the Dex effect was considerably 
weaker. 
 
Beside the overall lower effect of Dex on target gene expression, the most obvious difference 
betwen Dex and Preg treatment is the lacking induction of xenobiotic target genes by Dex, while 
cyp1a1 and cyp3a65 were highly induced by Preg. This absence of a xenobiotic marker gene 
response to Dex treatment suggests that at least the drug metabolism pahway involving these 
two CYP enzymes was not activated by larvae treatment with the synthetic GC. Keeping in mind 
the low Dex recovery rate found with UPLC-MS/MS, compared to the retrieved amount of Preg, 
it may be possible that the uptaken amount of Dex was high enough to trigger a therapeutic 
response (induce GC signaling and gene expression of several target genes), but not to activate 
the phase I drug metabolism enzymes cyp1a1 and cyp3a65 . 
 
Corresponding to the weak Dex impact on target gene expression, only few library compounds 
significantly altered the mRNA levels in response to Dex induction. However, most substances 
showed a trend to further induce mRNA expression of gilz (c), and, in few cases, also fkbp5 (a) 
and hsd11b2 (b) were up-regulated with Dex, although the same compounds decreased the 
levels of these genes in co-treatment with Preg.  
Trends for downregulation of fkbp5 (a) are visible with 10-HC (p=0.0030), Mife (p=0.0266) and 
Gestri (p=0.0302), whereas tendencies for induced expression can be observed with Nor 
(p=0.0254) and Stano (p=0.0109) 
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Five compounds significantly alterd the expression of hsd11b2 (b), 10-HC, Mife and Spiro 
reduced gene expression, while Aci and Stano further induced it. In addition, Gestri (p=0.0111) 
shows a trend to increase and Ret. acid (p=0.0420) a tendency to decrease the mRNA level.  
The expresion of gilz (c) was altered by all compounds except Spiro, Ethi and Estriol. Mife 
reduced mRNA expression significantly while Leflu, Fen, Nabu, Trani, Aci, Ret. acid, Nor, Stano, 
Estrone and DHEA showed trends to upregulate mRNA expression (p=0.0472-0.0067) and 10-HC 
(p=0.0161), as well as Gestri (p=0.0123) tended to decrease gilz levels. 
The mRNA levels of cyp11c1 (d) were not altered by any of the tested compounds, similar to the 
observations with Preg treatment. 
Two compounds had significant effects on cyp3a65 (e), Gestri reduced mRNA expression while 
Leflu induced it. Furthermore showed Ret. acid (p=0.0341) and DHEA (p=0.0399) trends to 
further induce gene expression, while a tendency for down-regulation was visible for 10-HC 
(p=0.0046). 
The other marker gene for xenobiotic metabolism, cyp1a1 (f), was significantly regulated by two 
compounds. Gene expression was remarkably high induced by Leflu with a ratio of 56 while 10-
HC down-regulated the mRNA level. Also Aci (p=0.0046), Ret. acid (p=0.0194) and Ethi 
(p=0.0483) showed trends to reduce  cyp1a1 expression. 
 
Evaluation of the gene expression results in the context of GRIZLY assay and chemical analysis 
outcomes 
Figure 45 summarizes the data of the whole tiered testing approach, i.e. the substance effects 
on GC signaling, their steroid level profiles and the gene expression patterns. Again, color code 
profiles are shown for controls and library compounds. No difference of the substance effect 
compared to the negative control is indicated in yellow. Significant reduction or co-induction of 
signal intensity/ steroid concentration/ gene expression compared to the stimulated untreated 
(negative) control is indicated in green and red, non-significant trends (p < α < 0.05) for reduction 
or co-/induction in orange and light green, respectively. Significance is defined as 
p < α < 0.0001=* for the GRIZLY assay, p < α < 0.005=* for chemical analysis and for gene 
expression results p < α < 0.0027=*. The applied concentrations for UPLC-MS/MS and qPCR 
experiments are indicated for each substance. In order to facilitate comparisons, the compounds 
were divided into four groups according to their GRIZLY behaviour and their impact on 
endogenous Cort levels. 
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Figure 45: Comparison of compound effects in GRIZLY, UPLC -MS/MS and qPCR experiments  
Color code profiles are shown for controls and lib rary compounds. No difference of the substance 
effect compared to the negative control ( Dex [20 µM]/ Preg [5 µM]  + DMSO) is indicated in yellow. 
A significantly  increased or decreased GRIZLY signal intensity, steroid level or gene expression  
compared to the negative control is indicated in green and red, respectively.  Non-significant 
trends (p < α < 0.05 )  for increase or decrease are shown in orange and light green, respectively. 
Significance is def ined as p < α < 0.0 001 for the GRIZLY retests,  as p < α < 0.005 for chemical 
analysis  and as p < α < 0.0027 for qPCR results. Val idated inhibitors and  superactivators from 
retesting are indicated with their  lowest observed effect concentration (LOEC) in the respective 
GRIZLY assay.  
 
Controls 
Regarding the gene expression analysis controls, the positive control for Dex-induced GC 
signaling (Dex + Mife) apparently counteracted the negative control (Dex + DMSO) effect on 
mRNA levels. Thus, the gene expression pattern of Dex + Mife is identical with that of the DMSO 
control. This, in turn, reflects the Mife effect on GC signaling within the GRIZLY assay, where 
Mife also produced the same signal patterns as the DMSO control.  
Likewise, this applies for the positive control of Preg-induced GC signaling (Preg + Mety). Mety 
completely reversed the effect of the negative control (Preg + DMSO) on mRNA expression 
levels, leading to identical gene expression patterns as the DMSO control. This, again, 
reproduced the effect of Mety on Preg-induced GC signaling within the GRIZLY assay. 
The same pattern of target gene expression as for Preg + Mety was observable for Preg + Mife, 
which also resembles the respective GRIZLY result. This further indicates that both control 
inhibitors, although acting via different mechanisms, have the same impact on Preg-induced GC 
signaling, even on the level of mRNA expression of the selected gene set. Within this set, also 
the Preg-induced expression of the xenobiotic clearance-related targets cyp1a1 and cyp3a65 
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DMSO + DMSO
Preg [5 µM] + DMSO - - - - - - -
Dex [20 µM] + DMSO - - - - - - - - -
Dex [20 µM] + Mety [40 µM] - - - - - - - - - -
Preg [5 µM] + Mety [40 µM] - - - - - - - -
Preg [5 µM] + Mife [1 µM] - - - - - - - -
Dex [20 µM] + Mife [1 µM] - - - - - - - - -
Compounds + Dex + Dex + Preg + Dex [µM] Group
Leflunomide 4 4
Fenbufen 8 4 4
Nabumetone 4 4 4
Tranilast 10 10 10 10
10-Hydroxycamptothecin 4 4 4 4
Mifepristone 0.2 0.4  0.2  1
Acitretin 4 8 4 4
Retinoic Acid 0.4 1.2 1.6 2
Gestrinone 4 4 4 4
Norethindrone 40 10 10 10
Ethisterone 4 4
Stanozolol 12 12 8 12
Spironolactone 6 2 2 2
Estrone 8 4 4
Dehydroepiandrosterone 20 4 4
Estriol 12 12
Controls
Retest LOEC [µM] Chemical analysis Gene expression analysis
Larvae
1
2
4
5
3
+ Preg + Dex + Preg
sign. decrease/ decreasing trend/ no change/ increasing trend/ sign. Increase of signal intensity/ steroid concentration in 
larvae; significance = p < α = 0.0001 for GRIZLY, p < α = 0.005 for chemical analysis and p < α < 0.0027 for qPCR results; trends = p < α = 0.05
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was counteracted by Mety and Mife, which strongly suggests a GR-mediated trancriptionl 
regulation of these genes in co-treatment with Preg, instead of, or in addition to,  an AhR/ PXR-
initiated mechanism. Furthermore, within the  Preg timecourse experiment from Figure 38, the 
endogenous amount of Preg was with 6833 ng/ 100 larvae 30% higher under treatment with 
Preg + DMSO (h) than with Preg + Mety (i), where 4810 ng/ 100 larvae were detected at the 
timepoint of qPCR analysis (4 h). The lower Preg level in the larvae could thus, also result in a 
lower xenobiotic activity and may contribute to the decrease of cyp3a65 und cyp1a1 mRNA 
expression upon Mety treatment. As Dex had no measurable effect on cyp1a1 and cyp3a65, 
expression of these targets was accordingly not altered by Mife. 
 
In view of the positive control effects on endogenous steroid levels, reduced Cort by Preg + Mety 
correlates with the GRIZLY and the gene expression outcomes. Also as expected, steroid level 
profiles of Dex + Mife and Preg + Mife are not following the Mife effects within GRIZLY and qPCR 
experiments, as Mife inhibits GC signaling by GR antagonism, a mechanism which does not 
necessarily involve reduction of the endogenous Cort concentration. 
Furthermore , it was shown that Mety had no impact on Dex-induced GC signaling, neither in the 
GRIZLY assay, nor on GC target gene expression or endogenous steroid levels. The only exception 
is a trend to induce the expression of cyp1a1 with Dex, potentially suggesting disrupted 
xenobiotic clearance, but the endogenous Dex concentration was not altered by Mety. 
 
Group 1 
The library compounds Leflu, Fen and Nabu were assigned to group 1. Fen and Nabu reduced GC 
signaling in GRIZLY 2 and GRIZLY 3, while Leflu inhibited the signal only in GRIZLY 3 and was, 
thus, suspected to disrupt the Cort biosynthesis. However, the steroid level profiles gave no 
indications for disruption of GC biosynthesis for any of the three compounds. 
 
Regarding the gene expression patterns of Leflu, the significant up-regulation of cyp3a65 and 
cyp1a1 in co-treatment with Dex is eye-catching. Also for Leflu + Preg was a strong induction of 
cyp1a1 visible, but the gene expression ratio was seven-fold higher with Dex (Figure 44 I+II f). 
This strong induction of the xenobiotic clearance marker gene by Leflu in co-treatment with both 
activators cannot be explained by GRIZLY or UPLC-MS/MS results, as the outcomes are different 
with Preg and Dex. Possibly, the effect of Leflu on cyp1a1 expression is reasoned by GC-signaling 
independent mechanisms. Although the GR is known to have a regulatory function on the 
expression of cyp1a1, this gene is also the major target of the Ahr transcriptional activity. 
Accordingly, Leflu may have triggered Ahr-medited cyp1a1 expression, independent from GR 
signaling. 
Regarding the other gene for xenometabolic activity, cyp3a65, mRNA induction was obserrvable 
with Dex while expression was down-regulated with Preg. Potentially, Leflu affected the uptake 
of Dex and Preg into the larvae differently, as it is supported by chemical analysis data, showing 
elevated Dex and reduced Preg in the larvae. Thus, the cyp3a65 expression in larvae may be 
induced as a response to the increased Dex concentration, while the decreased Preg level 
resulted in downregulation of cyp3a65. Although the elevated Dex in the larvae did not lead to a 
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significant increase in GRIZLY signal, the bioluminescent traces for Dex + Leflu in Figure 37 c are 
in accordance with the chemical analysis findings, indicating a tendency for increased GC 
signaling. The increased expression of the Dex target gene gilz further supports this assumption. 
In contrast, the observed inhibition of GC signaling by Preg + Leflu is supported by qPCR results. 
Although endogenous Preg levels were reduced, additional mechanisms must have led to the 
observed, strong, signal inhibition within the GRIZLY assay. A Preg-induced hsd11b2 expression 
was decreased by Leflu, but mRNA levels of gilz and fkbp5 were not affected, the compound 
disrupted the transcriptional regulation of several, but not all GR target genes. Due to these 
differences in the gene expression patterns of Leflu and Mife, Leflu certainly had no full 
antagonistic effect on all Preg-induced genes, but may still have directly antagonized the 
expression of some GR targets. Potentially, GR binding of Leflu may have induced 
conformational changes of the LBD, which led to differential recruitment of coactivators and 
repressors and resulted in gene-specific transrepression.   
 
Fen and Nabu had similar effects in all experiments. They inhibited Dex- and Preg induced GC 
signaling in the GRIZLY assay, thus, disruption of the Cort biosynthesis was not assumed. This 
was confirmed by chemical analysis, as the measured steroid levels neither gave indications for 
inhibition of Cort production, nor suggested they changes in drug uptake due to treatment with 
Fen and Nabu. On the level of gene expression, both compounds showed a trend to induce gilz 
in co-treatment with Dex, while a tendency to down-regulate this gene was observable in co-
exposure with Preg. Accordingly, with Dex, the gene expression patterns of Fen and Nabu show 
no resemblance with that of Mife, where Dex-induced expression of hsd11b2, gilz and fkbp5 was 
counteracted. With Preg, Fen and Nabu down-regulated several target genes of the GR 
antagonist Mife, but fkbp5 expression was not reduced. As for Leflu, the differences between 
the respective gene expression patterns suggest that Fen and Nabu inhibit GC signaling 
differently than Mife and Mety, but they may still compete with Dex and Cort for GR binding and 
mediate differential expression of several GR target genes. 
 
Group 2 
Group 2 contains the five compounds which inhibited in all three GRIZLY approaches, Trani, 
10-HC, Mife, Aci and Ret. acid.  
Trani showed no effect on any steroid measured by UPLC-MS/MS. On target gene expression, a 
trend for induced gilz was observable with Dex, while the mRNA levels of all targets were 
decreased with Preg. In co-treatment with Dex, Trani revealed the same gene expression pattern 
as Fen and Nabu, which reflects not the GRIZLY response and unfortunately provides no further 
information about the origin of Dex-induced signal disruption. Co-exposed with Preg, the Trani 
effect on target gene expression was similar to that of Mife and Mety, suggesting here parallels 
between the underlying mechanisms of GC signaling inhibition. However, in contrast to the 
positive controls, the substance showed a trend to decrease also cyp11c1, which might imply 
compound impacts on GC signaling different from or additional to the control inhibitor response.  
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For Mife, chemical analysis did not reveal reduced Cort levels, excluding this as an explanation 
for the observed inhibition in GRIZLY 3. Although Cort and Dex levels were even elevated, Mife 
dominated GC signaling via GR antagonism, which led to the observed inhibition in all three 
GRIZLY screens and which was also reflected on the level of gene expression, as Mife 
antagonized all targets of Dex and Preg.   
Interestingly, 10-HC had the same effect as Mife when co-treated with Preg, not only within the 
GRIZLY assay, but also in qPCR experiments, as it produced almost exactly the same gene 
expression pattern as Mife. The endogenous steroid levels were not found to be altered by 10-
HC. However, a minor trend for elevated Prog and Cort and reduced Preg might be perceived 
from Preg + 10-HC treatment in Figure 40 b-d, very similar to Preg + Mife, but with higher 
replicate variations and thus, less considerable. Accordingly, given the gene expression patterns 
and GRIZLY responses, a distinct comparability between the impact of 10-HC and Mife on Preg-
induced GC signaling is observable, which is also rather supported by chemical analysis. 
In combination with Dex, the gene expression pattern of 10-HC showed differences to that of 
Mife. Although both compounds inhibited hsd11b2, gilz and fkbp5, the effect of 10-HC on gilz 
was not significant, but instead, cyp3a65 and cyp1a1 were reduced. As these two xenobiotic 
genes were no signifcant targets of Dex, down-regulation by 10-HC appears to be a compound-
specific effect, potentially independent from Dex-mediated GC signaling. Furthermore 
anduniquely with 10-HC, a lower Dex concentration was measured in the larvae, which might 
explain the reduced expression of all Dex targets. The lower Dex level may be a consequence of 
reduced Dex uptake, an idea which appears to be supported by the down-regulation of cyp3a65 
and cyp1a1, indicating less xenometabolic activity due to the lower amount of Dex in the larvae. 
In summary, these results may suggest that the GRIZLY response to 10-HC underlies different 
mechanisms when GC signaling is stimulated either with Dex or with Preg. While GR antagonism 
of Cort by 10-HC might possibly have lead to reduced GC signaling in GRIZLY 3, reduced uptake 
of Dex might potentially explain the effect of 10-HC in GRIZLY 2. However, in GRIZLY 1, reduced 
uptake of the synthetic GC due to some effect of 10-HC cannot be completely excluded as an 
explanation for the observed GC signaling inhibition, but appears rather unlikely. 
 
The two other inhibitors in all three GRIZLY approaches, Aci and Ret. acid, both showed reduced 
Cort levels in co-treatment with Preg. Aci further also reduced Preg and Prog, which is why 
disrupted uptake or metabolism of Preg was hypothetized to underly the reduced Cort and thus, 
decreased GC signaling by Aci in GRIZLY 3. For the effect of Ret. acid, a disrupted Cort 
biosynthesis was considered a possible explanation. Regarding their impact on target mRNA 
levels, both compounds broadly counteracted the effect of Preg and showed high similarity with 
the gene expression patterns of Mife and Mety. For Aci, the only difference to the positive 
controls was a trend for reduced gilz, while the target was significantly down-regulated by Mife 
and Mety. Ret. acid had no effect on gilz and the decrease of fkbp5 was not significant. Thus, Ret 
acid may have a different target gene response profile than the positive controls but effect 
similarity on Preg-induced GC signaling is still suggested. 
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Regarding the impacts of Aci and Ret. acid on Dex-induced GC signaling, the Dex levels in larvae 
were not altered. Interestingly, both compounds had a similar effect on target gene expression. 
Aci and Ret. acid showed trends to induce gilz and to reduce cyp1a1. Also, hsd11b2 was induced 
by both substances, significantly by Aci. Ret. acid furthermore showed a tendency to induce 
cyp3a65. Especially the up-regulation of hsd11b2 is a specific effect of Aci and Ret. acid among 
the inhibitors in GRIZLY 2. As the induced levels of hsd11b2 and gilz are contrary to the Mife 
effect on target gene expression, rather increased than reduced GC signaling might be suspected 
from this. However, the GRIZLY response did not reflect GC signaling induction. This suggests 
that the two compounds apparently triggered gene-specific responses on hsd11b2, fkbp5 and 
gilz, probably via interaction within the promotor region of these target genes.  Additional, 
unknown mechanisms of Aci and Ret. acid must have led in the end to the observed inhibition of 
GC signaling.  
The disrupted regulation of cyp3a65 and cyp1a1 indicates that impaired xenobiotic clearance 
may play a role within the observed effects, although the Dex levels in larvae were not altered. 
Alternatively, cyp3a65 and cyp1a1, which are no targets of Dex or Mife, might also have been 
regulated by a mechanism other than GC activation of the GR or receptor antagonism. 
 
Group 3 
The substances which were assigned to group 3 superactivated in GRIZLY 2 and inhibited in 
GRIZLY 3. Furthermore, they decreased endogenous Cort in co-treatment with Preg.  
For Gestri + Preg, the qPCR results correlate with the inhibition in GRIZLY 3 and the reduced Cort 
levels. Gestri decreased the expression of all Preg targets, identical with the effects of Mety and 
Mife. This further confirms Cort biosynthesis disruption as the underlying mechanism of action, 
without any indications for additional impacts of Gestri on Preg-induced GC signaling. 
Together with Dex, Gestri superactivated GC signaling. Chemical analysis did nor indicate 
significant changes of endogenous Dex, neither can the qPCR data explain this effect. Gestri 
reduced the expression of all genes but cyp1a1 and addressed, thus, the same targets as Mife. 
Moreover, uniquely among all compounds, Gestri decreased the expression of cyp11c1 in co-
treatment with Dex down to a lower level than for the DMSO control. Although a potential 
interaction of Gestri with Dex uptake or metabolism might be suggested by the disrupted 
cyp3a65 expression, this was not confirmed by UPLC-MS/MS experiments, and might thus be 
less of an indicator for the effect mechanism of Gestri than the decrease of cyp11c1. 
 
With Nor, a high effect similarity to Mety on Preg-induced GC signaling was described according 
to the steroid level profile. The gene expression pattern supports this assumption, as Nor 
reduced the same targets as Mety (and Mife), except cyp3a65, which was not altered by Nor.  
Together with Dex, Nor had the same effect on GC signaling as Gestri, it also showed 
superactivation. Interestingly, the Nor effect on target gene expression had no similarity with 
the response to Gestri, as Nor showed a tendency to induce gilz and fkbp5, while the other 
genes remained unaffected. The upregulation of these two GC targets correlates with the 
elevated Dex level in larvae, observed by chemical analysis, and the superactivation in the 
GRIZLY assay. 
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Group 4 
All compounds from group 4 superactivated GC signaling in GRIZLY 2 and had the same or no 
effect in GRIZLY 3. Furthermore, for all of them, disrupted GC biosynthesis due to reduced 
endogenous Cort levels was hypothesized as a mechanism of action, but which cannot explain 
the superactivation of GC signaling in GRIZLY 2.  
When Stano was co-treated with Dex, it significantly elevated the Dex level in larvae. In 
accordance with this, the expression of the GC targets hsd11b2, gilz and fkbp5 was also induced. 
Accordingly, Stano up-regulated all targets which were reduced by Mife, and had thus, the 
opposite effect of the GR antagonist, on mRNA expression, as well as on GC signaling within the 
GRIZLY assay. While several compounds showed induction of gilz without inducing GC signaling 
in the GRIZLY assay, Stano was beside Nor the only compound which up-regulated hsd11b2 and 
superactivated in GRIZLY 2. Further, Stano and Nor were the only compounds which induced 
fkbp5 when co-treated with Dex. As Stano also revealed an elevated Dex level, without 
disruption of cyp3a65 and cyp1a1, like Nor, it is equally suggested for Stano that the effects in 
GRIZLY 2 and on GC target genes might be caused by the higher Dex concentration. Also 
comparable for both compounds, no alterations in the expression of cyp3a65 and cyp1a1 were 
observed in co-treatment with Dex, although it may have been exprectable from the elevated 
Dex level. Maybe, some other pathway counteracted the effect on cyp3a65 and cyp1a1 or 
xenometabolism was primarily regulated via other mechanisms. 
Regarding the qPCR results of Preg + Stano, hsd11b2, gilz, cyp3a65 and cyp1a1 were reduced. 
Stano decreased the same targets as Mife and Mety, except fkbp5. Accordingly, the gene 
expression pattern correlates well with reduced endogenous Cort, but the GRIZLY assay showed 
the opposite effect on GC signaling. The qPCR data strengthen the hypothesis that Stano 
disrupted GC biosynthesis, but also acted by another mechanism which led to co-induced GC 
signaling with Preg, at least on isolated GRE elements as used in the GRIZLY assay. Potentially, 
this mechanism involved induction of fkbp5, which could possibly have compensated its reduced 
expression due to lacking Cort, leading in the end to an unchanged mRNA expression level. 
 
Spiro showed the same gene expression pattern as Stano in co-treatment with Preg. This also 
correlates with the assumed disruption of Cort biosynthesis by Spiro, but as for Stano, another 
mechanism must have led to induced GC signaling in GRIZLY 3 and unchanged levels of fkbp5. 
For Dex + Spiro, no indication for induced Dex levels were given by chemical analysis. On target 
gene expression, Spiro had a rather low impact as it only reduced hsd11b2. Accordingly, no 
direct hint is given by UPLC-MS/MS or qPCR experiments why Spiro co-induced GC signaling in 
GRIZLY 2.  
In contrast to Stano, where superactivated GC signaling in GRIZLY 2 probably is the consequence 
of increased endogenous Dex concentrations, but the effect in GRIZLY 3 must have had a 
different reason, for Spiro, the effect in GRIZLY 2 and GRIZLY 3 can possibly be caused the same 
mechanism, regardless of the Cort biosynthesis disruption with Preg. 
 
Ethi had a co-inductive effect on GC signaling in GRIZLY 2 but not in GRIZLY 3. Although a minor 
trend for increased bioluminescent traces was also seen with Preg in Figure 32 l, suggesting 
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effect similarity of Ethi on both Preg- and Dex-induced GC signaling, the signal increase was not 
significant in GRIZLY 3.  
Chemical analysis showed elevated endogenous Dex with Ethi, which might explain the effect in 
GRIZLY 2. Dex target genes were not increased by Ethi, but, as visible in Figure 43. I, fkbp5 (a), 
hsd11b2 (b) and gilz (c) showed rather a slightly higher expression with Ethi than without. Thus, 
even though elevated Dex did not significantly increase the respective target mRNA levels, qPCR 
data rather support an Ethi-mediated accumulation of endogenous Dex to be the reason for 
superactivation in GRIZLY 2. Disrupted Dex metabolism might further be suggested by the 
decreased level of cyp1a1 by Ethi. 
With Preg + Ethi, disrupted Cort biosynthesis was suggested by chemical analysis. As Ethi had no 
significant effect in GRIZLY 3, the reduced Cort level did not result in a decrease of GC signaling. 
Within qPCR experiments, Ethi counteracted the Preg effect on hsd11b2, cyp3a65 and cyp1a1, 
similar to Mety and Mife, which partly correlates with the disrupted Cort biosynthesis. However, 
in contrast to the positive controls, Ethi did not decrease gilz and fkbp5, which may relate to the 
lacking inhibition of GC signaling in the GRIZLY assay. Apparently, similar to Stano and Spiro, Ethi 
acted beside the disruption of Cort synthesis via an additional mechanism, which compensated 
the effect of reduced Cort on GC signaling, and led to the insignificant effect on GC target genes, 
visible in Figure 44 lI, as mentioned above. 
To highlight the effect similarities between Stano, Spiro and Ethi, the missing decrease of fkbp5, 
noticeably correlates with their lacking GC signaling inhibition in GRIZLY 3. As, in contrast to all 
other disruptors of Cort biosynthesis (groups 2-5), Stano, Spiro and Ethi commonly did neither 
inhibit in GRIZLY 3, nor decreased fkbp5 expression, their effect mechanism might be suggested 
to involve regulation of this target.  
 
Group 5 
Estrone, DHEA and Estriol had no effect in GRIZLY 2, but showed reduced Cort as possible 
explanations for their inhibition in GRIZLY 3. Unlike Mety and several other GC biosynthesis 
disruptors, Estrone, DHEA and Estriol did not affect endogenous Preg or Prog levels. Accordingly, 
disruption of Cort biosynthesis might be their mechanism of action, but also reduction of 
endogenous Cort via different pathways could underlie these findings. 
In co-treatment with Preg, the gene expression patterns of all three compounds show high 
similarity with those of Mety and Mife, although none of them is identical to that of the positive 
controls. This observation might imply certain mechanistic differences, but they appear minor, 
regarding the high effect similarity of Estrone, DHEA and Estriol within all experiments.  
Estrone significantly down-regulated all target genes except cyp11c1, identical to Mety and Mife, 
but showed moreover a tendency to decrease also the expression of cyp11c1. DHEA significantly 
reduced the same targets as the positive controls, except cyp3a65, which remained unchanged. 
Therewith, the gene expressio pattern of DHEA is identical to that of Nor, suggesting high effect 
similarity between two putative disruptors of Cort biosynthesis, but in contrast to Nor, DHEA did 
not reveal elevated Preg levels during chemical analysis. Thus, down-regulation of cyp3a65 
appears to be independent from the compound mechanism on Cort reduction. Estriol also 
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decreased the expression of all positive control targets, but its effect on gilz and fkbp5 was not 
significant. 
When co-exposed to Dex, trends for induced gilz were observed for Estrone and DHEA and a 
tendency for elevated cyp3a65 was also visible with DHEA. However, as neither the Dex level 
was altered, according to UPLC-MS/MS experiments, nor GC signaling was affected, this 
observation seems to be rather unimportant in the context of the study. 
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Chapter 4 
4. Discussion 
In this thesis, I applied the transgenic Tg(GRE:Luc)zebrafish line, as well as the AB.9-GRE:Luc cell 
reporter, and modified the GRIZLY assay for the identification of GC signaling inhibitors. I 
selected and validated control conditions for activation and inhibition of GC signaling (section 
3.1.1) and performed three different variants of the GRIZLY assay in order to detect compound 
interference with the GC system at different points of action. In GRIZLY 1, I tested for inhibition 
of directly activated GC signaling in vitro in the cell culture system. In GRIZLY 2, inhibition of 
directly activated GC signaling was examined in vivo with Tg(GRE:Luc) zebrafish larvae, and in 
GRIZLY 3, inhibition of indirectly activated GC signaling was targeted. 
With these assays, I pursued a tiered testing approach (section 3.2) and screened an FDA 
approved drug library of 640 established compounds, with the aims 1) to assess the suitability of 
the GRIZLY assay for the detection of GC signaling inhibitors, 2) to identify disruptors of the GC 
biosynthesis pathway and3) to identify compounds with - so far - unknown potential to interfere 
with GC signaling or with unknown mechanisms of action. In tier 1 (section 3.2.1), I screened the 
drug library for toxic effects in cells and in larvae (section 3.2.1.1) and tested for inhibition of GC 
signaling in the three GRIZLY approaches (section 3.2.1.2). Interestingly, I identified not only 
inhibitors, but also superactivators of the GRE:Luc reporter. All compounds that significantly 
modulated (inhibited or superactivated) GC signaling in vivo and showed no toxic potential in 
vivo or in vitro were carried over to tier 2 (section 3.2.2), where I retested these candidates 
concentration-dependently under the same treatment conditions. From the confirmed hits, 
promising in vivo modulators of GC signaling were subjected to tier 3, where I elucidated the 
drug mechanisms of action in more detail. In tier 3a (section 3.2.3), I assessed by means of 
chemical analysis if the substances indirectly inhibited GC signaling, for instance by disruption of 
Cort biosynthesis. Additionally, in tier 3b (section 3.2.4), I performed qPCR analysis in order to 
examine effects of the compounds on a set of target genes. 
The tiered approach was a reasonable testing strategy, as it enabled me to identify and validate 
GC signaling disruptors from a library of substances by the combined testing in three different 
GRIZLY approaches. Furthermore, the follow-up studies in tier 3 helped me to narrow down the 
mechanisms of action possibly underlying the compound effects and gave me ideas which future 
experiments will be necessary to characterize their mechanisms in detail. 
 
In the following sections, I will first discuss the toxicity assessment results from tier 1 (section 
4.1) before I summarize the suitability of the GRIZLY assay for my intention to identify inhibitors 
of GC signaling (section 4.2). Then I will focus on the compound effects in the GRIZLY assay and 
the follow-up studies. I will survey first several general (section 4.3) and more specific (section 
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4.4) mechanisms of GC signaling disruption, which may have played a role within the effect 
outcomes of the identified substances. Based on the results of the tiered testing strategy 
(section 4.5), and according to the available literature, I will then discuss the identified GC 
signaling disruptors and their mechanisms of action in detail (section 4.6 - 4.11).  
4.1 Differences in compound toxicity between the three testing approaches 
Prior to the evaluation of the screening results for the detection of GC signaling inhibitors, I 
assessed the toxicity of the library compounds for each of the three GRIZLY testing approaches 
in order to distinguish GRIZLY signal inhibition between general compound toxicity and specific 
effects. As an outcome, several compounds showed toxicity in two or three testing setups, but 
also a number of candidates were considered toxic in only one single assay (as it was shown in 
Figure 24). I will discuss possible reasons for these discrepancies in the next sections. 
4.1.1 Stringency of toxicity assessment 
The disparity that I found a considerably lower number of toxic compounds in vitro than in vivo 
possibly relies on the different rigor by which toxicity was defined. In vitro, only statistically 
significant data from the cytotoxicity screen were considered, with a stringency of 
p < α < 0.0001. The in vivo screens, in contrast, were assessed more conservatively, as a 
compound was considered as potentially toxic when 10% of all larvae replicates were immotile 
or dead. Although I intended a high stringency in order to not include potential false-positive 
inhibitors in the following data analysis and testing procedures, some compounds thereby might 
have been false-positively determined as toxic. 
4.1.2 Increased in vitro toxicity  
In addition to the different stringency of toxicity assessment, which was probably the major 
reason for the different outcomes of the toxicity assessment in larvae and cells, also other 
mechanisms may have contributed to the observed discrepancies of toxicity between the three 
assays. For instance, disparities between in vitro and in vivo drug uptake could have played a 
role. While zebrafish fibroblast-like AB.9-GRE:Luc cells were directly exposed to the chemicals in 
their culture medium, for larvae, the bioaccessibility of compounds may be lower and substance-
specific, depending strongly on the particular chemical properties which control the potency to 
pass the skin barrier. Moreover, 5 dpf old larvae not only absorb chemicals via the skin and 
perhaps via the developing gills, they also start already to ingest substrates orally, which may 
allow for a certain amount of drugs to pass the intestinal tract. This furthermore increases the 
role of compound-specific bioavailability for the extent of pharmacological effects in larvae upon 
uptake. In vivo, the portion of a drug which reaches the systematic circulation is usually 
considerably reduced during the first-pass effect, where the liver metabolizes a big part of the 
incorporated amount (e.g. by the CYP enzymes), which might even lead to complete inactivation 
of an active compound. Accordingly, a decreased drug bioaccessability and bioavailability, 
possibly involving reduced compound activity and toxicity, might be suspected for the larvae 
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when compared to the in vitro exposure, where these whole-organism abilities for drug 
biotransformation and translocalization are lacking. This context could explain why seven 
identified compounds were only toxic in vitro but not in vivo. 
4.1.3 Increased in vivo toxicity  
On the other hand, a chemical´s bioavailability can also be increased by the organism. Numerous 
pharmaceuticals are orally inactive until they are transformed by liver enzymes into active 
metabolites. Also, drugs are often designed to be transported to and to function in a specific 
target organ or tissue. In the zebrafish larvae, several compounds could therefore have been 
activated metabolically and translocated to their pharmacological targets, which might then 
have led to toxic effects in vivo. For some of the 128 compounds, which were only toxic in the 
in vivo screens, this might have been the case.  
4.1.4 Xenometabolism 
Also the compound co-exposure with different activators, either Dex or Preg, can influence the 
pharmacological effect of the substance. As already described in 1.3.1.3, Dex and Preg can 
stimulate the xenobiotic metabolism and differentially induce the expression of several CYP 
enzymes (Gentile et al. 1996; Martignoni et al. 2004; Petkam, Renaud, and Leatherland 2003; 
Zanger and Schwab 2013). Especially the results from chemical analysis (section 3.5.1), which 
showed that the retrieved amount of Preg (31.33%) from larvae extracts was over three orders 
of magnitude higher than that of Dex (0.02%), suggest that an unequal amount of activator was 
taken up by the larvae. As a consequence, the larvae showed probably a different xenometabolic 
activity with the library compound, depending on the co-exposed activator. This consideration is 
also supported by the qPCR results, as Dex induced the expression of the two xenometabolic 
marker genes cyp3a65 and cyp1a1 about two-fold, while Preg triggered a five-fold induction of 
cyp3a65 and a four-fold increase of cyp1a1 expression (DMSO control compared to the negative 
control: Dex/ Preg + DMSO; Figure 44 e and f). Accordingly, this different xenometabolic activity 
may have contributed to compound toxicity in one, but not in the other in vivo GRIZLY assay. An 
increased activity of xenometabolic enzymes, for instance of members of the CYP1, CYP2 and 
CYP3 families, can lead to higher toxicant removal rates and reduced blood concentrations, not 
only of Dex or Preg, but also of the co-treated substance, or could also stimulate the production 
of toxic metabolites, depending on the pharmacological properties of the library compound. 
4.1.5 Future steps to investigate compound toxicity 
In order to determine the origin of compound toxicity, a systematic effect evaluation of the 
parent and its metabolites measured in all three GRIZLY approaches would be insightful. Also, a 
more detailed investigation of the expression and activity of the involved (xeno-) metabolic 
enzymes could help to follow up on the toxic potential of compounds. However, as it was the 
aim of this study to identify specific disruptors of GC signaling and to elucidate their mechanisms 
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of action, the indication of potential toxicity by a compound was sufficient reason to exclude it 
from subsequent experiments and to focus on the remaining substances. 
4.2 GRIZLY assay suitability for the detection of glucocorticoid signaling inhibitors  
The first main objective of this study was to assess the suitability of the GRIZLY assay for the 
detection of GC signaling inhibitors. Therefore, the GRIZLY assay was modified and applied in 
three different testing approaches to screen a library of 640 FDA approved compounds. After 
140 putatively toxic compounds were removed from the screen outcomes, 29 inhibitors and 5 
superactivators remained as significant screen hits in tier 1. This demonstrates the assay 
suitability for the detection of GC signaling inhibitors, even in large compound libraries and in 
higher throughput applications. Moreover, the GRIZLY assay enables not only to detect 
inhibitors, but also superactivators of GC signaling, compounds which can apparently not 
activate the reporter gene by themselves, but increase or elongate the GC signal when co-
exposed in combination with a GR agonist. These findings were validated in tier 2. Out of the 
screen hits, 24 compounds were selected for concentration-dependent retesting in all three 
GRIZLY assay approaches. With a retrieval rate of 78%, the GRIZLY assay was proven to be a 
reliable tool to identify disruptors of GC signaling. 
4.3 General mechanisms underlying treatment-specific effects  
In accordance with the relatively low mutual toxicity found for the compounds among the 
different testing setups, also the identified disruptors of GC signaling revealed only a moderate 
overlap between the three GRIZLY assays. After retesting, the correlation increased, due to 
concentration-dependency of the compound effects, but still, several substances disrupted GC 
signaling in one, but not in the other GRIZLY assay. Of the mechanisms that I discussed in section 
4.1.4, several may also apply for compound interference with pharmacological targets such as 
GC signaling.  
4.3.1 Drug uptake and metabolism 
Drug uptake and -metabolism plays a major role not only for compound toxicity (see section 
4.1.4) but also for specific pharmacological effects. The bioavailability and bioaccessability of a 
substance can be divergent in vitro and in vivo, which may affect the activation of metabolic 
enzymes (such as CYPs) differently (Gentile et al. 1996; Martignoni et al. 2004; Petkam et al. 
2003). Also, numerous pharmaceuticals are specifically designed to decrease the transcription 
and activity of the most abundant members of the CYP1, CYP2 and CYP3 families, which are 
involved in vertebrate drug and steroid metabolism (Zanger and Schwab 2013). Depending on 
their chemical properties, drugs can affect the production and the activity of xenobiotic 
enzymes, which can result in a fast elimination of the substance, but also in disruption of the 
endogenous hormone homeostasis (Creusot et al. 2015; Hotchkiss et al. 2008). 
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Ligand activated transcription factors such as PXR, AHR, CAR, VDR and GR can regulate the 
transcription of CYP genes directly or indirectly interfere with xenometabolic gene expression via 
receptor cross-talk and are, thus, possible targets for such pharmaceutical actions in humans 
(Bainy et al. 2013; Creusot et al. 2015; Goodwin et al. 2001; Kliewer et al. 1998; Moore and 
Kliewer 2000; Pascussi et al. 2000). For instance, the involvement of PXR and AhR in the 
transcriptional regulation of cyp3a65 has also been describedin zebrafish (Tseng et al. 2005). 
Thus, within the present study, changes in cyp3a65 and cyp1a1 expression by the compounds 
may indicate disruption of xenometabolic metabolism, which potentially also affected the 
endogenous hormone homeostasis. Also an indirect involvement of GR-mediated signaling may 
be indicated by such an effect.  
As a consequence of xenometabolic enzyme expression changes, the first-pass effect, 
biotransformation (metabolic activation or inactivation) and translocalization, not only of the 
substance tested, but also of the compound it is co-exposed with, can be altered. Within the 
present study, the unequal amount of absorbed activator (specified in section 4.1.4) certainly 
affected the activity of xenometabolic enzymes differently, which in turn may have altered the 
metabolism of the drug library compound. Vice versa, also the library compound could have 
altered the xenometabolism activity in larvae, which may have affected co-exposed Dex or Preg 
differently.  
As will be described in more detail in the following sections, drug uptake and -metabolism could 
have been altered with 10-HC (section 4.7.2.3) and the progestins (section 4.9.2). Spiro possibly 
was metabolically activated in vivo (section 4.10.2.3) and also Estrone, Estriol and DHEA may 
have been converted in vivo into the more potent endogenous estrogen Estriol (section 4.11.2). 
4.3.2 Context specificity 
GC effects are highly specific given the physiological and cellular context in which they occur. 
This is also true for the three GRIZLY approaches. For instance, the different exposure scenarios 
constitute diverging organismal and cellular environments. Thus, the in vitro assay (GRIZLY 1) is 
carried out in fibroblast-like cells in culture medium, while the in vivo assays (GRIZYL 2 and 
GRIZLY 3) comprise a large number of different tissue contexts with two different types of GC 
signaling activation (Preg-derived endogenous Cort and external Dex). This, in turn, will affect 
the biological activities, binding affinities and ant-/agonistic potencies of ligands for a specific 
receptor. Furthermore, different ligands can induce different conformational changes of the 
receptors and thereby create ligand-specific interaction surfaces for cofactors or specific DNA 
binding sequences and their genomic environments (Weikum et al. 2017). This results in ligand-
receptor complexes specific for certain target gene regulatory regions. Transcriptional regulation 
is also dependent on the availability of certain coactivators, corepressors and other transcription 
factors in the respective contexts (Africander et al. 2011; Hapgood et al. 2004; Heitzer et al. 
2007; Inhoffen and Hohlweg 1938; Louw-du Toit et al. 2017; Weikum et al. 2017). 
In application of the three GRIZLY assays and the follow-up studies on steroid metabolite and 
gene expression levels, I scanned with distinct compound treatment combinations a relatively 
broad range of cellular and physiological contexts. This allows me to detect context-specific 
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effects, that may have occurred for instance with the progestins (section 4.9.2), Stano (section 
4.10.1.3), Spiro (section 4.10.2.3), Estrone, Estriol and DHEA (section 4.11.3), as it will discussed 
in more detail in the respective sections. 
4.4 Specific mechanisms of glucocorticoid signaling disruption 
In addition to these general effects, the compounds may have interfered with one or several 
specific mechanistic pathways related to the GC system. I will describe a selection of important 
mechanisms in the following sections. Note that all of these mechanisms are also subject to the 
general considerations described in the previous chapter; they may therefore have diverse 
impacts in the different assays.  
4.4.1 Pre-receptor mechanisms of glucocorticoid signaling disruption 
Certain chemicals can disrupt the GC system without directly interfering with the GR. For 
instance by targeting specific enzymes that are involved in the production and availability of 
Cort, a compound can limit or increase the amount of GR ligand and thereby affect GC signaling.  
4.4.1.1 Disruption of glucocorticoid biosynthesis 
Several endocrine disruptive compounds (EDCs) can prevent the production and release of 
steroid hormones via the HPA axis (Gore 2010). Also, some chemicals are capable to disrupt the 
steroid hormone biosynthesis by inhibiting steroidogenic enzymes, for instance 3β-
hydroxysteroid dehydrogenase (3β-HSD) or 11β-hydroxylase (Louw-du Toit et al. 2017) (for an 
overview of the steroid hormone biosynthesis pathway see Figure 3). 
Beside direct compound interference with these enzymes, also indirect mechanisms of 
steroidogenic enzyme activity disruption are possible. For example, ligands of the PXR (such as 
Rifampicin) can alter the adrenal steroid homeostasis via drug - hormone interactions (Ihunnah 
et al. 2011; Zhai et al. 2007). Activation of the PXR may lead to increased plasma levels of certain 
steroid hormones (e.g. Coco), which can be accompanied by activation of several steroidogenic 
enzymes (e.g. CYP11a1, CYP11b2, 11β-hydroxylase, 3β-HSD). This could lead to disruption of the 
GC system, as it was for instance observed by (Zhai et al. 2007) in mice, where the PXR was 
genetically and pharmacologically activated.  
Within the present study, several compounds may have disrupted the steroid hormone 
biosynthesis pathway. For retinoids (with Preg; section 4.8.3), progestins (maybe with Dex; 
section 4.9.2), Stano (section 4.10.1.3), Spiro (section 4.10.2.3), Estrone, Estriol and DHEA 
(section 4.11.3), some indications for their potential to disrupt the biosynthesis of Cort are given, 
as will be discussed in the respective sections. 
4.4.1.2 Cortisol activation and inactivation 
Also other enzymes regulating the availability of active and inactive forms of steroid hormones 
in the blood can be affected by compound treatment, such as 11β-hydroxysteroid 
dehydrogenase 2 (11β-HSD2). This enzyme oxidizes active Cort (and Corticoin rodents) into the 
inactive metabolite Cortisone (and 11-dehydrocorticosterone in rodents)(Figure 3) and prevents 
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it from binding to the MR in sodium-transporting epithelia in mineralocorticoid target tissues 
such as kidney and colon (Leckie et al. 1998; Mune et al. 1995; Ferrari 2010; White et al. 1997; 
Louw-du Toit et al. 2017; Sanderson 2006; Alderman & Vijayan 2012). In vitro, the MR can be 
activated by both Cort and the natural mineralocorticoid Aldosterone, with equal affinity. In 
humans and vertebrates, whose major active GC is Cort (and not Cortico, as in rodents), Cort 
circulates at 100-1000-fold higher concentrations than Aldosterone (MILLER 1988). Thus, Cort 
would out-compete Aldosterone and activate the MR, if it were not for 11β-HSD2 (Leckie et al. 
1998; Mune et al. 1995; Ferrari 2010; White et al. 1997). 
Inactivation of 11β-HSD2 via enzyme inhibition (e.g. by licorice) or by mutation of the hsd11b2 
gene (in patients suffering from apparent mineralocorticoid excess (AME)) results in Cort-
induced mineralocorticoid effects such as sodium retention, hypokalaemia or salt-dependent 
hypertension (Ferrari 2010; Omar et al. 2012; Stewart et al. 1996). Human patients with 
deficient 11β-HSD2 activity usually exhibit increased ratios of Cort to Cortisone and a prolonged 
Cort half-life (Ferrari 2010).  
In this thesis work, UPLC-MS/MS data did not indicate an increase in endogenous Cort levels for 
any compound. However, according to literature, Spiro (section 4.10.2.3) and the estrogens 
(section 4.11.1) are likely to interfere 11β HSD2, which may to some extend have contributed to 
their effects on diverse levels, as discussed in detail in the specific paragraphs. 
4.4.2 Direct interference with GR signaling 
Endocrine disruptive chemicals (EDCs)can also bind to steroid hormone receptors and alter their 
transcriptional function on target gene expression. The receptor activity can be agonized or 
antagonized by EDCs via transactivation, transrepression, tethering (section 1.2.4) or other 
mechanisms and, thus, all types of mechanisms involved in GR-mediated regulation of 
transcription may possibly be targeted. 
4.4.2.1 Ligand-receptor binding affinity and nuclear localization 
Pharmaceuticals can potentially alter the binding affinity of the GR for the ligand (e.g. via 
conformational changes within the LBD of the GR) and reduce the localization of the receptor 
into the nucleus. For instance, as described in section 1.3.1.1, the immunosuppressive-drug-
binding proteins FKBP51 and FKBP52 are known regulators of the GR ligand-receptor binding 
affinity and nuclear localization. Immunosuppressive ligands (e.g. synthetic GCs) can substitute 
the negative regulator FKBP51 (fkbp5) for the positive regulator FKBP52 within the receptor-
protein heterocomplex, which induces the nuclear localization of the complex and/or elevates 
the intranuclear ligand concentration by inhibiting the steroid export proteins and, thus, 
increases GR activity (Davies et al. 2002, 2005; Mazaira et al. 2015; Pereira et al. 2014). 
Interestingly, in adipose tissue, increased expression of fkbp5 has been observed in response to 
Dex treatment, which probably serves to prevent excessive GC signaling by inhibiting GC-GR 
binding (Pereira et al. 2014). Such inhibitory mechanisms may constitute first indications for GC 
resistance. Similarly, in New World squirrel monkeys, which have high levels of circulating Cort 
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but show no indication of hypercorticism, it has been found that FKBP51 levels are increased, 
which resulted in a low ligand binding affinity of the GR (Denny et al. 2000; Storer et al. 2011). 
Likewise, within the present study, Preg strongly induced the expression of fkbp5 (Figure 44.II a). 
Most inhibitors of Preg-activated signaling (e.g. Trani, 10-HC, Gestri) showed reduced fkbp5 
mRNA levels, indicating a decreased GR signaling activity, while superactivators of Preg-induced 
GC signaling such as Stano (section 4.10.1.3) and Spiro (section 4.10.2.2), showed no reduced 
fkbp5 expression, although the mRNA levels of all other Preg target genes were decreased. This 
may suggest an increased GR activity with these compounds. 
4.4.2.2 GR activity modulation via posttranslational modifications 
The activity of the GR can also be modulated via posttranslational modifications (PTMs) in 
response to external stimuli. PTMs can enhance or decrease protein functionality by regulating 
stability, structure, activity and intracellular localization of the receptor and its interaction with 
other proteins (Liberman, Antunica-Noguerol, and Arzt 2014; Scheschowitsch et al. 2017). 
Examples for PTMs include phosphorylation, acetylation, ubiquitination, methylation, nitration, 
nitrosylation and SUMOylation (Anbalagan et al. 2012; Duma, Jewell, and Cidlowski 2006; 
Liberman et al. 2014). 
For compounds where direct interactions with GR activity are suggested in the present study, 
PTMs probably played important roles in numerous effects. Although it is hard to tell which of 
this study´s inhibitors interfered with GR signaling via PTMs, there is evidence in the literature 
for some of them (e.g. estrogens, see below, section 4.11.1).  
 
Receptor phosphorylation 
One important mechanism of PMT is receptor phosphorylation. As the GR is a phosphoprotein, 
phosphorylation modulates its functionality (Liberman et al. 2014; Wallace and Cidlowski 2001). 
The phosphorylation occurs generally within the DBD, where kinases such as mitogen-activated 
protein kinases (MAPKs) or cyclin-dependent kinases (CDKs) can modify the phosphorylation 
status ligand-dependently (Galliher-Beckley and Cidlowski 2009; Miller et al. 2005). For instance, 
cytokines (e.g. IL-2 and IL-4) can induce GR phosphorylation via the p38 MAPK pathway, which 
reduces the nuclear import of the GR and leads to GC resistance during chronic inflammation 
(Irusen et al. 2002). Furthermore, several MAPK proteins involved in nucleocytoplasmic GR 
shuttling can enhance the nuclear export of the GR and, thus, reduce the transcriptional 
efficiency and induce the hormone-dependent downregulation of the GR (Liu &DeFranco 2000). 
Generally, agonistic effects of GCs are accompanied by hyper-phosphorylation of the GR upon 
ligand binding, which induces a conformational change of the receptor that enables coactivator 
binding and which also plays an important role in the receptor protein turnover (Wallace and 
Cidlowski 2001). Antagonists, in contrast, do not induce hyper-phosphorylation but trigger 
conformational changes which enable corepressor recruitment (Africander et al. 2011; Nettles 
and Greene 2005; Schaaf and Cidlowski 2002). The phosphorylation state of the GR influences 
also the receptor stability, as well as its selectivity and sensitivity to GCs for downstream activity 
(Galliher-Beckley and Cidlowski 2009; Webster et al. 2001).  
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Within the present study, the GR agonists Dex and Cort certainly induced hyper-phosphorylation 
of the GR, but also other compounds could have had (at least partial) agonistic properties for the 
receptor (e.g. the progestins (section 4.9), Stano (section 4.10.1) or Spiro (section 4.10.2) and 
accordingly may have interfered with its phosphorylation state. 
4.4.2.3 GR beta as a dominant negative regulator of GR alpha 
The GR exists in various isoforms, of which GRα and GRβ have been most studied. Of these two, 
only GRα, the major isoform, possesses transcriptional activity, while it is commonly accepted 
that GRβ is not ligand-inducible and functions as a dominant negative regulator of GRα (Oakley, 
Sar, and Cidlowski 1996). GRβ can suppress the transcriptional activity of GRα, for instance by 
altering the receptor dephosphorylation status (Webster& Cidlowski 1994; Oakley & Cidlowski 
1993).  
Within this study, for instance the anti-inflammatories (section 4.6.3) may have altered the 
expression of GRα and GRβ and thereby decreased the activity of GRα, as it will be described 
below in detail. 
4.4.2.4 Ligand-dependent homologous downregulation 
The activity of the GRα isoform can be altered by hormone-dependent homologous 
downregulation via autoregulatory transrepression of the GR gene (Oakley and Cidlowski 1993; 
Shimojo et al. 1995). As described above (in section 4.4.2. 3), GRβ cannot bind ligands by itself, it 
is thus not susceptible to ligand-dependent homologous downregulation and accumulates 
instead (Oakley and Cidlowski 1993), which may in turn increase the impact of this dominant-
negative regulator on GRα. This mechanism often underlies GC resistance in response to long-
term medication of chronic inflammations with synthetic GCs (Corrigan et al. 1991; Okret et al. 
1986; Ramamoorthy and Cidlowski 2013; Rosewicz et al. 1988; van Rossum and Lamberts 2006; 
Schaaf and Cidlowski 2002). 
 
Within the present study, ligand-dependent homologous downregulation probably underlies the 
normally observable signal decrease of the GRE:Luc reporter after several hours of constant GC 
treatment. Upon activation, the GRE:Luc reporter lines respond with a strong signal increase, 
before a decline in bioluminescence activity is observed, which normally sets in after 4h of Dex 
treatment in cells (e.g. Figure 29 a, blue line) and after 10 - 14 h of exposure to Dex (e.g. 
Figure 29 e, blue line) or Preg (e.g. Figure 29 f, blue line) in larvae. This decrease may arise from 
GRα inactivation or decreases in GR protein levels. 
Certain GC signaling disruptors may have interfered with the homologous downregulation of 
GRα which is considered "normal" in GRIZLY experiments after continuous exposure to GCs for 
several hours. For instance, Stano (section 4.10.1.3) may have prevented the downregulation, 
while the anti-inflammatories (section 4.6.3), Estrone, Estriol and DHEA (section 4.11.1) 
potentially induced this process. 
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4.4.2.5 Receptor interaction with other signaling pathways 
Also other transcription factors can interfere with GR signaling. For instance, steroid hormone 
receptor crosstalk between the GR and the ER has been shown in human breast-cancer cell lines, 
where estrogen agonists provoked GR degradation and inhibited GR target gene expression 
(Kinyamu & Archer 2003). Crosstalk between the GR and diverse other transcription factors has 
been reviewed by Kassel & Herrlich (2007). 
Especially interactions between the GR and proinflammatory transcription factors such as AP-1 
and NF-κB have been the focus of numerous studies. For example, NF-κB has been shown to 
induce the expression of GRα and GRβ (Webster et al. 2001). Also mutual interactions between 
NF-κB and GR signaling have been reported (Auphan et al. 1995; Scheinman et al. 1995) and it 
was observed that GC treatment repressed the transcriptional activity of NF-κB (Bamberger et al. 
1995; Webster and Cidlowski 1999). Also interactions between GC and retinoic acid signaling 
have been extensively described (Aubry and Odermatt 2009; Bonhomme et al. 2014; Brossaud et 
al. 2013; Lefebvre et al. 1999; Tóth et al. 2011; Yamaguchi et al. 1999). 
Several compounds from the FDA library may have interfered with GR signaling via receptor 
crosstalk or via interactions with other transcription factors. For instance, for the anti-
inflammatories (section 4.6.3), retinoids (section 4.8.3) and progestins (section 4.9.2), such 
interactions have been described. 
4.4.2.6 Coactivator and corepressor recruitment 
Upon binding, ligand-specific recruitment of coactivators, such as the steroid receptor 
coactivator-1 (SRC-1), and corepressors, like the silencing mediator of retinoic acid and thyroid 
hormone receptor (SMRT), affects the transcriptional efficiency of the GR and the GC signaling 
response. The ratio of coactivators and corepressors within the promotor region regulates target 
gene transcription or transrepression (Heitzer et al. 2007). For instance, overexpression of the 
corepressor SMRT can counteract coactivator effects on GR-mediated target gene transcription 
(Szapary et al. 1999). 
In this study, two retinoids (section 4.8.3) were identified to inhibit GC signaling. Possibly, as 
they have been described to repress AhR-mediated induction of cyp1a1 through the SMRT 
corepressor, they may also have increased the amount of SMRT within the promotor 
environment of the 4 x GRE construct, which potentially contributed to the observed GRIZLY 
signal inhibition. 
4.5 Assessment of glucocorticoid signaling disruption by means of the tiered testing 
approach 
As a first step, the combined compound analysis of the GRIZLY assay allowed me to identify 
compounds with either similar or diverse in vitro and in vivo effects. Furthermore, I was able to 
pre-categorize potential disruptors of the Cort biosynthesis pathway, as several substances 
inhibited Preg- (GRIZLY 3), but not Dex- (GRIZLY 2) induced GC signaling, such as Leflu, Gestri, 
Nor, Estrone, DHEA and Estriol). 
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Chemical analysis helped me to confirm that these compounds (all except Leflu) indeed 
significantly reduced the amount of Preg-induced Cort production in larvae. Interestingly, some 
additional substances (Aci, Ret. acid, Ethi, Stano and Spiro), where the GRIZLY results gave no 
clear indication for a disrupted Cort biosynthesis, were shown via UPLC-MS/MS to decrease Cort 
levels in larvae. Also effects on drug uptake and metabolism could be detected with this 
technique for several compounds. 
Via qPCR, I analyzed the expression of a set of target genes in larvae co-treated with Dex/ Preg + 
the compounds. The two markers cyp1a1 and cyp3a65 should give further indications for 
xenometabolic disruption by the compounds. The mRNA levels of cyp11c1, encoding the Cort-
producing enzyme steroid 11β-hydroxylase and hsd11b2, the transcript of the Cort-metabolizing 
enzyme hydroxysteroid 11-β dehydrogenase 2, were measured in order to monitor changes of 
the Cort availability. Two GC target genes, gilz and fkbp5, were selected to detect changes in 
Preg- and Dex-induced GC signaling. The transcriptional induction of gilz is closely related to 
anti-inflammatory mechanisms of action while upregulation of fkbp5 (as described in section 
4.4.2.1) indicates an increased GR activity. With the combined assessment of these markers, I 
aimed to assess compound effects on three major mechanisms of GC signaling disruption, direct 
interference with GR signaling, inhibition of GC biosynthesis and disruption of GC homeostasis 
via drug metabolism.  
 
In the following sections I will discuss the identified compounds in groups according to their 
functionalities. Consulting the available literature, the biological functions and the major 
mechanisms of action of the substances will be described, with regard to potential interfaces 
with the GC system. Then I will summarize the compound effect profiles from the present study 
and interpret them within the context of evidences and hints provided by literature.I will survey 
their potential to interfere with the GC system via diverse mechanisms and outline perspectives 
for future investigations in order to validate putative mechanisms of GC signaling disruption for 
each functional group. 
4.6 Anti-inflammatories 
 
Figure 46: Anti-inf lammatories (extract from Figure 45)  
 
Leflu, Fen, Nabu and Trani are substances with anti-inflammatory properties. Although they are 
partly associated to different compound classes with diverse pharmacological targets, they have 
in common certain major anti-inflammatory mechanisms of action. In the following paragraphs, I 
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will first characterize the compound- and class-specific properties before I specify their 
respective anti-inflammatory pathways for the discussion of putative mechanisms of GC 
signaling disruption. 
4.6.1 The biological functions of anti-inflammatories and their mechanisms of action 
Leflunomide 
Leflu is an immunosuppressive, disease-modifying, antirheumatic drug (DMARD) (Singh et al. 
2012). Upon uptake, Leflu is converted via first-pass metabolism within colon and liver into its 
active metabolite teriflunomid (A771726) (O’Connor et al. 2006). Mechanistically, this DMARD is 
a pyrimidine biosynthesis inhibitor that has been approved for the treatment of immune-
diseases such as rheumatoid arthritis and multiple sclerosis (Cherwinski et al. 1995; O’Connor et 
al. 2006).  
 
1) Pyrimidine biosynthesis inhibition leads to immunosuppression  
Leflu prevents the biosynthesis of pyrimidine via inhibition of the enzyme dihydroorotate 
dehydrogenase (Davis et al. 1996). Although the immunosuppressive effects of the compound 
are not yet completely understood, they are believed to result from the depletion of pyrimidine 
supply, which inhibits the reproduction of fast-dividing cells, such as lymphocytes (Breedveld 
and Dayer 2000; Rückemann et al. 1998). However, also other mechanisms have been described 
for Leflu, including disruption of interleukin (IL)-mediated pathways (Miceli-Richard and 
Dougados 2003; Munier-Lehmann et al. 2013; O’Donnell et al. 2010) and inhibition of 
prostaglandin production (Burger et al. 2003). 
 
2) Pyrimidine biosynthesis disruption disables TNF-mediated activation of NF-κB and AP-1 
Manna et al. (2000) demonstrated that Leflu also inhibits TNF-induced activation of NF-κB and 
AP-1. For instance, the anti-inflammatory inhibited the activation of I-κBα kinase (IKK) and 
suppressed the degradation of I-κBα, the inhibitory subunit of NF-κB. Interestingly, the 
researchers found out that the repressing effects of Leflu on TNF signaling could be rescued by 
uridine, which led them to conclude that the biosynthesis of pyrimidine plays a crucial role in 
TNF-mediated signaling.  
 
3) AhR agonism 
Moreover, Leflu is a known agonist of the AhR (Miceli-Richard and Dougados 2003; O’Donnell et 
al. 2010). In one case study where O’Donnell and collegues (2010) investigated the mechanisms 
of action of this drug, Leflu, but not the active metabolite teriflunomid, increased the expression 
of endogenous AhR target- and reporter genes via the AhR. For instance, they observed in 
zebrafish that Leflu (but not teriflunomid) was able to inhibit in vivo tissue regeneration AhR-
dependently.  
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Fenbufen and Nabumetone 
Fen and Nabu are non-steroidal, anti-inflammatory drugs (NSAIDs) (Huerta et al. 2005). Fen is a 
member of the class of propionic acid derivatives, which includes also Ibuprofen and Ketoprofen 
(Chiba et al. 1985). Fen and one of its major metabolites, 4-biphenylacetic acid (BPAA), have 
been shown to be potent in vitro and in vivo inhibitors of prostaglandin synthesis in a variety of 
tissues (Palmer et al. 1990; Sloboda et al. 1980). 
Nabu belongs to the class of acetic acid derivatives, with Diclofenac being another prominent 
representative of this pharmacological group (Boyle et al. 1982). Nabu itself is non-acidic, but it 
is rapidly metabolized in the liver into its principal active metabolite 6-methoxy-2-naphthyl 
acetic acid. This metabolitewith its carboxylic acid group is primarily responsible for the 
therapeutic effect of Nabu, which is the reason why the anti-inflammatory is classified as a 
derivative of acetic acid (Haddock et al. 1984). 
 
Inhibition of cyclooxygenase enzymes leads to disruption of prostaglandin synthesis 
NSAIDs belong to the most commonly used drugs in the world (Green 2001). Most NSAIDs exert 
their anti-inflammatory properties by inhibiting cyclooxygenases (COXs), enzymes that are 
involved in the synthesis of prostaglandins (Smith et al. 2017). The COX enzymes are conserved 
among all vertebrate groups and two isoenzymes have been characterized in numerous species, 
including human and fish (Corcoran et al. 2010; Havird et al. 2008; Ishikawa and Herschman 
2007; Zou et al. 1999). COX-1 regulates prostaglandin baseline levels, while COX-2 needs to be 
stimulated by growth factors and pro-inflammatory cytokines in order to produce prostaglandins 
at inflammation sites. The majority of NSAIDs act on both COX isoforms and, thus, broadly inhibit 
prostaglandin synthesis (Fent et al. 2006; Lister and Van Der Kraak 2008; Mustafa and Srivastava 
1989; Vane 1994). 
 
Tranilast 
Trani is a derivative of the amino acid tryptophan which has been used predominantly in Japan 
and South Korea to treat inflammatory diseases due to its anti-allergic properties (Xia et al. 
2017). The compound is also used as a medication for several other diseases including 
autoimmune disorders, renal fibrosis, proliferative disorders, cardiovascular problems and 
cancer (Darakhshan and Pour 2015).  
 
Inhibition of multiple pro-inflammatory mediators 
Trani inhibits the production and release of many inflammatory mediators including cytokines 
and chemokines and thereby also suppresses the activation of NF-κB (Darakhshan and Pour 
2015). For instance, the compound reduces production and activity of pro-inflammatory 
cytokines such as TNF-α, IL-1 β and transforming growth factor (TGF)-β 1 in different cell types 
(Yamada et al. 1994; Xia et al. 2017; Martin et al. 2005; Pae et al. 2008). Furthermore, Trani was 
described to inhibit the release of prostaglandins and histamines from mast cells (Yamada et al. 
1994). Also, in a study by Pae et al. (2008), the drug has been shown to downregulate the 
expression of COX-2 to decrease thereby levels of COX-2-derived PGE2 in macrophages. 
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Common anti-inflammatory mechanisms of the four compounds 
In summary, although Leflu, Fen, Nabu and Trani originate from different chemical groups, they 
exert their anti-inflammatory properties via partly overlapping mechanisms. Together with 
natural and synthetic GCs, which also possess anti-inflammatory capacities (see section 1.2.5), 
the four compounds inhibit inflammatory processes via common biological and mechanistic 
targets.  
 
1) Inhibition of prostaglandin production 
All four anti-inflammatories are potential inhibitors of prostaglandin production. Also GCs can 
suppress the transcription of COX-2 via GR-mediated transrepression (e.g. via tethering to NF-
κB) and thereby prevent the synthesis of prostaglandins (Anacker et al. 2011; De Bosscher 
&Haegeman 2009). Prostaglandins can be found in almost every vertebrate tissue and they 
contribute to numerous physiological processes such as regulation of inflammation, 
reproduction, calcium transport, cell growth and hormone production. Accordingly, inhibition of 
prostaglandins by drugs with anti-inflammatory properties may potentially affect any of these 
functions. 
 
2) Suppression of the NF-κB  pathway 
Prostaglandins can furthermore induce the transcriptional activation of NF-κB (Camandola et al. 
1996). Accordingly, inhibition of prostaglandin production might lead to reduced NF-κB signaling. 
Beside this hypothesis of an indirect inhibition of NF-κB via disruption of the prostaglandin 
synthesis, all four anti-inflammatory compounds, as well as GCs, can directly suppress the 
activation of the NF-κB pathway. Exemplarily, for the NSAIDs Aspirin and Sodium salicylate, it 
was described that inhibition of NF-κB activity may be involved in their anti-inflammatory and 
growth inhibitory properties. Also for GCs, the direct interaction of the GR with NF-кB is one of 
their multiple anti-inflammatory mechanisms of action (as described in section 1.2.4). In 
addition, GCs are able to upregulate I-кB, the inhibitory subunit of NF-кB, which suppresses the 
activation of NF-кB (Cuzzocrea et al. 2007; de Lima Souza et al. 2012). 
4.6.2 The effects of anti-inflammatories within the present study 
Leflunomide 
In the GRIZLY assay, Leflu only inhibited Preg-induced GC signaling in larvae. A clear 
concentration-dependency was shown by retesting, where a LOEC of 0.5 µM was found for the 
compound (see appendix, Supplementary Figure III). Due to the effect of Leflu to inhibit Preg- 
but not Dex-induced GC signaling in vivo, the compound was considered a potential disruptor of 
Cort biosynthesis. However, chemical analysis gave no indications for changes in endogenous 
Cort levels, although the larvae-internal amount of Preg tended to be decreased compared to 
the control. This may indicate that the uptake of Preg from the medium was hampered in the 
presence of Leflu, but the strong signal reduction observed in GRIZLY 3 is unlikely to rely on this, 
as otherwise the Cort level would have to be reduced. Some other mechanisms must have 
played a role for the inhibition in GRIZLY 3. 
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For Leflu + Dex treatment, the internal amount of Dex in the larvae showed a trend to be 
increased, which is the opposite of the compound effect on Preg. Therefore, it was suspected 
that Leflu may have affected the uptake of Dex and Preg into the larvae differently, for instance 
by interfering with xenometabolic pathways. As the elevated Dex level did not significantly alter 
GC signaling in GRIZLY 2, although a tendency for a signal increase was visible (as shown in 
Figure 37 c), it may be suspected that the accumulation of Dex did not suffice to increase the 
effect on the reporter construct. Alternatively, Leflu may have had also an inhibitory effect on 
Dex-induced GC signaling, similar to the impact on Preg activation, but it could have been 
counteracted by the increased amount of Dex in the larvae. 
In qPCR experiments, Leflu showed heterogenous effects. Under Dex stimulation, the two 
xenometabolic marker genes were induced significantly and gilz was upregulated by trend. 
These results may be related to the elevated Dex level in the larvae. With Preg, hsd11b2 and 
cyp3a65 were significantly decreased, which could as well have to do with the lower amount of 
Preg measured in larvae homogenates. Interestingly, cyp1a1 was also strongly increased with 
Preg (ratio 8.3), although not statistically significant. Certainly, several general (section 4.3) or 
specific (section 4.4) mechanisms of GC signaling disruption contributed to these gene-specific 
effects. Only the strong increase of cyp1a1 in co-treatment with both activators is striking, as 
Leflu was the only compound leading to an induction of this marker. 
This effect most likely relies on the AhR agonistic property of Leflu that was described above 
(Miceli-Richard and Dougados 2003; O’Donnell et al. 2010). Although cyp1a1 can be regulated by 
the GR, it is predominantly a major target of the AhR. Thus, the expression of cyp1a1 was 
probably induced by Leflu via Ahr agonism and was maybe largely independent from the 
transcriptional activity of the GR.  
 
Fenbufen and Nabumetone 
The two NSAIDs showed very similar effects in all experiments. They both inhibited Dex- and 
Preg induced GC signaling in the GRIZLY assay in vivo but did not alter the bioluminescent signal 
in vitro. The lacking in vitro effect may reflect a need for compound metabolization and that the 
signal inhibition in vivo was triggered by metabolites of the two substances. For instance, BPAA 
and 6-methoxy-2-naphthyl acetic acid are metabolites of Fen and Nabu, respectively, for which 
therapeutic activities are known (Haddock et al. 1984; Palmer et al. 1990; Sloboda et al. 
1980).While a clear concentration-dependency was visible for Fen in GRIZLY 2 and GRIZLY 3 
(Figure 35 g + h) within the tested range of 4 - 20 µM, Nabu showed strong signal inhibition at all 
tested concentrations (Figure 35 c + d). Retesting with lower concentrations of Nabu 
[0.25 - 4 µM] confirmed a concentration-dependency for the inhibitory effect of the substance 
and LOECs of 2 µM and 0.25 µM could be determined for Nabu + Dex and Nabu + Preg, 
respectively. The data from these experiments are shown in the appendix as Supplementary 
Figure I. 
 
As the two anti-inflammatories inhibited in both in vivo assays, a disruption of Cort biosynthesis 
was deemed unlikely to underlie this effect. This was confirmed by chemical analysis, as the 
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measured steroid levels neither gave indications for inhibition of Cort production, nor did they 
suggest alterations in drug uptake upon treatment with Fen and Nabu. 
On the level of gene expression, both compounds showed a tendency to further increase gilz 
expression in co-exposure with Dex, while trends for reduced mRNA levels of this target were 
observed co-treatment with Preg. In addition to that, both NSAIDs decreased the Preg-induced 
expression of hsd11b2 and cyp1a1, and Nabu also down-regulated cyp3a65. As the two anti-
inflammatories disrupted the transcriptional regulation of several, but not all GR target genes, 
certain general (section 4.3) or specific (section 4.4) mechanisms of GC signaling disruption gene 
may be at work gene-selectively, similar to what was observed for Leflu.  
 
Tranilast 
Trani inhibited GC signaling in all three GRIZLY assays but showed no effect on any steroid 
measured by UPLC-MS/MS. For target gene expression, a trend for increased gilz induction was 
observed with Dex, while the Preg-induced expression of all targets was decreased with Trani. 
Thus, the anti-inflammatory showed the same gene expression pattern as Fen and Nabu when 
co-treated with Dex, indicating similarities in the gene-selective regulation by the three 
compounds.  
In co-exposure with Preg, Trani had a similar effect on target gene expression as Mife and Mety, 
but in contrast to the positive controls, the substance showed also a trend to decrease cyp11c1 
expression, which might imply an additional specific effects of this compound. The striking 
discrepancy between the rather low effect of Trani on Dex-induced, but the strong impact on 
Preg-induced target genes strongly suggests treatment-dependent, general (section 4.3) or 
specific (section 4.4) mechanisms of GC signaling disruption. 
4.6.3 Potential mechanisms of glucocorticoid signaling disruption by  
               antiinflammatories 
Leflu, Fen, Nabu, Trani, Dex and Cort inhibit pro-inflammatory processes via common biological 
and mechanistic targets. Therefore, from a combined treatment with two immunosuppressive 
substances, additive effects, addressing common immunomodulatory targets such as inducing 
the same anti-inflammatory gene or suppressing a pro-inflammatory pathway, could be 
anticipated. However, the effects of the four anti-inflammatories on GC signaling were not 
additive, as all four compounds showed inhibition in the GRIZLY assay. Based on common effect, 
it may still be suspected that similar mechanisms underlie the results. Accordingly, it appeared 
reasonable to me to discuss the major common mechanisms of the compounds, suppression of 
the prostaglandin production and inhibition of NF-κB signaling, for the potency to interfere with 
GC signaling.  
 
Interference with GR signaling 
1) Suppression of the prostaglandin production may decrease GR levels 
Prostaglandins can increase the expression of GRs. For instance, one research group found 
significantly reduced GR levels when they incubated synovial fibroblast cells with NSAIDs. 
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Interestingly, this effect could be reversed by prostaglandin treatment, as prostaglandin E2 
(PGE2), and also a synthetic analog of prostaglandin E1, Misoprostol, increased the GR levels in 
human chondrocytes (DiBattista et al. 1991; Pelletier et al. 1994). Thereby, a reciprocal 
regulation of prostaglandin synthesis and GR signaling is strongly suggested. Potentially, in the 
present study, the anti-inflammatories decreased the GR levels by inhibiting the prostaglandin 
production and interfered via this mechanism with the GC system. 
 
2) Suppression of the NF-κB pathway may affect GR signaling due to mutual antagonism 
Although the suppression of the NF-κB pathway is a common anti-inflammatory target of Leflu, 
Fen, Nabu, Trani, Cort and Dex, which not necessarily affects GC signaling, it may indirectly 
disrupt the GC system. Several proinflammatory transcription factors, such as NF-κB (as 
mentioned in section 4.4.2.5) or AP-1, can interact with the GR and may, thus, disrupt GC 
signaling (Dejager et al. 2014; Webster et al. 2001). For instance, NF-κB and the GR are known to 
have antagonistic effects on target gene transcription (De Bosscher, Vanden Berghe, and 
Haegeman 2006; McKay and Cidlowski 1998, 2000). Related to this, Webster et al. (2001) 
investigated whether the capability of NF-κB to repress GRα activity via tethering may rely on 
NF-κB-mediated alterations in GRα and GRβ expression. They showed that two different 
activators of NF-κB (the proinflammatory cytokines TNF-α and IL-1) increased the mRNA and 
protein levels of both GRα and GRβ in human cells of epithelial (HeLaS3) and lymphoid (CEMC7) 
origin. Interestingly, under all treatment conditions, GRβ expression increased to a greater 
extent than GRα. In this context, they furthermore showed that upon GC (Dex) treatment, GRα, 
but not GRβ, underwent ligand-dependent homologous downregulation (section 4.4.2.4), which 
aggravated the proinflammatory effect.  
 
Disruption of cortisol biosynthesis 
Inhibition of prostaglandin production can disrupt the biosynthesis of cortisol 
Prostaglandins are also involved in the production of Cort. For instance, it has been shown for 
NSAIDs that they can disrupt Cort biosynthesis in fish (Gravel and Vijayan 2006; Mommsen, 
Vijayan, and Moon 1999; Wendelaar Bonga 1997). Accordingly, inhibition of Cort synthesis is a 
mechanism of GC signaling disruption which may accompany prostaglandin-inhibiting, anti-
inflammatory drugs. However, in the present study, the Preg-induced endogenous Cort levels 
appeared unchanged according to chemical analysis, making it unlikely that this mechanism has 
contributed to the observed GC signaling disruption by the compounds. However, I cannot 
exclude that the compounds could still affect basal Cort levels in untreated larvae, which were 
not measured within this thesis work.  
 
Suppression of pro-inflammatory mediators may reduce the production of cortisol 
Also, upon inflammation, pro-inflammatory mediators (cytokines TNF-α, IL-1 β and transforming 
growth factor (TGF)-β 1) normally induce the production of Cort via the HPA axis (Adcock et al. 
2004; Heitzer et al. 2007; Schaaf and Cidlowski 2002; Weikum et al. 2017). Thus, the suppression 
of these mediators by the anti-inflammatories could also have led to reduction of endogenous 
Cort, but I observed no such effect. 
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Induced expression of gilz 
Interestingly, all four compounds overinduced the expression of gilz when they were co-treated 
with Dex. This observation might suggest that gilz is a common target of Dex, Cort, Leflu, Fen, 
Nabu and Trani, and that the four library compounds had a synergistic effect on its expression. 
 
GILZ as an indicator for suppression of the NF-κB pathway 
The glucocorticoid-induced leucine zipper (GILZ) protein is a known mediator for the anti-
inflammatory effects of GCs and plays, thus, an important role in GC immunomodulation 
(Ayroldi and Riccardi 2009; Ronchetti et al. 2015; Scheschowitsch et al. 2017). This inhibitory 
protein suppresses several pro-inflammatory mechanisms, including pathways of NF-κB, AP-1, 
rapidly accelerated fibrosarcoma 1 (Raf-1) protein and rat sarcoma (Ras) protein, which are all 
involved in mediating GC effects, and GILZ is also necessary for GC inhibition of cytokine-induced 
COX-2 expression (Ayroldi and Riccardi 2009; Coutinho and Chapman 2011; Mittelstadt and 
Ashwell 2001). For instance, GILZ inhibits the activity of NF-κB in T-cells and macrophages by 
binding to the p65 subunit of this transcription factor. Thereby, it inactivates NF-κB, which leads 
to impairment of target gene transcription (e.g. of cytokines, chemokines, growth factors) and 
suppression of inflammation (Ayroldi and Riccardi 2009; Scheschowitsch et al. 2017). 
Accordingly, gene expression induction of this target by GCs indicates activity of anti-
inflammatory mechanisms, possibly including suppression of the NF-κB pathway. Its increased 
induction by Dex treatment upon co-exposure with the anti-inflammatories may act 
synergistically with the other anti-inflammatoryproperties of the compounds.  
4.6.4 Next steps 
In summary, Leflu, Fen, Nabu and Trani may have affected the production of prostaglandines in 
larvae and possibly suppressed certain pro-inflammatory pathways, such as NF-κB and AP-1. This 
hypothesis is supported by the common effect of all compounds on the expression of gilz. 
However, more experiments will be necessary for a detailed investigation of these anti-
inflammatory mechanisms. Measurements of COX enzymes, prostaglandin levels and NF-κB 
activity will certainly help to evaluate such hypotheses. 
 
In order to follow-up on the compound mechanisms to disrupt GC signaling, a direct interference 
with the GR can be assessed by measuring the GRα/β expression in larvae under the same 
treatment conditions. 
Disruption of the GC biosynthesis by the four compounds was deemed unlikely in the present 
study as no changes in Preg-induced Cort levels were observed in chemical analysis experiments. 
The anti-inflammatories may still have decreased basal Cort levels, but this will have to be 
quantified with a more sensitive analysis equipment. 
Beyond this, it will be interesting to assess whether the production of selected pro-inflammatory 
mediators in zebrafish can be stimulated in larvae via an external stressor and if this will increase 
the endogenous Cort synthesis. Larval treatment with the anti-inflammatories should then 
suppress the activation of these mediators and prevent an increased Cort production. 
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4.7 Glucocorticoid receptor antagonist and anti-neoplastic  
 
Figure 47: Glucocorticoid receptor antagonist  and anti -neoplastic (extract from Figure 45)  
 
This chemical group consists of two compounds with different pharmacological properties. Mife, 
a GR antagonist, was the reference inhibitor of directly activated GC signaling within the present 
study and also a compound in the drug library. 10-HC is an antineoplastic drug. However, the 
two compounds showed very similar effects in GRIZLY and qPCR experiments, which is why I 
grouped them together in order to discuss potential mechanistic similarities. 
4.7.1 Mifepristone 
4.7.1.1 The biological function of Mifepristone and its mechanisms of action 
Mife (RU 486) is a synthetic 19-norsteroid and a derivative of the progestin norethindrone that 
was developed in the early 1980s (Healy and Fraser 1985). The compound antagonizes PR, GR 
and AR via competitive binding and has, thus, strong antiglucocorticoid and antiprogestogenic as 
well as antiandrogenic properties (Pecci et al. 2009).  
 
Anti-progestin 
Due to its antiprogestogenic activity, Mife is majorly used as an abortifacient as it antagonizes 
the pregnancy-maintaining effects of progesterone, but also finds application for the treatment 
of endometriosis (von Hertzen et al. 2002; Michael Kettel et al. 1996; Pecci et al. 2009).  
 
Anti-glucocorticoid 
In an early study by Gagne et al. (1985), who assessed the potency of Mife to antagonize the GR 
in vitro and in vivo, the compound was observed to have a threefold higher affinity for the GR in 
the cytosol of rat hepatoma tissue culture (HTC) cells than Dex. This high affinity was described 
by the authors to rely on a very low dissociation rate of the receptor complexes. Also, Mife was a 
potent full antagonist of dexamethasone-induced enzyme activity of tyrosine aminotransferase 
(TAT) in whole rat cells. In vivo, the compound completely inhibited the Dex-induced activity of 
hepatic tryptophan oxygenase (TO) in adrenalectomized rats. 
Due to its strong GR antagonistic potential, Mife is frequently applied as an established 
reference substance for the assessment of anti-GC effects, although the interactions of the 
compound with PR and AR are undesirable for this purpose. Nevertheless, up to now, Mife is the 
only GR antagonistic drug on the market (Pecci et al. 2009). 
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In addition to being a reference GR antagonist, Mife also finds medical application. The anti-GC 
properties make it a useful medication to treat Cushing´s syndrome, as the drug counteracts 
hypercortisolism (Chu et al. 2001; Fleseriu et al. 2012). Also, Mife has been shown to be an 
effective treatment for major depression, where GR antagonism induces an HPA feedback loop 
mechanism which increases ACTH levels and induces endogenous Cort production (DeBattista et 
al. 2006; Flores et al. 2006). 
4.7.1.2 The effects of Mifepristone within the present study 
Within the present study, Mife served as a reference GR antagonist for in vitro and in vivo 
experiments. Accordingly, the compound inhibited GC signaling in all three GRIZLY assays. The 
anti-GC effect of Mife was also validated in qPCR experiments, as it suppressed the expression of 
all genes that were induced by Dex (hsd11b2, gilz and fkbp5) and Preg (hsd11b2, gilz, fkbp5, 
cyp3a65 and cyp1a1) within the set of selected targets. 
4.7.2 10-Hydroxycamptothecin (10-HC) 
4.7.2.1 The biological function of 10-HC and its mechanisms of action 
10-HC (also known as SN-38) is the active metabolite of irinotecan, an analogue of 
camptothecin. Irinotecan is an antineoplastic agent and one of the major drugs used in 
metastatic colorectal cancer treatment (Basseville et al. 2011; Kehrer et al. 2002; Raynal et al. 
2010). It serves as a prodrug which is in vivo converted by carboxylesterases into the 
pharmacologically active compound 10-HC (Humerickhouse et al. 2000). 10-HCexerts its 
antineoplastic properties via inhibition of the enzyme DNA topoisomerase I (Ebrahimnejad et al. 
2010; Gupta et al. 1997). The compound interacts with DNA topoisomerase I, whereby cleavage 
complexes are formed which prevent DNA replication and transcription (Basseville et al. 2011). 
This mechanism induces cytotoxicity in cancer-diseased tissues (Ebrahimnejad et al. 2010). 
 
The potential of 10-HC to interfere with glucocorticoid signaling 
I grouped 10-HC together with Mife as the two compounds had very similar effects on GC 
signaling within the GRIZLY assay and in qPCR experiments. Therefore, I suspected that they 
might share mutual mechanisms of action. However, I was unable to retrieve direct indications 
for 10-HC to antagonize the GR from the searched literature. Only two publications that I found 
suggest links between 10-HC and the GC system: 
Akagi and collegues (2009) described an enhanced chemotherapeutic effect of 10-HC in co-
treatment with Dex in rat-1 cells, indicating potential common mechanisms of the two 
compounds. 
In a study by Ahowesso et al. (2011), 10-HC induced circadian disruption in mice. Treatment with 
the antineoplastic affected body temperature, rest-activity, plasma corticosterone (the major GC 
in rodents) and the expression of several clock genes (e.g. Rev-erbα, Per2, and Bmal1) in the 
livers of the animals. 
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4.7.2.2 The effects of 10-HC within the present study 
Within the present study, 10-HC inhibited GC signaling in all three GRIZLY assays, like the GR 
antagonist Mife. Also, the gene expression patterns of 10-HC in co-treatment with Dex and Preg 
showed high similarity with those of Mife. The only remarkable difference between the 
responses of Dex + 10-HC and Dex + Mife on target gene transcription was that the 
antineoplastic decreased the mRNA levels of the two xenometabolic marker genes cyp3a65 and 
cyp1a1, which were no targets of Dex and Mife. This might correlate with the results from 
chemical analysis, where a lower Dex level was measured in the larvae. Although upregulated 
xenometabolic marker genes could be expected in correlation with a lower amount of Dex, 
effects on gene expression (after 4 h of exposure) may underlie different temporal dynamics 
than changes on larvae internal amounts of xenobiotics (24 h of exposure) and thus, the mRNA 
levels of cyp3a65 and cyp1a1 could indeed have been increased at another timepoint. 
The endogenous concentrations of Preg, Prog and Cort were not altered by 10-HC, thus, 
disruption of the Cort biosynthesis by 10-HC was neither suggested by UPLC-MS/MS 
experiments, nor by the GRIZLY results. Also, in contrast to the effect of 10-HC in co-exposure 
with Dex, no metabolic changes were indicated in larvae co-treated with Preg + 10-HC. 
4.7.2.3 Potential mechanisms of glucocorticoid signaling disruption by 10-HC  
1) Interference with GR signaling 
Although the effect similarities with Mife may suggest common mechanisms of action between 
the GR antagonist and 10-HC, the searched literature gave no direct indications for the 
antineoplastic to antagonize the GR. Neither have alterations in GR expression or -activity been 
directly described for this compound. According to the two studies mentioned before (section 
4.7.2.1; Akagi et al. 2009; Ahowesso et al. 2011), 10-HC may interfere with GC signaling at 
diverse levels, but the underlying mechanisms are unclear. However, also the function of the 
circadian clock and other GC-unspecific pathways (section 4.3) that were triggered by 10-HC 
treatment may have indirectly affected the GRIZLY response and Dex/ Preg target gene 
expression within the present study. 
 
2) Extensive metabolization of 10-HC in detoxification organs via the pregnane X receptor 
Interestingly, after irinotecan is converted into 10-HC, this active metabolite is extensively 
metabolized in detoxification organs such as liver and the intestine, where it can be inactivated 
by glucuronidation (via UDP-glucuronosyl transferases (UGTs) such as UGT1A1, UGT1A6, 
UGT1A7, UGT1A9) (Ihunnah et al. 2011; Mathijssen et al. 2004; Raynal et al. 2010), by CYP 
enzymes (such as CYP3A4 and CYP3A5) (Basseville et al. 2011) and by detoxification processes 
via different xenobiotic transporters (e.g. multidrug resistance protein 1 (MDR1) or breast cancer 
resistance protein (BCRP) (Basseville et al. 2011). 
In chemosensitivity studiesseveral research groups examined if these cellular defense 
mechanisms may underlie the frequently observed resistance of colon cancer to irinotecan 
(Mathijssen et al. 2004; Raynal et al. 2010). As the PXR is predominantly expressed in the liver 
and the gastrointestinal tract, the xenoreceptor is suspected to play a major role in the response 
of colon cancer cells to 10-HC. The transcription factor is activated by multiple drugs and 
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environmental pollutants and regulates the expression of genes involved in xenometabolism and 
xenobiotic transport. Thus, considering the metabolic pathways of 10-HC and the tissue 
distribution of the PXR, the receptor is believed to mediate the cellular defense against drugs by 
upregulating the expression of detoxification genes (Basseville et al. 2011; Raynal et al. 2010).  
Within this context, for instance Basseville et al. (2011) demonstrated via Chromatin 
immunoprecipitation (ChIP) in a colon cancer cell line that upon treatment with 10-HC, the PXR 
heterodimerized with the RXR in the nucleus and induced the expression of the CYP3A4 gene. 
They also confirmed via RNA interference experiments that the RXR was indeed involved in the 
overexpression of CYP3A4 and furthermore identified CYP3A5 as an additional target gene of the 
xenoreceptor. As upregulation of CYP3A4 is a major mechanism of drug resistance, they 
concluded that the PXR plays a pivotal role in tumor resistance to 10-HC. 
 
These findings may relate to the present study where with 10-HC + Dex, less Dex was measured 
in larvae extracts and the expression of cyp3a65 and cyp1a1 was altered. Possibly, 10-HC was 
strongly metabolized in the larvae, which also led to a decrease of the internal Dex 
concentration. An involvement of the PXR within this xenometabolic process may be suggested 
by the regulation of cyp3a65, a supposed PXR target in zebrafish(Bainy et al. 2013; Kubota et al. 
2015; Tseng et al. 2005). These correlations may indicate thatchanges in drug uptake and -
metabolism (section 4.3.1) possibly contributed to the observed effects of 10-HC + Dex in GRIZLY 
2 and on target gene expression, but they can neither explain the inhibition of GC signaling in 
vitro, nor the impact of 10-HC on Preg-induced GC signaling in GRIZLY and qPCR experiments. 
Thus, additional mechanisms have to be involved in these effects.  
 
3) Suppression of gene transcription via DNA topoisomerase I inhibition 
Considering the pharmacological activity of 10-HC as an antineoplastic which prevents DNA 
replication via inhibition of topoisomerase I, the obvious conjecture is that the compound had a 
cytotoxic impact on cells and larvae that might have reduced their responsiveness to GC signal 
activation. However, no toxicity was detected in both cells (via the LDH and the alamarBlue® 
assay; [11 µM]) and larvae (reaction to a tactile stimulus and lethality; [4-20 µM]) (section 3.3.1). 
In contrast, the parent compound of irinotecan, camptothecin, was itself present in the FDA 
library and showed toxicity in cells and larvae; hence, it was excluded from further experiments. 
Accordingly, some subliminal toxic effects might still have occurred with 10-HC, which may not 
have led to a significant result in the two cytotoxicity assays and neither decreased the motility 
nor increased the lethality in larvae at the timepoint assessed, but potentially it prevented DNA 
transcription via DNA topoisomerase I inhibition. This could have led to the observed inhibition 
within the GRIZLY assay and the qPCR experiments, as the transcription of the luciferase 
reporter gene and the selected GC target genes may have been hampered by DNA 
topoisomerase I inhibition. Although toxicity would be expected to result from this sooner or 
later, maybe it occurred not immediately and the exposure duration was too short for 
transcription inhibition to lead to cell death. 
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4.7.2.4 Next steps 
In order to pursue whether the effects of 10-HC might involve effects on the expression of the 
GR or its isoform ratio, the mRNA and protein levels of the two GR isoforms and their ratio will 
be assessed in future experiments. Also in vitro GRα binding studies may provide more detailed 
information about direct or indirect interactions of the compound with receptor activity. Should 
these findings indicate a potency of 10-HC to interact with GR signaling, this would be a so far 
unknown effect mechanism of the drug.  
Regarding the considered increased larval xenometabolism of Dex + 10-HC and a putative 
involvement of the PXR in these processes, it will be insightful to assess the expression levels of 
the xenoreceptor and its target genes (e.g. cyp3a65) in time series with short intervals. An 
increased expression of CYP genes would be expected at a certain time point in larvae treated 
with Dex + 10-HC in case that the PXR played a role in the decreased Dex level found in larvae 
homogenates. 
Considering suppression of gene transcription via DNA topoisomerase I inhibition as a possible 
effect mechanism for 10-HC within the present study, toxicity should occur in cells and larvae 
under prolonged exposure. It might thus be surveyed if toxic effects can be observed if cells and 
larvae are treated with the same conditions for 36 or 48 h.  
4.8 Retinoids 
 
Figure 48: Retinoids  (extract from Figure 45)  
4.8.1 The biological functions of retinoids and their mechanisms of action 
Ret. acid and Aci belong to the group of retinoids, which are derivatives of Vitamin A (retinol). 
Ret. acid is the carboxylic form and the main active metabolite of retinol (Aubry and Odermatt 
2009; Park et al. 1999). Synthetic retinoids such as Aci, a second generation retinoid, are 
produced to mimic retinoid signaling and -function for specific medical applications (Sue Lee and 
Koo 2005). 
During vertebrate growth and development, Ret. acid plays an important role, as it is involved in 
the embryonic anterior/ posterior patterning. After embryogenesis, Ret. acid is essential for 
cognitive functions, adult brain plasticity, anxiety-like behavior and epithelial differentiation 
(Aubry and Odermatt 2009; Bonhomme et al. 2014; Brossaud et al. 2013; Chen et al. 2014). In 
medicine, retinoids are applied in chemoprevention and for the therapy of some types of cancer, 
as they inhibit several biological functions including tumor growth, angiogenesis and metastasis 
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(Bonhomme et al. 2014; Chen et al. 2014; Marill et al. 2003; Soprano, Qin, and Soprano 2004). 
Aci usually finds application for the treatment of psoriasis (Lee and Li 2009). 
 
Classical pathway 
Ret. acid acts by binding and activating the retinoic acid receptor (RARα, β, or γ), which forms a 
heterodimer with the retinoid X receptor (RXRα, β, or γ) (Huang, Chandra, and Rastinejad 2014; 
Ihunnah et al. 2011; Park et al. 1999). RXRs can also be liganded by Ret. acid, but only by the 
9 cis (not the all-trans) isomer of the compound (Chen et al. 2014; Huang et al. 2014). The 
heterodimeric RAR/ RXR complexes bind to specific retinoic acid response elements (RAREs) on 
the DNA upstream of Ret. acid target genes, where they act as transcription factors and regulate 
the expression of genes which are involved for instance in cellular differentiation, arrest and 
apoptosis (Chen et al. 2014; Ihunnah et al. 2011; Lee and Li 2009). 
 
Non-classical pathway 
Beyond this classical pathway, Ret. acid function involves interplays with numerous other 
important signaling molecules. It can modulate NF-κB and diverse other transcription factors, 
which act for instance downstream of IFN-γ, VEGF, TGF-β and MAPK, and through these 
interactions, Ret. acid can affect their transcriptional activity (Chen et al. 2014; Connolly, 
Nguyen, and Sukumar 2013; Cras et al. 2012). Also, RAR and RXR can heterodimerize with other 
receptors and regulate the signaling pathway of the partner receptor. These interactions are 
referred to as non-classical pathways, which may have opposite functions to those of the 
classical, RAR/RXR heterodimer-mediated pathway. For instance, interference with the signaling 
of estrogen receptor alpha (ERα), peroxisome proliferator-activated receptor (PPAR), liver X 
receptors (LXRs) and vitamin D receptor (VDR) have been described (Chen et al. 2014; Connolly 
et al. 2013; Páez-Pereda et al. 2001).  
 
The potential of Retinoic acid to interfere with GR activity 
Also, retinoid signaling can interfere with GR pathways and either enhance or decrease the 
effects of GCs (Aubry and Odermatt 2009; Bonhomme et al. 2014; Brossaud et al. 2013; Lefebvre 
et al. 1999; Tóth et al. 2011; Yamaguchi et al. 1999). For instance, Tóth et al. (2011) observed 
that Ret. acid had a synergistic effect on GR activity in thymocytes, as the Ret. acid-liganded 
RARα/ RXR heterocomplex interacted with the GC-liganded GR and enhanced its transcriptional 
activity. In contrast, Aubry & Odermatt (2009) reported an inhibitory effect of the retinoid on GR 
activity, where Ret. acid prevented GR transactivation in skeletal muscle cells.  
Apparently, Ret. acid and GCs can also influence the expression of their receptors reciprocally. 
Brossaud et al. (2013) found in a hippocampal cell line that Ret. decreased the expression of GR 
via a negative GR feedback loop when the cells were co-treated with Dex + Ret. acid. They also 
observed that Dex and Ret. acid both interact through regulations of RARβ and GR and that the 
two compounds can regulate the mRNA and protein expression of their own and of the other 
receptors. In accordance with an inductive effect of Dex treatment on RAR and RXR expression, 
Yamaguchi et al. (1999) observed in cultured rat hepatocytes that Dex increased mRNA and 
protein levels of RXRα. Furthermore, the researchers showed that this Dex-induced increase in 
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RXRα expression could also influence the ligand-dependent transcriptional activation of other 
receptors that heterodimerize with RXRs, as Dex treatment intensified the Ret. acid-dependent 
upregulation of RARβ mRNA expression. In contrast to this, also counteracting effects of Dex on 
retinoid-mediated mechanisms have been reported. Lefebvre et al. (1999) showed in a human 
myeloma cell line that several Ret. acid-induced apoptotic features were inhibited by Dex 
treatment, such as the expression of the enzyme transglutaminase. Thus, the regulatory 
interactions between the two systems appear to be context dependent. 
 
The potential of Retinoic acid to disrupt the Cortisol biosynthesis pathway 
Ret. acid can also interfere with the Cort biosynthesis pathway. For instance, Páez-Pereda et al. 
(2001) observed that Ret. acid suppressed the production of ACTH in vitro, in human pituitary 
ACTH-secreting tumor cells and in a lung cancer cell line, as well as in vivo, in tumors of mice 
secreting ACTH. Within this context, the researchers furthermore found that Ret. acid inhibited 
the proliferation of cells within the adrenal cortex and through this also the production of 
corticosterone. 
4.8.2 The effects of retinoids within the present study 
Within the present study, the two retinoids inhibited GC signaling in all three GRIZLY assays. 
Chemical analysis revealed reduced Cort levels for both compounds, and in larvae treated with 
Aci also lower concentrations of Preg and Prog were measured. Accordingly, a disrupted Cort 
biosynthesis pathway is suggested for Ret. acid and Aci when co-treated with Preg. This is 
further supported by the gene expression profiles, as the two compounds counteracted the 
upregulation of all Preg target genes (except gilz in case of Ret. acid). Surprisingly, elevated 
induction of mRNA levels of hsd11b2, gilz and cyp3a65 (in case of Ret. acid) were found in larval 
co-exposure to Dex, rather than the repression expected based on the GRIZLY data (and the 
gene expression changes observed under Preg stimulation). Only cyp1a1 was also decreased by 
Ret. acid/ Aci + Dex, consistent with the downregulation of this xenometabolic marker by Ret. 
acid/ Aci + Preg. Apparently, for these genes, Ret. acid and Aci interfered with Dex-induced GC 
signaling partly via different mechanisms than with Preg treatment. 
4.8.3 Potential mechanisms of glucocorticoid signaling disruption by retinoids 
1) Interference with GR signaling 
The signal inhibition of Ret. acid and Aci in all three GRIZLY assays suggests a direct impact of the 
compounds on GC signaling. As described in section 4.8.1, retinoid interactions with GR 
pathways, leading to potentially reciprocal effects on receptor activity and mRNA/ protein 
expression, have been reported in literature (Aubry and Odermatt 2009; Bonhomme et al. 2014; 
Brossaud et al. 2013; Lefebvre et al. 1999; Tóth et al. 2011; Yamaguchi et al. 1999). Via non-
classical pathways, either the retinoids themselves may have interfered with GC signaling, or the 
RAR/ RXR heterodimer decreased the GR activity via receptor crosstalk with the liganded GR (see 
section 4.4.2.5). 
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For instance, Brossaud et al. (2013) described that Ret. acid amplified the GC-evoked 
homologous downregulation of GR expression via a negative GR feedback loop in vitro, when 
they co-treated hippocampal neurons (HT22) with Dex and Ret. acid. They also found that Dex 
and Ret. acid both interact through regulations of RARβ and GR and that the two compounds can 
act synergistically and oppositely on their own and the reciprocal receptor mRNA and protein 
expression. Also for the results of the present study, an amplified homologous downregulation 
(section 4.4.2.4) of the GR by the retinoids would be a possible mechanism leading to the 
observed effects in the GRIZLY assay. Maybe, Ret. acid and Aci accelerated or intensified this 
negative feedback loop, synergistically with Dex / Cort, and thereby reduced the GRα expression, 
whereupon the GRα : GRβ ratio decreased and the activity of remaining GRα could be further 
attenuated (section 4.4.2.3).  
 
2) Disruption of Cortisol biosynthesis  
In addition to direct interactions with GR signaling, disrupted Cort biosynthesis in larvae co-
exposed to Ret. acid/ Aci + Preg is suggested according to the present UPLC-MS/MS data (section 
4.4.1.1). Reduced Cort production in larvae could moreover explain the decreased mRNA levels 
of hsd11b2, gilz, fkbp5 (only with Ret. acid), cyp3a65 and cyp1a1, which was observed under the 
same treatment conditions. 
In Dex-treated larvae, reduced Cort production would not have been detectable by means of the 
applied UPLC-MS/MS system due to sensitivity issues. If steroidogenesis was indeed disrupted 
with Ret. acid/ Aci + Dex, and less Cort was produced, this would not have altered Dex signaling 
in the larvae. Thus, no conclusion can be drawn from these data about the retinoid effect on the 
endogenous Cort production with Dex treatment. 
However, the hypothesis of a disrupted Cort production due to retinoid treatment would be 
consistent with the above mentioned study by Páez-Pereda et al. (2001), where the researchers 
observed that Ret. acid inhibited the production of ACTH and corticosterone in vivo, in ACTH-
secreting tumors in mice and in vitro, in human pituitary ACTH-secreting tumor cells and in a 
small-cell lung cancer cell line. As described in section 1.2.1, ACTH regulates the synthesis of GCs 
and, thus, a decreased ACTH production could have led to the decreased Cort levels within the 
present study. Also clinical studies were conducted to assess the effect of Ret. acid on ACTH 
production in Cushing’s disease, but the outcomes are diverse, with either increases or 
decreases in pomc (gene encoding the proopiomelanocortin (POMC) protein, a precursor of 
ACTH) transcription and the underlying mechanisms are not completely understood (Lau, 
Rutledge, and Aghi 2015). Thus, the findings of this thesis work suggest that the effects of Ret. 
acid on the production of Cort are conserved in zebrafish, but the molecular mechanisms are 
unclear. Possibly, as a retinoid-amplified homologous downregulation of GRα can be suspected 
to imply a negative feedback loop on the endogenous GC production (via ACTH), this might be an 
explanation for the decreased Cort levels in larvae. 
 
3) Indirect interactions with glucocorticoid signaling 
Also indirect compound interactions with GC signaling could have occurred in co-treatment of 
the retinoids with Dex/ Preg. For instance the opposing effects of Dex/ Preg + retinoid on the 
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expression of cyp3a65 may suggest diverging xenometabolic effects (section 4.1.4) under the 
different treatment conditions. Although the expression of numerous CYP enzymes can be 
regulated by the GR (Dvorak and Pavek 2010), most members of the CYP3A family are 
predominantly regulated by the PXR (Bainy et al. 2013; Kubota et al. 2015; Lehmann et al. 1998; 
Tolson and Wang 2010) Accordingly, also the cyp3a65 zebrafish gene is a candidate target of the 
PXR (Bainy et al. 2013; Kubota et al. 2015). Thus, receptor crosstalk between the GR and the PXR 
can occur (Pascussi et al. 2000), potentially regulating the transcription of cyp3a65 ligand- and 
context-specifically. In accordance with this idea, several coactivators for steroid hormone 
signaling, e.g. steroid receptor coactivator 1 (SRC-1) and glucocorticoid receptor interacting 
protein 1 (GRIP-1) have been reported to play pivotal roles in tissue specific PXR target gene 
induction (Tolson and Wang 2010). Moreover, the expression of cyp3a65can also be regulated 
GR independently, for instance via the PXR alone, or via receptor interactions between the PXR 
and the RXR (Moore and Kliewer 2000), which can activate xenobiotic response element (XRE) 
sequences within the promotor region of the cyp3a65 gene (Tseng et al. 2005). 
In order to consider these findings for the interpretation of the cyp3a65 expression within the 
present study, other transcription factors may have altered the mRNA level of cyp3a65 in 
addition or alternative to the GR, and GR/PXR or PXR/RXR crosstalk (section 4.4.2.5) possibly 
played a role therein. These interactions were probably diverse between the different co-
treatments and led to context- and ligand-specific responses such as downregulation of the 
target gene in co-treatment of the retinoids + Preg but to an elevated mRNA level with Dex + 
Ret. acid. 
 
Similarly, the observed downregulation of the second xenometabolic marker gene, cyp1a1, by 
Ret. acid/ Aci + Dex/ Preg may also be attributed to retinoid interference with other nuclear 
receptors, such as the AhR. For instance, retinoids have been described to repress the pathway 
of AhR-mediated induction of cyp1a1 through the silencing mediator for retinoid and thyroid 
hormone receptors (SMRT) corepressor (Fallone et al. 2004), which could explain the decreased 
mRNA levels within the present study. 
4.8.4 Next steps 
Regarding direct interference with GR signaling, the transcriptional activity of GRα appears to 
play a major role therein, which makes evaluation of GRα/GRβ levels and their ratio a 
reasonable starting-point to pursue mechanisms of retinoid and GC signaling interactions.  
 
In order to follow up on retinoid interference with the GC biosynthesis pathway, the HPA axis 
status can be further investigated under Ret. acid/ Aci + Dex/ Preg treatment, for instance via in 
situ hybridization assessing the ACTH/ pomc expression in the zebrafish larvae. Also, zebrafish 
models for Cushing’s disease, as recently developed by Liu (2011) and colleges, could serve as a 
valuable tool to trace this effect. Moreover, translational research with this system might 
provide essential knowledge on retinoid therapies for the treatment of Cushing’s disease. 
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For further investigations of nuclear receptor crosstalks (possibly involving RAR, RXR, GR, PXR 
and AhR) under Dex/ Preg + retinoid co-treatment, target gene expression analysis in 
dependency of different retinoid concentrations, as well as receptor binding studies, can 
certainly provide useful information. However, a more detailed understanding will require a 
comprehensive mapping of interactions between putatively involved nuclear receptors and their 
activities in the regulation of key genes of the target regulatory networks. 
4.9 Progestins 
 
Figure 49: Progestins (extract from Figure 45)  
4.9.1 The biological functions of progestins and their mechanisms of action 
Ethi, Nor and Gestri belong to the steroid hormone group of progestins. Progestins are synthetic 
progestogens which were designed to be potent PR agonists. Thus, in cells of target organs, they 
are expected to mediate their effects predominantly by transcription regulation of specific target 
genes via binding to and regulating the activity of the PR. Most progestins are structurally very 
similar to Prog, 17α-hydroxyprogesterone or testosterone, as they were first derived from 
testosterone and were then chemically modified in order to enhance their progestogenic 
properties and to develop synthetic drugs which mimic the function of Prog, the major 
endogenous progestogen (Africander et al. 2011; Bray et al. 2005; Graham and Clarke 1997; 
Louw-du Toit et al. 2017).  
 
Progesterone 
Prog is a key hormone in the regulation of female reproduction, which involves the release of 
mature oocytes, maintenance of pregnancy, milk protein synthesis and sexual behavior in PR-
expressing organs including uterus, ovary, mammary gland, brain and pituitary gland. Targeting 
these biological functions, progestins are used in reproductive medicine with manifold 
applications for hormone replacement therapy (HRT), contraception and treatment of 
reproductive disorders or cancer (Africander et al. 2011; Bray et al. 2005; Graham and Clarke 
1997; Louw-du Toit et al. 2017). 
 
Ethisterone 
The oldest and first marketed orally active compound with progestogenic activity is Ethi, one of 
the three progestins identified within this study to interfere with GC signaling. Ethi was 
structurally directly derived from testosterone and although minor structural changes increased 
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the binding affinity of Ethi for the PR over that for the AR, its progestogenic effects were still 
likely to be accompanied by androgenic side-effects (Inhoffen and Hohlweg 1938). Nowadays, 
newer generations of progestins replace Ethi for applications in reproductive medicine. Among 
those is the group of 19-nortestosterone progestins, structurally derived from Ethi, to which 
Gestri and Nor belong (Djerassi 1992; Louw-du Toit et al. 2017). 
 
Gestrinone 
Gestri is described as a mixed PR agonist and a selective progesterone receptor modulator 
(SPRM) (Bromham et al. 1995). According to Tamaya et al. (1986), who conducted a study on 
human endometrial cytosol, Gestri binds with moderate affinity to the PR, but it possibly 
occupies "almost all specific binding sites of steroids in the steroid target cells in spite of the 
presence of endogenous steroids". One earlier in vitro receptor binding study from Raynaud et al. 
(1980), where steroid hormone receptors were obtained from diverse rodent tissue 
homogenates, found a higher relative binding affinity of Gestri for the AR and the GR than for 
the PR (AR > GR > PR > MR). Although in vitro binding studies have to be evaluated carefully, as 
further discussed in the following paragraphs, these observations imply a general potential for 
Gestri to directly interfere with GR binding, which may be considered for the discussion of the 
present results. 
 
Norethindrone 
The progestogenic activity of Nor (also termed Norethisterone) was described to be about 20-
fold higher than that of Ethi (Djerassi 1992). However, due to its structural ability to bind the AR, 
weak androgenic effects can also be expected. Moreover, Nor has a weak estrogenic potential, 
as a small portion of the progestin can be metabolically converted into the synthetic estrogen 
Ethinylestradiol (Kuhnz et al. 1997; Paulsen et al. 1962). Interestingly, according to Ronacher et 
al. (2009), Nor has no transactivation and transrepression potency (tested on NF-κB or AP-1) for 
the GR. They showed furthermore that Nor has a very high binding IC50 (1688 +/- 300 nM) to the 
GR in transfected COS-1 cells.  
4.9.2 The effects of progestins within the present study 
In the GRIZLY assay, Ethi, Nor and Gestrisuperactivated Dex-induced signaling in vivo. By 
contrast, only Gestri and Nor inhibited Dex-induced signaling in vitro and Preg-induced signaling 
in vivo. Chemical analysis revealed trends for elevated Dex levels in larvae co-treated with 
Dex + Ethi and Dex + Nor. Furthermore, all three compounds led to reduced Cort concentrations. 
Ethi treatment additionally decreased Prog levels, while for Gestri and Nor, Prog was unchanged. 
Ethi did not change Preg levels, which increased in larvae co-treated with Nor and Gestri. The 
qPCR data are ambiguous for the progestins in co-treatment with Dex, as only with Nor a trend is 
visible for two target genes (gilz and fkbp5) to be upregulated, which would be in accordance 
with the outcome of GRIZLY 2. In co-exposure with Preg, all three compounds downregulated 
several of the target genes, supporting a reduced GC signaling by Cort. 
 
4.9 Progestins  
136 
Although the opposite responses between the different GRIZLY approaches were rather 
unexpected, the follow-up experiments helped to confirm these findings in part. The UPLC-
MS/MS and qPCR results furthermore provided additional starting points for considerations 
about the – apparently complex – mechanisms of action possibly underlying the compound 
effects. Several are depicted as follows: 
 
1) Direct interactions with GR signaling  
As implied by their structural characteristics, direct interactions of progestins with GRs are 
generally possible and may, thus, have contributed to the observed effects of Ethi, Gestri and 
Nor on Dex- and Preg-induced GC signaling in the GRIZLY assay. In GRIZLY 1, possibly high 
concentrations of both, Dex and the progestins would reach the cells, and any progestin binding 
could lower the total signal, suggesting a partial antagonism of the progestins under these 
treatment conditions (a context-specific effect; section 4.3.2). 
In larvae, the physiological environment might be different, which could lead here to partial 
agonistic effects of the progestins. Also, as it was assessed earlier (in section 3.5.1 and discussed 
in section 4.1.1), Dex enters the larvae at much low concentrations than Preg. Maybe, according 
to the structural similarity between Preg and the progestins, the relative concentrations of Ethi, 
Gestri and Nor might also be higher in larvae than that of Dex, which may have made context-
specific (section 4.3.2), synergistic effects of the progestins on GR activation possible in GRIZLY 2. 
Considering that Gestri was described in literature to possibly exhibit binding affinity for the GR 
(Raynaud et al. 1980; Tamaya et al. 1986), a direct GR antagonism of this compound may be 
supposed to underlie the observed inhibition in GRIZLY 1 and a synergistic GR agonism the 
superactivation in GRIZLY 2. Also for Nor, although no activity on the mammalian GR was 
described (Africander et al. 2011; Ronacher et al. 2009), for the zebrafish receptor, a potential 
direct ant/agonism of the compound could still have had a relevant impact on the outcome of 
the GRIZLY assay. The reduced Cort levels found for Gestri, Nor and Ethi in co-exposure with 
Preg are likely to explain signal inhibition by Gestri and Nor in GRIZLY 3. In case of Ethi, the 
compound may have had a stronger partial agonistic activity than the other two progestins, 
which possibly even counteracted the downregulation of reporter gene expression in GRIZLY 3 
that could have been expected from the reduced Cort production. 
 
2) Superactivation in the presence of glucocorticoids 
Interestingly, the experiments in which larvae were exposed to Ethi, Nor and Gestri in absence of 
Dex or Preg did not show an agonistic potential of any of the three progestins alone (Figure 33 
a). Also experiments with other progestins, which were not contained in the FDA library, such as 
Levonorgestrel [10-50 µM] and Melengestrol acetate [10-50 µM], showed no direct activation of 
GC signaling, but superactivation in combination with Dex (see appendix, Supplementary 
Figure IV). Apparently, the presence of Dex or of directly administered Cort (Figure 33 b) was 
necessary to superactivate GC signaling. Potentially, ligand binding of the GCs induced 
conformational changes at the GR which then allowed also the progestins to agonize the GR. 
Alternatively, these results could indicate that a cofactor environment depending on the GC-
liganded GR at the reporter gene promotor (context-specifically; section 4.3.2) may enable for 
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other transcription factors to bind (Weikum et al. 2017), which could in turn allow for receptor 
crosstalk between the GR and other nuclear receptors, such as the PR (see examples for 
receptor crosstalk in section 4.4.2.5). Possibly consistent with the "hit and run" (Keeton et al. 
2002)and "assisted loading" (Voss et al. 2011) models of GR signaling, initial chromatin binding 
of the activated GR may have triggered chromatin remodeling in the regulatory sequence. This 
could have exposed a higher number of DNA binding sites and facilitated the attachment of 
additional factors and possibly other nuclear receptors, which reinforced the activation of the 
GC target gene (Cohen and Steger 2017; Goldstein et al. 2017; Petta et al. 2016). 
 
3) Changes in xenometabolism 
The UPLC-MS/MS measurements showed elevated Dex levels in the larvae treated with 
Dex + Ethi and Dex + Nor, which possibly underlie changes in Dex-uptake and -metabolism 
(section 4.1.4). Thus, the higher amount of Dex could have contributed to the co-activating 
effect of Ethi and Nor observed in GRIZLY 2. 
 
4) Disruption of cortisol biosynthesis 
Chemical analysis data suggest inhibition of Preg-induced biosynthesis of Cort as a potential 
mechanism of action of all three compounds (section 4.4.1.1). In particular, Gestri and Nor 
induced the same steroid level profile as the reference inhibitor Mety, thus, a common 
mechanism of action could be suspected for Gestri, Nor and Mety. As Mety specifically inhibits 
11β-hydroxylase, this enzyme is a good candidate to be also a point of disruption by Gestri and 
Nor. In accordance with that, the gene expression changes induced by Gestri, Nor and Mety 
across the different targets are also comparable, which would equally be consistent with 
common mechanisms of action. 
Ethi may have disrupted the biosynthesis pathway earlier than Gestri and Nor, as Prog levels are 
reduced in addition to Cort (for details of the steroidogenesis pathway see Figure 3). Inhibition 
of 3β-HSD, the enzyme that converts Preg and 17α-hydroxypregnenolone into Prog and 17α-
hydroxyprogesterone would be a possible explanation for this steroid level profile. Preg might 
not accumulate as Preg and 17α-hydroxypregnenolone can still be metabolized into downstream 
androgens when 3β-HSD is inhibited. 
 
5) Lower concentrations of Norethindrone and Gestrinone superactivate glucocorticoid 
signaling 
During retests with lower concentrations of Nor and Gestri, which were conducted in order to 
assess the concentration-dependency of their effects (Figure 34), both compounds 
superactivated Dex signaling in all concentrations. Surprisingly, in co-treatment with Preg, Nor 
(significant at 0.25-1 µM) and Gestri (a trend at 0.25 µM) also showed co-activating potential in 
the lowest concentrations. 
Possibly, a higher concentration of Nor (>2 µM) and Gestri (>0.25 µM) was necessary to disrupt 
the Preg-induced Cort production, while lower concentrations still enabled the endogenous 
conversion of Preg into Cort. In this case, the GCs liganded the GR and activated GC signaling. 
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Assuming from the increased GRIZLY response, Nor (and maybe Gestri) could then interfere with 
GC signaling, which led to the observed superactivation. 
This, in turn, could rely on several of the already mentioned mechanisms. The progestins may 
have directly interfered of with GC signaling, for instance via the above considered GC-induced 
changes of either the GR conformation (may enable partial GR agonism for progestins) or the 
chromatin structure within the promotor region of target genes (could facilitate chromatin 
binding of additional factors, e.g. the progestin-liganded PR). Alternatively, the superactivation 
could result from compound-mediated changes in drug uptake and -metabolism, as it was 
suspected already for Nor + Dex treatment. The larvae-internal amount of Preg may have been 
elevated, which could have led to higher Cort levels and enhanced GC signaling.  
 
Summary: multilayered effect mechanisms 
To summarize these considerations, several multilayered effect mechanisms possibly apply for 
the compounds. These, in turn, may have been context-specifically influenced by diverse general 
(section 4.3) and specific (section 4.4) mechanisms of GC signaling disruption. In the next 
sections the considered mechanisms will be discussed with regard to the available literature 
describing effects of progestins in general and of Ethi, Nor and Gestri specifically on GC signaling. 
4.9.3 Potential mechanisms of glucocorticoid signaling disruption by progestins 
Direct interactions with GR signaling 
According to the available literature, studies investigating the three discussed progestins are 
very limited, in particular animal or clinical studies elucidating their effects in vivo are rare 
(Louw-du Toit et al. 2017). Especially for Ethi, the oldest of the three progestogenic compounds, 
this circumstance may be explained by the rapid evolution of newer generations of progestins 
for medical applications, which are in the focus of most publications from the last decades. 
However, some common information about their principal progestogenic mechanisms is 
important for the evaluation of the compound effects observed in the present study. In general, 
for most if not all progestins, their entire mechanisms of action are not completely understood. 
Like for all steroidogenic ligands, their binding affinities and agonistic or antagonistic potencies 
for a specific receptor, as well as their biological activities are context-specific (section 4.3.2) 
(Africander et al. 2011; Hapgood et al. 2004; Heitzer et al. 2007; Inhoffen and Hohlweg 1938; 
Louw-du Toit et al. 2017; Weikum et al. 2017). 
 
Furthermore, a high structural similarity of the PR to the AR especially, but also to the MR and 
the GR, allows progestogens in principle per se to bind also to these other membersof the 
nuclear receptor superfamily. The molecular modifications of progestins targeted higher 
efficacies and provided increased bioavailability and stability of the compounds compared to 
natural Prog. However, these structural changes also affected their pharmacokinetics, relative 
binding affinities and potencies not only for the PR, but also for AR, MR and GR, providing each 
progestin with a potentially unique effect spectrum (Africander et al. 2011; Bray et al. 2005; 
Louw-du Toit et al. 2017). 
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Thus, the variety of progestins shares several progestogenic activities with each other and with 
Prog, but their structural diversity comes also along with variable and individual patterns of 
hormonal activities, partly due to binding with different affinities to one or several members of 
the steroid hormone receptor group, possibly agonizing or antagonizing them. Although these 
interactions do not always induce a downstream signaling response, they can mediate ligand-
specific progestogenic activities, as well as numerous side-effects. The unwanted effects of 
progestins are considered to be partly mediated by their binding to other steroid hormone 
receptors in non-target tissues. For instance, increased risks for breast cancer, negative effects 
on immune functions, cardiovascular complications, higher blood pressure, weight gain and 
reduced bone density belong to the risks which may accompany progestin medications and are 
effects that are functionally closely associated with progestin interference with GRs and MRs 
(Africander et al. 2011; Inhoffen and Hohlweg 1938; Louw-du Toit et al. 2017; Schindler et al. 
2003). 
 
As an example, the most prominent, first-generation progestin, Medroxyprogesterone acetate 
(also a 19-nortestosterone derivative, like Gestri and Nor), was described to bind to the GR even 
with higher affinity than Cort(Africander et al. 2011) and was shown to exert GC-like activity (as 
an agonist or partial agonist), possibly by interfering with immune and cardiovascular functions 
and affecting bone density (Bamberger et al. 1999; Ishida, Ishida, and Heersche 2002; Kontula et 
al. 1983; Koubovec et al. 2005; Kurebayashi et al. 2003; Ronacher et al. 2009; Saitoh et al. 2005).  
 
Disruption of Cortisol biosynthesis  
Also, progestins are able to disrupt the endogenous steroid production(section 4.4.1.1) in the 
organism. Due to their structural similarity with Prog, 17α-hydroxyprogesteroneand 
testosterone, they can compete not only with other ligands for binding to steroid hormone 
receptors, but also with endogenous metabolites for binding to steroidogenic enzymes. This 
competitive inhibition can disrupt the steroidogenesis and provoke feedback mechanisms via 
the HPA axis (for reviews see Africander et al. 2011 and Louw-du Toit et al. 2017). The reduction 
of Preg-induced Cort levels seen in co-treatment with all three progestins may, therefore, well 
be a consequence of such an inhibition of steroidogenic enzymes. 
These mechanisms depend highly on the biological environment, including availability of 
enzymes and steroidogenic metabolites, as well as on the route of administration and the 
concentration of the respective progestin. Accordingly, other studies investigating disruptions of 
the Cort biosynthesis pathway or inhibited function of steroidogenic enzymes by progestins 
were certainly conducted under different physiological conditions, but some publications are 
here considered for further discussion. 
 
Interestingly, very few clinical studies on humans  are available which assess progestin effects on 
endogenous steroid hormone levels, although these pharmaceuticals are developed for human 
medical applications. In one study, women administered with Medroxyprogesterone acetate 
showed decreased levels of endogenous Prog, 17α-hydroxyprogesterone and Cort, which were 
explained by progestin-induced inhibition of the HPA axis (Aedo et al. 1981; van Veelen et al. 
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1984). Also, decreased Cort levels were found in women using Levonorgestrel for contraception 
(Toppozada et al. 1997). 
Apart from such few exceptions, the available literature mainly consists of animal and in vitro 
studies, which can contribute to the understanding of progestogenic (side-) effects, and may 
help to narrow down the putative points of Cort biosynthesis disruption. 
 
1) 3β HSD, 17α-hydroxylase and 17, 20-lyase 
In one in vitro study by Arakawa et al. (1989), the effects of Nor, Gestri, Levonorgestrel (also a 
19-Nortestosterone derivative and, thus, structurally very similar to Nor and Gestri) and other 
progestins (Danazol, Desogestrel and 3-keto-desogestrel) on rat ovarian steroidogenic enzymes 
3β-HSD, 17α-hydroxylase and 17, 20-lyase were assessed. They found that all progestins 
inhibited 3β-HSD and 17, 20-lyase, with Gestri showing an especially distinct suppression of 3β-
HSD (Ki = 3.0 μEM) and of 17, 20-lyase (30 μEM). This correlates with the results of the present 
study, where elevated Preg and reduced Cort levels were found in zebrafish larvae treated with 
Preg + Nor and Preg + Gestri. For larvae treated with Preg + Ethi, Preg levels were not altered, 
but Prog and Cort were reduced. Even though the disruption of Preg-stimulated Cort production 
is not one hundred percent comparable with steroidogenesis inhibition at endogenous steroid 
levels, these steroid level profiles may suggest that all three progestins inhibited 3β-HSD and/or 
17,20-lyase within the present study and thereby disrupted the biosynthesis of Cort.  
 
Also, decreased mRNA expression of genes encoding 17,20-lyase, 17α-hydroxylase (both 
cyp17a1) and 3β-HSD (hsd3b1) were found by Overturf et al. (2014), who conducted an in vivo 
study in fish and exposed fathead minnows (Pimephales promelas) to Levonorgestrel. However, 
they also found reduced levels of Preg, Prog, 17α-hydroxyprogesterone and testosterone, which 
is different from the results of the present study, where Preg was induced while Prog was not 
affected and Cort was reduced by Gestri and Nor. As considered above, within the present study, 
the Cort production was stimulated in larvae by Preg treatment, which may lead to different 
metabolite accumulations upstream of Cort than the disruption of Cort production at 
endogenous levels. Accordingly, despite this difference, 17,20-lyase, 17α-hydroxylase and 3β-
HSD may still have been affected within the present study, but also another steroidogenic 
enzyme could have been inhibited in the zebrafish larvae. As the steroid levels of larvae co-
treated with Preg and either Nor, Gestri or Mety are identical to each other, disruption of the 
specific target enzyme of Mety, 11β-hydroxylase, appears more likely to underlie the effect of 
Gestri and Nor than inhibition of 17,20 lyase, 17α-hydroxylase or 3β-HSD. However, for 
Preg + Ethi, inhibition of 3β-HSD and maybe also 17α-hydroxylase constitutes still a possibility 
supported by the metabolite measurements. 
 
2) 11β-hydroxylase 
Further supporting the hypothesis that Gestri and Nor might have disrupted 11β-hydroxylase 
within this thesis work, one other fish study showed inhibition of several gonadal steroidogenic 
enzymes of carp (Cyprinus carpio) in vitro, upon cell treatment with Nor and other progestins 
(Levonorgestrel, Cyproterone acetate). Here, all progestins inhibited 17, 20-lyase, and Nor (as 
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well as Cyproterone acetate) furthermore inhibited gonadal 11β-hydroxylase (Fernandes et al. 
2014). Although their effect was observed in vitro and only for gonadal 11β-hydroxylase, these 
findings may imply that the activity of adrenal 11β-hydroxylase in fish can also be disrupted by 
Nor in vivo.  
 
3) 11β-HSD2 
In another in vitro study, on human H295R adrenal cells, treated with Nestorone 
(19-Norprogesterone derivative) and Drosperineone (derivative of MR antagonist 
Spironolactone), also reduced Cort levels were observed with both progestins. This effect was 
accompanied by elevated Cortisone levels in case of Nestorone, suggesting an increased activity 
of the responsible enzyme 11β-HSD2 (Louw-du Toit et al. 2017). 
Considering an involvement of 11β-HSD2 in the reduction of Cort levels within the present study, 
all tested compounds significantly decreased the Preg-induced mRNA expression of hsd11b2. 
This correlates with their common inhibitory effect on Preg-induced GC signaling, as hsd11b2 is a 
GR target gene (Alderman and Vijayan 2012) and, thus, inhibition of GC signaling resulted in 
reduced transcription of hsd11b2. Accordingly, the present results give no indication for an 
increased activity of 11β-HSD2 by any of the tested compounds compared to the negative 
control (Preg + DMSO), making this explanation for the reduced Cort levels unlikely. Rather, they 
further support inhibition of upstream enzymes involved in the GC biosynthesis pathway as the 
origin for the decreased amount of Cort. 
 
4) 3β-HSD - a common progestin target 
Interestingly, Louw-du Toit et al. (2016) also found Nestorone, Nomegestrol acetate and 
Drospirenone to act upstream and to reduce the biosynthesis of steroid hormones by inhibiting 
the activity of 3β-HSD in vitroin (non-steroidogenic) COS-1 cells expressing human 3β-HSD. 
Inhibition of human 3β-HSD was also shown for Medroxyprogesterone acetate, as described for 
in vitro competitive binding studies by Lee, Miller, and Auchus (1999), and again by Louw-du Toit 
et al. (2017).  
 
According to the cited studies, 3β-HSD is a common target of numerous progestins, disrupting 
the Cort biosynthesis within completely different study approaches. This knowledge highlights 
that progestins, albeit their precise structural differences and the diverse biological and 
physiological environments their effects were investigated in, still have some common targets. 
Therefore, animal and cell culture studies clearly provide essential information about the effect 
mechanisms of this pharmacological group, although they may not always reflect the compound 
effects in humans, as emphasized also by Louw-du Toit et al. (2017) and Miller & Auchus (2011).  
 
Indirect interactions with glucocorticoid signaling 
Beside the above mentioned direct interactions with diverse steroid hormone receptors (section 
4.4.2.5) or their potential to disrupt the production of GCs, progestins were also described to 
interfere with several biological processes, which can equally lead to numerous side-effects 
accompanying their progestogenic effects. For instance, depending on their concentrations, 
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route of administration and target organism, progestins can alter drug pharmacokinetics, 
metabolism and bioavailability (as reviewed by Africander et al. 2011 and Louw-du Toit et al. 
2017), which was assumed to underlie the observed superactivation of Ethi and Nor on Dex-
induced GC signaling according to the elevated Dex concentration found by chemical analysis.  
4.9.4 Next steps 
Within the present study, potential side-effects of progestogenic treatment on diverse 
physiological processes, covering possible mechanisms of direct interaction with other steroid 
hormone receptors, changes in drug pharmacokinetics, -metabolism and -bioavailability, as well 
as disruption of the endogenous steroid hormone production were observed in zebrafish larvae 
exposed to progestins. As, for instance, progestin treatment of zebrafish larvae (Preg + Ethi) 
decreased the endogenous concentrations of Prog and Cort just as well as it was found in 
women upon medical progestin (Medroxyprogesterone acetate) administration (Aedo et al. 
1981; van Veelen et al. 1984), this study highlights that although the (side-)effects of progestins 
rely on various parameters, zebrafish larvae are well-suited organisms to investigate their 
pharmacological effects in vivo.  
 
Regarding the effects of Ethi, Nor and Gestri within this thesis work, additional experiments will 
be necessary to validate the hypothesized mechanisms of action. Further experiments using 
various concentration combinations of the different ligands in both cell culture and larvae, as 
well as quantification of uptake of the progestins to map out the effective concentrations in the 
larvae, may help to solve these issues. 
 
In order to assess direct interactions of progestins with GR signaling, the compound behavior will 
be surveyed in cells, in application of diverse concentrations of Dex/ Cort + progestins. In the 
next step, zebrafish nuclear receptor binding assays can certainly provide more substantiated 
information about the progestin potential to ant-/agonize the GR or to induce nuclear receptor 
crosstalk under the applied exposure conditions. 
 
The assumed changes in drug uptake and metabolic activity due to progestin treatment by Nor 
and Ethi in combination with Dex can be addressed by a more detailed gene expression analysis, 
where additional marker genes for more specific xenometabolic enzymes can be measured. Also, 
via chemical analysis, metabolites of Dex could be quantified, which may provide more 
information about the drug turnover within the larvae. 
 
The hypothesis that Ethi, Nor and Gestri disrupted the Cort biosynthesis pathway will also be 
followed up by chemical analysis, where more metabolites involved in steroidogenesis (see 
Figure 3) will be measured, which should facilitate to pinpoint a point of biosynthesis disruption 
and will help to validate the suggestions for affected enzymes. Following these efforts, further 
validation steps will include the application of specific inhibitors of the respective enzymes and 
enzyme activity measurements. 
  4. Discussion 
143 
4.10 Synthetic ligands for androgen receptor and mineralocorticoid receptor 
 
Figure 50: Synthetic ligands for AR and MR (extract from Figure 45)  
 
The two compounds Stano and Spiro showed similar effects within the present study. Both are 
synthetic steroids, but they are designated to act on different targets. While Stano is a synthetic 
AR agonist and Spiro predominantly acts as an MR antagonist, neither of the two compounds 
would be necessarily expected to activate GC signaling. Surprisingly, within the GRIZLY assay, 
both steroids significantly co-induced the Dex-and Preg-mediated signal in larvae. 
4.10.1 Stanozolol 
4.10.1.1 The biological functions of Stanozolol and its mechanisms of action 
Stano is a synthetic anabolic-androgenic steroid which is structurally derived from 
dihydrotestosterone (DHT), a natural androgen(Boada et al. 1999). Due to its anabolic and 
performance-enhancing properties, the usage of Stano is not allowed in sports competitions of 
humans and animals (Kicman 2008). In medicine, the synthetic androgen predominantly finds 
application for the treatment of anemia (Resegotti et al. 1981; Yuan, Liu, and Huang 1998). 
 
The potential of Stanozolol to disrupt the Cortisol biosynthesis pathway 
Already 30 years ago, Lambert et al. (1986) conducted an in vitro study in guinea-pig adrenal 
cells, where they assessed compound effects of the secretion of Cort from ACTH-stimulated 
cells. They found that Stano [50 µM] (and other compounds such as Etomidate, Metyrapone, 
Megestrol acetate, Cyproterone acetate, Danazol) interfered with the biosynthesis of Cort. Three 
years later, it was shown by another group that Stano is a competitive inhibitor of CYP17A1, as 
the anabolic androgen inhibited the activity of 17α-hydroxylase and 17,20-lyase in pigs, with IC50 
values of 2.9 µM and 0.74 µM, respectively (Nakajin et al. 1989). Inhibitory effects on the 
steroidogenic activity of CYP17A1 were also observed for other synthetic androgens (such as 
testosterone acetate) and for anabolic steroids (as for instance Mestanolone and Furazobol) in 
diverse studies (for review see R. Salvador et al. 2013).  
 
Unlike natural androgens, Stano cannot be aromatized into estrogens due to the 17α-alkyl 
group, which was added to the compound by synthetic modification. Thus, it possesses no 
estrogenic activity (Kicman 2008). However, Stano can still induce the expression of aromatase, 
which in turn increases the conversion of endogenous androgens into the natural estrogen 
Estradiol, as it was for instance observed in a human breast cancer cell line (MCF-7) by Sirianni 
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and collegues(2012). Based on this finding, the researchers further confirmed an estrogenic 
activity of Stano by showing that the compound was capable to induce the expression of the ER 
target gene CCND1 (cell cycle regulator cyclin D1), which encodes a key protein for the control of 
breast cancer cell proliferation. Therefore, Stano can possibly disrupt the steroidogenesis 
pathway by interfering with several enzymes. 
 
The potential of Stanozolol to interfere with GR signaling 
Like numerous anabolic androgens, Stano may have anticatabolic effects that are suspected to 
rely on compound interference with GR target gene expression (Bates, Chew, and Millward 
1987; Kicman 2008). However, anabolic androgens normally possess a very low GR binding 
affinity and, thus, have no important GR antagonistic potential (Hickson et al. 1990). Interactions 
with GR signaling via mechanisms other than receptor antagonism have been described for 
instance by Fernández and collegues (1995), who observed that in contrast to natural androgens 
Stano and Danazol (both androgenic 17α-alkyl derivatives) were able to interact with steroid 
binding sites in rat liver microsomes that are capable to bind various GCs and also Prog. The 
researchers showed in vivo that Stano significantly reduced the binding capacity of radioactively 
labeled [3H] Dex and demonstrated that Stano, Danazol and Methyltestosterone mediated a 
significant increase in the concentration of the GR. 
4.10.1.2 The effects of Stanozolol within the present study 
Within the present study, Stano superactivated GC signaling in both in vivo assays but inhibited 
the Dex-induced signal in vitro. For larvae treated with Dex + Stano, chemical analysis revealed 
that the amount of Dex was strongly increased. In correlation to that, also the expression of the 
three Dex target genes hsd11b2, gilz and fkbp5 was induced by the androgen. In contrast, when 
larvae were co-treated with Preg + Stano, reduced Cort levels were measured by UPLC-MS/MS. 
Also, the expression of all Cort target genes except fkbp5 was significantly decreased. According 
to this, it appears likely that Stano may have disrupted the biosynthesis of Cort (section 4.4.1.1), 
which possibly resulted in a decrease of target gene expression, but that another mechanism, 
which led to superactivation on the isolated 4 x GRE elements and possibly affected fkbp5 
expression, took place in parallel. 
4.10.1.3 Potential mechanisms of glucocorticoid signaling disruption by Stanozolol 
Disruption of Cortisol biosynthesis 
According to the cited literature, Stano may have interfered with the steroidogenesis pathway 
via interactions with several of the involved enzymes (section 4.4.1.1). It could have inhibited 
17α-hydroxylase via competitive binding and thereby blocked the production of Cort (Lambert et 
al. 1986; Nakajin et al. 1989). As described already for the progestins (section 4.9.3), Stano could 
possibly compete with Preg and Prog for enzyme binding due its structural similarity with the 
two progestogens and, thus, decrease the amount of active 17α-hydroxylase available for the 
downstream synthesis of Cort. 
Another option is that Stano induced the activity of aromatase, as it was described by Sirianni 
and collegues (2012) and, thereby, increased the production of estrogens (Estradiol) from 
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endogenous androgens in larvae. As it will be discussed below (in chapter 4.11) in more detail, 
estrogens are also potential disruptors of the Cort biosynthesis pathway. 
 
Superactivation of the 4 x GRE:Luc reporter in vivo 
Regarding the observed superactivation of the 4 x GRE:Luc reporter, it may be possible that the 
Stano-liganded AR interacted context-specifically (section 4.3.2) with the (isolated) 4 x GRE in the 
transgenic larvae due to close similarity between the hormone responsive elements (HREs) of 
the two receptors. This potency for overlapping specificities between these two steroid 
hormone receptors to bind to the transgenic reporter construct leaves space for speculations. 
Three imaginable scenarios are discussed below: 
 
Option 1 
The AR can activate transcription via the the 4 x GRE with more potency than the GR, and induce 
the expression of the luciferase reporter gene, which leads to a stronger bioluminescent signal 
than the Dex- or Preg-liganded GR. However, experiments assessing the ability of androgens to 
activate the 4 x GRE reporter when they were exposed alone showed no signal induction. This 
lack of induction was observed for Stano in larvae (Figure 33a), for DHEA (endogenous 
androgen) in cells (see appendix, Supplementary Figure V) and for Methyltestosterone, 
Trenbolone (both synthetic androgens) and 11-Ketotestosterone (major endogenous androgen 
in fish) in larvae and cells (data not shown). As already described in the results part (3.2.2.2), the 
observed superactivation by Stano (and Gestri, Nor, Ethi and Spiro) apparently needs the 
presence of a GR agonist. Therefore, option 1 is rather unlikely. 
 
Option 2 
The GC-liganded GR activated the artificial 4 x GRE, but the presence of Stano may have 
stabilized the GR. For instance, Stano could have prevented homologous downregulation of GRα 
which can be expected upon GC treatment and which, in this study, may be assumed to underlie 
the normally observable signal decrease in the GRIZLY assay after 10 - 14 h in GC-exposed larvae 
(see section 4.4.2.4). As it was clearly visible from the bioluminescent traces of Stano + Dex 
(Figure 32 s), the induced signal remained on a plateau between 10 and 14 h and then, instead 
of the normal decrease, a second and stronger increase was observed. The For Stano + Preg, not 
such a distinct plateau was observable between 10 and 14 h but instead; the signal appeared to 
continuously increase up to 16 - 18 h and then remained on a constant level until the end of the 
measurement (Figure 32 t). Both kinetics may suggest an extendedtranscriptional activation of 
the receptor on the luciferase reporter gene via the 4 x GRE. Potentially, prevention of 
homologous downregulation or even upregulation of GRα by Stano increased the amount of 
active receptors; an idea that would be supported by the increased GR concentrations observed 
by Fernández et al. (1995) in rat liver microsomes upon incubation with Stano + [3H] Dex. 
 
Option 3 
Although Stano superactivated Dex- and Preg-stimulated GC in the GRIZLY assay, this 
overstimulation was not mirrored for Preg + Stano in the UPLC-MS/MS and qPCR experiments. 
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Instead, reduced Cort production was measured in Preg-treated larvae upon co-exposure with 
Stano, accompanied by decreased GC target gene expression. As 26% of the control amount of 
Cort (Preg + DMSO, 100 %) were produced with Preg + Stano, the Cort production was not 
completely blocked and the remaining amount probably sufficed to induce transcriptional 
activity at the 4 x GRE. This consideration leads to option 3, where the GC-liganded GR regularly 
activated the 4 x GRE, but the Stano-liganded AR took over and further activated the 4 x GRE 
when either GRα started to decrease (probably due to homologous downregulation) or when 
the available amount of Cort was limiting in case of Preg + Stano. Thereby, an extended and 
overinduced GRIZLY signal could be expected, as it was visible in Figure 32 s + t. 
A possible explanation for this observation might be that the liganded AR binds to the artificial 
4 x GRE and thereby induces the expression of the luciferase reporter gene. As it was discussed 
above for the group of progestins (section 4.9.2), initial chromatin binding of the activated GR 
may have induced chromatin remodeling in the regulatory sequence, whereby the accessibility 
of DNA binding sites for other nuclear receptors such as the AR could have been increased 
(Cohen and Steger 2017; Goldstein et al. 2017; Petta et al. 2016). 
 
Suppression of the 4 x GRE:Luc reporter in vitro 
Surprisingly, Stano showed no superactivation in the GRIZLY assay in cells as it showed larvae. In 
GRIZLY 1, it inhibited GC signaling, although some interaction between the artificial 4 x GRE, GR, 
Stano and AR could equally have been possible in vitro. As Stano is orally active and its first-pass 
metabolism within the liver is sterically hindered by the 17α-alkyl group (Kicman 2008), no 
metabolic activation within the larvae is likely to explain these discrepancies and a similar 
compound behavior in vitro and in vivo could be expected. However, also here, the different 
physiological context (section 4.3.2) between in vitro and in vivo exposure may have played an 
important role, which possibly enabled an antagonistic effect of Stano on the GR, leading to 
inhibition of 4 x GRE:Luc reporter gene transcription. Possibly, due to the more direct chemical 
exposure in cells than in larvae, much higher compound concentrations may reach the cells 
which maybe allowed for competitive binding of the androgen to the GR, leading to receptor 
antagonism in vitro.  
4.10.1.4 Next steps 
In order to follow up on the considered mechanisms of GC signaling disruption by Stano, 
measurements of the expression levels of both GR isoforms will help to substantiate the 
hypothesis of an inhibited homologous downregulation or an induced expression of GRα by 
Stano (option 2). In case that option 2 cannot be confirmed, transcriptional activation of the 
4 x GRE:Luc reporter via the AR (option 3) may be true. To validate this, co-treatment 
experiments of transgenic larvae with Dex/ Preg + Stano in combination with a specific AR 
antagonist (such as Flutamide) could be useful, as the GRIZLY signal should be reduced by the 
antagonist if the AR plays a role (when compared to the Dex/Preg + Stano control). In addition, 
ChIP (Chromatin ImmunoPrecipitation) experiments with the reporter sequence will help to 
identify the receptors and cofactors that bind to the GRE element under the applied treatment 
conditions. By means of this, it can be verified if the AR is indeed involved in the observed effect 
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and it can possibly be pinpointed which cofactors contributed to the superactivation of the 
4 x GRE:Luc reporter.  
4.10.2 Spironolactone 
4.10.2.1 The biological functions of Spironolactone and its mechanisms of action 
Spiro is a synthetic steroid and a prodrug that has been marketed since 1959 for several medical 
applications including the treatment of high blood pressure, heart failure, low potassium, 
transgender hormone therapy, edema, hepatic cirrhosis and kidney disease. It is a member of 
the steroidal group of spirolactones, to which also Canrenone, Canrenoate (both major 
metabolites of Spiro), Potassium Canrenoate (Canrenoate-K; also a prodrug), Eplerenone and 
Drospirenone belong. All spirolactones are antagonists of the MR and some also possess 
progestogenic and/ or antiandrogenic properties. Spiro antagonizes the MR with high potency 
(Fagart et al. 2010; Kolkhof and Bärfacker 2017) and can also interfere with AR (anti-androgen; 
mechanisms include relatively strong AR antagonistic potential) (Bonne and Raynaud 1974; 
Luthy, Begin, and Labrie 1988; Rathnayake and Sinclair 2010), ER (mixed agonist and antagonist) 
(Levy et al. 1980), PR (agonist) (Sabbadin et al. 2016), GR (antagonist) (Campen and Fanestil 
1982; Couette et al. 1992; Kolkhof and Bärfacker 2017) and PXR (agonist) (Cheng et al. 1976; 
Pelkonen et al. 1998) activity. However, after administration, the prodrug Spiro is converted in 
vivo and exerts its pharmacological effects majorly via its three major active metabolites: 7α-
thiomethyl-spironolactone (TMS), 6β-hydroxy-7α-thiomethyl-spirono-lactone (HTMS) and 
Canrenone (Gardiner et al. 1989; Garthwaite and McMahon 2004; Karim 1978; Kolkhof and 
Bärfacker 2017), with TMS being the major metabolite (Karim 1978). Thus, the effect profiles for 
Spiro on the respective nuclear receptors may differ in vivo, depending on the metabolization 
state of the drug (Gardiner et al. 1989; Garthwaite and McMahon 2004; Karim 1978; Kolkhof and 
Bärfacker 2017). 
 
The potential of Spironolactone to interfere with GR signaling 
As specified above, Spiro can interact with many types of nuclear steroid hormone receptors, 
but the affinity for a certain receptor may be different for its metabolites. The pharmacological 
in vivo effects of Spiro are described in numerous publications, but unfortunately it is often not 
clear if the parent or an intermediate product exerts the observed effects (Kolkhof and Bärfacker 
2017). 
Campen & Fanestil published 1982 that Spiro showed a threefold higher affinity for the GR than 
Dex in rat hepatoma tissue culture (HTC) cells and that it was a potent full antagonist of Dex-
induced tyrosine aminotransferase (TAT) enzyme activity in whole rat cells. Also in vivo, the 
researchers showed that Spiro completely inhibited Dex-induced enzyme activity in 
adrenalectomized rats. They concluded from these findings that Spiro is a GR antagonist but that 
it lacked GR agonist activity. This is in accordance with other publications assessing the effects of 
Spiro, where antagonism (Couette et al. 1992; Kolkhof & Bärfacker 2017), but not agonism of the 
compound was described for the GR.  
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The potential of Spironolactone to disrupt the Cortisol biosynthesis pathway 
Spiro and/ or its metabolites can inhibit diverse steroidogenic enzymes including 11β-
hydroxylase, 17α-hydroxylase and 17,20-lyase (Cheng et al. 1976; Colby 1981; Helfer, Miller, and 
Rose 1988; Menard et al. 1974; Rourke et al. 1991). For instance, Spiro inhibited the activity of 
adrenal 17α-hydroxylase in guinea pigs and dogs (Menard et al. 1974). Also, Kossor and 
collegues (1991) observed in guinea pig adrenal microsomes that Spiro is converted by 17α-
hydroxylase into the reactive metabolite 7α-thio-spironolactone. The researchers further 
described a mechanism-based inhibition of 17α-hydroxylase within this metabolization step as 
Spiro binds competitively to the enzyme and thereby reduces its availability for functions within 
the steroidogenesis pathway. 
 
More recent publications are available describing the effects of the Drospirenone, a member of 
the spirolactone group that was derived from Spiro and which is a potent PR agonist. For 
instance, as already mentioned in the chapter discussing progestin effects (section 4.9.3), in one 
study, Drospirenone increased the levels of Preg, Prog and 17α-hydroxyprogesterone in an 
adrenal cell line (H295R) and reduced the activity of CYP17A1 (17α-hydroxylase, 17,20-lyase) and 
3β-HSD in COS-1 cells transfected with human CYP17A1 or 3β-HSD (Louw-du Toit et al. 2017). In 
in vitro experiments, Drospirenone was shown to inhibit 17,20-lyase in carp gonads (Fernandes 
et al. 2014). Furthermore, in a human study with women carrying an implant containing 
Drospirenone, reduced ratios of 17α-hydroxyprogesterone to Prog were measured and reduced 
activities of 17α-hydroxylase and 17,20-lyase were reasoned by De Leo and collegues(2007), 
which correlates with the results from the above mentioned in vitro studies. 
4.10.2.2 The effects of Spironolactone within the present study 
In the GRIZLY assay, Spiro showed the same effects as Stano, as it inhibited GC signaling in vitro, 
but superactivated the Dex- and Preg-induced signal in vivo. Chemical analysis revealed no 
alteration of the larvae-internal Dex concentration, but in Preg-treated larvae, the amount of 
Cort was slightly reduced while Preg and Prog levels tended to be elevated. Thereby, a disrupted 
Cort biosynthesis was suggested. 
The qPCR data for Dex-treated larvae showed that Spiro decreased solely the expression of 
hsd11b2, which is in contrast to the co-inductive effect within GRIZLY 2. However, although the 
hsd11b2mRNA levels were significantly reduced compared to the negative control (Dex + DMSO) 
due to low variations between the replicates, the effect was not very pronounced,with a gene 
expression ratio of 0.86. 
The qPCR results for larvae treated with Preg + Spiro revealed the same pattern as for 
Preg + Stano, the mRNA levels of all Cort target genes were reduced, except for fkbp5, which was 
not altered. The expression ratio of hsd11b2 (0.62) and gilz (0.69) was significantly and 
moderately decreased, possibly due to the reduced Cort production. The expression ratios of the 
two xenometabolic marker genes cyp3a65 (0.25) and cyp1a1 (0.34) showed stronger 
suppression by Spiro, suggesting an inhibitory effect of the compound on xenometabolic 
enzymes. Regarding the non-reduced expression of fkbp5, another mechanism of action might 
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have compensated for the lacking Cort, as it was hypothesized above for Stano. This mechanism 
might also be involved in the superactivation of GC signaling in GRIZLY 2 and GRIZLY 3.  
In summary, the effects of Spiro among the different assays are heterogenous, which suggests 
complex interactions of Spiro and/ or several metabolites with the GC system, possibly involving 
different mechanisms of action which may compensate themselves. 
4.10.2.3 Potential mechanisms of glucocorticoid signaling disruption by Spironolactone 
As Spiro can be endogenously converted into diverse active metabolites, it is not clear if the 
Spiro-triggered responses within the present study were induced by the compound itself or by 
one of its metabolites (e.g. TMS, HTMS, Canrenone). However, the differing response of cells 
and larvae to Spiro treatment may indicate that the compound was metabolized in vivo and, 
thus, acted via different mechanisms in larvae than in cells.  
 
GR antagonism in vitro 
The concentration-dependent signal inhibition in GRIZLY 1 and the above mentioned literature 
describing GR antagonism by Spiro (Campen and Fanestil 1982; Couette et al. 1992; Kolkhof and 
Bärfacker 2017) allow me to assume that the compound antagonized the GR in vitro. It appears 
likely that Spiro was not converted into metabolites in the cells, due to lacking metabolic 
enzymes, and had itself, as a prodrug, an antagonistic effect on GR signaling. This antagonism 
possibly occurred context-specifically (4.3.2) within this cellular environment, where a relatively 
high amount of Spiro may have entered the cells.  
 
In vivo transformation into an active metabolite with different effect mechanisms  
In larvae, Spiro may have been converted into a metabolite with a different behavior, which led 
to the superactivation of GC signaling according to the results of GRIZLY 2 and GRIZLY 3. The 
above cited literature implying interactions of Spiro and/or its metabolites with diverse nuclear receptors allow 
speculations about partial agonism of the metabolite on one of these receptors to be involved in 
the in vivo effect. 
Interestingly, the active metabolite Canrenone was also a compound contained in the FDA 
library (screen concentration 11.7 µM), but its effects did not reach statistical significance due to 
the stringent cut-off criteria of p < α < 0.0001 and the compound was therefore not considered a 
screen hit. However, Canrenone strongly superactivated GC signaling in both in vivo screens, in 
co-exposure with Dex (Mean rel. AUC = 386.25; p-value = 0.004) and with Preg (Mean rel. 
AUC = 297.46; p-value = 0.009). In vitro, it had no effect (Mean rel. AUC = 127; p-value = 0.08) in 
the GRIZLY assay. These findings strongly support my argumentation that Spiro was not 
metabolized in vitro and inhibited GC signaling in the cells as a prodrug (via GR antagonism), 
while it was metabolized in vivo (metabolic activation, section 4.3.1), where the metabolite 
induced superactivation in GRIZLY 2 and GRIZLY 3. From the close similarity of the in vivo effects 
measured for Spiro and Canrenone, it appears likely that Spiro was converted into the active 
metabolite Canrenone in the larvae, which exerted the GRIZLY effect.  
 
Superactivation of the 4 x GRE:Lucreporter in vivo 
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Regarding the in vivo effects of Spiro treatment, as before for Stano, different options can be 
proposed to explain the superactivation in the GRIZLY assay and the heterogeneous behavior 
inGRIZLY, UPLC-MS/MS and PCR experiments: 
 
Option 1 
Possibly, the active metabolite of Spiro was able to bind to the GR and to activate the 4 x GRE 
reporter construct, once the chromatin structure was opened by Dex or Cort (as it was also 
considered for the progestins (section 4.9.2) and for Stano (section 4.10.1.3). Apparently, this 
was not possible within the promotor regions of the selected endogenous target genes, as they 
were not transcriptionally upregulated by Spiro. Maybe, as it was already discussed for the 
superactivating effect of Stano in the in vivo assays (4.10.1.3; option 2 and 3), the observed 
overinduction of the GRIZLY signal is enabled within the regulatory region of the 4 x GRE:Luc 
reporter due to context-specific (section 4.3.2) availabilities of coactivators and corepressors, 
but not within natural GREs, which lead to the dissimilar outcomes of transcriptional activity 
within the 4 x GRE:Luc reporter and the examined endogenous target genes of Dex and Cort. 
 
Option 2 
Alternatively, the metabolite of Spiro was able to activate the 4 x GRE reporter construct and 
endogenous GC target gene expression, but on Dex target genes this was not identified due to 
different mechanisms of action, counteracting the inductive effect context-specifically (4.3.2). 
The reduced Cort production and the downregulation of Preg- but not of Dex-target genes 
support such opposing effects, which will be discussed in detail within the next paragraphs. 
 
Disruption of Cortisol biosynthesis 
The reduced Cort levels in larvae treated with Preg + Spiro that were measured by UPLC-MS/MS 
are in accordance with the literature mentioned above (Cheng et al. 1976; Menard et al. 1974; 
Rourke et al. 1991; Helfer et al. 1988; Kossor et al. 1991; Louw-du Toit et al. 2017; Fernandes et 
al. 2014; De Leo et al. 2007), where Spiro (or an active metabolite of it) was described to 
interfere with steroidogenic enzymes. Spiro or the metabolite most likely disrupted the 
biosynthesis of Cort (section 4.4.1.1) in Preg-treated larvae within the present study. The steroid 
level profile indicates an accumulation of Preg and Prog, which may narrow the point of 
inhibition down to 17α-hydroxylase (see the steroid biosynthesis pathway in Figure 3). The 
findings from Kossor and collegues (1991) mentioned above support the idea that Canrenone is 
the active agent and that 17α-hydroxylase is the point of steroidogenesis disruption. However, 
also additional inhibitory effects on other steroidogenic enzymes, i.e. on 11β-hydroxylase could 
be possible. 
 
However, Spiro may also have altered the larvae-internal levels of Preg, Prog and Cort via 
another mechanism. As one of the major mechanisms of action described for Spiro and its 
metabolites is MR antagonism  (Fagart et al. 2010; Kolkhof and Bärfacker 2017), it could be 
expected that MR antagonism (similar to GR antagonism) initiates a positive feedback loop via 
the HPA axis (at least in mammals), which induces the de novo Cort production in order to 
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produce more ligands that can activate the MR. Accordingly, an increased Cort level could be 
anticipated in the larvae, which would provide a possible explanation for the observed 
superactivation in both in vivo assays. As instead the opposite effect, a tendency for reduced 
Cort was found in larvae treated with Preg + Spiro, the impacts of a decreased Cort biosynthesis 
due to inhibition of steroidogenic enzymes and of a stimulated de novo Cort production via the 
HPI-axis may possibly have compensated each other. This interplay may have led to the 
observed increased levels of Preg and Prog and the decrease of Cort, which was less pronounced 
than it was observed with other putative inhibitors of the steroid biosynthese pathway within 
this study (e.g. Mety, Gestri, Nor). 
In larvae treated with Dex + Spiro, changes of the endogenous Cort level could not be detected 
due to sensitivity limitations of the UPLC-MS/MS system. However, here, an induced Cort 
production due to MR antagonism would probably be counteracted by the effect of Dex on the 
GR, as GR agonism is known to decrease the endogenous Cort production via a negative 
feedback mechanism. As an outcome, in larvae treated with Dex + Spiro, the Cort level would 
probably not be noticeably altered. 
 
Effects on target gene expression 
The trend for reduced Cort production in larvae treated with Preg + Spiro probably explains the 
decreased mRNA levels of the Cort target genes hsd11b2, gilz, cyp3a65 and cyp1a1. The only 
target that was not altered by Spiro is fkbp5, which might be explained by the fact that this gene 
was the most sensitive of the Cort targets, whose expression was possibly strongly upregulated, 
even with a reduced amount of Cort. 
For Dex + Spiro, the qPCR results are less easily interpretable, as hsd11b2 was the only 
downregulated target, with a significantly but not very pronounced decreased gene expression 
ratio of 0.86. It may be considered that Spiro affected the steroidogenesis pathway in Dex-
treated larvae similarly to what was assumed with Preg, but as the steroid levels were not 
quantifiable under these treatment conditions, no clear indications are given. Still, the 
downregulation of hsd11b2 may suggest a decreased Cort production, as a reduced synthesis of 
the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) might result from lower Cort 
mediated stimulation of expression.  
 
As described in section 4.4.1.2 (Ferrari 2010; Leckie et al. 1998; Mune et al. 1995; White et al. 
1997), 11β-HSD2 plays an important role for GC and mineralocorticoid signaling, because the 
enzyme prevents MR activation by Cort within mineralocorticoid target tissues. If 11β-HSD2 is 
inhibited, the ratio of Cort to Cortisone increases and the half-life of Cort may be prolonged, 
which would lead to Cort-induced mineralocorticoid effects, as it was observed in humans 
(Ferrari 2010). Downregulation of hsd11b2 is the only common feature between the gene 
expression patterns from larvae treated with Dex + Spiro and Preg + Spiro and none of the other 
GRIZLY superactivators found in the FDA library significantly suppressed the Dex-induced 
transcription of hsd11b2 (only Gestri showed a trend). Hence I wondered if the effect on 
hsd11b2 might be specific for Spiro treatment, wherein MR antagonism possibly plays a role.  
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4.10.2.4 Next steps 
According to the heterogeneous effects of Spiro, complex compound and metabolite 
interactions with the GC system were suggested and discussed above, but substantial future 
work will be necessary to investigate the underlying mechanisms of action. In the first step, 
larvae and cell exposure to important active metabolites of Spiro (such as Canrenone, TMS, 
HTMS,) and assessment of their effects within GRIZLY, UPLC-MS/MS and qPCR experiments will 
enable to allocate the effect origin. Possibly, certain mechanisms of action can be assigned to 
single metabolites. 
Once the metabolites responsible for the discussed mechanisms are identified, GR activity can 
be measured under diverse treatment combinations by in vitro receptor binding studies. In 
addition, ChIP experiments of the 4 x GRE reporter gene sequence can be conducted, which will 
enable to identify the receptors and cofactors that bind to the sequence under diverse 
treatment combinations.  
In order to pursue if steroidogenic enzymes are affected, the production rate of Spiro 
metabolites can be quantified relative to that endogenous metabolites by UPLC-MS/MS and the 
enzyme activity of selected enzymes can be quantified spectrophotometrically. For instance, in 
order to follow up on a potential competitive inhibition of 17α-hydroxylase by Spiro, the activity 
of 17α-hydroxylase could be assessed by comparing the endogenous metabolization rate for 
Preg to 17α-hydroxypregnenolone with that of Spiro to 7α-thio-spironolactone. 
Furthermore, as the applied UPLC-MS/MS technique was not sensitive enough to quantify Cort 
levels in Dex-treated larvae, alterations of the endogenous Cort production by Spiro could be 
measured in future experiments via gene expression analysis of the pomc gene, where 
upregulation of the genewould indicate elevated ACTH activity and induced Cort production.   
4.11 Natural estrogens and androgens 
 
Figure 51: Natural estrogens and androgens  (extract from Figure 45)  
4.11.1 The biological functions of Estrone, Estriol and dehydroepiandrosterone (DHEA) 
and their mechanisms of action 
Estrone and Estriol 
Estrone (E1) and Estriol (E2) are natural estrogens with relatively weak agonistic potentials for 
the ER, when compared to the third and most potent natural estrogen Estradiol (E3). In humans, 
distinctly lower binding affinities and transactivation capacities of Estriol relative to Estradiol 
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were found in vitrofor ERα (11.3% and 10.6%) and ERβ (17.6% and 16.6%). For Estrone, even 
lower relative binding affinities and transactivation capacities for ERα (4% and 2.6%) and ERβ 
(3.5% and 4.3%) were measured in the same study (Escande et al. 2006). However, Estrone, but 
not Estriol, can be metabolized into Estradiol (for an overview of the steroid hormone 
biosynthesis pathway see Figure 3), which mediates most of the estrogenic in vivo potency of 
Estrone (Kuhl 2005). Both compounds can be applied in hormone replacement therapies for 
menopausal symptoms, but nowadays, Estrone has been replaced by more potent estrogens. 
(Nabulsi et al. 1993; Ross et al. 2000) 
 
DHEA 
DHEA is a natural androgen that serves as a hormonal biosynthetic precursor without an active 
role on its own. It is metabolized by 3β-HSD and additional specific steroidogenic enzymes into 
other androgens (e.g. Testosterone, the major androgen in humans; Dihydrotestosterone (DHT) 
and androstenedione)or into estrogens (Miller 2002). In the latter case, DHEA is first converted 
into Estrone, then into Estradiol (see Figure 3), which is why it finds also medical application in 
hormone replacement therapies for menopause (Labrie et al. 1998). Additionally, it is 
occasionally prescribed for the treatment of adrenal insufficiency in combination with the 
standard medication of Cort and synthetic mineralocorticoids (e.g. Fludrocortisone) in order to 
restore the steroid levels normally produced by the zona reticularis (Alkatib et al. 2009; Allolio et 
al. 2007; Gurnell et al. 2008). 
 
The potential of estrogens and DHEA to interfere with GR signaling 
For DHEA, antiglucocorticoid properties are often described in the available literature. For 
instance, research investigating the posttraumatic stress disorder (PTSD), a disease that is 
associated with HPA axis and immune function alterations, revealed a close correlation between 
endogenous levels of Cort and DHEA (Olff et al. 2007). In this disease, increased DHEA and 
decreased Cort levels, in combination with an induced production of the proinflammatory 
cytokines TNF-α and IL-6 are often found in human patients (Gill, Vythilingam, and Page 2008). In 
human depressed patients, decreased Cort : DHEA ratios (when compared to healthy controls) 
can be measured, which result from the antiglucocorticoid effects of DHEA, as the androgen 
precursor protects the organism from adverse effects of Cort overexpression (Young, Gallagher, 
and Porter 2002). However, the molecular mechanisms underlying the antiglucocorticoid 
properties of DHEA appear to be not yet completely understood. Although Kalimi et al. (1994) 
described more than two decades ago that DHEA mediates its antiglucocorticoid effects by 
modulating the GR, as they observed downregulation of GR expression in rat liver upon DHEA 
treatment, publications investigating this mechanism of action in more detail appear to be 
limited.  
Quite recently, the group of Pinto and collegues (2015) found out that DHEA dose-dependently 
induced the mRNA expression of GRβ, while GRα levels remained constant in a THP1 monocytic 
cell line. They concluded that the antiglucocorticoid effect of DHEA on the expression of proteins 
related to GC signaling may be caused by the decreased GRα : GRβ ratio that inhibits GRα activity 
(as it was described in section 4.4.2.3).  
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Also Estrogens have been characterized to interfere with GR signaling in mammals (Heitzer et al. 
2007). For instance, it was observed in a human model breast cancer cell line (MCF-7) that 
treatment with the ER agonists Estradiol, Diethylstilbestrol and Genistein modulated 
transcriptional regulation of GR expression. The ligand-bound ER inhibited the induction of 
mRNA and protein levels of the GR. The researchers concluded from these and from additional 
data that ER agonists downregulate the GR via the proteasomal degradation pathway (descibed 
e.g. by Kinyamu & Archer 2003 and Calligé & Richard-Foy 2006), which is a mechanism related to 
posttranslational modification (section 4.4.2.2). Also, interference of estrogens with the activity 
of 11β-HSD2 (section 4.4.1.2) has been reported for several in vivo and in vitro studies, 
suggesting this enzyme to be a main regulator of estrogen-mediated disruption of GC signaling 
(Tremblay et al. 1999). 
 
The potential of estrogens and DHEA to disrupt the Cortisol biosynthesis pathway 
It was already described for the progestins (section 4.9.3), for Stano (section 4.10.1.3) and for 
Spiro (section 4.10.2.3), which are structurally very similar to endogenous progestogens or 
androgens, that they can competitively bind to enzymes within the steroidogenesis pathway and 
decrease the enzyme functionality for the production of Cort (Africander et al. 2011 and Louw-
du Toit et al. 2017). Likewise, also DHEA can possibly inhibit the Cort synthesis, as the androgen 
is naturally converted into Androstenedione by 3β-HSD, the key enzyme involved in the 
biosynthesis of practically all steroids (see Figure 3). Thus, if this enzyme is majorly occupied by 
DHEA, the conversion of Preg into Prog and of 17α-hydroxypregnenolone into 17α-
hydroxyprogesterone by 3β-HSD may be reduced, which can disturb all downstream synthesis 
steps.  
Similarly, also the estrogens could competitively bind to steroidogenic enzymes and thereby 
disrupt the Cort biosynthesis. For instance, one research group investigated the impact of 
flavonoid phytochemicals on the production of Cort and on the activity of several steroidogenic 
enzymes (Ohno et al. 2002, 2004). They found out that several flavonoid phytochemicals, among 
those genistein, a phytoestrogen and a potent ER agonist, significantly decreased the synthesis 
of Cort in human adrenocortical H295R cells. Furthermore, Genistein and other flavonoids 
significantly inhibited the activity of 3β-HSD and 21-hydroxylase, two enzymes which are 
necessary for the conversion of Preg to Cort (see Figure 3). Genistein and Daidzein were shown 
to be competitive inhibitors of 3β-HSD. Also other steroidogenic enzymes were blocked by some 
flavonoid phytochemicals, for instance 6-hydroxyflavone inhibited the activity of CYP17A1 and 
11β-hydroxylase. 
Likewise, the estrogenic potential to inhibit 3β-HSD was described by another study, in which 
Estradiol significantly reduced the activity of this enzyme and, thus, prevented the 
metabolization of DHEA into Androstenedione within the brain of adult zebra finch (songbird; 
Taeniopygia guttata) (Pradhan, Yu, and Soma 2008). 
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4.11.2 The effects of Estrone, Estriol and DHEA within the present study 
Within the present study, all three natural sex hormones inhibited Preg-induced GC signaling in 
vivo. Estrone and DHEA furthermore decreased the activity of Dex in GRIZLY 1, but at higher 
concentrations than which were significantly effective in GRIZLY 3 [each 4 µM]. In GRIZLY 1, 
Estrone [8 µM] reduced the signal down to 50 - 80% and DHEA [20 µM] led to 70 - 95% of 
maximal GC signaling activity, as it was described for Figure 36 b and f. 
Their impact in GRIZLY 3 was more pronounced, as here both compounds inhibited Preg-induced 
signaling more or less completely, with no remaining signal intensitiy with Estrone (Figure 36 d) 
and 5 - 35% of the maximal activity with DHEA (Figure 36 h). In order to demonstrate a clear 
concentration-dependency of their inhibitory effects, retests with lower concentrations of both 
compounds were conducted, which showed a LOEC of 0.25 µM for Estrone and of 4 µM for 
DHEA (both in in appendix, Supplementary  Figure II). The inhibitory effect of Estriol in GRIZLY 3, 
although significant, was not that pronounced, as the estrogen only led to a signal decrease 
down to 50 - 80% of the maximal activity of Preg (Figure 37 h), even though it was applied in a 
three-fold higher concentration [12 µM] than Estrone and DHEA. 
4.11.3 Potential mechanisms of glucocorticoid signaling disruption by of Estrone, Estriol and 
DHEA 
In vivo 
Interestingly, the extent of signal inhibition by each compound correlates well with the data 
obtained by UPLC-MS/MS experiments. All three substances significantly disrupted the 
biosynthesis of Cort (section 4.4.1.1), but while with Estrone only 3% of the total amount of 
Preg-derived Cort (Preg + DMSO control = 100%) were produced, and with DHEA only 5%, Estriol 
still allowed 57% of the maximal amount of Cort to be synthesized. From this correlation, a 
dependency of the strength of the GRIZLY 3 response (Preg-induced signal inhibition: Estrone [4 
µM] > DHEA [4 µM] >>> Estriol [12 µM]) on the respective fraction of produced Cort (Inhibition 
of Cort production: Estrone [4 µM] > DHEA [4 µM] >>> Estriol [12 µM]) is clearly noticeable. This 
correlation strongly suggests a disrupted steroidogenesis to be the mechanism underlying the 
signal inhibition in GRIZLY 3 by Estrone, Estriol and DHEA. DHEA potentially competed with Preg 
for the binding and the enzymatic activity of 3β-HSD, whereby the Cort biosynthesis pathway 
was disrupted. Estrone (or Estradiol, as Estrone could have been metabolized into this more 
potent estrogen) and Estriol may also have inhibited 3β-HSD, or potentially also other enzymes 
such as 21-hydroxylase, like it was already described for Genistein and Estradiol (Ohno et al. 
2002, 2004; Pradhan et al. 2008). 
 
Also qPCR analysis data correlate highly with GRIZLY 3 and UHPLC-MS/MS results, as Estrone 
treatment resulted in the strongest, DHEA in a slightly weaker and Estriol in the weakest 
downregulation of Preg-induced target genes (Estrone [4 µM] > DHEA [4 µM] >>> Estriol 
[12 µM]), as visible in detail in Figure 44.I(with cyp3a65 being the only exception, as its 
expression was comparably low with Estrone and Estriol, but not suppressed by DHEA). 
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A possible reason for the different effect magnitudes of Estrone, DHEA and Estriol may be that 
Estrone and DHEA were converted into the more potent estrogen Estradiol (metabolic 
activation, section 4.3.1), which may have exerted the disruption of Cort biosynthesis, 
whereupon the Preg-stimulated GRIZLY signal and target gene expression was suppressed. 
Estriol, in contrast, could not be metabolized to Estradiol and had, thus, a weaker inhibitory 
effect due to the lower potency of this estrogen. Alternatively, also without metabolic 
transformation, natural Estrone, DHEA and Estriol may have had different potencies to disrupt 
the steroidogenesis pathway. Moreover, they could have been taken up by the larvae to 
different degrees. 
 
In vitro 
Estriol, the compound with the apparently lowest capability to disrupt the synthesis of Cort in 
vivo, was also the only candidate out of the three sex steroid hormones which had no effect in 
GRIZLY 1. As the other two substances reduced GC signaling in vitro at higher concentrations, 
they appear to have partly antagonistic properties on the GR, possibly due to a particular cellular 
context (section 4.3.2), which may have enabled a specific mechanism of GR signaling disruption 
(section 4.4.2). 
Similarly to this, inhibition of GC signaling in GRIZLY 1 was observed before for several other 
ligands of steroid hormone receptors within the present study, as also Nor, Spiro and Stano 
inhibited GC signaling in vitro at higher concentrations and Gestri at the same concentration that 
had co-activating effects in vivo in GRIZLY 2. It may be assumed that all these steroidal ligands 
(including GCs) are generally available in higher concentrations in vitro than in vivo, as an 
increased uptake of the compounds by the cells is likely, due to a lower number of transport 
barriers to pass and more limited metabolic capabilities of cells compared to the whole organism 
by the cells. Accordingly, due to this specific cellular context (section 4.3.2), there might be a 
higher chance for the steroids to unspecifically bind to the GR, whereby they could partly 
compete with GCs or otherwise cause the observed (partial) antagonistic effects. However, it has 
to be noted the antagonism of each compound is still relatively weak when compared to the 
potent GR antagonist Mife. 
 
The higher antagonistic potential of Estrone over DHEA and Estriol (Estrone [8 µM] > DHEA [20 
µM] >>> Estriol [-]) in vitro may also suggest that within the in vivo experiments of this study, a 
variable uptake of the compounds or diverse potencies of the natural steroid hormones to 
interfere with GC signaling (i.e. to disrupt the Cort biosynthesis) may rather underlie the 
different effect strengths of the compounds than a potential metabolization of Estrone and 
DHEA into Estradiol, which is restricted to steroidogenic tissues (i.e. the adrenal gland) and 
could, thus, not have occurred within the AB.9-GRE:Luc cells.  
4.11.4 Future steps 
The present results indicate that Estrone, Estriol and DHEA disrupted the biosynthesis of Cort. In 
order to further validate this hypothesis, it is necessary to assess if Estrone and DHEA exerted 
their effects themselves or whether the compounds were converted into Estradiol or other 
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metabolites, which were responsible for the in vivo activity. For this, Estradiol will be co-treated 
with Dex/ Preg and the effects of these exposure combinations in GRIZLY, UPLC-MS/MS and 
qPCR experiments will be compared with the results for Estrone and DHEA. Furthermore, the 
endogenous levels of Estradiol under all exposure conditions will be assessed via UPLC-MS/MS. 
Once the effect origin is clarified, also the precise point of inhibition can be located by chemical 
analysis, testing for accumulation and deficiency of metabolites directly serving as substrates 
and products of a specific steroidogenic enzyme (e.g. accumulation of DHEA and deficiency of 
Androstenedione would indicate inhibition of 3β-HSD). In addition, the activity of the 
presumably affected enzyme can be quantified, for instance in application of a photometrical in 
vivo assay. Moreover, regarding the putative partial GR antagonism by Estrone and DHEA in 
vitro, receptor binding studies and measurements of GRα : GRβ levels should help to verify this 
speculation. 
4.12 Conclusion and future perspectives 
The GRIZLY assay served as a reliable, easy and fast tool to identify compounds that interfere 
with GC signaling via diverse pathways and enabled to select from a large library of substances a 
few candidates of high interest. The parallel application of both the cell and larvae system 
allowed furthermore to differentiate between in vitro and in vivo effects, while the comparison 
between direct and indirect stimulation of GC signaling in vivo served the pre-categorization of 
underlying effect-mechanisms and suggested promising follow-up studies. By means of 
concentration-dependent retesting, the identified hits were confirmed and high reliability of the 
GRIZLY results was demonstrated. According to the first aim of this study, the GRIZLY assay has 
been proven to be a suitable tool for the detection of GC signaling inhibitors. Moreover, it 
enables also the detection of superactivators, i.e. compounds which can increase GC signaling, 
which constitutes an additional useful application of the GRIZLY assay.  
 
The tiered testing approach was a good strategy to systemically extract the candidates of 
interest from a large amount of substances. Identified screen hits were confirmed by 
concentration-dependent retesting. Verified inhibitors and superactivators of the GRIZLY signal 
were then subjected to chemical and gene expression analysis in order to gain more information 
about their putative mechanisms of GC signaling disruption.  
 
The UPLC-MS/MS system robustly detected and validated inhibition of the Cort biosynthesis by 
several compounds and helped to narrow down the point of disruption within the 
steroidogenesis pathway. Thus, it was a very suitable technique to achieve the second aim of 
this study, the identification of GC biosynthesis disruptors. Chemical analysis moreover allowed 
to identify changes in larvae-internal levels of Dex and Preg, which gives indications for 
potentially disrupted drug uptake or -metabolism being possibly the reason for several observed 
compound effects.  
 
Gene expression analysis was beneficial regarding numerous aspects of the effect evaluation. It 
served as an additional validation for the UPLC-MS/MS data, and  the qPCR experiments 
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revealed new information about compound effects on target gene expression. The obtained 
effect spectra expand the information on compound effects and are a highly useful readout for 
future investigations, as they mirror well the potential effect complexity of a drug or pollutant. 
For some compounds, where the spectrum showed consistent effects within all experiments, 
one major mechanism of action is strongly indicated, such as GR antagonism in case of Mife or 
GC biosynthesis disruption in case of Estriol. For other drugs, in contrast, multilayered effects 
were indicated, suggesting several combinational or counteracting mechanisms to occur 
simultaneously. Furthermore, the effect spectra allowed to identify clusters among molecular 
effects of GC signaling disruptors and revealed patterns common to chemical classes of 
compounds. Thus, it enabled the achievement of the third aim of this study, to identify 
compounds with - so far - unknown potential to interfere with GC signaling and with unknown 
mechanisms of action. The obtained results from the tiered testing approach helped me to 
narrow down the mechanisms of action possibly underlying the compound effects and gave me 
ideas which future experiments will be necessary to characterize their mechanisms in detail. 
 
Regarding future applications of the GRIZLY assay for pharmaceutical and environmental risk 
evaluation, especially the possibility for whole-organism assessment in zebrafish larvae provided 
by the assay is a huge advantage when investigating drug effects. The compound bioavailability, 
metabolism, pharmacokinetics and interference with endogenous synthesis pathways are 
implicated in the effect outcomes, as observed within the current study, where the compound 
effects and their interactions with other drugs (natural prehormone Preg and synthetic GC Dex) 
could be assessed regarding their impacts not only on steroid hormone receptor signaling, but 
also on drug pharmacokinetics, drug metabolism, steroidogenesis and target gene transcription.  
Thus, in vivo studies in zebrafish larvae, like the GRIZLY assay, enable us to understand the 
manifold effect mechanisms of pharmaceuticals in the whole organism. This will help to further 
elucidate their - possibly severe - side effects and may increase the comprehension of cell- and 
tissue-specific intracellular responses to drugs and their relative benefit to risk ratio. 
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Figure I:  Concentration-dependency of the inhibitory effect of Nabu on Dex- (a)  and Preg (b)-
induced GC signaling. The LOEC of Nabu was determined at 2 µM in co -treatment with Dex and at 
0.25 µM in combination with Preg.  
 
 
 
 
  
Figure II:  Concentration-dependency of the inhibitory effect of Estrone (a)  and DHEA (b)  on Preg-
induced GC signaling. The LOEC of DHEA was determined at 4 µM and that of Estrone at 0.25 µM.  
 
 
 
 
 
 
 
D e x a m e th a s o n e  [2 0  µ M ] +  N a b u   la rv a e
T re a tm e n t
R
e
la
ti
v
e
 A
U
C
 [
%
]
D
M
S
O
 +
 D
e
x
0
.2
5
 µ
M
 +
 D
e
x
0
.5
 µ
M
 +
 D
e
x
1
 µ
M
 +
 D
e
x
2
 µ
M
 +
 D
e
x
4
 µ
M
 +
 D
e
x
8
 µ
M
 +
 D
e
x
1
2
 µ
M
 +
 D
e
x
1
6
 µ
M
 +
 D
e
x
2
0
 µ
M
 +
 D
e
x
M
if
e
 1
.0
 µ
M
 +
 D
e
x
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0
*
*
** *
*
*
a P re g n e n o lo n e  [5  µ M ] +  N a b u   la rv a e
T re a tm e n t
R
e
la
ti
v
e
 A
U
C
 [
%
]
D
M
S
O
 +
 P
re
g
0
.2
5
 µ
M
 +
 P
re
g
0
.5
 µ
M
 +
 P
re
g
1
 µ
M
 +
 P
re
g
2
 µ
M
 +
 P
re
g
4
 µ
M
 +
 P
re
g
8
 µ
M
 +
 P
re
g
1
2
 µ
M
 +
 P
re
g
1
6
 µ
M
 +
 P
re
g
2
0
 µ
M
 +
 P
re
g
M
e
ty
 4
0
 µ
M
 +
 P
re
g
-2 0
0
2 0
4 0
6 0
8 0
1 0 0
1 2 0
1 4 0
** ** *
*
*
* * *
b
P re g n e n o lo n e  [5  µ M ] +  E s tro n e  la rv a e
T re a tm e n t
R
e
la
ti
v
e
 A
U
C
 [
%
]
D
M
S
O
 +
 P
re
g
0
.2
5
 µ
M
 +
 P
re
g
0
.5
 µ
M
 +
 P
re
g
1
 µ
M
 +
 P
re
g
2
 µ
M
 +
 P
re
g
4
 µ
M
 +
 P
re
g
8
 µ
M
 +
 P
re
g
1
2
 µ
M
 +
 P
re
g
1
6
 µ
M
 +
 P
re
g
2
0
 µ
M
 +
 P
re
g
M
e
ty
 4
0
 µ
M
 +
 P
re
g
-2 0
0
2 0
4 0
8 0
1 0 0
1 2 0
1 4 0
*
*
* * * * * * * *
a P re g n e n o lo n e  [5  µ M ] +  D H E A  la rv a e
T re a tm e n t
R
e
la
ti
v
e
 A
U
C
 [
%
]
D
M
S
O
 +
 P
re
g
0
.2
5
 µ
M
 +
 P
re
g
0
.5
 µ
M
 +
 P
re
g
1
 µ
M
 +
 P
re
g
2
 µ
M
 +
 P
re
g
4
 µ
M
 +
 P
re
g
8
 µ
M
 +
 P
re
g
1
2
 µ
M
 +
 P
re
g
1
6
 µ
M
 +
 P
re
g
2
0
 µ
M
 +
 P
re
g
M
e
ty
 4
0
 µ
M
 +
 P
re
g
0
1 0
2 0
6 0
8 0
1 0 0
1 2 0
*
* ** *
b
*
Appendix 
182 
 
Figure I II:  Concentration-dependency of the inhibitory effect of Leflu on Preg -induced GC 
signaling. The LOEC was determined at 0.5 µM.  
 
 
 
 
 
 
Figure IV: Bioluminescent traces of  Levonorgestrel  when exposed alone to larvae ( a)  or  in co-
treatment with Dex (b)  and of Melengestrol acetate alone ( c)  and with Dex (d) .  
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Figure V: No signal activation by DHEA  via receptor binding to the 4 x  GRE sequence in transgenic 
AB.9-GRE:Luc  cel ls .  
 
 
 
 
 
Tabelle A  Optimized ESI-MSMS parameters and MRM transitions between precursor ions and 
product ions for each compound 
 
 
 
 
 
a Retention time 
b Declustering potential 
c Quantifier ion/ qualifier ion 
d Collision energy 
e Cell exit potential 
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Cortisol 0.57 363.1 86 120.9/105.0 35/63 10/10 
Corticosterone 0.76 347.1 91 329.3/120.9 23/33 20/10 
Dexamethasone 0.71 393.1 61 373.3/355.2 13/19 22/20 
Progesterone 1.17 315.2 86 97.0/109.1 35/33 8/10 
Pregnenolone 1.14 299.3 96 281.3/159.2 18/32 10/15 
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